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VABSTRACT
Interleukin-5 (IL-5) is a cytokine primarily produced by activated T cells 
and mast cells. This cytokine is believed to be a late acting factor in eosinophil 
development and, in mouse, to have additional roles in regulating B cell 
development and antibody production. The receptor for IL-5 consists of two 
subunits, the a  and ß chains. The a  chain binds IL-5 with low affinity but the 
ß chain has no measurable binding activity on its own. However, the two 
subunits combine to form the high affinity receptor required for signal 
transduction.
The strikingly selective elevation in eosinophil numbers in response 
to parasite infections and allergies, such as asthma, has made IL-5 a focus of 
special attention in the studies of these conditions. Hence, an understanding 
of the mechanisms that regulate the activities of this cytokine has important 
implications for the development of strategies for therapeutic intervention 
in various clinical conditions associated with eosinophilia. Regulation of the 
biological activities of IL-5 can be accomplished at four levels: regulation of its 
secretion; regulation of its receptor expression; regulation of its activities by 
other cytokines; and regulation by soluble inhibitors, such as soluble 
receptors or antagonists.
The work described in this thesis is aimed at gaining a better 
understanding of the mechanisms that regulate the expression of the mouse 
IL-5 receptor a-chain (IL-5Ra) gene in a cell type-specific manner. Towards 
this goal, a X  genomic library was screened with the mouse cDNA for IL-5Ra 
as a probe. The result was isolation of six overlapping genomic clones which 
were sequenced. Comparison of the gene with the cDNA sequence shows that 
the mouse IL-5Ra gene is organised into 13 exons and spans 38.6 kb between 
the transcription initiation site and the polyadenylation signal sequence. 
Exons 1, 2 and 3 are not translated, exon 4 encodes the signal peptide and the 
next six exons form the extracellular part of the receptor protein which is 
organised into three fibronectin type El-like domains. The transmembrane 
domain is encoded by exon 11 and, exons 12 and 13 form the cytoplasmic 
portion of the receptor. Consistent with it being a member of the class I 
cytokine receptor superfamily, the overall genomic structure of the mouse 
IL-5Ra is very similar to that of the other members of this family.
v i
Since the majority of tissue-specific eukaryotic genes are regulated at 
the level of transcription, the regulation of the mouse IL-5Ra gene was 
investigated to establish if it is similarly regulated. Transcripts of the gene 
were characterised and gene regulation studies were carried out using stable cell 
lines established by transfection of the upstream region fused to the luciferase 
reporter gene into cell lines that do and do not express the mouse IL-5Ra 
gene. This study uncovered a 4.8 kb region situated 6.5 kb upstream of the 
transcription initiation site that mediated transcriptional repression. 
Interestingly, there is a 1 kb stretch of sequence in this region that bears all the 
hallmarks of CpG islands. Although the exact mechanism for transcriptional 
repression is not clear at this stage, it is possible that it may be mediated by a 
repressor protein or the methylation of the CpG islands. This is the first 
evidence of a negative regulatory element which could explain the cell 
type-specific and temporal expression of the mouse IL-5Ra gene.
While in vitro techniques are extremely useful in gaining an insight 
into the function of a gene product, establishing its in vivo role remains the 
most important test of function. To this end, gene targeting constructs were 
prepared to enable the generation of an IL-5Ra deficient mouse and a mouse 
only able to express the transmembrane form of the receptor protein. The 
first mouse was designed to investigate the biological role of the IL-5Ra and 
the intention of the second mouse was to probe the role of the soluble form 
of this receptor about which little is known. However, time did not permit 
the completion of this section of work which is still in progress.
On the whole, the studies in this thesis have provided a complete 
characterisation of the primary structure of the mouse IL-5Ra gene and its 
transcripts, and made contributions to the understanding of its regulation. 
Successful completion of the gene targeting work may lead to important 
advances in the understanding of the biology of IL-5 and its receptor.
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CHAPTER ONE
GENERAL INTRODUCTION
1.1 Historical background
The strikingly selective elevation of eosinophil numbers 
resulting from certain parasitic infections and allergic responses in 
humans has long been recognised and has led to the postulation of the 
existence of a specific eosinophil promoting factor.
Later observations that T lymphocytes were required to generate 
the eosinophilia associated with parasitic infections (Basten and Beeson 
1970) and that supernatants from activated spleen cells could induce 
eosinophil colony formation (Metcalf et al. 1974) led to the search for 
an eosinophil growth factor. Such a factor was described as eosinophil 
differentiation factor (EDF) and shown to be produced by alloreactive 
T-cell clones and a T-cell hybrid (NLMP-TH1) (Warren and Sanderson 
1985).
2Other studies examining the role of T-cells in the growth and 
differentiation of B-cells revealed that T-cell supernatants had the 
capacity to induce B-cell proliferation and antibody secretion (Schimpl 
and Wecker 1972). This capacity was attributed to a differentiation 
factor designated T-cell replacing factor (TRF) (Takatsu et al. 1980;
Swain and Dutton 1982). B-cell growth stimulating activity in T-cell 
supernatants was attributed to another factor designated B-cell growth 
factor (BCGFII) which was subsequently found to be identical to TRF 
(Flarada et al. 1985). Comparative studies between EDF and BCGFII 
demonstrated that the two were closely related and that they 
co-purified (Sanderson et al. 1986). Subsequent gene cloning provided 
definitive evidence that one protein was responsible for both activities 
and henceforth designated interleukin-5 (Azuma et al. 1986; Kinashi et 
al. 1986; Campbell et al. 1987; Tanabe et al. 1987; Yokota et al. 1987; 
Campbell et al. 1988).
Since then, the association of IL-5 with eosinophil differentiation 
and function has made this cytokine a focus of special attention in the 
study of parasitic infections and allergic disorders.
1.2 The structure of IL-5
The functional IL-5 molecule is a disulphide linked 
homodimeric glycoprotein of 40 - 50 kD in size. The homodimeric 
configuration is essential for biological activity. Modification or 
mutation of the two conserved cysteine residues results in monomeric 
molecules that have no biological activity (Takahashi et al. 1990; 
Tsuruoka et al. 1990; Ingley et al. 1991a; McKenzie et al. 1991a).
3Functional analysis using human/mouse IL-5 chimeric molecules 
identified eight residues at the C-terminus to be important for species 
specificity (McKenzie et al. 1991b). Removal of these residues by 
cyanogen bromide degradation and oxidation of Metl07 (the ninth 
residue from the C-terminus) resulted in the complete loss of activity 
of IL-5 confirming the importance of these residues (Kodama et al.
1991).
The IL-5 receptor is composed of two subunits, the a  and ß 
chains. The a-chain is IL-5 specific and binds the ligand with low 
affinity but the ß-chain, which is also common to receptors of GM-CSF 
and IL-3, has no measurable binding activity on its own. However, both 
chains are required for the formation of the high affinity receptor and 
for signal transduction (Koike and Takatsu 1994; Mui and Miyajima 
1994).
Another study using GM-CSF and IL-5 hybrids indicated that the 
N-terminus of IL-5 interacted with the ß-subunit of its receptor 
(Shanafelt et al. 1991). The above results suggest that the C-terminus 
and N-terminus of the IL-5 molecule form receptor binding sites for 
the a  and ß subunits of its receptors (Goodall et al. 1993).
The crystal structure of human IL-5 (Milbum et al. 1993) revealed 
that IL-5 has a novel dimeric structure. Each monomer consists of four 
a-helices and two ß-sheets (Figure 1.2). One domain of the dimer 
configuration is made up of three N-terminal helices (helix A, B and C) 
from one monomer and the C-terminal helix (helix D') of the second 
monomer. The ß-sheets lie on the opposite sides of the dimer (Figure 
1.2). This four helical bundle motif has been referred to as the cytokine
Figure 1.2. Tube drawing of the crystal structure of human IL-5 showing the
monomer (left) and dimer configuration (right)(Devos et al. 1995). The 
dimer is made up of two domains with each domain adopting the four 
a-helical bundle structure which has been referred to as the cytokine
fold. The helical bundle is made up of three helices of one monomer 
(A, B and C) and the fourth helix (D') of the second monomer. The ß-
sheets (labeled green in the monomer) lie on the opposite sides of the 
dimer. The dimer configuration may be envisioned as two helical- 
bundle domains related by a two-fold axis.
4fold and is predicted to fit into the binding crevice of the relevant 
cytokine receptors (Bazan 1990). A similar cytokine fold motif has been 
described in recently solved crystal structures of human growth 
hormone (De Vos et al 1992), porcine growth hormone (Abdul-Meguid 
et al 1987), GM-CSF (Diederiechs et al 1991), M-CSF (Pandit et al 1992), 
IL-2 (Bazan and MacKay 1992) and IL-4 (Smith et al 1992; Walter et al 
1992).
Site specific mutagenesis of human IL-5 has implicated residues 
clustered in the loop connecting ß-sheet 1 and helix B, in part of the 
ß-sheet 2 and in the C-terminal region to be associated with the binding 
to the a-chain of the IL-5 receptor (Tavernier et al 1995). The same 
study also identified an IL-5 mutant (E13A) that has receptor binding 
activities similar to the wild-type but significantly reduced proliferative 
activation ability upon receptor binding. Hence it acts as a potential 
receptor antagonist. Interestingly, homologous positions in related 
cytokines GM-CSF (E21) and IL-3 (E22) have been shown to interact with 
the common ß-chain of the three receptors (Shanafelt et al 1991; Lopez 
et al 1992b).
1.3 The predicted structure of IL-5 receptor a-chain
The 60 kD IL-5 specific subunit of the IL-5 receptor which binds 
IL-5 with low affinity is the a-chain (IL-5Ra). Comparison of the 
human and the mouse IL-5Ra cDNAs shows a 70% homology at the 
amino acid sequence level (Takaki et al 1990; Murata et al 1992; 
Tavernier et al 1992). The mouse IL-5Ra is 415 amino adds in length 
while the human has 420 amino adds. The extracellular portion is
made up of three tandemly repeated fibronectin type IE-like domains 
(Figure 1.3), a structure typical of certain cell surface molecules having a 
binding role (Patthy 1990). This motif was originally described to be 90 
residues in length and repeated 15 times in fibronectin (Skorstengaard 
et al. 1986). Within the middle fibronectin-like domain of the IL-5Ra 
there are two pairs of conserved cysteines and the membrane proximal 
fibronectin-like domain contains the tryptophan-serine-(x)-tryptophan- 
serine (WSXWS, where X is any amino acid) motif (Figure 1.3). The 
conserved cysteines and WSXWS domains constitute the characteristic 
class I cytokine receptor module (Gearing et al. 1989; Bazan 1990; 
Cosman et al. 1990; Fukunaga et al. 1991). This module was predicted to 
be made up of two discrete folding domains of seven antiparallel 
ß-sheets folding into two ß barrels with the WSXWS box lying in the 
hinge region (Bazan 1990). There is experimental support for the 
WSXWS motif having a binding role in receptor-ligand interaction 
(Miyazaki et al. 1991; Bischoff et al. 1992; Yawata et al. 1993). The model 
also allowed another receptor molecule to contact the other surface of 
the bound cytokine (Bazan 1990). This prediction has largely been 
confirmed for another member of the cytokine receptor superfamily, 
the growth hormone receptor, whose crystal structure complexed with 
its ligand was elucidated recently (De Vos et al. 1992). This system has 
frequently been used as a paradigm for modelling interactions between 
ligand and receptors within the members of the class I cytokine 
receptor superfamily because of the similarity in the structure of the 
receptors and their ligands (Goodall et al. 1993).
The cytoplasmic domain of the IL-5Ra is short, about 55 amino 
adds, and does not contain consensus sequences for tyrosine kinases or 
the catalytic domain of protein kinases. Instead it has a membrane
C j
___________  IL-5
^ a  chain j  ^
[Conserved Cysj
Figure 1.3. Schematic representation of the predicted structure of IL-5
receptor (Koike and Takatsu 1994). The extracellular portions 
of the a  and ß chains are made up of fibronectin type Ill-like 
domains which are represented by circles. The conserved 
cysteine residues and WSXWS motif form the cytokine 
receptor motif conserved between members of the class I 
cytokine receptor superfamily. The overall structure of the 
a  chain of the IL-5 receptor is similar to the a  chains of the 
receptors of IL-3 and GM-CSF. Moreover, the ß chain is shared 
by all three receptors and is required in the formation of the 
high affinity receptor complex and signal transduction.
6proximal proline-rich region (Figure 1.3) referred to as "box 1" which is 
conserved within the cytokine receptor superfamily (Fukunaga et al. 
1991; Murakami et al. 1991). The predicted structure of IL-5Ra is 
strikingly similar to the a-chains of the receptors of IL-3 and GM-CSF 
although they do not share significant sequence homology (Cosman et 
al. 1990; Miyajima et al. 1993). However, these three cytokines do have 
overlapping activities in eosinophil development in vitro (Arai et al. 
1990; Sanderson 1992).
In mice, the IL-5Ra is expressed on 70% of peritoneal B cells 
(Ly-1+/CD5+) (Hitoshi et al. 1990) and on 4-8% of splenic B cells 
(Rolink et al. 1990). It is also expressed on the IL-5 dependent cell lines 
Y16, T88-M and B13 (Mita et al. 1989). In humans, it has been detected 
in eosinophils (Chihara et al. 1990; Migita et al. 1991; Ingley and Young 
1991b) and the eosinophilic cell line HL-60 (Plaetinck et al. 1990; Ingley 
and Young 1991b).
1.4 The predicted structure of IL-5 receptor ß-chain
In contrast to the a-chain, the ß-chain of the IL-5 receptor does 
not bind any cytokine on its own. However it is needed in association 
with the a-chain to form the high affinity receptor and for signal 
transduction (Devos et al. 1991a; Takaki et al. 1993).
The mouse ß-chain (AIC2B) is also utilised by the receptors of 
related cytokines, GM-CSF and IL-3, in the formation of high affinity 
receptors. It is therefore referred to as the common ß-chain (Hara and 
Miyajima 1992; Park et al. 1992). During the cloning of AIC2B, another
cDNA clone, AIC2A, was isolated and this clone has 91% homology to 
AIC2B at the amino acid sequence level. Despite the high homology 
with AIC2B, AIC2A does not participate in the high affinity binding of 
IL-5 or GM-CSF. In fact, the AIC2A has low affinity binding with IL-3 
and it can associate with the a-chain of IL-3 receptor to form the high 
affinity receptor. Therefore in the mouse, the a-chain of IL-3 receptor is 
capable of forming the high affinity receptor with either AIC2A or 
AIC2B (Hara and Miyajima 1992). On the other hand, in humans, only 
one common ß-chain (KH97) for all three receptors has been detected 
(Hayashida et al. 1990; Kitamura and Miyajima 1992; Takaki et al. 1993).
Like the a-chain, AIC2A, AIC2B and KH97 also belong to the 
class I cytokine receptor superfamily. The extracellular domains of 
these polypeptides consist of two tandemly repeated cytokine receptor 
modules and it has been predicted that they form a duplicated double 
barrel structure (Bazan 1990). The cytoplasmic domain is much longer 
than that of the a-chain (Figure 1.3), ie. 430 amino acids compared to 55 
amino acids of the a-chain, and the ß receptor has been shown to 
mediate signal transduction (Sakamaki et al. 1992; Sato et al. 1993). 
Unlike the a-chain, the common ß-chain has been found to be 
expressed in a wide variety of hematopoietic cells, including progenitor 
cells (McClanahan et al 1993) .
The demonstration of shared receptor subunits between IL-5, IL-3 
and GM-CSF provides an explanation for the cross competition in 
binding assays (Lopez et al. 1991) and the overlapping activities of these 
three cytokines in eosinophil development in vitro (Arai et al. 1990; 
Sanderson 1992). Similar biological activities are reflected in the
8induction of phosphorylation of similar protein molecules (Kanakura 
et al. 1990; Linnekin and Farrar 1990; Murata et al. 1990).
The sharing of a receptor subunit is not peculiar to the IL-5, 
GM-CSF and IL-3 subfamily. Other members of the class I cytokine 
receptor superfamily can now be grouped further into subfamilies 
according to the subunit shared. In the IL-6 subfamily, gpl30 is shared 
by IL-6, leukocyte inhibitory factor (LIF), oncostatin M (OSM) and ciliary 
neurotrophic factor receptors, whereas in the IL-2 subfamily the • 
y-chain of IL-2 receptor is shared by IL-2, IL-4, IL-7 and IL-15 (reviewed 
by Sato and Miyajima 1994a).
1.5 Cytokine-receptor interaction and signal transduction
Signal transduction is a consequence of the interaction between a 
cytokine and its receptors and subsequently may lead to cell proliferation or 
differentiation. In the class I cytokine receptor superfamily, interaction 
of cytokines and receptors is believed to result in homo-, hetero-dimerisation or 
oligomerisation of receptor subunits which is critical for initiating the 
signalling cascades. Examples supporting this concept can be found in 
the homodimerisation of the growth factor hormone receptor, G-CSF 
receptor and erythropoietin receptor and heterodimerisation or 
oligomerisation of receptors of the IL-6 / LIF/CNTF/OSM subfamily, the 
IL-2/IL-4/IL-7/IL-15 subfamily and the IL-5/IL-3/GM-CSF subfamily 
(reviewed by Stahl and Yancopoulos 1993; Kishimoto et al. 1994; Mui 
and Miyajima 1994; Heldin 1995). Deletion studies have demonstrated 
that the cytoplasmic regions of the a  and ß subunits of the IL-5 receptor
are necessary for signal transduction (Sakamaki et al. 1992; Takaki et al. 
1993; Comelis et al. 1995).
The mechanisms of signal transduction by the cytokine receptors 
are currently under intense investigation. The recognition of a 
membrane proximal region (box 1 and box 2) which shares limited 
similarity among members of the cytokine receptor superfamily 
(Murakami et al. 1991; O'Neal and Yu-Lee 1993) and its demonstrable 
significance in signal transduction implied that these receptors may 
utilise similar mechanisms for the initiation of cytoplasmic signalling 
cascades (Kishimoto et al. 1994; Sato and Miyajima 1994a; Taniguchi 
1995). One of the earliest biochemical events in the signal transduction 
cascade is tyrosine phosphorylation such as that induced by receptors 
that have intrinsic tyrosine kinase activity, for example the epidermal 
growth factor and platelet-derived growth factor receptors (Ullrich and 
Schlessinger 1990). Although receptors of the IL-5/IL-3/GM-CSF 
subfamily do not possess intrinsic kinase activity, rapid tyrosine 
phosphorylation of a similar set of proteins has been observed for all 
three cytokines upon receptor binding (Kanakura et al. 1990; Murata et 
al. 1990). The use of tyrosine kinase inhibitors suggested that 
phosphorylation is required for subsequent cellular responses (Satoh et 
al. 1992a).
One candidate signalling pathway downstream of the tyrosine 
kinase step utilised by mitogenic cytokines is the Ras pathway. Tyrosine 
kinase activity activates Ras through the GDP/GTP exchange factor 
SOS, which is linked to activated receptors by the SH2-containing 
adapter molecules She and Grb2. The SH2 domains of these signalling 
molecules bind phosphorylated polypeptides. Downstream of this
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pathway is Raf, a serine/threonine kinase. Raf regulates MAP kinase 
kinase, a protein tyrosine/threonine kinase, which in turn activates 
MAP kinase, another serine/threonine kinase, leading to the induction 
of various genes including c-fos and c-jun (Fantl et al. 1993; Feig 1993). 
Recent studies have demonstrated that IL-5, IL-3 and GM-CSF do 
indeed utilise the Ras pathway through the membrane distal region of 
the cytoplasmic domain of the common ß-chain (Sakamaki et al. 1992; 
Satoh et al 1992b; Sato et al. 1993). This pathway is schematically 
represented in Figure 1.5.
In addition, the activation of pim-1 (a serine/threonine kinase) 
and c-myc has been found to be associated with the membrane 
proximal region of the cytoplasmic domain of the common ß-chain 
(Sato et al. 1993). Other signalling molecules like the p70S6 kinase 
(a kinase responsible for the phosphorylation of the 40S ribosomal 
protein S6), phospholipase C, phosphatidylinositol-3-kinase, vav 
and Bruton's tyrosine kinase, whose roles in the cytokine receptor 
signalling are not well understood at this stage, were also found to be 
induced by the activation of IL-5Ra and the common ß-chain 
(Sakamaki et al. 1992; Sato et al. 1993; Sato et al. 1994b).
Another candidate signalling pathway requiring tyrosine 
phosphorylation that links receptor activation to nuclear events is 
the recently discovered JAK (Janus Kinase) family of tyrosine kinases. 
This family consists of JAK1, JAK2, JAK3, and TYK1, each having the 
characteristic two kinase domains. The carboxy-terminal domain 
contains all the motifs associated with protein tyrosine kinases while 
the amino-proximal domain contains kinase motifs but lacks several 
residues essential for catalytic activity. One popular model of signalling
ßFigure 1.5. A model of signaling pathways mediated by the receptors of
IL-5/IL-3/GM-CSF (adapted from Miyajima et al. 1993). The two 
major pathways activated by cytokine (ck) binding are the Ras 
and JAK-Stat pathways. The activation of the Ras pathway 
through She binding and phosphorylation is associated with the 
membrane-distal region of the ß-chain, while the activation of 
the JAK-Stat pathway requires the membrane-proximal region 
of the a-chain. In addition, the activation of c-myc and pim-1 
is dependent on the membrane-proximal region of the ß-chain. 
PTK: protein tyrosine kinase; PLC: phospholipase C; PKC: 
protein kinase C; and PI3K: phosphatidylinositol-3-kinase.
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proposes ligand induced receptor dimerisation and oligomerisation, 
resulting in a ligand dependent increase of JAKS in the receptor 
complex. Following the increased concentration of JAKS brought about 
by aggregation of the receptors and increased binding affinity, cross 
phosphorylation of JAKS occurs leading to activation of kinase activity. 
The activated kinase then goes on to phosphorylate the receptor as well 
as cellular substrates, including the signal transducer and activator of 
transcription (Stats), that are recruited to the receptor-kinase complex 
(reviewed by Ihle et al. 1994; Shuai 1994; Wilks and Harpur 1994).
The membrane proximal region of the cytoplasmic domain of 
IL-5R(x, the proline-rich region, was found to be required for tyrosine 
phosphorylation of JAK2 kinase (Sato et al. 1994b; Takaki et al. 1994b) 
and signal transduction involved signal transducer Stat5 (Mui et al. 
1995) and Statla (Van der Brüggen et al. 1995). While a number of 
cytokines had been known to induce JAK2, there was evidence to 
suggest that different transducers might be activated. Induction of JAK2 
by IFN-y and IL-3/GM-CSF resulted in the phosphorylation of different 
sets of proteins (Lamer et al. 1993). Hence, it seems each receptor selects 
specific substrates for JAK2, possibly leading to different target 
specificity (Ihle and Kerr 1995).
1.6 Soluble cytokine receptors
Receptors, being the "sensory organs" of cells, were thought to be 
membrane bound. Hence the discovery of soluble cytokine receptors 
has generated considerable interest. There are two pathways for 
generating soluble receptors. The first is by limited proteolytic cleavage
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of the transmembrane form of the receptor protein (shedding). The 
second pathway of generating soluble receptor is by alternative splicing 
of mRNA, which either results in splicing out the transmembrane 
encoding exon leading to a frameshift and premature translational 
termination or introduction of a new exon that directs polypeptide 
chain termination before the transmembrane exon (reviewed by 
Heaney and Golde 1993; Rose-John and Heinrich 1994).
The mode of generation of the soluble receptors of the IL-5Ra is 
not conserved between human and mouse. In the mouse, alternative 
splicing removes the transmembrane exon and results in the insertion 
of several amino acids and premature termination (Takaki et al. 1990). 
In humans, an exon (the 'soluble exon') exists upstream of the exon 
encoding the transmembrane domain. This exon contains an in-frame 
termination codon, and hence this exon must be spliced out to generate 
the full length transmembrane receptor. Translation would result in 
premature termination and the production of a soluble receptor. This 
form of soluble receptor represents 95% of IL-5Ra transcripts in the 
human eosinophilic cell line HL60. Another minor form of the soluble 
IL-5Ra found in the same cell line probably arises from the lack of 
splicing resulting in reading into the intron preceding the 'soluble 
exon' and encountering a termination codon (Tavernier et al 1992).
The physiological roles of soluble receptors are not fully 
understood at this stage. Nevertheless, three possible roles have been 
proposed. First, the ability of soluble receptors to bind to their 
respective ligands suggest a role as an antagonist. In the presence of a 
sufficient amount of soluble receptor, binding of ligand to membrane- 
associated receptor may be blocked resulting in diminished or inhibited
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signalling. The second role is that of an agonist. The soluble receptor- 
cytokine complexes may be transported to tissues or cells that do not 
normally express these genes and activation may occur due to the 
formation of complexes with other receptor subunits. The third is a 
passive role as a carrier. In its capacity as a carrier, the soluble receptor 
could bind its ligand and stabilise it by preventing its degradation or 
clearance and at the same time act as a reservoir, slowly releasing 
the ligand and thereby modulating the concentration of the active 
ligand in the extracellular milieu. This latter function may be more 
prominent in ligands having multimeric receptor components. The 
membrane associated receptor subunits are able to combine to form 
a high affinity interaction with the ligand and, hence, compete 
successfully with the low affinity binding of the soluble receptors. 
Alternatively, as a carrier, the soluble receptor could target the ligand 
for elimination from the body (reviewed by Fernandez-Botran 1991a; 
Heaney and Golde 1993; Rose-John and Heinrich 1994). Clarification of 
the role of the soluble form of the IL-5Ra awaits further work.
The keen interest in elucidating the function of soluble receptors 
lies in their potential therapeutic value as anti-inflammatory or 
immunosuppressive agents.
1.7 Chromosomal localisation of the genes encoding IL-5 and 
its receptors
The IL-5, IL-3, IL-4, GM-CSF and IL-13 genes are closely linked on 
mouse chromosome 11 and human chromosome 5 (Lee et al. 1989;
Van Leeuwen et al. 1989; Frolova et al. 1991; McKenzie et al. 1993).
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In contrast, the genes encoding the receptors for IL-5, IL-3 and 
GM-CSF do not show any clustering. The IL-5Ra gene was mapped to 
human chromosome 3 (Isobe et al. 1992; Tuypens et al. 1992) and 
mouse chromosome 6 (Gough and Raker 1992; Imamura et al. 1994). 
The IL-3Ra and GM-CSFRa genes were localised to human X-Y 
pseudoautosomal region (Gough et al. 1990; Kremer et al. 1993). On the 
other hand, the mouse IL-3Ra was mapped to chromosome 14 
(Miyajima et al. 1995) and the mouse GM-CSFRa to chromosome 19 
(Disteche et al. 1992). Finally, the common ß subunit gene was mapped
to human chromosome 22 (Shen et al. 1992) and mouse chromosome 
15 (AIC2A and AIC2B) (Gorman et al. 1992).
1.8 The biological activities of IL-5
The main source of IL-5 is from activated T-helper (CD4+) cells 
(Sanderson et al. 1988). Recently IL-5 has also been demonstrated to be 
produced in eosinophils from human intestinal mucosa (Desreumaux 
et al. 1992), nasal mucosa (Bradding et al. 1993) and blood (Dubucquoi et 
al. 1994a). In addition, IL-5 mRNA expression has also been reported in 
HTLV-1 infected T-cells (Noma et al. 1989), Reed-Sternberg cells in 
Hodgkin's disease (Samoszuk and Nansen 1990), lymph node tissue of 
angiolymphoid hyperplasia (Kimura's disease) (Inoue et al. 1990) and 
Epstein-Barr virus transformed B-cell lines (Paul et al. 1990). In mice, 
T-cell subpopulations other than CD4+ have also been shown to 
produce IL-5, such as, CD3+ y5-T-cell receptor positive T-cells (Taguchi 
et al. 1991) and CD8+ cells (Cardell et al. 1991). IL-5 is also produced by 
mast cells (Plaut et al. 1989; Bradding et al. 1994).
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IL-5 produced by mammalian cells has an apparent molecular 
weight of about 40-50 kD. The variation in molecular weight is largely 
due to the heterogeneous nature of post-translational glycosylation. 
However, the carbohydrate moiety, as yet, does not have any 
demonstrated effect on its biological activities (Proudfoot et al. 1990; 
Tominaga et al. 1990a; Kunimoto et al. 1991; Ingley et al. 1991a).
Human and mouse IL-5 share about 70% homology at the amino 
add level (Azuma et al. 1986; Yokota et al. 1987; Campbell et al 1988) 
Despite the high degree of conservation, the mouse and human IL-5 
display significant species spedfidty. The human IL-5 is 100-fold less 
active on mouse target cells than its mouse counterpart. On the other 
hand, the mouse IL-5 has been reported to be 20-fold less active on 
human compared to mouse bone marrow (Clutterbuck et al. 1987).
The induction of eosinophil production and their activation by 
IL-5 was first demonstrated in mouse bone marrow cultures 
(Sanderson et al. 1985). This action was found to be lineage specific as 
only eosinophil numbers increased. In contrast, the related cytokines 
IL-3 and GM-CSF induced eosinophils as well as a wide range of other 
hematopoietic cells (Arai et al. 1990; Sanderson 1992). The induction of 
eosinophils is markedly increased in parasite-infected mice. 
Administration of anti-IL-5 monodonal antibody to parasitised mice 
completely suppressed blood eosinophilia, indicating that IL-5 is the 
main factor responsible for eosinophilia in this model (Coffman et al. 
1989a; Rennick et al. 1990). Kinetic studies of IL-5 mediated generation 
of eosinophils from bone marrow demonstrated that IL-5 is only active 
at a late stage of eosinophil differentiation (Yamaguchi et al. 1988a) and 
preincubation of mouse bone marrow cells with IL-3 and GM-CSF
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induced a marked increase in eosinophil precursor cells that are 
responsive to IL-5 (Warren and Moore 1988). Human IL-5 has 
essentially the same activities on human eosinophils and their 
precursors (Harada et al. 1985; Lopez et al. 1988; Lu et al. 1990).
IL-5 also has other direct effects on eosinophil functions other 
than increased survival and generation of eosinophils. It has 
chemotactic activity for eosinophils (Yamaguchi et al. 1988b; Wang et 
al. 1989) and has been shown to increase adhesion of human 
eosinophils to plasma coated glass beads, a phenomenon mediated by 
enhanced expression of intergrin molecules of the CD11/18 family 
(Walsh et al. 1991).
Although IL-5 has profound proliferative effects on eosinophil 
precursors and enhances eosinophil activation and survival in hum ans and 
mice, it does have other different biological activities in the two 
systems. IL-5 is clearly active in the proliferation and differentiation of 
mouse B-cells in vitro which is the basis of its discovery as a B-cell 
growth factor. In combination with other cytokines, IL-5 regulates 
immunoglobulin production in mice, in vitro at least. It induces IgM 
production by increasing the level of mRNA of secreted forms of 
p-chains and regulates transcription of the IgH chain gene (Yuan et al.
1990; Webb et al. 1991). IL-5 together with IJ^ -2 regulates the amount of 
IgGl isotype secreted (McHeyzer 1989) and with IL-4, IL-5 promotes IgE 
and IgGl secretion (Purkerson and Isakson 1992a; Mandler et al. 1993).
IL-5 with TGF-ß enhances IgA production in LPS stimulated mouse 
B-cells by acting on surface IgA positive B-cells (Matsumoto et al. 1989; 
Coffman et al. 1989b; Sonoda et al. 1992). This suggests that IL-5 acts as a 
maturation factor for cells committed to become IgA-secreting cells
rather than as a class-switching factor. IgA is highly important in 
mucosal immunity.
On the other hand, despite early results (Azuma et al. 1986;
Yokota et al. 1987), the activity of IL-5 on human B cells remains 
controversial. While there have been some reports of the ability of 
IL-5 to induce or enhance the production of IgM (Azuma et al. 1986;
Bertolini et al. 1993) and IgA (Yokota et al. 1987), other investigators 
were unable to demonstrate its capacity to induce either proliferation 
of human B cells or immunoglobulin production in a variety of assay 
systems (Clutterbuck et al. 1987; Sanderson et al. 1988; Fattah et al. 1990).
In addition, IL-5 also activates human basophils to enhance the 
release of histamine (Denburg et al. 1991) and leukotriene C4 (Bischoff 
et al. 1990; Hirai et al. 1990).
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1.9 The effects of over-expression of IL-5
Our understanding of the physiological role of IL-5 in vivo in 
eosinophil development and B-cell function has been enhanced by 
studies on transgenic mice constitutively expressing IL-5 (Dent et al. 
1990; Tominaga et al. 1990b) and lethally X-irradiated syngeneic mice 
transplanted with bone marrow cells which have been transfected with 
a retroviral vector carrying the mouse IL-5 gene (Vaux et al. 1990). 
These studies showed elevated levels of serum IL-5, IgM and IgA, and 
marked increases in the numbers of lymphocytes (Lyl+ B-cells) and 
eosinophils. In addition, there was infiltration of eosinophils into 
various tissues including bone marrow, spleen, liver, gut, peritoneal
cavity, lungs and lymph nodes. Administration of neutralising IL-5 
antibodies lowered the level of peripheral blood eosinophils. These
findings suggested that the expression of IL-5 was sufficient to produce
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the full pathway of eosinophil differentiation. Despite the massive 
long lasting eosinophilia and tissue infiltration by eosinophils the 
animals appeared to be quite healthy. Hence, an expanded number of 
eosinophils was not in itself harmful suggesting that they need to be 
activated by additional factors to degranulate and cause the tissue 
damage seen in allergic reactions and other diseases (Sanderson 1991).
1.10 The link between IL-5, eosinophilia and disease
Eosinophilia has long been observed to be associated with 
various clinical conditions such as parasitic infections, neoplasia, and 
allergic and autoimmune diseases. In these conditions, increased levels 
of IL-5 have been demonstrated and IL-5 appears to be the major cytokine 
responsible for the eosinophilia observed (Sanderson 1992). For 
instance, patients infected by the filarial parasite Loa loa had similar 
levels of IL-3 and GM-CSF to normal individuals but the infected 
patients had markedly increased levels of IL-5 (Limaye et al. 1990).
1.10.1 Parasitic infections
The immune response to infections involves the secretion of 
cytokines from activated T-cells. A subpopulation of T-cells that plays a 
critical role in this response is the CD4+ T helper (Th) cells. These cells 
can be separated on the basis of cytokine secretion profiles into two
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main subsets (Thl and Th2), although other subsets have also been 
noted. The Thl subset uniquely secretes IL-2, interferon-y (IFN-y) and 
tumour necrosis factor-ß (TNF-ß), whereas the Th2 subset secretes IL-4, 
IL-5, IL-6 and IL-10. Both subsets produce IL-3, GM-CSF and tumour 
necrosis factor-a (TNF-a) (Mosmann and Coffman 1989; Swain et al. 
1991). IL-12 and IL-13 are cytokines produced cells other than Th cells, 
but IL-12, like IFN-y and IFN-a, induces the development of the Thl 
pathway (Hsieh et al. 1993) whilst IL-13, like IL-4 and IL-10, favors the 
development of the Th2 responses (Punnonen et al. 1993). This forms 
the basis of reciprocal cross-inhibition between the two main subsets. 
Thl products are inflammatory mediators and selectively activate 
macrophages, thereby enhancing cellular immunity. As such, the Thl 
immune response may be most useful in dealing with intracellular 
pathogens. On the other hand, Th2 products are thought to stimulate 
various aspects of B cell growth and differentiation in antibody 
production. Therefore, the Th2 response may be more appropriate in 
infections with extracellular pathogens against which antibody will 
have the greatest efficacy (Mosmann et al. 1991; Paul and Seder 1994).
Until recently it has been a widely accepted view that 
eosinophilia in helminth infections plays a protective role as was 
suggested by previous data based largely on in vitro killing assays 
(Butterworth 1984). However, recent cytokine depletion studies using 
monoclonal antibodies have prompted a re-evaluation of this view. In 
vivo depletion of circulating and tissue eosinophils with anti-IL-5 fails 
to eliminate protective immunity in mice against Shistosoma mansoni 
(Sher et al. 1990), Nippostrongylus brasiliensis (Coffman et al. 1989a) 
and Trichinella spiralis (Herndon and Kayes 1992). Whether
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eosinophilia is merely an indicator of parasitic infection or has clinical 
significance is not clear.
Infectious agents have been observed to frequently cause 
polarisation of immune responses to either Thl or Th2 types. At issue 
is which Th response is generally protective against parasitic infections. 
It appears that cellular immunity mediated by Thl is effective against 
some intracellular pathogens and humoral immunity mediated by Th2 
is important for protection against extracellular pathogens. However, 
no cytokine response universally provides the best protection for the 
host against all parasites. This is because parasites have evolved 
strategies that fool the host immune system into making a response 
that protects the parasites rather than the host. These strategies can be 
broadly classified as passive or active.
The passive evasion strategy generally involves minimising 
exposure of the pathogen to the host immune surveillance system. 
This can involve the parasite remaining dormant or constantly 
varying its surface proteins, such as antigenic modulation by 
trypanosomes. On the other hand, the active strategy requires the 
pathogens to secrete proteins that will engage mediators of the host 
immune system, such as cytokines. These pathogen products function 
by either inhibiting cytokine action or subverting the host immune 
system through molecular mimicry. Inhibitory pathogen products can 
be unique proteins or they may resemble cytokine receptors. Receptor 
mimics are capable of binding and blocking the activities of a specific 
cytokine, eg. the products of Shrope fibroma virus and vaccinia virus 
target TNF and IL-1 respectively. Subverting the host immune system 
by molecular mimicry is a more complex process where the protein
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secreted has significant homology and similar activity to a host 
cytokine, eg. the BCRF1 product of Epstein-Barr virus is an analog of 
IL-10 (reviewed by Maizels et al. 1993; Marrack and Kappler 1994; 
Spriggs 1994).
1.10.2 Asthma
The importance of the underlying inflammatory response in 
asthma is now generally recognised and is the target for long term 
treatment. The inflammatory reaction involves leukocyte infiltration 
and activation, and leads to tissue damage. The dominant 
inflammatory cell types involved in asthma are T-cells, eosinophils, 
neutrophils, macrophages and mast cells. With the exception of 
neutrophils and macrophages, these cell types have been reported to 
produce mRNA for IL-5 (Broide et al. 1992; Robinson et al. 1992; 
Bradding et al. 1994). There is increasing speculation that eosinophils 
may be the major factor in the development of respiratory malfunction 
in asthma based on the ability of eosinophil products such as the major 
basic protein, eosinophil peroxidase, eosinophil-derived neurotoxin 
and eosinophil cationic protein to cause direct cytotoxicity to lung 
epithelium. Levels of these proteins have been correlated with the 
severity of clinical symptoms in asthma. While the presence of IL-5 
and eosinophils generally correlates with clinical symptoms, there are 
other inflammatory cells and cytokines involved in the inflammatory 
response (Sanderson 1992; Seminario and Gleich 1994).
Animal studies have generally supported a role for IL-5 in 
controlling pulmonary eosinophilia but its association with bronchial
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hyper-reactivity has been less dear. However in one study in guinea 
pigs, treatment with anti-IL-5 monodonal antibody inhibited the 
development of hyper-reactivity (Van Oosterhout et al. 1993).
In addition to the involvement of IL-5 in asthma, another 
cytokine that appears to play a role is IL-4 which is also produced by 
T-cells (Robinson et al. 1992) and mast cells (Bradding et al. 1994). 
Transendothelial migration of eosinophils in mice was found to be 
mediated by IL-4 and could be inhibited by neutralising anti-IL-4 
antibody (Moser et al. 1993). Sensitisation challenge of IL-4 defident 
mice with aerosolised ovalbumin showed less marked eosinophilia 
and inflammation compared to the wild type (Brusselle et al. 1993).
1.10.3 Graft rejection and tumours
Eosinophilia in renal transplantation and liver grafts is known 
to indicate poor prognosis for graft survival. Conversely, eosinophilia 
associated with neoplasias, such as carcinomas of the cervix, lung and 
stomach, and Hodgkin's disease has been associated with favourable 
prognosis. Whether eosinophils play a role in these diseases or merely 
serve as a marker for T-cell activities is not clear (reviewed by 
Sanderson 1992).
1.11 Aim of thesis
In light of the key role of IL-5 in eosinophil development, 
understanding the mechanisms that regulate the activities of this
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cytokine is critical to the development of strategies for therapeutic 
intervention in various clinical conditions associated with 
eosinophilia. The regulation of the biological activities of IL-5 can be 
accomplished at four levels: 1) regulation of its secretion; 2) regulation 
of its receptor expression; 3) regulation of its activity by other cytokines, 
as seen in the reciprocal cross-inhibition of Thl/Th2 subsets; and 4) 
regulation by soluble inhibitors, either soluble receptors or antagonists.
The aim of the project described in this thesis was to characterise 
the mouse IL-5 receptor a-chain gene and to study the mechanisms 
regulating its expression in a cell type-specific manner. This involved 
the isolation and complete sequence determination of the IL-5Ra gene 
and analysis of its promoter region to identify sequences involved in 
cell type-specific regulation. In addition, constructs were also prepared 
for use in altering the endogenous IL-5 receptor a-chain gene in mice 
by homologous recombination. One construct was designed to 
inactivate the endogenous gene and the other to generate mice that 
only express the transmembrane form of the receptor and not the 
soluble form. The aim here is to further study the function of both 
forms of the receptor in vivo.
CHAPTER TWO
CLONING AND SEQUENCING OF THE 
MOUSE IL-5R0C GENE
2.1 Introduction
The development of vectors, such as bacteriophage X and PI, 
cosmids and yeast artificial chromosomes (YAC), that have the capacity 
to accommodate large inserts has facilitated the construction of 
representative genomic libraries for the mapping and analysis of 
complex genomes. The usual approach to isolating a gene is to screen 
a recombinant genomic DNA library consisting of several million 
individual clones. Each clone contains a different segment of the 
genome. A cloning strategy for isolating the clone containing the 
desired gene is formulated according to the information available for 
the particular gene and the strategy used for determining the sequence 
of the isolated gene is dependent on its size and complexity.
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2.1.1 Screening strategy
A genomic library can be screened for the presence of a desired 
gene by hybridisation to a nucleic acid probe or by detection of specific 
gene fragments using the polymerase chain reaction (PCR) (reviewed 
by Maniatis et al 1989, Ausubel et al. 1994). The nucleic add probe used 
can either be a fragment of the gene, its cDNA or a gene-specific 
oligonucleotide. Normally, a gene fragment or cDNA is preferred over 
an oligonucleotide because they can be labelled to much higher specific 
activity, thus, enhancing the sensitivity of detection. Gene detection by 
PCR is simple and more rapid because the results of a PCR screen are 
known on the same day without the need for lengthy autoradiography. 
However, the PCR procedure suffers from the drawback of not being 
able to detect overlapping dones if the size of the gene is greater than 
the capacity of the cloning vector. Nevertheless, it is useful for 
detecting specific gene fragments and serves as a supplementary 
screening procedure to the use of nucleic acid probes.
2.1.2 Sequencing strategy
The amount of sequence data that can be obtained from a 
sequendng reaction is limited by the resolution of the sequencing gel. 
Current technologies allow about 500 nucleotides of sequence data to be 
reliably obtained from one set of sequendng reactions. The 
characterisation of long regions of DNA necessitates the breaking of a 
large fragment into smaller ones. The manner in which these smaller 
fragments are generated is the fundamental issue in the choice of the
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overall sequencing strategy. Current strategies fall into two general 
categories: random and directed.
The random or shotgun strategy generates a library of smaller 
fragments from a large fragment of DNA after random digestion with 
DNase I (Anderson 1981) or physical shearing by sonication (Deininger 
1983; Bankier et al 1987). The individual smaller fragments are 
sequenced randomly and ordered by finding overlaps. This approach 
has the advantage of rapid initial accumulation of data but may suffer 
at the end of the project from repeated sequencing of the same regions 
and from difficulties in closing remaining gaps. It has nevertheless 
been successfully used for large sequencing projects such as the 
C. elegans genome project and gives data on both strands (Sulston et al.
1992).
The directed strategy allows direct and sequential sequence 
analysis of large DNA fragments from one end to another. The two 
basic approaches used in this strategy are primer walking and 
progressive (nested) deletions. In primer walking, the initial sequence 
is determined by a vector-specific primer and then followed by 
synthesis of a new primer from the newly acquired sequence. These 
steps are repeated until the DNA fragment is completely sequenced 
(Strauss et al. 1986). One nested deletion approach uses exonuclease in 
to generate progressive unidirectional deletions from one end of the 
DNA fragment (Henikoff 1984). The drawback of this method is the 
requirement that the DNA fragment be free of the restriction enzyme 
site used to linearize the vector prior to exonuclease HI treatment.
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2.1.3 Overview of this chapter
The aim of the work described in this chapter was to clone and 
sequence the mouse IL-5Ra gene. This was essential for the study of 
its regulation and for its manipulation by gene targeting. It was decided 
to determine the complete sequence of the gene rather than just the 
intron/exon junctions in order to provide a sound basis for a 
comprehensive study of the gene and its regulation. In addition, 
knowledge of the complete sequence of the IL-5Ra gene would greatly 
facilitate manipulation of the gene in the construction of targeting 
vectors designed to generate mice in which the IL-5Ra gene had been 
modified by gene targeting.
2.2 Materials and Methods
2.2.1- Plasmids, cell lines and reagents
A BALB/c mouse leukocyte genomic library was obtained from 
Clontech (Palo Alto, CA). Restriction enzymes and DNA modifying 
enzymes were from New England Biolabs (Beverly, MA), Promega 
(Madison, MI) or Pharmacia (Uppsala, Sweden). Phagemid pBluescript 
SK(-) was from Stratagene (La Jolla, CA). Bactotryptone, yeast extract 
and agar used as bacterial culture media were from Difco (Detroit, MI). 
Seakem agarose was from FMC Bioproducts (Rockland, ME). 
[a32P]dATP (3000 Ci/mmol) was from Amersham(Buckinghamshire, 
UK). M13 and T3 dye primer sequencing kits were from Applied 
Biosystems (Foster City, CA).
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The oligonucleotides used in this chapter were MF71 (5'-TCG 
GCT ACC ATG GTG CCT GTG-3'), MF73 (5'-ATG GCA AAA TGC CAT 
CAA AAC CTG-3'), MF100 (5'-TGA ACT CAT ACA GGA CTC CTG G- 
3'), MF101 (5'-GTA GCT GAG TGC TAC CAC TGG-3'), CL17 (5'- TAG 
CCT GAC CCA GCT CAT CCG T-3'), CL18 (5'-ACT GAC ACC GTC GTT 
CAA AAG TAA-3'), CL19 (5'-CTA CTT CAA GGA TAA AGG CGA-3') 
and CL21 (5'-GAA GTC CTA TTT ACA ACC GTC CT-3'). All 
oligonucleotides were synthesised using an Applied Biosystems 380B 
DNA Synthesiser (Applied Biosystems, Foster City, CA) operated by 
staff of the Biomolecular Resource Facility (JCSMR).
Several strains of Escherichia coli were used in the work here: 
D H 5a [<{>80d/acZAM15, recAl, endAl, gyrA96, thi-1, /isdR17(ric",mic+), 
supE4A, relAl, deoR, A(lacZY A-argF)Ul69] (Sambrook et al. 1989) was 
used as host for the propagation and preparation of pBluescript SK(-) 
DNA; ED8654 [P e l4 ‘(McrA-) lac-3 or lacYl galK2 galT22 supE44 supF58 
metBl hsdR514 (r]c"mic+) trpR55] (Murray et al. 1977) was used as host 
for plating of bacteriophage X; TGI [FtraD36 lacM A(lacZ)M15] supE 
hsdA5 thi A(lac-proAB) (Sambrook et al. 1989) was used as host for 
bacteriophage M13mpl8; and DH11S [mcrA A(mrr hsdRMS mcrBC) 
A(lac-proAB) A(recA1398) deoR rpsLsrl'  thi'/F 'proAB+ /ACNZAM15] 
(Lin et al. 1992) was used as host for pBluescript SK(-) in the production 
of single-stranded DNA.
2.2.2 Minipreparation of plasmid DNA
This method was developed during the course of the work here 
from two previously published methods (Miki et al. 1989; Studier 1991).
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All manipulations described in this section were carried out at room 
temperature and centrifugation was done in a microcentrifuge at 
12 OOOxg unless stated otherwise.
A single bacterial colony containing the desired plasmid was 
grown overnight in 2 ml of Terrific broth (1.2% tryptone, 2.4% yeast 
extract, 0.4% glycerol, 0.17 M KH2PO4 and 0.72 M K2HPO4) (Tartof and 
Hobbs 1987) supplemented with 100 pg/m l ampicillin. Bacterial cells in 
1.5 ml of overnight culture were collected by centrifugation for 1 
minute. The bacterial pellet was completely resuspended in 100 pi of 
water and followed by the addition of lOOpl of lysis solution (0.1 M 
NaOH, 2% SDS and 10 mM EDTA). The lysate was mixed by gentle 
inversion. To ensure complete lysis and inactivation of nucleases, the 
suspension was heated at 100°C for 2 minutes. After that, 50 pi of 1M 
MgCl2 was added to precipitate proteins and the mixture gently mixed 
using a vortex mixer. The lysate was incubated on ice for 3 minutes and 
centrifuged for 1 minute to pellet the precipitate. The cleared lysate was 
then neutralised with 50 pi of 7.5 M of ammonium acetate, incubated 
on ice for another 3 minutes and centrifuged for 1 minute to remove 
the genomic D N A / protein /SDS complex. The supernatant was then 
transferred to a fresh tube containing 100 pi of 2M Tris-HCl pH 8.9 and 
2 pi of 10 m g /m l RNase A (DNase inactivated by boiling), and incubated 
at 37°C for 20 minutes. Plasmid DNA was then precipitated with 250 pi of 
isopropanol and collected by centrifugation for 5 minutes. The DNA 
pellet was rinsed with 70% ethanol, vacuum dried and then dissolved in 
water or TE (10 mM Tris-HCl pH 7.5 and 1 mM EDTA).
2.2.3 Large scale preparation of plasmid DNA
This procedure is a modification of the original alkali lysis 
method (Bimboim and Doly 1979). The bacterial culture was grown 
overnight in 250 ml of Terrific broth (as described in Section 2.2.2.). 
Bacterial cells were recovered by centrifugation at 5 000 rpm at room 
temperature in a Sorvall GS3 rotor and resuspended in 20 ml of GTE 
solution (50 mM glucose, 25 mM Tris-HCl pH 8 and 10 mM EDTA).
2 ml of freshly prepared lysozyme solution (20 m g/m l in 10 mM 
Tris-HCl pH 8) was then added to the suspension and the mixture 
incubated at room temperature for 10 minutes to obtain partial lysis. 
After that 40 mi of lysis solution (0.2 M NaOH and 1% SDS) was added 
and mixed in by gentle inversion. The lysate was neutralised with 30 
ml of ice cold 7.5 M ammonium acetate and incubated on ice for 10 
minutes. Flocculant material was removed by centrifugation at 5 000 
rpm at 4°C for 10 minutes in a Sorvall GS3 rotor. The supernatant was
transferred into a fresh centrifuge bottle containing 900 pi of 10 m g/m l 
RNase A (DNase inactivated by boiling) and incubated at 37°C for 20
minutes. Following RNase digestion, the DNA was precipitated with 54 
ml of isopropanol and the suspension centrifuged at 5 000 rpm for 20 
minutes at room temperature in a GS3 rotor. The DNA pellet was then 
rinsed w ith 70% ethanol and vacuum dried.
For cesium chloride banding, the DNA pellet was dissolved in 
10 ml of TE and 10 g of cesium chloride was added. After the cesium 
chloride had dissolved, 800 pi of 10 m g/m l ethidium bromide was 
added. The protein-ethidium bromide precipitate was removed by 
centrifugation at 10 000 rpm for 5 minutes at room temperature in a 
Sorvall SS34 rotor. The supernatant was then loaded into a 13.5 ml
Beckman Quick-seal tube and centrifuged at 60 000 rpm for 24 hours at 
20°C in a Ti75 rotor (Beckman). After centrifugation, the lower of the 
two bands which contained the plasmid DNA was harvested by side 
puncture with an 18 gauge needle attached to a syringe. The ethidium 
bromide in the DNA sample was removed by extraction with water 
saturated butan-l-ol. Salts in the DNA sample were removed by 
ethanol precipitation of the DNA and rinsing of the DNA pellet with 
70% ethanol. The pellet was then dried under vacuum and dissolved 
in water or TE.
2.2.4 Agarose gel purification of DNA fragments
The "centrifugation through blotting paper" method of 
purification of agarose gel fractionated DNA fragments described by 
Weichenhan (1991) was used. Essentially, a gel slice containing the 
desired DNA fragment was placed in a blotting paper (Whatman 541) 
cone which had been inserted into an microcentrifuge tube with a hole 
at the bottom of the tube. This tube was placed into another tube and 
the two tubes centrifuged at 12 OOOxg for 1 minute at room temperature. 
The agarose was retained by the blotting paper but the eluate 
containing the DNA was collected in the second tube. The DNA was 
then purified by phenol/chloroform extraction.
2.2.5 Quantitation of DNA and RNA
The amount of DNA or RNA in solution was quantitated by 
measuring its optical density (OD) at 260 nm and the concentration
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calculated from reference values. The reference values used were as 
follows: for double stranded DNA, an OD of 1 equals 50 pg/m l and for 
RNA an OD of 1 equals 40 pg/m l. The purity of the preparations was 
monitored by calculating the ratio of the OD obtained at 260 nm and 
280 nm. This ratio should be 1.8 and 2.0 for DNA and RNA respectively 
for pure preparations (Maniatis et al. 1989).
2.2.6 Restriction enzyme digestions
Digestion of DNA with restriction enzymes was performed in 
buffers supplied by the manufacturers and under conditions 
recommended by them. However, the amount of enzyme used was 
usually increased by two fold to ensure complete digestion.
2.2.7 Blunt ending DNA fragments
The 5-protruding or 3'-recessed ends of DNA created by 
restriction enzyme digestion were made blunt-ended by treatment with 
T4 DNA polymerase or the Klenow fragment of DNA polymerase I. 
Typically, 1 U of enzyme per 0.5 jig of DNA was used in a 20 pi reaction 
mixture consisting of 10 mM Tris-HCl pH 7.2, 5 mM MgCl2, ImM DTT 
and 0.05 mM dNTPs, and the mixture incubated for 30 minutes at 25°C. 
The reaction was terminated by heating at 70°C for 20 minutes.
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2.2.8 Dephosphorylation of DNA termini
This method of removal of phosphate groups from the termini 
of DNA was developed by C.L.Tan (personal communication). At 
the end of restriction enzyme digestion the DNA was purified by 
phenol/chloroform extraction and precipitated with ethanol. The 
pellet was then dissolved in a buffer consisting of 50 mM Tris-HCl 
pH 8.5, 0.1 mM EDTA and 1 U of calf intestinal alkaline phosphatase 
(CIP) per 2 pmol of DNA ends was added and the mixture incubated 
at 37°C for 15 minutes. After that, an equal amount of CIP was added 
and incubation continued at 56°C for 45 minutes. The reaction was 
terminated by the addition of SDS and Proteinase K to a final 
concentration of 0.5% and 100 |ig/m l respectively, and the mixture 
incubated at 56°C for a further 30 minutes. The reaction mixture was 
then purified by phenol/chloroform extraction.
2.2.9- DNA ligations
Typically, the amount of DNA used in ligation reactions was 10 
ng of vector DNA with a five-fold molar excess of insert DNA for 
cohesive end ligations. However, for blunt end ligations up to twenty 
fold molar excess of insert DNA was used. The ligation was carried out 
in a 20 pi reaction mixture consisting of 30 mM Tris-HCl pH 7.8, 10 mM 
MgCl2, ImM DTT, ImM ATP and 1 Weiss unit of T4 DNA ligase which 
was incubated at 15°C for 18 hours.
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2.2.10 Preparation and transformation of competent 
bacterial cells
The method of competent cell preparation described by V.
Simanis was used (Hanahan 1985). A 2 ml starter culture of the desired 
bacterial cells grown with agitation overnight at 37°C in SOB medium 
(2% bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1,10 mM 
MgCl2 and 10 mM MgS0 4 ) was added to200mlSOB and grown at 37°C 
until optical density at 600 nm reached the range between 0.4 and 0.6. 
The culture was then chilled on ice for 15 minutes and the bacterial 
cells were pelleted by centrifugation at 1 OOOxg for 10 minutes at 4°C.
The cell pellet was completely resuspended with 67 ml ice-cold RF1 
buffer (100 mM RbCl, 50 mM MgCl2, 10 mM CaCl2, 15% glycerol and 30 
mM potassium acetate, pH 5.8) and incubated on ice for 15 minutes.
The cells could be kept on ice for up to 2 hours because some cells, like 
HB101, acquire increased competency with longer incubation on ice. 
Following this, the cells were pelleted by centrifugation at 1 OOOxg for 10 
minutes at 4°C and completely resuspended in 16 ml of ice-cold RF2 
buffer (10 mM RbCl, 75 mM CaCl2, 15% glycerol and 10 mM MOPS [3- 
(N-morpholino)-propanesulfonic acid], pH 6.8). The competent cells 
were stored in 200 pi aliquots at -70°C.
For transformation, frozen competent cells were thawed on ice 
and up to 20 pi of ligation mixture was added and the mixture held on 
ice for 20 minutes. The mixture was then heat shocked at 42°C for 90 
seconds, returned to ice for 3 minutes and then 800 pi of SOC (SOB 
supplemented with 20 mM glucose) was added. The transformed cells 
were then allowed to recover and express the antibiotic resistance gene 
(ß-lactamase) by incubating at 37°C for 60 minutes with agitation. After
that, the cells were plated out on LB agar plates containing 100 pg /m l 
ampicillin and grown overnight.
35
2.2.11 Rapid screening procedure for recombinant plasmids
The "colony cracking" procedure was used for the screening 
of primary transformants for recombinants (Maniatis et al 1982). A 
single bacterial colony was picked with a toothpick, dispersed in 30 pi 
of lysis solution (50 mM NaOH, o.5% SDS, 5 mM EDTA and 0.025% 
bromocresol green) and the mixture incubated at 65°C for 30 minutes. 
The lysate was then loaded onto a 0.7% agarose gel and electrophoresed 
until the marker dye reached the opposite end of the gel. After 
electrophoresis, the gel was stained with ethidium bromide (lpg/m l) 
for 30 minutes at room temperature. A larger sample plasmid size 
compared to the control plasmid indicated that the sample plasmid 
carried inserted DNA.
2.2.12 Random primer method of labelling DNA probes
The DNA probe labelling procedure was based on the extension 
of random primers bound on the probe template (Feinberg and 
Vogelstein 1983). Gel purified DNA fragment was denatured by heating 
to 100°C for 5 minutes and quenched on ice immediately. A typical 
labelling reaction consisted of 25 ng denatured template, 640 pmoles of 
random hexanucleotide primer (Pharmacia), 20 mM Tris-HCl pH 7.5,
10 mM MgCl2, 10 mM DTT, 200 pM each of dCTP, dGTP and d'iTP, 50 
pCi of [a-32P]<±ATP and 5 U of Klenow fragment of DNA polymerase I
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in a total volume of 50 jil. The reaction mixture was incubated at room 
temperature for 60 minutes, after that the reaction was terminated by 
heating at 100°C for 2 minutes and the unincorporated label removed 
by Sephadex G-50 chromatography (NICK column, Pharmacia) 
according to the manufacturer's instructions. The specific activity of 
the purified probe was determined by liquid scintillation counting and 
usually lay between 108 - 1010 cpm/pg. The labelled probe was heated to 
100°C for 3 minutes before adding it to the hybridisation solution.
2.2.13 Hybridisation to labelled probe
This method was a modification of the procedure described by 
Church and Gilbert (1984). The nylon or nitrocellulose filter membrane 
containing bound DNA was first blocked with non-homologous DNA 
to reduce background activity in a pre-hybridisation solution [0.1 M 
Na2HPC>4 pH 7, 0.5% SDS, 0.1 m g/m l denatured fragmented salmon 
sperm DNA (Sigma) and 0.5% bovine serum albumin (fraction V, 
Boehringer Mannheim)] for at least 30 minutes at 50°C. After this, the 
filter was transferred to the hybridisation solution (0.23 M Na2HPC>4 
pH 7, 50% formamide, 7% SDS and 0.5% bovine serum albumin) and 
incubated at 42°C for 18 hours with gentle agitation. The volume of 
hybridisation solution used was adjusted to suit the size of the filters. 
Typically, a minimal volume of hybridisation solution was used, just 
sufficient to cover the filter in a plastic box.
Following hybridisation, the filter was rinsed briefly with 2X SSC 
(IX SSC = 0.15 M NaCl and 0.015 M trisodium citrate pH 7) at room 
temperature and then washed sequentially in 2X SSC and 0.1% SDS;
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0.5X SSC and 0.1% SDS; and 0.1X SSC and 0.1% SDS, for 15 minutes 
each at room temperature. A final high stringency wash was carried 
out in 0.1X SSC and 0.1% SDS at 60°C for 20 minutes.
The filter was then covered with Saran wrap and 
autoradiography performed by sandwiching the filter and a sheet of 
film (Kodak X-OMAT AR) between two intensifying screens (Cronex 
Lightning Plus, DuPont). Exposure of the film was allowed to proceed 
at -70°C for 18 hours or more. The exposed film was developed using 
an automatic film developer (Kodak X-OMAT M20 Processor).
2.2.14 Polymerase chain reaction
The method of enzymatic amplification of specific DNA 
fragments used here was a modification of the procedure developed by 
Saiki et al. (1988). A typical 20 fil polymerase chain reaction (PCR) mix 
consisted of 10 pg or less of plasmid template or 150 ng of genomic 
DNA template, 20 pmol each of two flanking primers, 200 jiM dNTPs, 
10 mM Tris-HCl pH 9, 50 mM KC1, 1.5 mM MgCl2, 0.1% Triton X-100 
and 1 U of Taq DNA polymerase (Promega). In some instances, the 
concentration of MgCl2 needed to be optimised for certain primer pairs 
in order to obtain maximal yield of products. The requirement for 
MgCl2 also tends to increase with the increasing size of the PCR 
products. The repeated cycling of denaturation, annealing and 
extension reaction was carried out using an automatic thermal cycler 
(Corbett FTS-1) set for denaturation at 94°C for 1 minute, annealing at 
56°C for 1 minute and extension at 72°C for 1 minute. This cycle was
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repeated 30 - 40 times. At the end of the procedure, the PCR products 
were analysed by agarose gel electrophoresis.
2.2.15 RNA preparation
The method of total RNA preparation used here was a 
modification of the guanidinium thiocyanate procedure (Chomczynski 
and Sacchi 1987). To guard against ribonuclease contamination, 
solutions were treated in 0.1% diethyl pyrocarbonate (DEPC) followed 
by autoclaving whenever possible and glassware baked at 180°C for at 
least 18 hours.
Approximately 2 X 107 cells were harvested, washed once with 
phosphate buffered saline (137 mM NaCl, 2.7 mM KC1, 4.3 mM 
Na2HPC>4 and 1.4 mM KH2PO4 pH 7.4) and resuspended in 500 pi of 
lysis solution (4 M guanidinium thiocyanate, 25 mM trisodium citrate, 
0.5% Sarkosyl and 0.1 M 2-mercaptoethanol). The lysate was then 
passed through an 18 gauge needle 6-10 times to break up clumps of 
partially lysed cells and to shear chromosomal DNA. After that, 50 pi of 
2 M sodium acetate (pH 4), 500 pi of water saturated phenol and 100 pi 
of chloroform/isoamyl alcohol (49:1) were added sequentially to the 
lysate. The mixture was vortexed for 20 seconds and incubated on ice 
for 15 minutes. Following centrifugation at 12 OOOxg for 20 minutes at 
4°C, the top aqueous layer was carefully removed, avoiding the cellular 
debris at the aqueous/organic interface, and transferred to a fresh tube 
containing an equal volume of isopropanol. The RNA was allowed to 
precipitate at -20°C for 60 minutes and the RNA pellet collected by
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centrifugation at 12 OOOxg for 20 minutes at 4°C. The pellet was then 
rinsed with 70% ethanol, dried under vacuum and dissolved in water.
2.2.16 Isolation of the mouse IL-5Rcc cPNA using PCR
Total RNA from BCLi(5Bib) cells was prepared by the method 
described in Section 2.2.18. Reverse transcription of IL-5Ra mRNA was 
performed using a modification of the method described by Berchtold 
(1989) in a total volume of 40 pi consisting of 2 pg of total RNA, 40 U of 
RNasin (placental ribonuclease inhibitor; Promega), 400 U of Moloney 
murine leukemia virus reverse transcriptase, 0.2 pg of oligo(dT)i2-i8/
0.1 m g/m l of bovine serum albumin, 0.5 mM dNTPs, 50 mM Tris-HCl 
(pH 8.3), 7.5 mM KC1, 3 mM MgCl2 and 10 mM DTT. The reaction 
mixture was incubated at 37°C for 60 minutes.
PCR was carried out on 2 pi of cDNA from the reverse 
transcription mixture described above using thermostable P f u  DNA 
polymerase (Stratagene), primers MF71 and MF73 and the conditions 
described in Section 2.2.14. The primers MF71 and MF73 were designed 
to amplify the 1.2 kb coding region of the full-length IL-5Ra cDNA. The 
PCR product was subdoned into the Smal site of pUC119.
2.2.17 Genomic library screening using labelled probe
The method of transfer of bacteriophage X  plaques onto 
nitrocellulose filters was a modification of the procedure of Benton 
and Davis (1977). A X EMBL-3 SP6/T7 genomic library prepared from
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BALB/c leukocyte DNA was obtained from Clontech and Escherichia 
coli ED8654 was used as host for propagation of the bacteriophage. 
Plating bacteria were prepared by growing ED8654 overnight in LBM 
broth (1% bactotryptone, 0.5% yeast extract, 0.5% NaCl, 0.2% maltose 
and 10 mM MgSÜ4) at 37°C with agitation. The phage was plated out by 
mixing the plating bacteria with the phage, incubating at 37°C for 20 
minutes, then adding top agarose (0.7% agarose in LBM broth) pre­
warmed to 45°C and the mixture was spread over pre-warmed (37°C) 
agar plates. Two sizes of culture plates were used: 190 mm x 210 mm 
baking dish yielded a maximum of about 2 x 105 pfu/plate and 90 mm 
petri dish yielded 1 xlO4 pfu/plate. A total of about 1 xlO6 plaques was 
screened.
The phage plaques were transferred onto nitrocellulose filters 
(Schleicher & Schuell) by overlaying the culture plates with dry 
nitrocellulose filters. The filters were marked for orientation. After 2 
minutes the filters were removed from the plates and allowed to dry 
briefly. The filters were then placed, plaque side up, on Whatman 3MM 
filter paper soaked with denaturing solution (0.5 M NaOH and 1.5 M 
NaCl) for 2 minutes and then transferred to a neutralising solution (0.5 
M Tris-HCl pH 8.0 and 1.5 M NaCl) for 2 minutes followed by rinsing 
in 2X SSC. The filters were blotted dry and baked in a vacuum oven at 
80°C for 2 hours.
The filters were then hybridised to the labelled mouse IL-5Ra 
cDNA probe as described in Section 2.2.13. Owing to the high density 
plating of the plaques, it was not possible to accurately pick positive 
plaques. Instead, a circular area of about 5 mm in diameter of top 
agarose around the positive plaque was removed, the phage eluted
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and plated at low density. The plaques were then transferred to a 
nitrocellulose filter, processed and hybridised to the cDNA probe as 
before. Positive plaques could now be picked with certainty and were 
put through two more rounds of plaque purification.
2.2.18 Genomic library screening using PCR
This method of library screening was adapted from the method 
described by Bloem and Yu (1990). An EMBL-3 SP6/T7 bacteriophage X  
genomic library prepared from BALB/c leukocyte DNA (Clontech) was 
plated out on 90 mm petri dishes as described in Section 2.2.17. Plaques 
were transferred to 80 mm nitrocellulose filters (Schleicher & Schuell) 
and the phage on each filter was eluted with 2.5 ml of SM buffer 
(50 mM Tris-HCl pH 7.5, 0.1 M NaCl, 8 mM MgS04 and 0.01% gelatin). 
The eluate was extracted with chloroform to lyse host cells. Primers 
MF100 and MF101, which bind specifically to the 3'-untranslated region 
of the mouse IL-5Ra gene and generate a PCR product of 500 bp were 
used. These primers and 5 pi of the cleared eluate were used to detect 
the presence of the 3'-end of the gene using PCR conditions described 
in Section 2.2.14.
The plate giving a positive signal was again overlaid with a
fresh nitrocellulose filter and divided into 36 sections by slicing the 
filter and agar with a scalpel. Plaques from each section were eluted in 
150 pi of SM buffer, extracted with chloroform and 5 pi of cleared eluate 
was used in the PCR screening procedure described above.
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The eluate from the subsection giving a positive signal was 
plated out at low density. The plate was then overlaid with a fresh 
nitrocellulose filter and divided into 8 sections by slicing with a scalpel 
and screened by PCR as above.
The section giving a positive signal usually had 20-30 plaques. 
These plaques were picked individually, eluted and screened by PCR as 
before. The positive plaque was then subjected to two further rounds of 
plaque purification.
2.2.19 Bacteriophage X DNA preparation
The method used here was a modification of the procedure 
described by Sambrook et al. (1989). The purified phage was plated out 
at high density on a baking dish (190 mm x 210 mm) as described in 
Section 2.2.18. The phage was eluted with 30 ml of SM solution (50 mM 
Tris-HCl pH 7.5, 0.1 M NaCl, 8 mM MgS04 and 0.01% gelatin) for 1 
hour at room temperature with gentle agitation. The eluate was 
extracted with an equal volume of chloroform to lyse the cells and 
cellular debris was removed by centrifugation in a Sorvall SS34 rotor at 
10 000 rpm for 10 minutes. The supernatant was treated with DNase I 
(Boehringer Mannheim) and RNase A (Sigma), each at a final 
concentration of 20 pg/ml, at 37°C for 1 hour. The phage was then 
precipitated with 15 ml of PEG solution (30% polyethylene glycol 8 000 
and 3M NaCl) and the mixture held on ice for 1 hour. The phage pellet 
was collected by centrifugation in the SS34 rotor at 10 000 rpm for 10 
minutes at 4°C, and then dissolved in 500 pi of SM. The phage was 
repelleted by ultracentrifugation in the TL-100 table-top ultracentrifuge
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(Beckman) using the TLS-55 swingout rotor at 55 000 rpm for 70 
minutes at 25°C. The pellet was then dissolved in 200 |il of phage lysis 
solution (10 mM Tris-HCl pH 7.5, 1 mM EDTA and 0.2% SDS), 
Proteinase K added to give a final concentration of 100 pg/ml and the 
mixture incubated at 65°C for 30 minutes. Finally, the phage DNA was 
purified by two phenol/chloroform extractions followed by a 
chloroform extraction, precipitated with ethanol, air dried and 
dissolved in 50 jil of TE.
2.2.20 Single stranded DNA preparation
The method used here was based on a modification of the 
procedure described by Garber (1993). Culture of phage M13mpl8 and 
phagemid pBluescript SK(-) clones were different, but the same 
procedure was used for the preparation of single stranded DNA from 
both cultures.
Plaques of recombinant M13mpl8 clones were picked 
individually and inoculated into 2 ml of LB broth containing a 1:50 
dilution of an overnight TGI culture. The infected culture was 
incubated at 37°C for 6 hours with agitation and then harvested. 
Recombinant pBluescript SK(-) clones in DH11S were infected with 
helper phage M13K07 in 2 ml of TB broth (supplemented with 100 
pg/ml ampicillin) and grown for 2 hours at 37°C with agitation, before 
kanamydn was added to a final concentration of 75 pg/ml. The culture 
was harvested after a further 18 hours of incubation at 37°C.
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Cultures of Ml 3 and phagemid were harvested by centrifugation 
at 12 OOOxg for 5 minutes at room temperature. 1 ml of supernatant was 
added to 250 pi of PEG solution (20% polyethylene glycol 8 000, 2.5 M 
NaCl), and the mixture incubated for 15 minutes at room temperature 
to allow the phage particles to precipitate. The phage pellet was 
collected by centrifugation at 12 OOOxg for 3 minutes, the supernatant 
removed completely and the pellet was then dissolved in 40 pi of lysis 
solution (10 mM Tris-HCl pH 7.5,1 mM EDTA and 0.2% SDS) and 1 pi 
of Proteinase K (20 mg/ml) added. The mixture was incubated at 65°C 
for 30 minutes, then 20 pi of 7.5 M ammonium acetate was added and 
the mixture kept on ice for 10 minutes to precipitate protein/SDS 
complexes. The precipitate was removed by centrifugation at 12 OOOxg 
for 5 minutes at room temperature. The DNA in the supernatant was 
then precipitated with two volumes of ethanol, rinsed with 70% 
ethanol, vacuum dried and dissolved in water.
2.2.21 DNA sequencing
The DNA sequencing methodology developed by Smith et al. 
(1986) was utilised for all sequencing work. The dye primer system in 
this method utilises a sequencing primer with a fluorescent dye 
attached to its 5'-end and the reaction is based on a modification of the 
chain termination method of DNA sequencing (Sanger et al. 1977). The 
modified sequencing reaction utilizes the thermal cycling principle 
analogous to PCR but using only one primer. This procedure is 
commonly referred to as thermal cycle sequencing.
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The Ml 3 and T3 dye primer cycle sequencing kits (Applied 
Biosystems) were used according to the manufacturer's instructions. 
Briefly, four separate extension and termination reactions were carried 
out. Each reaction contained four deoxynucleoside triphosphates 
(dNTPs), one dideoxynudeoside triphosphate (ddNTP) and one dye- 
primer. The dye-primer has a different fluorescent dye for each 
reaction. At the end of the sequendng reaction, all four reactions were 
pooled and analysed by electrophoresis. The four different reactions 
were distinguished by their fluorescence emission spectra.
The electrophoresis of sequencing reactions and automated 
sequence data collection were carried out by staff of the Biomolecular 
Resource Facility (JCSMR) using the ABI Automated Sequencer 373A.
2.2.22 - Unidirectional nested deletion of DNA using 
exonuclease III
This method was based on a modification of the procedure 
described by Henikoff (1984). Plasmid DNA was prepared by cesium 
chloride banding (Section 2.2.3) and the amount used for exonuclease 
m  deletion depended on the number of time-points desired. Generally, 
0.2 jig of DNA was used per time-point. The DNA was digested with 
two restriction enzymes. The first restriction enzyme digest generated a 
3-overhang which blocks the activity of exonuclease HI. The second 
restriction enzyme digest generated a 5' overhang or blunt end adjacent 
to the insert from which deletions were to proceed. Exonuclease III 
digestion into the insert thereby becomes a unidirectional process. 
When a suitable 3'-overhang end was not available to protect the
46
vector, a 5-overhang was filled in with a-phosphorothioate dNTPs in 
order to prevent deletion into this end of the DNA.
The linearised DNA was purified by phenol/chloroform 
extraction and dissolved in exonuclease buffer (66 mM Tris-HCl pH 8 
and 0.66 mM MgCh). Exonuclease HI was added to give a ratio of 100 U 
to 1 |ig of DNA. Deletions were carried out at 30°C and terminated at 
30 seconds intervals to give deletion of about 300 bases per interval or 
time-point. Typically, a 2.5 pi of sample was removed at each time 
point and added to a tube containing 7.5 pi of SI nuclease mix (2.4 U SI 
nuclease, 0.34 M NaCl, 1.4 mM ZnSC>4, 6.7% glycerol and 0.04 M 
potassium acetate pH 4.6) kept on ice. After all samples had been taken, 
the tubes were incubated at room temperature for 30 minutes. Then 
1 pi of SI stop buffer (0.3 M Tris base and 0.05 M EDTA) was added to 
each tube and the mixture incubated at 70°C for 10 minutes to 
inactivate the SI nuclease. The samples were then extracted with 
chloroform, precipitated with 2.5 volumes of ethanol and the 
precipitate dissolved in 10 pi of Klenow buffer (5mM Tris-HCl pH 7.2, 
10 mM MgSC>4 and 1 mM DTT). After that, 1 pi of 0.1 U /p i of Klenow 
fragment of DNA polymerase I was added to each sample and the 
mixture incubated at 37°C for 3 minutes, then 1 pi of 0.125 mM dNTPs 
was added and incubation continued for another 3 minutes at 37°C. 
The Klenow enzyme was then inactivated at 70°C for 10 minutes and 
50 pi of ligation mix (0.4 U T4 DNA ligase, 50 mM Tris-HCl pH 7.6,10 
mM MgCl2, 1 mM ATP, 1 mM DTT and 5% polyethylene glycol) added 
and the mixture incubated for at least one hour at room temperature.
For transformation into competent bacterial cells, 10 pi of 
ligation mix was used and transformants were screened for the extent of
of deletion by the rapid screening procedure (Section 2.2.11). The results 
were confirmed by restriction enzyme digestion of plasmid miniprep.
2.2.23 Random fragmentation of DNA by sonication
This method was based on a modification of the procedure 
described by Bankier et al. (1987). The DNA fragment (5 pg) to be 
sequenced was excised from its vector, gel purified and self-ligated to 
generate concatamers. The DNA was then purified by extraction with 
phenol/chloroform, ethanol precipitation, vacuum dried and 
resuspended in 300 pi of sonication buffer (0.1 M Tris-HCl pH 7.5, 0.5 M 
NaCl and 5 mM EDTA). Sonication was performed by immersing the 
probe of the sonicator (Ystrom Sonic Pen) into the DNA solution in a 
microfuge tube and sonicating the solution with 6 x 10 second bursts at 
a power setting of 3. Between each burst, the DNA was kept on ice for 1 
minute to keep it cool. After sonication, the DNA was fractionated on a 
1% agarose gel and DNA corresponding to sizes between 500 to 350 base 
pairs was purified and treated with the Klenow fragment of DNA 
polymerase I to repair frayed ends. The fragments were then subcloned 
into the Smal site of M13mpl8.
2.2.24 Random sequencing
The random sequencing strategy used here was based essentially 
on the procedure described by Bankier et al (1987). The DNA segment 
to be sequenced was fragmented as described in Section 2.2.23 and 
subcloned into M13mpl8. Clones containing fragments of the DNA
were identified by plating transformed host cells (TGI) in top agarose 
containing 250 pg/m l of isopropyl-ß-D-thiogalactopyranoside (IPTG) 
and 250 fig/m l 5-bromo-4-chloro-3-indolyl-ß-D-galactoside (X-Gal). 
White plaques were picked for making single stranded templates 
(Section 2.2.20) which were sequenced (Section 2.2.21).
2.2.25 Directional sequencing following exonuclease 
digestion
Genomic DNA inserts of 18-21 kb in size within X vectors were 
excised by X k o l  digestion, subcloned directly into the X h o l  site of 
pBluescript SK(-) (Stratagene) and large scale plasmid DNA was 
prepared by the method described in Section 2.2.3.
Supercoiled plasmid DNA was double digested with the 
appropriate restriction enzymes and subjected to unidirectional nested 
deletion using exonuclease Eli (Section 2.2.22). Screening for stepwise 
300 bp deletion was carried out (Section 2.2.11) and the size of the 
deletions confirmed by restriction enzyme digestion of plasmid DNA 
and analysis by agarose gel electrophoresis. Single stranded DNA 
templates were then prepared (Section 2.2.20) from selected deletion 
clones and sequenced (Section 2.2.21).
2.2.26 Computer analysis of DNA sequence
Individual sets of DNA sequence data automatically collected by 
the Automated Sequencer 373A (Applied Biosystems) from sequencing
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gels was edited with the editing program, SeqEd (Applied Biosystems), 
to remove vector sequences and any poor quality sequence from the 
3' end. The sequence data were then entered into Staden's sequence 
assembly program (Staden 1982, 1987). This program automatically 
aligns overlapping sets of sequence data into a contiguous sequence 
(contig) which is eventually assembled with other overlapping contigs 
to form a complete and continuous sequence.
A commercial sequence analysis program, Mac Vector (Kodak) 
was used for sequence manipulations, such as restriction mapping, 
searching for open reading frames, or consensus binding sites of 
transcription factors, sequence comparisons using Pustell’s DNA 
homology matrix and translation of DNA sequences into protein.
2.2.27 Genomic Southern analysis
The method used was a modification of procedures described by 
Southern (1975) and Reed and Mann (1985). Five micrograms of 
BALB/c mouse liver genomic DNA (courtesy of Dr Ming-Chiu Fung) 
was digested separately with a five-fold excess of K p n l, EcoRI and 
BamHI in a total volume of 30 pi under conditions recommended by 
the manufacturer (Promega) for 2 hours at 37°C. After digestion, the 
digested genomic DNA was fractionated in a 0.7% agarose gel, stained 
with ethidium bromide (10 pg/m l) and photographed under UV 
illumination. The DNA in the gel was then depurinated w ith 0.25 M 
HC1 for 15 minutes and neutralised with 0.4 M NaOH for 15 minutes. 
After that the DNA in the gel was transferred to a positively charged 
nylon membrane filter(Hybond N+, Amersham) by standard capillary
blotting for 4 hours at room temperature with 0.4 M NaOH as transfer 
buffer.
A 300 bp NaeI fragment about 6.4 kb upstream  of exon 1 of the 
IL-5Ra gene was labelled by the random primer labelling method 
(Section 2.2.12.) and used as a probe for hybridisation to the membrane 
bound DNA (Section 2.2.13).
2,3 Results
2.3.1 Cloning and sequencing of the mouse IL-5Roc gene
The publication of the cDNA sequence (Takaki et al. 1990) of 
IL-5Ra enabled primers to be designed for the isolation of the full 
length cDNA by reverse transcription-polymerase chain reaction 
(RT-PCR) from BCLi(5Bib) cells. The cDNA was used as a probe for 
screening of a BALB/c mouse genomic library.
A total of 1 x 106 plaques from the genomic library was screened 
and the positive plaques characterised by restriction analysis. Four 
overlapping clones: X32, XK, XH and XL (Figure 2.3.2.1) were selected 
for further study. Initially the random sequencing strategy was used, 
where clone XL was fragmented by sonication and subcloned into 
M13mpl8. Sequencing of random subclones resulted in some regions 
having a redundancy of greater than 10 and gaps that could not be 
closed despite sequencing additional subclones. Flence, the directed 
strategy using exo III to make progressive deletions was adopted. Inserts 
from all X clones were excised with Xhol and subcloned into the
X h o l  site of pBluescript SK(-) in two orientations. Designation for the 
plasmid clones was: X32 : p32/87(+) and pSNC5(-); XK: pK12(+) and
pK19(-); XH: pH2(+) and pH3(-); and XL: pL5(+) and pL8(-) [where (+) 
denotes 5'-3' orientation with respect to the upstream T3 promoter and
(-) denotes the reverse orientation]. An example of exonuclease III 
m ediated unidirectional nested deletion is shown in Figure 2.3.1.1. 
Together w ith the rapid screening method for detecting recombinants 
and restriction enzyme digestion of selected clones, it was found that 
inserts up to 18 kb in size could be sequenced using this strategy.
Upon sequencing all four genomic clones, it was discovered that 
the 3'-end of the gene wras missing. A rapid PCR screening strategy 
using primers specific for the 3-end of the gene (MF100 and MF101) 
was used to screen about 2.5 x 105 plaques and isolate this missing 
region of the gene. The result was isolation of two overlapping clones: 
XD and X16 (Figure 2.3.2.1). Both were subcloned into the Xhol site of 
pBluescript SK(-) and designated pD10(+) and pD21(-), and pl6/109(+) 
and pl6/113(-) respectively.
Clones 32, K, H, L and D were sequenced and the sequence data 
assembled by the Staden gel assembly program (Staden 1982) to give 
55 647 nucleotides of contiguous sequence (see appendix for complete 
sequence). This represents the complete sequence of the mouse IL -5Ra 
gene. Comparison of the coding regions of the gene with the published 
cDNA sequence showed the sequence data to be of high quality even 
when only obtained on one strand. However, 60% of the gene sequence 
was obtained on both strands including the upstream region.
M 50 -<■ 1 M
12 kb 
* 8 kb 
 ^5 kb 
v 3 kb 
V2 kb
Figure 2.3.1.1. Agarose gel analysis of exonuclease in  mediated unidirectional nested 
deletion of pSNC5 (18 kb). The plasmid was digested with Notl and
the 5'-protruding end was filled-in with a-phosphorothioate dNTPs 
to protect this end of the plasmid from exonuclease HI digestion. A 
C/fll site adjacent to the insert was then digested with the restriction 
enzyme to provide an exonuclease III susceptible end. Following that,
exonuclease III digestion was carried out at 30°C, each lane from 1-50 
represents successive aliquots taken at 30 seconds time-point at which 
the digestion was terminated [M = lkb size marker (BRL)].
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When the exonic sequences (determined on both strands) were 
compared with that of the cDNA (Takaki et al. 1990), three point 
mutations were detected. One point mutation in exon 3 (C -> T), one in 
exon 7 (GTC -> GTT) and one in exon 8 (GAA -> GAG). Exon 3 is not 
part of the coding region and the point mutations in exon 7 and 8 did 
not result in amino add changes. These changes were therefore 
considered to be conservative. There were also point mutations in the 
introns which were detected at the region where two genomic clones 
overlap. These changes were probably due to allelic differences or gene 
polymorphism between individual mice, since the genomic DNA used 
for construction of the library was derived from more than one mouse.
2.3.2 Structure and organisation of the mouse IL-5Ra gene
Comparison of the cDNA and genomic sequences revealed that 
the mouse IL-5Ra gene was organised into 13 exons and 12 introns 
(Figure 2.3.2.I.), spanning 38.6 kb between the first exon and the 
polyadenylation site. In addition, 11.1 kb of sequence upstream of the 
first exon and 5.9 kb of sequence downstream of the polyadenylation 
site was also characterised. Exons 1, 2 and 3 were not translated. Exon 4 
contained the signal peptide and each exon pair: 5 and 6; 7 and 8; and, 9 
and 10; encoded one fibronectin type Hi-like domain of the extracellular 
portion of the receptor. One pair of conserved cysteines of the class I 
cytokine receptor superfamily was found in exon 7 and another pair in 
exon 8. The WSXWS motif was located in exon 10. The first serine 
residue in this motif is actually a glycine in the mouse IL-5Ra gene. 
Exon 11 encoded the transmembrane domain and exons 12 and 13 
made up the cytoplasmic domain. The proline-rich region conserved
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between members of the class I cytokine receptor superfamily and 
referred to as 'box 1' (Murakami et al. 1991) was found in exon 12. Exon 
13 also encoded the 3'-untranslated region of the mRNA in addition to 
the cytoplasmic domain.
All exon-intron boundaries contain splice donor and acceptor 
sequences that conform to the 5'-GT and 3'-AG rule for introns 
(Breathnach and Chambon 1981) as shown in Table 2.3.2.I. The 
generation of two soluble forms of IL-5Ra reported earlier (Takaki et al. 
1990) could be explained by alternative splicing. The secreted soluble 
form arose from the splicing together of exon 10 and 13, and the 
removal of exon 11 and 12. Another soluble form was generated by the 
removal of exon 11, also through alternative splicing.
Base composition analysis using the MacVector package revealed 
a 1 kb region, 6.5 kb upstream of exon 1, that has a GC-content of about 
80% (Figure 23.2.2.) and clusters of sites for restriction enzymes BssHII, 
Eagl, SacU, NaeI, Narl and Smal (Table 2.3.2.2J. Clustering of these 
methylation-sensitive rare cutter restriction sites has been used as one 
of the criteria for identifying CpG islands (Bickmore and Bird 1992).
The lack of methylation of these CpG dinucleotides in highly GC-rich 
regions has been shown to be associated with the presence of genes or 
transcription units (Brandeis et al. 1993; Tate and Bird 1993).
2.3.3 Genomic Southern analysis
To verify that the 5-end of the cloned gene has not undergone
rearrangement during the preparation of the genomic library, a 
genomic Southern blot was prepared by digesting BALB/c mouse liver
Table 2.3.2.1. Exon-intron organisation of the mouse IL-5Ra gene.
Exon sequences are in capital letters and intron sequences are 
in lowercase letters.
No.
Exon
size(bp)
5'-splice donor Intron
size(bp)
3-splice acceptor Phasing 
of intron
l 191 TGTACCAAG gtgag 3241 ttaag GATCTAACC
2 62 CACAGCCCC gtaag 441 tcaag CTGTTTATT
3 37 CTTTTCCAG gtatt 724 aacag TATTCGGCT
4 85 AAA AAG T gtaag 1468 aatag TT TTA CTT l
5 146 AA GAC GAA gtaag 1351 tttag TAT GAT AC 0
6 139 CCA CCA G gtaaa 2625 cctag GA TCT CCT l
7 154 TAC TAC AG gtcag 76 tttag G TTT GGT 2
8 188 GCC ATT G gtaag 2250 cctag AC CAA GTG 1
9 146 CAC ATT CAG gtaag 3722 tttag AAG GAA AAA 0
10 139 TAT GTG G gtgag 15058 accag GA AAG GAA 1
11 94 TGC AGA GT gtagg 993 gtcag G TGT CAT 2
12 85 GAA TAT GAG gtaat 3150 tgcag AAA CCT TCG
8413 ACG TTT TGA
100
8 0 -
6 0 -
% GC
40
2 0 -
0 -
Figure 2.3.2.2. Base composition analysis of the mouse IL-5Ra gene nucleotide 
sequence. A region between 35 kb and 4.5 kb from the 5'-end of
the gene (indicated by arrows) showed a GC content of about 80%. 
Such GC-rich regions typically contain CpG islands which are 
indicative of the presence of genes.
lu'l'iIM'lWWHIH^ rFTrfr'r'PT'^ W1 WWfWI'll
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10000 20000 30000
Mouse IL-5Ra gene
40000 50000 bp
Table 2.3.2.2. Clusters of GC-rich restriction enzyme sites in the 55.6kb mouse IL-5Ra 
gene. Clustering of these methylation-sensitive rare cutter restriction 
enzyme sites is indicative of the presence of CpG islands in the 
mammalian genome.
Enzyme #Cuts Positions
BssHII 4 4063 4325 4344 4883
EagI 2 4460 4800
Nael 5 3921 4287 4460 4504 4804
Narl 3 4076 4270 4289
Sacll 5 3842 4082 4278 4311 4360
Smal 7 3561 3571 4047 4181 4321
5167 9698
Sequence Range: 1 to 55647 bp
genomic DNA separately with Bam¥Ll, EcoRI and Kpnl restriction 
endonucleases and fractionated. The blot was probed with a 300 bp NaeI
fragment derived from 5'-end of the cloned genomic DNA (Figure 
2.3.3.1). The B a m H l digest gave the expected 5.4 kb fragment, but the 
size of the EcoRI fragment could not be estimated because only one 
EcoRI site flanking the probe was known and the other site extended 
beyond the cloned DNA. An 8.5 kb fragment was expected from the 
K p n l digest but a fragment of about 4.5 kb was obtained instead. On 
closer examination of cloned sequences around this region, a single 
base substitution at position 7687 from the 5-end could indeed 
generate a K p n l site and give rise to the observed 4.5 kb fragment. 
Hence, the restriction fragment length polymorphism is likely to be 
due to gene polymorphism. To further confirm this observation, PCR 
was used to specifically amplify this region because the PCR primers are 
not sensitive to base substitutions provided the mismatches are not at 
the 3'-end of the primers. Two pairs of primers, CL17/CL21 and 
CL18/CL19, were designed for this purpose [see Figure 2.3.3.2.(A)]. The 
genomic clone containing the 5-end of the gene, p 32/87, and genomic 
DNA derived from BALB/c mouse liver were used as templates for 
PCR. Both templates generated PCR products of the expected size, 
thereby confirming that this region in the genomic clone is identical to 
that of the normal gene.
The integrity of the internal genomic clones was confirmed by 
virtue of their overlapping ends and the integrity of the 3'-end of the 
cloned gene was verified by its homology to the 3'-untranslated region 
of the reported cDNA.
^  -£• 
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Figure 2.3.3.1. Genomic Southern analysis of mouse genomic DNA. Five 
micrograms of genomic DNA derived from liver of Balb/ c 
mice was digested with BamHI, EcoRI and Kpnl; fractionated 
on a 0.7% agarose gel; transferred to a nylon filter; and 
hybridised with a labeled 300 bp Nael fragment from the
5'-end of the IL-5Ra gene as the probe.
A.
~  r
1 kb 2
1 kb
CL19 CL21 >
3 4 —  5 
probe
• I r
6 7 8
CL18
5.4 kb BamHI fragment
Exon 1
4
CL17
4.5 kb Kpnl fragment
Prim ers PCR products (bp)
CL18/CL19 1524
CL17/CL21 2121
B . .5?
i\-s>
i— I
M 1 2 3 4 5 6
Lane No.
1.4 = No template control
2.5 = genomic clone (p32/87)
3.6 = genomic DNA
M = 1 kb marker (BRL)
Figure 2.33.2. Verification of the integrity of the 5'-end of the m ouse IL-5Ra 
gene by PCR of genomic clone (p32/87) and genomic DNA 
derived from liver of Balb/ c mice. (A) Map of the location of 
the NaeI fragm ent used as a probe, and BamHI and Kpnl 
fragm ents detected by the probe in the Southern blot (see 
figure 2.3.3.1) and positions of PCR prim ers on the 5'-end of 
the gene; (B) agarose gel analysis of the PCR products.
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The above genomic Southern analysis and genomic PCR results 
confirmed that the cloned mouse IL-5Ra gene is essentially identical to 
the normal chromosomal gene and is not rearranged.
2.3.4 Comparison of human and mouse IL-5Ra gene
Comparing the human (Tuypens et al. 1992) with the mouse 
IL-5Ra gene (Figure 2.3.4.1) revealed a significantly high degree of 
conservation in structure and organisation of the two genes with the 
exception of the hum an gene having an extra exon downstream of exon 10 
(designated exon 'S'). Both genes have three untranslated exons at the 
5'-end, followed by seven exons coding for the extracellular dom ain (exon 
4-10), one exon coding for the transmembrane domain (exon 11) and 
two exons coding for the cytoplasmic domain (exons 12 and 13). 
Noteworthy is the conservation of the size of intron 7 which is 79 and 
76 bp in human and mouse respectively. Other introns are less similar.
While the sizes of the 5'-untranslated exons are not well 
conserved, the remaining coding exons are mostly identical in size in 
the human and mouse genes (see Table 2.3.4.1). The coding region has 
been reported earlier to share 70% homology at the amino acid level 
between the two species (Tavernier et al. 1991; Murata et al. 1992).
Sequence similarity comparison between human and mouse 
outside the coding region was restricted to 561 bp of sequences 
upstream of the transcription start site of the human IL-5Ra (Sun et al. 
1995) due to the lack of availability of sequence further upstream. 
Alignment of this region using the COMPARISON program within the
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Exon No. Exon size (bp) 
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Functional domains
1 36
s
191
 ^Untranslated exons
I
2 142 62
3 68
37
4 85 85 Signal Peptide
5 146 146
' Fibronectin type EH
/
6 139 139
7 154 154
>
Fibronectin type EH 
" [conserved cysteines]
/
8 188 188
9 146 146 Fibronectin type EH 
* [WSXWS]
/
10 139 139
S 84 -
11 97 94 Transmembrane
12 85 85
Cytoplasmic exon 
[box 1 (proline-rich)]
13 87 84 Cytoplasmic exon
Table 23.4.1. Comparison of the sizes of exons of the human (Tuypens et al.
1992) and mouse IL-5Ra gene. The sizes of the coding exons 4 
to 13 are very well conserved. The human species, however, 
has an extra exon, designated 'S’, that is responsible for the 
generation of the soluble form of the receptor protein.
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Genetics Computer Group (GCG) package (Devereux et al. 1984) showed 
that the region covering position -314 to -561 bp upstream of the 
transcription start site of the human IL-5Ra gene has 68% homology 
with the region covering 160 to 407 bp upstream of exon 1 of the mouse 
gene (Figure 2.3.4.2). This region of the mouse gene covers position 
-147 to -393 relative to the transcription start site of the gene (Chapter 
3). Within this region is a consensus binding site for transcription 
factor NF-IL-6. The significance of this region with respect to gene 
regulation will be investigated further in Chapter 4. Computer-assisted 
screening of the 5'-untranslated sequences for consensus binding sites 
of other transcription factors will also be covered in Chapter 4.
2.3.5 Computer-assisted sequence similarity searches
The 55.6 kb of cloned genomic sequences was broken down into 
16 blocks of sequences and compared with sequences in the Genbank, 
EMBL, sequence tagged site and expressed sequence tag databases using 
the BLASTN algorithm (Altschul et al. 1990). This comparison 
identified numerous repetitive elements summarised in Table 2.3.5.1. 
which are annotated in the complete nucleotide sequence of the IL-5Ra 
gene in the appendix.
Further sequence similarity analysis was carried out in an 
attempt to uncover novel sequences within the cloned genomic 
sequences by searching similar databases with other BLAST algorithms 
such as BLASTX, TBLASTN and TBLASTX. The result was the 
identification of a region between 6.2 to 7.0 kb upstream of exon 1 that 
has high homology to the human and Caenorhabditis elegans
human
mouse
human
mouse
human
mouse
human
mouse
human
mouse
human
mouse
-314 ACAGTTATCAGATAATGGCTATCTGGACGAGAGATTCTTTCGTTTGACAG -363
I I I I I I I I I I I I I I  I I I I I I I I  I I I I I I I I I407 AGAGTTCTCAGATTGTGG.TATATGAAGGAGGCAAGCCTTTGTCAGTGAA 359
-364 CAGTTTGGTTGTTGGGAGTTCCAGTTCAGCTCCTGCACA....GTTGCTC -409 
I I I I I I I I I I  I I I I I I I I I  I I I I I I  I I 
358 CAGTATGATCACTAAGA.CTCTAGTGTGGGCCCTCTCTAATGGGTTGCTC 310
-410 T.GTACAAATCCTCCTCCATATTTGCTTAGAGAAAACGTGTTGCCATCCC -458
I I I I I I I I I I I I I I I I I I I I I I I I I I
30 9 TCTTGGGAATCTTCTTCCA.......AAGAGCAGTTGTGTGGTCTTTCC 2 68
-459 ATCATGAAGGAAGCTGCCTGAGAGTTTTTAACCATTACAGCCGTGATGAT -508
II II I I I I I I I II I I I I I I I I I I I I I I I I I I I I I
267 ATTGTAAGAGAAACTGCAGGTGTCTTCTTAACCATGACAGTTCTGATGAT 218 
NF-IL-6. . . . .
-509 GAAAGAGTGAAGAA.CCGCCTCTAAGTTAAA...AAGTGCACCCAGAGAT -554
I I I I I I I I I I I I I I I I I I I I I I I I I I  I I  I I I I I I I I I I I
217 GAAAGAGTAAAGAACCCGCCTTAAAGTCAAACACCAGTGCACCCAGAAAG 168
-555 AAGGTTC -561
I I I I167 TAGATGC 160
Figure 2.3.4.2. Sequence alignment of the human (Sun et al 1995) and the mouse 
IL-5R.CX sequence 500 bp upstream of exon 1 showing 68% identity.
Table 2.3.5.1. List of repetitive elements in the IL-5Ra gene uncovered by
sequence similarity comparison with databases using the 
BLASTN algorithm.
Position Description of repetitive element
7128 - 7806 Mouse LINE1 repetitive element
10624-10675 AC dinucleotide repeats
11715-11790 Repetitive element resembling hum an microsatellite DNA 
UT7972
14716 -14737 Mouse R repetitive element
14757 -14821 Mouse poly GT repeats
17790 -17833 AC dinucleotide repeats
17835-17878 CT dinucleotide repeats
18537-18666 Mouse B1 repetitive element
20068 - 20200 Mouse B1 repetitive element
22899 - 23068 Repetitive element resembling rat SA2CA microsatellite
25229 - 25268 AC dinucleotide repeats
25918 - 26617 Mouse LINE1 repetitive element
26698 - 26735 Mouse poly GT repeats
27089 - 27212 Mouse D3nds3 microsatellite DNA
31996 - 32092 CTT trinucleotide repeats
33018 - 33063 AC dinucleotide repeats
34613 - 34828 Mouse B2 repetitive element
37768 - 37821 CT dinucleotide repeats
39228-39266 Mouse poly GT repeats
40993 - 41173 Mouse B1 repetitive element
47826 - 48012 Mouse B1 repetitive element
49319-49568 Mouse lim l2 repetitive element
49587 - 49710 Mouse R repetitive element
50998 - 51118 Mouse B1 repetitive element
53588 -53970 Mouse MT repetitive element
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fork head domains. Sequences from all three spedes were translated 
into six possible reading frames (Fickett 1982) and further analysed with 
the aid of Pustell's protein matrix (Pustell and Kafatos 1982) within the 
Mac Vector package. The most significant matches were aligned using 
the PILEUP program within the Genetics Computer Group (GCG) 
package (Devereux et al 1984) and shown in Figure 2.3.5.I. The 
alignment shows that the mouse and C. elegans share 67% identity, 
and, mouse and human share 84% identity at the amino add level.
This level of homology is highly significant. Such conservation between 
distantly related species implies the proteins have functional importance.
It seems likely therefore that there is a gene encoding a member 
of the forkhead family of transcription factors immediately upstream 
of the mouse IL-5Ra gene. The region is within the highly GC-rich 
region identified in Section 2.3.2. Expression of this gene was not 
detected in BCLi(5Bib) cells by Northern analysis indicating no obvious 
connection with IL-5Roc gene expression. Also expression was not 
detected in a variety of adult mouse tissues (submaxillary gland, brain, 
heart, lung, liver, spleen and testis) (results not shown). This may 
imply expression of the fork head gene homologue during 
development although this obviously requires further investigation.
2.4 Discussion
The full-length mouse IL-5Ra gene has been successfully isolated 
and completely sequenced in this study. It consists of 13 exons spanning 
38.6 kb between the first exon and the polyadenylation site. In addition,
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11.1 kb of upstream sequence and 5.9 kb of sequence beyond the 
polyadenylation signal sequence were determined. The total 
coverage of 55 647 bp was fully determined on one strand and about 
60% of the complementary strand was also sequenced. With the 
exception of conservative base substitutions that do not alter amino 
acid sequence, the sequence of the exons is identical to the reported 
cDNA (Takaki et al 1990). This study represents the first report on the 
full-length mouse IL-5Ra gene and its complete nucleotide sequence. 
An earlier report on the same gene (Imamura et al 1994) only described 
partial characterisation of the gene as the isolated gene was not full 
length and was only partially sequenced.
Comparison of the gene with the published cDNA shows that 
exons 1, 2, and 3 are not translated, exon 4 encodes the signal peptide, 
the extracellular domain consists of exons 5 to 10, exon 11 encodes the 
transmembrane domain and the cytoplasmic domain consists of exons 
12 and 13. Exon 13 also encodes the 3'-untranslated region. This 
genomic structure helps to explain the mechanism for the generation 
of the soluble receptor protein reported earlier (Takaki et al 1990). This 
protein arises from the removal of exon 11 and 12 by alternative 
splicing. Another transcript with the potential of coding for another 
form of soluble receptor protein has been identified but the protein 
could not be detected. This transcript results from the removal of exon 
11 also by alternative splicing.
The genomic structure of the mouse IL-5Ra gene is very similar 
to its human counterpart (Tuypens et al 1992). However, there is a 
notable difference in that the human gene has an extra exon 
(designated exon 'S' in Figure 2.3.4.I.) located upstream of the exon
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coding for the transmembrane domain. This exon is responsible for the 
generation of the soluble receptor protein by causing translational 
termination if not removed by alternative splicing (Tavernier et al.
1992; Tuypens et al. 1992). A similar mechanism for the generation of 
the mouse soluble IL-4 receptor has been reported (Wrighton et al 
1992). RT-PCR on BCLi(5Bib) cells, a mouse cell line that expresses the 
IL-5Ra gene, and sequence similarity comparisons could not establish 
the existence of a similar transcript in the mouse (result not shown). In 
addition, yet another form of the human soluble receptor can be 
generated by not splicing out the intron upstream of exon S.
Translation of this intron again results in translational termination 
(Tavernier et al. 1992; Tuypens et al. 1992). Thus, it appears that 
although the genomic structure is largely similar in mouse and 
human, each has evolved a different mechanism for the expression of 
the soluble receptor protein. The availability of the complete gene 
sequence will facilitate analysis of any additional transcripts which may 
be identified.
Consistent with it being a member of the class I cytokine receptor 
superfamily, the genomic structure of the mouse IL-5Ra gene shows 
considerable homology with other members of the family. These 
include hIL-5Ra (Tuypens et al. 1992), mIL-3Ra (Miyajima et al. 1995), 
AIC2A/AIC2B (Gorman et al. 1992), mIL-4R (Wrighton et al. 1992), 
m and hIL-7R (Pleiman et al. 1991), hIL-9R (Chang et al. 1994), m and 
hEPOR (Winkelman et al 1990; Yousouffian et al 1990), hIL-2Rß 
(Shibuya et al. 1990) and hGHR (Godowski et al. 1989). The cytokine 
receptor motif, consisting of two pairs of cysteines and a WSXWS box, 
is encoded by four exons in all members of the superfamily, with 
exception of mIL-3Ra and hIL-2Rß which have five exons. The first and
second of these exons encode one pair of conserved cysteines each, and 
the fourth exon encodes the WSXWS motif. One fibronectin type 
Hi-like domain is formed by the first and second exon and another 
fibronectin type IE-like domain is formed by the next two exons. The 
human and mouse IL-5Ra have two additional exons that encode for a 
third fibronectin type El-like domain at the amino terminus (Figure 
2.3.4.1.).
Another conserved feature of the cytokine receptor family is the 
intron-exon boundaries around the exons encoding the cytokine 
receptor motif. In the mouse IL-5Ra gene, intron 6 lies between the 
first and the second nucleotide of a codon (phase 1 intron), intron 7 is 
between the second and third nucleotide of a codon (phase 2 intron), 
intron 8 is another phase 1 intron, intron 9 lies between codons (phase 
0 intron) and intron 10 is yet another phase 1 intron (see Table 2.3.1.1). 
This pattern of 1-2-1-0-1 phasing of introns between exons of the 
cytokine receptor motif where phase 1 introns separate the fibronectin 
type IE domains, as predicted by Patthy (1990), is found to be conserved 
in the genes of members of this family. These include the hIL-5Ra 
(Tuypens et al. 1992), mIL-3Ra (Miyajima et al. 1995), mIL-4R 
(Wrighton et al. 1992), hIL-9R (Chang et al. 1994), h and mEPOR 
(Winkelman et al. 1990; Yousouffian et al. 1990), hIL-2Rß (Shibuya 
et al. 1990) and hGHR (Godowski et al. 1989). These conserved features 
provide support for the hypothesis that the members of this family 
may have evolved from a primordial gene (Patthy 1990).
Base composition analysis of the mouse IL-5Ra gene uncovered 
a 1.0 kb region, situated 6.5 kb upstream of exon 1, which has a GC 
content of about 80%. This level of GC content and the clustering of
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methylation-sensitive rare cutter restriction enzyme sites is diagnostic 
of this region having CpG islands. These islands are known to be free 
of methylation compared to the heavily methylated non-island CpGs 
in the rest of the genome. CpG islands have been found at the 5'-region 
of a number of housekeeping and tissue-specific genes, making them 
useful markers in physical mapping of the genome. Methylation of 
these islands is known to result in transcriptional repression and 
inactivation of genes associated with these islands (reviews by Bird 
1987; Brandeis et al. 1993).
In the past, non-coding and intronic sequences have been 
considered as 'superfluous or junk DNA' because these sequences 
have been observed to have little conservation between species 
compared with their associated exons, and hence, are perceived to be 
non-functional. However, this perception is beginning to change as 
evidence accumulates that non-coding DNA may be of functional 
importance. For example, inclusion of introns has been shown to 
enhance the expression of transgenes in mice (Brinster et al. 1988). Also 
several examples of conservation of intronic sequences between species 
have been reported recently. For example the human and mouse T-cell 
receptor genes share 71% homology over 100 kb even though only 
about 6% of this DNA is coding sequence (Koop and Hood 1994). In 
addition, the single intron of the oligodendrocyte-myelin glycoprotein 
gene has an overall 75% homology between human and mouse (Mikol 
et al. 1993). Regulatory elements have also been found in the 
3-untranslated regions of the mRNA lin-14 (Wightman et al. 1993) 
and tra-2 (Goodwin et al. 1993) of C. elegans. Furthermore, statistical 
techniques borrowed from linguistics were recently used to analyse 
non-coding DNA (Mantegna et al. 1994). This study found that non-
coding sequences could not be completely random because the chance 
of finding a particular base at a given point in a sequence showed weak 
statistical dependence on nearby bases and that non-coding regions are 
more similar to natural languages than coding regions. These findings 
suggested the possibility of non-coding regions carrying biological 
information. As such, rather than being considered a catalogue of 
useful coding regions interspersed with useless junk, each 
chromosome is begining to be viewed as a complex information 
organelle which carries out a variety of functions including storage, 
duplication, expression and evolution of information (Mattick 1994; 
Nowak 1994).
The non-coding and intronic sequences of the mouse IL-5Ra 
gene were determined for the above reasons. One approach to detecting 
important sequences in these regions is to conduct sequence similarity 
comparison with sequences in databases such as GenBank, EMBL, 
expressed sequence tags and sequence tagged sites databases using 
algorithms such as BLAST (Altschul et al. 1990). These comparisons 
can occasionally point out the existence of functional and/or regulatory 
elements through the identification of highly conserved sequence 
blocks. The result of these comparisons was the identification of 
numerous repetitive elements (Table 2.3.5.1.).
In addition, sequence similarity comparisons also found an 
interesting region 6.2 to 7.0 kb upstream of exon 1 that has 84% identity 
to a new member of the human fork head family of transcription 
factors (Galili et al. 1993) and 67% identity with the C. elegans homolog 
(Kohara et al. 1994) at the amino acid sequence level (Figure 2.3.5.2.). 
The fork head family is a diverse family of transcription factors
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involved in tissue-specific and developmental gene regulation. 
Members of this family of transcription factors share a common DNA 
binding motif, the fork head domain, which has a structure similar to 
the helix-loop-helix class of transcription factors (Weigel and Jackie 
1990). This level of homology in the fork head amino acid sequence 
between species is highly significant and is restricted to the fork head 
domain. This suggests the existence of a member of the fork head 
family of genes upstream of the mouse IL-5Ra gene.
Sequence similarity comparison of intronic sequences of the 
mouse IL-5Ra gene, including the 15 kb intron 10, with the databases 
was also carried out, but did not uncover any novel or functional 
elements other than repetitive elements. This does not, however, 
mean that these sequences are devoid of important elements because 
early assumptions of non-functionality of introns meant that most 
introns remain unsequenced, thereby making pattern recognition 
difficult. The discovery of novel or regulatory elements is likely to 
depend on the development of highly sensitive screening or assay 
procedures.
Significantly, the isolation and complete sequence determination 
of the mouse IL-5Ra gene in this chapter will provide the basis for 
detailed analysis and manipulation of this gene in later chapters and in 
the future.
CHAPTER THREE
DETERMINATION OF THE 
TRANSCRIPTION INITIATION AND 
POLYADENYLATION SITE OF THE 
MOUSE IL-5RCX GENE
3.1 Introduction
Central to the molecular characterisation of a gene is the analysis 
of RNA transcribed from its genomic sequence. This analysis is a 
necessary pre-requisite to elucidating the regulatory mechanisms of the 
gene. The majority of eukaryotic genes are regulated at the level of 
transcription (Maniatis et al 1987; Herschbach and Johnson 1993).
Other types of regulation do occur, however, and may involve RNA 
processing (splicing), RNA transport, mRNA degradation and 
translation.
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The analysis of RNA initially involves isolating RNA from 
various tissues or cells and the detection of the transcript of interest by 
Northern analysis. Alternatively, reverse transcription of the RNA 
into cDNA followed by its detection by polymerase chain reaction using 
specific primers (RT-PCR) can be used. The transcript can be further 
characterised by mapping its 5' and 3'-termim using primer 
extension, SI nuclease analysis, ribonuclease protection assay and 
anchored-PCR. These techniques furnish information on the structure 
and steady state levels of the transcript. Where gene expression is 
inducible, the rate of transcription can be determined by the nuclear 
run-off technique.
3.1.1 Choice of RNA isolation
The first step in analysing gene transcription is to isolate intact 
and undegraded messenger RNA. The isolation of undegraded RNA 
from cells and tissues involves three steps: (1) cell lysis and inhibition 
of endogenous nucleases, (2) deproteinisation of the RNA sample, and 
(3) physical separation of the RNA from other components of the 
homogenate (Sambrook et cd. 1989; Ausubel et al. 1994).
To release RNA from intact cells, detergents, chaotropic agents or 
physical disruption are commonly employed. Inhibitors such as 
heparin, placental ribonuclease inhibitor or ribonucleoside-vanadyl 
complexes are often added to protect the RNA from degradation. 
However, when chaotropic agents such as guanidinium salts are used 
such inhibitors are not required. This is because guanidinium salts are 
strong protein denaturants that they effectively combine the first two
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steps of RNA isolation. Denaturation is enhanced by including 
reducing agents, like 2-mercaptoethanol or dithiothreitol, to 
break down intramolecular protein disulphide bonds. This method 
isolates total cellular RNA because subcellular fractionation is not 
possible under conditions of complete cell disruption. Milder 
procedures use non-ionic detergent to break open the plasma 
membrane, leaving the nuclei intact, enabling cytoplasmic RNA to be 
recovered after brief centrifugation to remove the nuclei (Chirgwin 
et a l 1979; Ausubel et al. 1994).
With either procedure, further deproteinisation can be 
accomplished by proteinase K digestion or acid phenol extraction. 
Extraction with acid phenol has the added advantage of removing the 
contaminating cellular DNA.
Physical separation of RNA from other macromolecules of the 
homogenate is achieved by selective precipitation or selective 
sedimentation. Selective precipitation is based on solubility using 
ethanol or isopropanol with lithium chloride. Selective sedimentation 
by ultracentrifugation through a dense solution of cesium chloride is 
based solely on the high buoyant density of RNA compared with other 
cellular macromolecules (Glisin et al. 1973). This method of 
precipitation is very useful for removing undissolved tissue and 
recovery of RNA from very dilute solutions.
Most methods of RNA isolation are based on the basic principles 
described above. The method developed by Chomczynski and Sacchi 
(1987) which uses guanidinium thiocyanate/detergent for cell lysis and 
add phenol extraction for deproteinisation and removal of DNA was
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chosen for the work described here because it involves fewer 
manipulations making the procedure faster and simpler to perform. 
These features also facilitate the handling of a large number of samples 
and higher yields of RNA.
3.1.2 Detecting specific transcripts
Having isolated RNA from the cells or tissues of interest, the 
presence of specific transcripts may be detected by Northern 
hybridisation or reverse transcription-polymerase chain reaction 
(RT-PCR) analysis.
In Northern analysis, RNA is fractionated by agarose gel 
electrophoresis under denaturing conditions. Such conditions are 
necessary to disrupt secondary structures formed by intramolecular 
base pairing of single stranded RNA molecules and results in more 
accurate size separation of the individual RNA molecules. The three 
types of denaturants in RNA gels are formaldehyde, glyoxal/DMSO 
and methylmercuric chloride. The last reagent is not widely used due 
to its highly toxic nature. Following gel electrophoresis, fractionated 
RNA is transferred to a nitrocellulose or nylon membrane and 
immobilised. The resulting blot can then be hybridised with an 
appropriate labelled probe (Alwine et al. 1977; Lehrach et al. 1977). 
Formaldehyde denaturation was used for the work described in this 
thesis because of its convenience and reliability, and because unlike the 
glyoxal method, this procedure does not require buffer recirculation 
during electrophoresis when the formaldehyde is only present in the 
agarose gel.
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A potentially more sensitive method for detecting an RNA 
transcript of interest is RT-PCR analysis. In this procedure the 
transcript is converted to cDNA by reverse transcriptase primed by 
oligo(dT), random or specific oligonucleotides. The cDNA is then 
enzymatically amplified by a heat-stable polymerase through repeated 
rounds of denaturation and extension with a pair of specific flanking 
primers. Specific amplification of the transcript generates a product of 
known size detectable by agarose gel analysis (Frohman et al. 1988). 
Confirmation can be made by sequencing the product or by Southern 
hybridisation.
3.1.3 Mapping transcriptional initiation sites
Several methods are available for determining the termini, 
structure and steady state levels of RNA. They are primer extension,
SI nuclease analysis, ribonudease protection assay and anchored-PCR. 
These methods are commonly used to map the 5’-terminus of mRNA. 
It is desirable to use more than one method because they are 
complementary and each method is subject to a different type of 
artifact. Therefore, results from one method serve to confirm or 
validate results from another.
Primer extension is based on the extension of a radioactively 
labelled primer by reverse transcriptase using the RNA as template. 
The primer is usually designed to anneal about 100 bases downstream 
from the predicted 5'-terminus of the mRNA template and extended 
to the end of the template. The size of the extension product is then 
measured by comparing with a size marker using denaturing
polyacrylamide gel electrophoresis and autoradiography. The length of 
the extension product reflects the distance between the primer binding 
site and the 5'-terminus of the mRNA. The information can then be 
related back to the genomic sequences to identify the transcription 
initiation site (Sambrook et al. 1989).
Another method for mapping mRNA is the ribonuclease 
protection assay. This assay is based on the hybridisation of a single 
stranded RNA probe to the mRNA under study and the degradation 
of the single stranded RNAs with ribonuclease. The duplex formed 
by the probe and mRNA is resistant to ribonuclease degradation. The 
protected probe can then be separated from the mRNA and sized by 
denaturing polyacrylamide gel electrophoresis. Similar to primer 
extension studies, the size of the protected probe identifies the site of 
transcription initiation of the gene (Zinn et al. 1983; Melton et al. 1984).
SI nuclease analysis is similar in principle to the ribonuclease 
protection assay except that single stranded DNA probe is used and SI 
nuclease replaces ribonuclease for the degradation of the unprotected 
probe (Berk and Sharp 1977). However, the ribonuclease protection 
assay has significant advantages over the SI nuclease assay: RNA 
probes are easier to generate and can be labelled to very high specific 
activity, treatment of RNA:RNA duplexes with ribonuclease is more 
reliable and reproducible than treatment of DNArRNA duplexes with 
SI nuclease which can be sensitive to temperature and enzyme 
concentration. For these reasons, the ribonuclease protection assay was 
preferred over SI nuclease analysis for the RNA mapping study 
described in this chapter.
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Anchored-PCR is a procedure for amplifying sequences between 
a defined internal site and an unknown site on a template. The unique 
sensitivity and specificity of this procedure facilitates the isolation and 
characterisation of unknown ends of low copy number transcripts. 
When multiple bands appear on an autoradiograph of primer 
extension or ribonudease protection assay, it is often difficult to rule 
out spurious results even with proper controls. However, the products 
of anchored-PCR can be subdoned and sequenced to provide a definite 
answer.
In the anchored-PCR approach, the mRNA is converted to 
cDNA by reverse transcription using primers specific for the region of 
interest. Alternatively, random primers or oligo(dT) may be used to 
generate a whole spectrum of cDNAs. Following cDNA synthesis, a 
homopolymeric tail or oligonucleotide, called the anchor, is added to 
the 5’-end of the cDNA. The tailed cDNA is then amplified by PCR 
using a primer which anneals to the known region of the cDNA and 
another primer which anneals to the anchor. Specificity and sensitivity 
of the procedure is acheived by using primer pairs internal to the 
earlier primers in a nested PCR (Frohman et al. 1988; Loh et al. 1989).
3.1.4 Overview of this chapter
The expression of IL-5Ra in mice is restricted to a narrow range 
of cell lineages, namely, eosinophils, basophils and certain B-cells. 
Since tissue specific expression of many genes is controlled at the level 
of transcription, the first step towards addressing the regulation of 
IL-5Ra gene was to analyse its transcripts.
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For this analysis, sources of IL-5Ra mRNA were identified by 
screening several cell lines by RT-PCR and Northern analysis. At the 
same time it was necessary also to identify cell lines that do not express 
IL-5Ra using the same techniques. This enabled the comparison of 
these two category of cells in the studies of cell type-specific expression 
of the IL-5Ra gene (described in Chapter 4).
Another aspect of RNA analysis described in this chapter is the 
determination of the transcription initiation and polyadenylation site 
of this gene. Primer extension, ribonuclease protection assay and 
anchored-PCR were used to analyse the 5'-end of the mRNA of IL-5Ra 
and anchored-PCR was used to analyse its 3'-end.
3.2 Materials and Methods
3.2.1 Reagents and cell lines
Restriction enzymes and DNA modifying enzymes were from 
Promega (Madison, WI) or New England Biolabs (Beverly, MA) unless 
stated otherwise. Avian myeloblastosis virus reverse transcriptase 
(AMV-RT), RNasin (placental ribonuclease inhibitor) and Tacj DNA 
polymerase were from Promega and Moloney murine leukemia virus 
reverse transcriptase (MMLV-RT) was from Gibco/BRL (Grand Island, 
NY). Deoxynucleoside triphosphates (dNTPs), Polyl.PolyC, and Nick 
columns were from Pharmacia (Uppsala, Sweden). T4 RNA ligase was 
from New England Biolabs. Acrylamide solution (Long Ranger™
Gel) was from AT Biochem (Malvern, PA) and scintillation fluid 
(OptiScint™) was from LKB (Leicestershire, UK). Glycogen was from
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Boehringer (Mannheim, Germany). Ribonuclease protection assay kit 
(RPAII™) was from Ambion (Austin, TX), T3 Dye Primer sequencing 
kit was from Applied Biosystems (Foster city, CA), [y-^PJATP (3000 
Ci/mmol) and [a-32P]dCTP (3000 Ci/mmol) were from Amersham 
(Buckinghamshire, UK) and [a-32P]UTP (3000 Ci/mmol) was from 
Bresatec (Adelaide, Australia). Oligonucleotides were synthesised by 
the Biomolecular Resource Facility (JCSMR) and are listed in Table 
3.2.1.
All cell lines used in the work in this thesis are of mouse origin 
and were cultured in a basal culture medium consisting of RPMI1640 
medium (Gibco/BRL; Grand Island, NY), 10% fetal calf serum (CSL; 
Melbourne, Australia), 2 mM glutamine (CSL), 60 Jig/ml penicillin 
(CSL) and 100 pg/ml streptomycin (Sigma; St. Louis, MO). Culture 
media for BCLj (5Bjb) (B-cell leukemia line), A20 (B-cell line) and CH27 
(B-cell line) were supplemented with 0.05mM 2-mercaptoethanol 
(Sigma). Media for FDC-P1 (myeloid line) and M C/9 (mast cell line) 
were supplemented with 0.1% of culture supernatant of SF9 cells 
infected with baculovirus expressing mouse IL-3 as a source of IL-3 
(M.C. Fung, unpublished result) and CTLL.2 (T-cell line) with 1% of 
culture supernatant of a6310 cells (Karasuyama and Melchers 1988) as a 
source of mouse IL-2. Ml (myeloblast line), YAC-1 (T lymphoma), EL4 
(thymoma) and P815 (mastocytoma) were grown in the basal culture 
medium without other additives.
M C/9 and a6310 cells were kind gifts from P. Hodgkin (JCSMR), 
CTLL2 was from J. Ruby (JCSMR), BCLi(5Bib), YAC-1, and P815 were 
from A. Mulbacher (JCSMR) and, A20 and CH27 were from A. Gautam 
(JCSMR).
Table 3.2.1 List of oligonucleotides.
O ligonucleotide Sequences (5*-3')
T3 A TT AAC CCT C AC TAA AGG G A
CL16 TCC C IT  TAG TGA GGG TTA AT
CL8 GA G  CTT CTT CTA GTT TGG TAT
C L ll GCT ATA G AA CTG CAT ACC GGG ACC TGT
CLIO G A A  CAC ATT AC A TAC AGA GCC ATC AAC
MF71 TCG  G CT ACC ATG G TG OCT GTG
MF72 C A T T  AA TGG CTC AAG CAA GCG TG
MF73 A TG  GCA AAA TGC CAT CAA AAC GTG
MF100 TGA ACT CAT ACA GG A  CTC CCT G
MF101 GTA GCT GAG TGC TAC CAC TGG
CL13 G TA GTG ATA GAG GG A CCT AGT GCT AGT TA
CL14 TTA C A T  AGT CCT G A A  GAG CTA AAG ACA ATG A
CL12 G CT ACC GCG GCC GCT TTTTTT TTT TT T TT
^ L 1 2
CL16 MF72
TM
MF100 CL13CU4
>  >
<  <  <  -
CL8 CL11 CLIO ^MF73 1F101
Figure 3.2.1 Map of the mouse IL-5Ra cDNA showing the locations of oligonucleotide 
primers. Unfilled box represents coding region of the cDNA, filled box 
denote the transmembrane domain, horizontal line joining the box represents 
the untranslated region of the cDNA and the arrows denote the position and 
orientation of the primers.
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3.2.2 Isolation of RNA
The method used for isolating total RNA from tissue culture 
cells was a modification of that described by Chomczynski and Sacchi 
(1987). Extreme care was exercised to prevent solutions and reagents 
from being contaminated with ribonuclease. Milli-Q water used for 
making up solutions was pretreated with diethyl pyrocarbonate (DEPC) 
by adding DEPC to 0.1%. The mixture was allowed to stand at 37°C for 
at least two hours and then autoclaved. All glassware was baked at 
180°C overnight to destroy contaminating ribonuclease.
Approximately 2X10? cells were harvested and washed once with 
phosphate buffered saline (137 mM NaCl, 2.7 mM KC1, 4.3 mM 
Na2HP0 4 , 1.4 mM KH2PO4 pH 7.4) and resuspended in 500 pi of lysis 
solution (4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5% 
Sarkosyl and 0.1 M 2-mercaptoethanol). The lysate was then passed 
through an 18 gauge needle 6 to 10 times to break up clumps of 
partially lysed cells and to shear chromosomal DNA. To each lysate,
50 pi of 2 M sodium acetate pH 4.0, 500 pi of water-saturated phenol 
and 100 pi of chloroform/isoamyl alcohol (49:1) was added sequentially 
and vortexed for 10 seconds. The sample was then kept on ice for 15 
minutes and centrifuged at 12 OOOxg for 20 minutes at 4°C. The top 
aqueous phase was carefully removed, transferred to a fresh tube and 
an equal volume of isopropanol added. RNA was allowed to 
precipitate at -20°C for 60 minutes and the suspension centrifuged at 
12 OOOxg for 20 minutes at 4°C to collect the pellet. The supernatant was 
discarded and the pellet rinsed with 70% ethanol and then dried under 
vacuum. The dried RNA pellet was then dissolved in water and its
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concentration estimated spectrophotometrically from absorbance at 260 
nm. The RNA was stored at -70°C.
3.2.3 Reverse transcription-polymerase chain reaction
This protocol was adapted from procedures described by Lee et al. 
(1988) and Berchtold (1989). Reverse transcription of total RNA was 
performed in a total volume of 40 |il containing 2 pg of total RNA, 40 U 
RNasin (placental RNase inhibitor), 400 U Moloney murine leukemia 
virus reverse transcriptase, 0.2 pg oligo(dT)i2-i8/ 0-1 m g/m l bovine 
serum albumin, 0.5 irtM dNTP, 50 mM Tris-HCl (pH 8.3), 75 mM KC1,
10 mM DTT and 3 mM MgCl2- The reaction mixture was incubated at 
37°C for 60 minutes and then boiled for 5 minutes to hydrolyse the 
RNA. The cDNA was stored at -20°C until needed.
In order to detect all the three forms of the IL-5Ra transcripts, the 
primer pair MF72/MF73 (see Table 3.2.1 and Figure 3.2.1.1 for sequence 
and position of primers on the cDNA) was used because the variation 
in the three forms lies in the alternative splicing of the exon encoding 
the transmembrane domain. The full length, the intermediate or 
medium form and the soluble form generate PCR products of 627 bp, 
534 bp and 449 bp respectively. A typical PCR reaction mix consisted of 
2 pi of reverse transcription mixture, 20 pmol of each primer, 1 U Taq  
DNA polymerase, 0.2 mM dNTP, 10 mM Tris-HCl (pH 8.4), 50 mM KC1, 
1.5 mM MgCl2 and 0.1 m g/m l gelatin in a total volume of 20 pi. An 
automated thermal cycler (Corbett FTS-1) was used for automated 
amplification cycles as follow: 1 cycle at 94°C 1 for minute; 30 cycles at 
94°C for 30 seconds, 56°C for 30 seconds and 72°C for 1 minute; and 1
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cycle at 72°C for 10 minutes. On completion of the amplification cycles, 
the samples were analysed by 1.5% agarose gel electrophoresis.
3.2.4 Northern hybridisation
The procedures for electrophoresis of RNA and transfer to nylon 
membrane were modified from the methods originally described by 
Lehrach et al (1977). Before gel electrophoresis, RNA samples were 
denatured in a total volume of 20 |il consisting of 2.2 M formaldehyde,
50% formamide, 0.02 M MOPS [3-(N-Morpholino)-propanesulfonic 
acid] pH 7, 5 mM sodium acetate and 1 mM EDTA, heating at 65°C for 
10 minutes and chilling on ice. Loading solution was then added to 
give a final concentration of 5% glycerol, 0.025% bromophenol blue 
and 0.05 mg/ml ethidium bromide. The samples were loaded onto a 
1% agarose gel containing 2.2 M formaldehyde, 0.02 M MOPS, 5 mM 
sodium acetate and 1 mM EDTA and electrophoresed in the same 
buffer but without formaldehyde at 60V constant voltage until the 
bromophenol blue marker had migrated two-thirds of the way down 
the gel.
The ethidium bromide stained gel was then photographed under UV 
illumination to detect the RNA. The gel was then treated with 50 mM 
NaOH for 15 minutes to hydrolyse large RNA fragments and facilitate 
their transfer to the nylon membrane, neutralised with 50 mM HC1 
and rinsed with distilled water. Transfer of RNA from the gel to the 
nylon membrane was achieved by standard capillary blotting in 20x 
SSC (standard saline citrate: lx SSC is 0.15 M sodium chloride, 0.015 M 
trisodium citrate, pH 7). After overnight transfer, the nylon membrane
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was baked for 2 hours at 80°C under vacuum to fix the RNA to the 
membrane. Labelling of the cDNA probe by the random priming 
method has been described in Section 2.2.12. Prehybridisation, 
hybridisation, washing of the membrane and autoradiography have 
been described in Section 2.2.13.
3.2.5 Primer extension studies
The procedure used was essentially that of Sambrook et al. (1989). 
In this method the chosen primer should bind to the RNA template at 
70-100 nucleotides downstream of the predicted 5' terminus to ensure 
that the extended product does not exceed 350 nucleotides in length. 
Larger DNA fragments are more difficult to resolve by denaturing 
polyacrylamide gel electrophoresis.
Primer CL8 (see Table 3.2.1 and Figure 3.2.1.1) binds 97 
nucleotides downstream of the 5'-terminus of the published cDNA 
(Takaki et al. 1990) and was chosen for the above reasons. The primer 
was end-labelled in a 20 pi reaction mixture containing 10 pmol of CL8 
primer, 20 pmol of [a-32P]ATP (3000 Ci/mmol), 70 mM Tris-HCl (pH 
7.6), 10 mM MgCl2, 5 mM DTT and 15 U of T4 polynucleotide kinase 
incubated at 37°C for 15 minutes and then heat inactivated at 90°C for 5 
minutes. To remove the unincorporated label, the reaction mixture 
was loaded onto a pre-equilibrated Sephadex G 50 column (Nick 
column), washed into the column with 400 pi of TE buffer and eluted 
with 400 pi of TE buffer. The extent of incorporation of the label into 
the primer and its specific activity were determined by the methods 
described in Section 2.2.12.
TI
The RNA template, total RNA from BCLi(5Bib) cell line, and 
labelled primer were co-precipitated by mixing 20 pg of RNA, 105 cpm 
of labelled primer (equivalent to about 1.5 pmol), sodium acetate (pH 
5.2) to a final concentration of 0.3 M and 2.5 volume of ethanol. The 
RNA-primer precipitate was recovered by centrifugation at 12 OOOxg for 
20 minutes at 4°C, rinsed with 70% ethanol and air dried. The 
precipitate was then dissolved in 30 pi of hybridisation buffer 
consisting of 40 mM PIPES (piperazine-N,N'-bis[2-ethanesulfonic acid]) 
pH 6.4, ImM EDTA, 0.4 M NaCl, 80% formamide. The hybridisation 
mixture was heated at 80°C for 10 minutes to denature the nucleic adds 
and then transferred to a 50°C water bath and incubated overnight for 
hybridisation to occur.
After hybridisation, the mRNA-primer hybrid was precipitated 
by adding 170 pi of water and 400 pi of ethanol The mixture was held 
at -20°C for 30 minutes, followed by centrifugation at 12 OOOxg for 20 
minutes at 4°C, rinsing with 70% ethanol and air dried. The precipitate 
was then dissolved in reverse transcriptase mixture consisting of 
50 mM Tris-HCl (pH 7.6), 60 mM KC1, 10 mM MgCl2 /10 mM DTT,
2 mM dNTPs, 20 U RNasin (placental RNase inhibitor), 50 pg/m l 
actinomycin D and 16 U avian myeloblastosis virus reverse 
transcriptase. Reverse transcription was allowed to proceed for 2 hours 
at 37°C. The reaction was stopped by the addition of 1 pi of 0.5 M EDTA 
and the RNA template was hydrolysed with 50 mM NaOH at 60°C for 
30 minutes. The reaction mixture was then neutralised with one-tenth 
volume of 3 M sodium acetate (pH 5.2) and the extension products 
precipitated with two volumes of ethanol at -20°C for 30 minutes and 
collected by centrifugation at 12 OOOxg for 20 minutes at 4°C. The pellet 
was dissolved in 80% formamide, 10 mM EDTA (pH 8), 1 mg/ml
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xylene cyanol and 1 m g/m l bromophenol blue, then the solution was 
heated at 95°C for 5 minutes and chilled on ice before loading onto a 
200 mm x 450 mm x 0.4 mm 5% polyacrylamide-8 M urea gel and 
electrophoresed in a buffer containing 89 mM Tris, 89 mM boric acid 
and 2 mM EDTA, at constant power (35 kW) until the bromophenol 
blue dye was about 10 cm from the bottom of the gel. On completion of 
electrophoresis, the gel was transferred to a Whatman 3MM filter paper 
and dried under vacuum at 80°C for 1 hour. Autoradiography was 
carried out by placing the dried gel into an X-ray cassette and overlaying 
it with a sheet of film (Kodak X-OMAT AR). The cassette was then kept 
at -70°C overnight or for the desired length of exposure. The exposed 
film was developed using an automatic film developer (Kodak X- 
OMAT M20 Processor).
3.2.6 Ribonuclease protection assay
This procedure, taken from the RPAII kit (Ambion), was 
essentially based on the method described by Melton et al. (1984) but 
modified and streamlined by the manufacturer to make the procedure 
simple and reproducible.
A genomic fragment for synthesising the single stranded RNA 
probe was first subdoned into pBluescript SK- (Stratagene) and 
designated p5/258SH. To synthesise the probe, p5/258SH was first 
linearised with restriction enzyme Apal. However, since cleavage with 
Apal leaves DNA with 3-protruding ends which could act as sites for 
the initiation of transcription (Schenborn and Mierendorf 1985), the 
fragment was made blunt ended using T4 DNA polymerase and
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purified by phenol/chloroform extraction. Transcription of this 
fragment generated an anti-sense probe starting from a position 62 
nucleotides downstream of the published cDNA and going upstream for 
a length of 390 nucleotides. The probe was transcribed under the 
control of the T7 promoter in a 20 pi reaction mixture containing 1 pg 
linearised template DNA, 40 mM Tris-HCl (pH 7.5), 6 mM MgCl2,
2 mM spermidine, 10 mM NaCl, 10 mM DTT, 2.5 mM each of ATP,
GTP and CTP, 100 pM UTP, 50 pCi [cx-32P]UTP (3 000 Ci/mmol), 20 U 
RNasin and 4 U T7 RNA polymerase, at 37°C for 1 hour. At the end 
of the reaction, the DNA template was removed by digestion with 10 U 
of RNase-free DNase I at 37°C for 10 minutes and the probe was then 
purified by electrophoresis on a denaturing 5% poly aery lamide-8M 
urea gel. The position of the labelled RNA probe was located by brief 
autoradiography and the probe was then excised and eluted in 1 ml of 
buffer containing 0.5 M ammonium acetate, 1 mM EDTA and 0.2%
SDS. Specific activity of the probe was determined by liquid 
scintillation counting.
The probe and the total RNA were then concentrated by 
precipitation using a mixture of 105 cpm of labelled probe and 20 pg of 
RNA in 0.5 M ammonium acetate to which 2.5 volumes of ethanol 
was added and incubated at -20°C for 30 minutes and then centrifuged 
at 12 OOOxg for 20 minutes at 4°C. The pellet was allowed to dry in air 
briefly and redissolved in 20 pi of hybridisation buffer containing 80% 
formamide, 100 mM sodium citrate (pH 6.4) and 300 mM sodium 
acetate (pH 6.4) and 1 mM EDTA. The solution was then heated at 90°C 
for 3 minutes and held at 45°C overnight to allow hybridisation to 
occur. A control using yeast tRNA in place of the sample RNA was 
treated in an identical fashion.
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After overnight hybridisation, various concentrations of RNase 
(0.3-2.5 U /m l RNase A and 100-1 000 U /m l RNase Tl), in 200 \x\ were 
added to the samples and incubated at 37°C for 30 minutes to optimise 
the degradation of the unprotected probe. Following this, the reactions 
were stopped and the RNA:RNA hybrids precipitated. The pellets were 
dissolved in 10 |il of 80% formamide, 0.1% xylene cyanol, 2 mM EDTA 
and 0.1% bromophenol blue, and the samples electrophoresed on a 
denaturing 5% polyacrylamide-8M urea gel. The labelled bands were 
detected by autoradiography as described for primer extension studies.
3.2.7 Anchored-PCR
This procedure is based on that of Troutt et a l (1992) and 
Belyavsky et al. (1989). Specific mRNA sequences of the IL-5Ra were 
converted to cDNA by reverse transcription with the specific 
oligonucleotide, CLIO, for anchored-PCR of the 5'-terminus and with 
CL12 [an oligo(dT)-containing adapter primer] for anchored-PCR of the 
3'-terminus (refer to Table 3.2.1 and Figure 3.2.1 for sequences of and 
location of all primers on the cDNA). For the 5'-anchored-PCR, the 
reverse transcription mixture consisted of 3 jig total RNA from the 
BCLi(5Bib) cell line, 20 pmoles CLIO primer, 400 U Moloney murine 
leukemia virus reverse (MMLV-RT) transcriptase, 50 U RNasin,
0.1 m g/m l bovine serum albumin, 0.5 mM dNTPs, 500 mM Tris-HCl 
(pH 8.4), 75 mM KC1, 3 mM MgCl2 and 10 mM DTT, in a total volume 
of 50 jil which was incubated at 37°C for 1 hour. For the 3’-anchored- 
PCR, all components of the reverse transcription reaction were the 
same as that for the 5'-terminus, except 0.5 |ig of CL12 was used instead 
of CLIO.
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After reverse transcription, excess primer was removed by 
selective precipitation using cetyltrimethyl ammonium bromide 
(CTAB). To the 50 pi reverse transcription reaction mixture, the 
following were added: 20 pi of 0.1 M NaCl/40 mM EDTA, 1 pi of 
0.5 pg /m l Polyl.Poly C and 3 pi of 10% CTAB. Following centrifugation 
at 12 OOOxg for 20 minutes at room temperature, excess primer 
remaining in the supernatant was removed. The pellet was dissolved 
in 14 pi of 1 M NaCl and reprecipitated by adding 25 pi of H2O and 1 pi 
of 10% CTAB. After centrifugation, the pellet was dissolved in 10 pi of 
1 M NaCl and reprecipitated with 27 pi ethanol, centrifuged and dried. 
The pellet was resuspended in 20 pi of 50 mM NaOH/2 mM EDTA and 
heated at 65°C for 30 minutes to hydrolyse the RNA. The cDNA was 
concentrated by neutralising with 2 pi of 3 M sodium acetate (pH 5.2) 
and precipitated with 1 pi of 1 pg/p l glycogen and 70 pi of ethanol. After
1 hour at -20°C the mixture was centrifuged and the pellet dried.
The cDNA for 3’-anchored PCR was dissolved in 30 pi of water, but for 
5'-anchored PCR, the anchor oligonucleotide, CL16, was ligated to the 
cDNA.
Prior to ligating CL16 to the cDNA, it has to be blocked at its 
3'-end with dideoxyATP to prevent self-ligation. This was performed 
in a reaction mixture consisting of 1 nmol CL16, 14 nmol ddATP, 10 U 
terminal deoxynudeotidyltransferase, 100 mM potassium cacodylate,
2 mM C0CI2 and 0.2 mM DTT in 70 pi which was incubated at 37°C for
1 hour. After that the 5'-end of the modified CL16 was phosphorylated 
in a reaction mixture consisting of 50 pmol of modified CL16,100 pmol 
ATP, 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2/ 5 mM DTT, 5 U T4 
polynucleotide kinase in 20 pi which was incubated at 37°C for 15 
minutes.
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The ligation of the modified anchor oligonucleotide CL16 to the 
5'-end of the cDNA was carried out in a 20 pi ligation mix containing 
10 pmol of modified CL16, 50 mM Tris-HCl (pH 8), 10 mM MgCl2,
10 pg/m l bovine serum albumin, 10 mM hexamine cobalt chloride,
2 pM ATP, 25% polyethylene glycol 8 000 and 10 U T4 RNA ligase 
which was incubated overnight at 22°C. The ligation reaction was 
terminated by adding 32 pi of 0.5 M NaCl/10 mM Tris-HCl (pH 8)/lm M  
EDTA and the modified cDNA was precipitated by the addition of 1 pi 
of 1 p g / jil glycogen and 100 pi of ethanol. The pellet was collected by 
centrifugation and then dissolved in 30 pi of water.
In 5-anchored PCR, the first round of PCR was carried out using 
primers CL11 and the universal primer T3 (which anneals to CL16). 
After that 2 pi of the resultant PCR product was used for nested PCR 
using primers CL8 and T3 (see Figure 3.2.7.1). A PCR reaction mixture 
typically contained 20 pmol of each primer with the following cycling 
profile: 1 cycle at 94°C for 2 minutes; 35 cycles at 94°C for 30 seconds, 
52°C for 30 seconds and 72°C for 1 minute; and 1 cycle at 72°C for 10 
minutes in a Corbett FTS-1 thermal cycler. The PCR products were 
fractionated on a 1.5% agarose gel and gel slices for each band of PCR 
product centrifuged through a cone of filter paper (Whatman 541). The 
eluate was extracted with phenol /chloroform and the fragment made 
blunt ended with T4 DNA polymerase and then subcloned into the 
Smal site of pBluescript SK(-). Recombinant clones were sequenced 
using T3-dye primer fluorescence sequencing protocol (see Section 
2.2.21).
In 3'-anchored PCR, the first round of PCR was carried out using 
primer pair CL13 and universal primer CL12. A 2 pi volume of the
mRNA 5' AAAAAA Anneal first strand primer CLIO to mRNA
5’cDNA
<-Eza
CLIO
1
------- ------------------ AAAAAA
1 X / / / 1
Convert mRNA to cDNA 
by reverse transcription
1
r
Degrade RNA template by 
alkaline hydrolysis
Ligate anchor oligonucleotide 
CL16 to cDNA
PCR with CL11 and universal 
primer T3
Nested PCR with CL8 and 
universal primer T3
Figure 3.2.7.1 Schem atic representation o f  the 5 -a n ch o red  PCR procedure.
mRNA 5* AAAAAAAAAA
TTTTT
CL12
Anneal oligo(dt)-containing 
universal primer (CL12) to 
mRNA
Y
5’ —  
cDNA ^
AAAAAAAAAA
T IT IT v
CL12
Extend primer by reverse 
transcription
Y
TTTTT
CL12
Destroy RNA template 
by alkakine hydrolysis
TTTTT
< -----
CL 12
PCR using CL13 and 
universal primer CL12
V
CL 14
■TTTTT Nested PCR using CL14 and
universal primer CL12
Figure 3 2 .7.2 Schematic representation of the 3'-anchored PCR 
procedure.
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resultant PCR reaction mixture was used for nested PCR with primer 
pair CL14 and CL12 (see Figure 3.2.7.2). The PCR conditions and 
subcloning of the PCR product, if necessary, were similar to that 
described for 5'-anchored PCR.
3.3 Results
3.3.1 Cell lines expressing the mouse IL-5Ra gene
The exquisite sensitivity of detecting RNA by PCR, commonly 
referred to as reverse transcription-PCR (RT-PCR), made this the 
method of choice in the screening for the mouse IL-5Ra transcripts in 
various cell lines. The primer pair chosen for this purpose was MF72 
and MF73 (Table 3.2.1 and Figure 3.2.1) because they flank the 
transmembrane region of the mouse cDNA of IL-5Ra. Alternative 
splicing has been shown to generate three forms of transcripts: the full 
length transcript containing the transmembrane coding sequences, an 
'intermediate or medium form' of the transcript which lacked the 
transmembrane coding sequences and the soluble form of the 
transcript also lacking in the transmembrane sequences which has been 
shown to be the secreted form of the mouse IL-5Ra (Takaki et al. 1990). 
PCR with the MF72/MF73 primer pair was predicted to generate 
products 627, 534 and 449 bp in length corresponding to the full length, 
intermediate and soluble transcript respectively, if these transcripts 
were expressed.
Out of the 10 cell lines screened by RT-PCR, only two cell lines of 
B-cell lineage were found to express the mouse IL-5Ra transcripts. They
Table 3.3.1 Survey of cell lines for expression of the mouse IL-5Ra mRNA 
by RT-PCR (L = full length, M = intermediate form, S = soluble 
form; +++ to + = strong positive to positive, + = weak positive, 
-  = negative).
Cell line Description L
IL-5Ra
M S
BCL1 B-cell leukemia +++ +++ +++
A20 B-cell lymphoma
- - -
CH27 B-cell lymphoma ++ + +
FDC-P1 early myeloid line
- - -
CTLL2 T-cell line
- - -
Ml myeloblast line
- - -
YAC-1 T-cell lymphoma
- - -
EL4 thymoma
- - -
P815 mastocytoma
- - -
MC/9 mast cell line
- - -
2 *
5
w
T—l
si U <  w
2c0u
<U
* Ö
c - c m 
<u *5
1 §
627
534
449
—  1016 bp
__  507
—  298
Figure 3.3.1.1 RT-PCR analysis of mRNA from various cell lines. RNA was 
reverse transcribed with oligo(dT) and PCR carried out using 
primers MF72/73 for 30 cycles. PCR products were fractionated 
on a 2% agarose gel. The 627 bp, 534 bp and 449 bp products 
correspond to the full length, intermediate and soluble form of 
the IL-5Roc transcripts (see also table 3.3.1).
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were BCLi(5Bib) and CH27 (Figure 3.3.3.1 and Table 3.3.1). Judging from 
the intensity of the PCR products resolved on a 2% agarose gel, the 
BCLi(5Bjb) expressed equal amounts of the three transcripts. In 
contrast, CH27 expressed more of the full length transcript than the 
intermediate transcript and the soluble transcript was barely detectable 
under UV illumination. It is not surprising to find the IL-5Ra 
transcript being expressed within a restricted range of cell types because 
earlier studies had indicated only eosinophils, basophils/mast cells and 
CD5+ population of mouse B-cells were responsive to IL-5 (Sanderson 
et al. 1988; Hitoshi et al. 1990; Denburg et al. 1991).
3.3.2 Determination of the size of the mouse IL-5Rq mRNA in 
BCU(5Bib) cells
An apparent discrepancy exists between the reported size of the 
mouse IL-5Ra mRNAs and the cDNA characterised to date. Takaki 
et al. (1990) reported mRNAs of 5.0 and 5.8 kb were produced by the cell 
lines Y16, BCLi-B20 and MOPC104E. This is considerably larger than the 
longest cDNA reported to date of size 3.6 kb, incidentally by the same 
group. With the availability of the complete sequence of the gene it was 
desirable to investigate in detail the transcriptional initiation and 
polyadenylation sites used.
The expression of IL-5Ra mRNA in BCLi(5Bib) and the 
non-expression in EL4 was confirmed by Northern blotting with the 
IL-5Ra cDNA as probe (Figure 3.3.1.2). The size of the IL-5Ra mRNA 
produced by BCLi(5Bib) is much closer to of previously isolated
EL4 BCL1(5Blb)
I I I I
10 15 5 10 15 u8
28S —  
18S —
—  IL-5 Ra
Figure 3.3.I.2. Northern analysis of total RNA from BCLl(5Blb) and EL4 cell 
lines for the presence of mouse IL-5Ra transcripts. The signal 
detected in BCLl(5Blb) was estimated from 28S (4.7 kb) and 
18S (1.9 kb) ribosomal RNAs to be 3.8 kb in size which is close 
to that of the published cDNA (3.6 kb).
cDNAs. BCLi(5Bib) cells showed a single band estimated to be 3.8 kb in 
size relative to the 18S (1.9 kb) and 28S (4.7 kb) ribosomal bands.
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3.3.3 Mapping the transcriptional initiation site
Primer extension is the simplest and most rapid technique for 
the determination of the 5'-end of mRNAs. In this experiment, the 
primer CL8 (Table 3.2.1) which binds 98 nucleotides downstream of the 
5'-end of the published cDNA sequence was used. Total RNA extracted 
from the BCLi(5Bib) cell line was used as a source of IL-5Ra transcripts 
and total RNA from EL4 cell line was used as a negative control. 
Hybridisation of the end-labelled CL8 to the total RNA, followed by 
extension with AMV reverse transcriptase and analysis of the products 
by denaturing polyacrylamide gel electrophoresis and autoradiography 
revealed multiple bands in similar positions in the BCLi(5Bib) cells 
and the negative control (Figure 3.3.2.1). The most likely explanation 
for this unexpected phenomenon was that the primer was not 
sufficiently specific and was binding to other RNA species in the total 
RNA.
To check the specificity of primer CL8, it was used to probe a 
Northern blot of BCLi(5Bib) and EL4. The result showed smearing in 
lanes for both BCLi(5Bib) and EL4 (results not shown) instead of the 
one band seen in Figure 3.3.1.2 when the Northern blot was probed 
with the cDNA. This confirmed that the primer CL8 was not specific 
for the IL-5Ra transcripts and was binding to other RNA species.
Figure 33.2.1. Primer extension analysis of total RNA from BCLl(5Blb)
and EL4 cells by reverse transcription with primer CL8. The 
same primer was used in a sequencing reaction which acts as 
a size ladder for the primer extension products. EL4 was used
as the negative control since it did not express the IL-5Ra RNA.
Another attempt to map the transcription initiation site was 
carried out using ribonuclease protection assay. Again multiple bands 
were observed on the autoradiographs despite attempts to optimise the 
degradation of unprotected probe with a range of ribonuclease 
concentrations. When the probe was used to probe the BCLi(5Bib) and 
EL4 Northern blot, smearing along the length of the lanes was 
observed, similar to the probing with labelled CL8 primer, again 
suggesting the lack of specificity of the probe.
A third method, anchored-PCR, wTas attempted to overcome 
probe non-spedfidty. In this procedure, the IL-5Ra transcript was 
converted to cDNA with a specific primer (CLIO) and then second 
strand synthesis and PCR were carried out using primer T3 which is 
complementary to the anchor oligonucleotide (CL16) that had been 
ligated to the 5’-end of the cDNA, The first round of PCR was carried 
out with primer pair T3 and CL11. the latter primer being internal to 
CLIO. One round of nested PCR was also carried out using primer 
pairs T3 and CL8, with CL8 being internal to CL11. The use of internal 
primers in each step of the PCR helps to increase the spedficity and 
sensitivity of the procedure (see Figure 3.2.7.1 for summary). PCR 
products of 150 and 350 bp in size were obtained by this procedure 
(Figure 3.3.2.2) and these fragments were subcloned and sequenced. The 
300 bp PCR product turned out to be an artifact but the 150 bp PCR 
product defined a transcription initiation site located 14 nucleotides 
upstream of the published cDNA sequence (Figure 3.3.2.3 and 
Figure 3.4.1.1)
Figure 33.2.2. 5'-anchored PCR analysis of the 5'-terminus of IL-5Ra mRNA from BCLl(5Blb) cell 
line. Total RNA was reverse transcribed with primer CLIO. Anchor primer CL16 was 
then ligated to the resultant cDNA and two consecutive rounds of nested PCR was 
carried out using primer pairs T3/CL11 and T3/CL8. The PCR products were 
fractionated on a 1.5% agarose gel.
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Figure 3.3.3.1. 3'-anchored PCR analysis of the 3'-terminus of mouse IL-5Ra mRNA from 
BCLl(5Blb) cell line. Total RNA was reverse transcribed with primer 
CL12 and followed by two consecutive rounds of nested PCR using 
primer pairs CL12/CL13 and CL12/CL14. PCR with primers MF72/73 
was used as a positive control. The PCR products were then fractionated 
on a 1.5% agarose gel.
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3.3.4 Mapping the polyadenylation site
Anchored-PCR was also carried out for the 3'-end of the mouse 
IL-5Ra transcript to determine the polyadenylation site(s) used in 
BCLi(5Bib) cells. Following two rounds of nested PCR, summarised in 
Figure 3.2.7.2, only one PCR product of the expected size, 500 base pairs, 
was detected (Figure 3.3.3.1), reflecting that the same polyadenylation 
signal sequence in the published cDNA (Takaki et al. 1990) was used by 
these cells. The position of this polyadenylation site in the 3'-region of 
the IL-5Ra gene is shown in Figure 3.3.4.1.
3.4 Discussion
Before addressing the transcriptional regulation of the IL-5Ra 
gene, it was essential to establish which cells expressed the gene and 
determine the transcriptional initiation site. While the secretion of 
IL-5 is inducible in T-cells of the Th2 subpopulation (Mosmann and 
Coffman 1989), the IL-5Ra gene is constitutively expressed in 
eosinophils, basophils and some B-cells (CD5+) in mice (Sanderson 
et al. 1988; Hitoshi et al. 1990; Denburg et al. 1991). Studies by other 
workers have established the expression of mouse IL-5Ra gene in 
myeloma line MOPC104E and IL-5 dependent early B-cell lines Y16, 
T88-M and B13 (Mita et al. 1988; Rolink et al. 1989; Takaki et al. 1990). 
These cell lines were not available locally and so it was decided to 
screen available cell lines derived from B-cell and mast cell lineage by 
RT-PCR. Other cell lines not expected to express the IL-5Ra gene were 
also screened to confirm they were indeed negative so that they could 
be used later to identify sequences involved in the cell type-specific
38033 ATATTACAAT TGTATAAAAA TGTATTCTCT AAATATCTTC ATTAATGAAG
38083 CTGTATCTAT AGGTCTTTTT GATGGGCTGA ACATAGAAGC AAACACACTT
______________CL13_____________________ ^
38133 ATGTGTTGGG AAGAGGAATA AGTAGTGATA GAGGGACCTA GTGGTAGTTA 
________________ CL14______________________ w
38183 TTTTACATAG TCCTGAAGAG CTAAAGACAA TGAAAGAAGA AATGGTACTC
38233 ACAAGAGAGA GAGCTATGTC GGGGTCCTGT CAGCCAAATC TTGCTAGTAT
38283 ATGCAATAGT GTCTGGGTTT GGTGGTTGTA TATTGGATGG TTCCCTGGGT
38333 GGGGCAGTCT CTGGATGGTC TTTCCTTCCA TCACAGCTCT GAAATTTGTC
38383 TCTGTAACTC CTTCCATGAG TATTTTGTTC CCCATTCTAA GAAGCAGTGA
38433 AGTATCCACA CTTTGGTCTT CCTTCTTCTT GAGTTTCATG TGTTTTGCAA
38483 ATTGTGTGCC TGGCAATACA GAAGCAGATG CTCACAGTCA TCTATTGGAT
38533 GAAACACAGG GCCCCTAATG AAGGAGCCAG AGAAAGTACC CAAGGAGCTA
38583 AAAGGGTCTG CAACCCTATA GCAGGAACAA CAATATGAAC TACCCAGCAA
PolyA
38 633 CCCTCAGAAA TGTAAATGAA GAAAATATCT Ka TAAAKa ä T GCCTTAAAAA
38683 AAAGAAAAGG TACTCAAAAT CCACAACATA ACTTACTTTT TATGTACTTT
38733 ATAGAGATGG TTTAGTCAGG TTTCATAATC TGGGTGAAGT GCACATGG
Figure 33.4.1. Nucleotide sequence of the mouse IL-5Ra gene near the polyadenylation 
site. This site was mapped by 3-anchored PCR. In this procedure the 
mRNA was converted to cDNA by reverse transcription and the 3'-end of 
the cDNA was amplified by nested PCR using primer pairs CL13/CL12 
and CL14/CL12 (see Figure 3.2.7.2). The position of primers CL 13 and 
CL14 is indicated above and primer CL12 binds onto the polyA tail of the 
cDNA. The 500 bp PCR product (Figure 3.3.3.1) maps to the boxed 
consensus sequence for polyadenylation.
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expression of the mouse IL-5Ra gene. The B-cell lines BCLi(5Bib) 
and CH27 were found to express the mouse IL-5Ra transcripts.
Interestingly, judging from the intensity of PCR products resolved on 
agarose gel, the full length, intermediate and soluble form transcripts 
were expressed at equal levels in BCLi(5Bib) while in CH27 cell line 
more full length transcript was expressed than the intermediate form 
and the soluble form transcript was barely detectable. The significance 
of the variation in levels of the intermediate and soluble form 
transcripts between the two cell lines is not clear at this stage. Both the 
intermediate and the soluble form lack the transmembrane coding 
sequences. In contrast to the soluble form, the intermediate form 
transcript does not appear to be translated and the product secreted (Takaki 
et al. 1990). The function of the intermediate form transcript clearly requires 
further investigation.
An important aspect in the molecular characterisation of genes is 
the precise mapping of those genomic sequences transcribed into RNA.
This requires identification of the genomic site(s) at which 
transcription is initiated. To this end, three methods were employed: 
primer extension, RNase protection assay and anchored-PCR. The 
region around the transcription start site appeared not to be unique.
The primer used in primer extension studies and the RNA probe used 
in ribonudease protection assay yielded multiple bands. When the 
same probes were used to probe a Northern blot of BCLi(5Bib) and EL4 
total RNA, even the negative control lane (EL4) showed extensive 
smearing along the lane in contrast to probing of a similar Northern 
blot with the cDNA as probe which yielded a broad but single band. 
However, the highly specific and sensitive anchored-PCR procedure 
enabled the site of transcription initiation to be mapped to a position
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14 bp upstream of the published cDNA sequence (Figure 3.4.1.1).
While the current work was in progress, a report on the partial 
characterisation of the mouse IL-5Ra gene was published (Imamura 
et al. 1994). These workers determined the transcription initiation site, 
by primer extension, to a position 14 nucleotides upstream of the 
position determined here. The reason for this discrepancy is not 
known but given the problems encountered in primer extension 
studies and ribonuclease protection assay in this study, the result 
reported here is considered to be more definitive because sequencing 
of the anchored-PCR products allowed direct sequence comparison 
with genomic sequences.
Mapping of the transcription initiation site facilitated the 
prediction of the promoter region of the IL-5Ra gene. A putative 
TATA-like motif, TAAATA, was located at 57 nucleotides upstream 
of the transcription initiation site (Figure 3.4.1.1). The TATA motif is 
typically situated 20 - 30 nucleotides upstream of the transcription 
initiation site but can vary between 40 to 120 nucleotides upstream of 
this site depending on the promoter (Nussinov 1990). No CCAAT 
motif, which usually lies 60 - 80 nucleotide upstream of the 
transcription initiation site, was detected. The TATA and CCAAT 
sequences in the vicinity of the transcription initiation site generally 
provide binding sites for RNA polymerase II and transcription factors 
to support basal level of transcription (Lewin 1990). On the other hand, 
examples of functional tissue-specific promoters having TATA but 
lacking in CCAAT sequences have been reported for the 
promoters of 0C2A-adrenergic receptor (Handy and Gavras 1992) and 
substance P receptor (Hershey et al. 1991). Besides the promoter 
sequence, other consensus sequences that serve as binding sites for
GATA-1
-745 CTGTCACTGT CAGGGCTGAT GACGGATGAG CTGGGTCAGG CTA^ATAbAC
-695 CCTAGCAATT TATTAGAGCC AGACTCCTAG GCAATTCTCT CTCTACATGT
-645 TCACTTAAGG GTTCAGAGCT TCATAACAAA GCAGAAGTCA GGAGTCTCAG
PU.l
-595 AAATGCACTT CAAAATCAGG GTGEÄGGÄÄb CTGCCCATGT GTCAGGCCCT
-545 GTGACCTATC AACTCACAAG CCTTCTGTTG GGATATTGAC CAAACACAGT
AC dinucleotide repeats
-495 ATCTTTGCTT ATATGCAAGC ACACACTTGC GTGCAKCACA CACACACACA
-445 CACACACACA CACACACACA CACACACACA CACACACfcAG GCTAAAGCTC
AP3
-395 GCAGAGTTCT CAGAltTGTGG TA T^TGAAGG AGGCAAGCCT TTGTCAGTGA
-345
-295
-245
-195
ACAGTATGAT CACTAAGACT CTAGTGTGGG CCCTCTCTAA TGGGTTGCTC 
____ NF-KB
TCT1 GGGAAT CTTC^TCCAA AGAGCAGTTG TGTGGTCTTT CCATTGTAAG
NF-IL6
AGAAACTGCA GGTGTCTTCT TAACCATGAC AGTTCTGÄTG ATGAAAGAGr ' 
SP1 -----------------------------
AAAGAijcCCG CCt*TAAAGTC AAACACCAGT GCACCCAGAA AGTAGATGCA
-145 CAGCTGCAGG CTCAGAGCTC GGCAGCCACT GTACTTCTTA GTAACCAGGA
API TATA
-95 ATCAAACGTT tlGACTCA^TG TGGGGTTGGT AGGGCAG^T A  AATA(fcc^TTT
-45 TCTATGACTA GGCTGGAGAC ACGCCCAGGA CCCCCACCAA AAGGAGGGAC
+6
+56
+106
+156
AGGAAAAGAG AAATAATTGG TAAACACAGA AAATGTTTCA ATAGAAAAAA 
PU.l
g a g g a a Kc a g  a a c a c t g t g t  a g c c c t g t t a  t c a g c a g a g a  c a g a g c t a a c
____________CL8_______________^0__________ CL 11___________________
GCTGGGGATA CCAAACTAGA AGAAGCTCAC TGGACAGGTC CCGGTATGCA 
^ ______________CLIO___________________
GTTCTATTTT TGTTGATGGC TCTGTATCTA ATGTGTTCAT TTGTACCAAG
Figure 3.4.1.1. Nucleotide sequence of the mouse IL-5Ra promoter region. Consensus 
sequences for the binding of various transcription factors are boxed. 
The site for initiation of transcription mapped by 5-anchored PCR is 
indicated by a bent arrow and +1. Primer binding sites for primers 
CL8, CLIO and CL11 used in the anchored PCR are also shown.
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transcription factors have been identified within 745 nucleotides from 
the transcription start site using the SIGNAL SCAN program (Pestridge 
1991): GATA-1 (GATA at -702), PU.l (GAGGAA at -572 and +56), AP3 
(TGTGGTA at -380), NF-Kß (GGGAATCTTC at -291), NF-IL6 
(TGATGAAAG at -207), SP1 (CCCGCC at -189) and API (TGACTCA at 
-85). Potential binding sites for nuclear factors PU.l may be of 
considerable interest because PU.l is expressed in B-cells and 
macrophages (Klemsz et al. 1990). Between position -405 and -460 there 
is a stretch of AC dinudeotide repeats which is also found in the 
human IL-2Rß promoter region (Shibuya et al. 1990). This type of 
repeat has been associated with the formation of Z-DNA (Rich et al. 
1984) and a multisubunit protein (Aharoni et al 1993) that binds to it 
has been reported although its biological significance is still unknown. 
The relevance of these consensus sequences to the regulation of the 
mouse IL-5RCC gene was addressed by deletion mutagenesis of the 
promoter region in conjunction with transfections and luciferase 
reporter assays, and this work is described in Chapter 4.
Northern analysis of BCLi(5Bjb) cells showed the presence of a 
single mRNA band for IL-5Ra of approximately 3.8 kb (Figure 3.3.1.2). 
This contrasts with the results of Takaki et al. (1990) who reported two 
mRNA species of sizes 5.0 and 5.8 kb were produced by Y16, BCLi-B20 
and MOPC104E cells but is much more consistent with the size of the 
longest cDNA (3.6 kb) isolated to date. From the gene sequence 
(Chapter 2), the expected sizes of the three alternatively spliced 
transcripts were calculated to be 3.6 kb (transmembrane form), 3.5 kb 
(intermediate or medium form) and 3.4 kb (soluble form) which are in 
good agreement with the mRNA band observed here.
CHAPTER FOUR
TRANSCRIPTIONAL REGULATION OF 
THE MOUSE IL-5R0C GENE
4.1 Introduction
The regulation of eukaryotic gene transcription is dependent 
on the interaction of promoter elements and cis-acting regulatory 
sequences with gene regulator)Tproteins within the nucleus. The 
major approaches used to identify these sequences and to gain an 
understanding of the underlying mechanisms by which genes may be 
expressed in a tissue-specific manner or respond to extracellular signals 
involve the introduction of cloned genomic sequences into cells in 
culture. Such studies usually involve modification of the cloned 
genomic sequences either by deletion or point mutations. The effect 
of these changes on the expression of the gene can be tested by 
introducing the modified gene into eukaryotic cells in culture and 
examining transient or stable expression.
Introduction of a mutant gene into a cell which contains a 
functional copy of the same gene causes practical problems in 
differentiating between the product of the introduced gene and that of 
the endogenous gene. To overcome this problem, putative regulatory 
sequences or their modified derivatives are usually fused to a reporter 
gene and the expressed reporter gene product is measured in extracts 
prepared from the transfected cells. In recent years, this approach has 
led to the identification of distinct promoter, enhancer and silencer 
elements in many eukaryotic genes, some of which appear to be 
involved in mediating tissue-specific and inducible expression 
(reviewed by Maniatis et al 1987; Herschbach and Johnson 1993).
4.1.1 Reporter genes
The genes used as reporter genes code for proteins which are 
expressed in very low or undetectable levels in the cells of interest. 
Since transcription of the reporter gene is placed under the control of 
the putative regulatory sequences being studied, detection of the 
reporter gene activity is directly attributable to those sequences.
Some of the most commonly used reporter genes are those 
which encode the enzymes bacterial chloramphenicol acetyl transferase 
(CAT), firefly ludferase (LUC), bacterial ß-galactosidase (ß-Gal), alkaline 
phosphatase and ß-glucuronidase (GUS). Growth hormone is an 
example of a non-enzymic reporter gene (reviewed by Alam and Cook 
1990; Bronstein et al 1994).
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The ideal reporter gene should give a low background and 
encode a product of high stability for which there is a rapid, sensitive 
and reproducible assay. Most of these criteria are fulfilled by CAT, 
making it the most widely used reporter gene. The CAT reporter gene 
system has been extensively validated and is the most widely accepted 
measure of promoter activity. However, luciferase has gained 
increasing popularity in recent years over CAT because it is 30-1000 
times more sensitive and the assay is cheaper, easier, more rapid and 
does not use radioactive reagents (De Wet et al. 1987; Gould and 
Subramani 1988; Williams et al. 1989). A disadvantage of luciferase is 
that a luminometer is required for the assay and this instrument is not 
common laboratory equipment.
The enzymatic properties of luciferase have been well studied. 
The original luciferase was cloned from the North American firefly, 
Photinus pyralis (De Wet et al. 1985). The enzyme has a molecular 
mass of 62 kD and requires only ludferin, ATP, Mg2+, and molecular 
oxygen in order to generate yellow green light (560 nm). In the 
conventional assay, a flash of light is produced that rapidly decays after 
enzyme and substrate are mixed and therefore an automated injection 
luminometer is required for measurements of photon production. 
However, in the presence of coenzyme A, the kinetics of light 
production can be prolonged, leading to a higher photon counting rate 
within a given integration time than in the conventional assay. The 
net result is enhanced sensitivity of detection and measurements can 
now be carried out using luminometers without automated injection 
capabilities or in scintillation counters (Wood 1991).
4.1.2 Methods for transfection
The ability to introduce modified DNA into cultured cells forms 
one of the cornerstones of molecular biology that has aided in the rapid 
characterisation of cloned sequences. Numerous procedures have been 
developed and the four frequently used transfection procedures are: 
calcium phosphate co-precipitation (Graham and Van der Eb 1973;
Chen and Okayama 1987), DEAE-dextran mediated transfection 
(McCutchan and Pagano 1968; Luthman and Magnusson 1983; Lopata et 
al. 1984), liposome mediated transfection (Feigner et al. 1987) and 
electroporation (Wong and Neuman 1982; Potter 1988).
Of these methods of gene transfer, electroporation has proved to 
be the most versatile. Electroporation utilises a brief high voltage 
electric field to induce the uptake of DNA from the surrounding 
medium presumably through the formation of transient micropores in 
the cell membrane. This technique is therefore not dependent on 
special characteristics of the cell and can be used for virtually any cell 
type. Both transient and stable cell lines can be generated with this 
technique. In addition, no special reagents are needed other than the 
electroporation device and cuvettes, and the procedure is reproducible 
and very easy to perform (Wong and Neuman 1982; Potter 1988; 
Ausubel et al. 1994).
4.1.3 Transient versus stable transfection
Transfection of plasmids containing reporter gene linked to 
putative regulatory sequences into cultured cells actually results in
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only a small number of cells taking up the DNA. Supercoiled DNA 
tends to remain episomal while linearised DNA promotes stable 
integration into the host cell genome.
Transient expression of reporter genes from episomal DNA has 
been detected for up to 72 hours. During this period the transfected 
plasmids are presumably converted to non-replicating 
minichromosomes which are gradually degraded (Reeves et al. 1985). 
One advantage of transient assays is the convenience of the short time 
between transfection and harvest. On the other hand, regulatory 
sequences may have aberrant properties when studied outside the 
normal chromosomal environment. For example, the chicken ß-actin 
promoter sequences are inactive when the transfected DNA is 
episomal, but are active when the DNA is stably integrated at any of a 
number of sites in the chromosomes (Fregien and Davidson 1986).
Stable integration of introduced DNA into the host cell genome 
is a rare event and the resulting lower copy number of introduced 
DNA, compared to transient transfection, helps to ensure that 
trans-acting factors which are normally present in small amounts are 
not titrated out (Alwine 1985; Fregien and Davidson 1986). In addition, 
in the chromosomal environment, the introduced DNA is subjected to 
regulatory mechanisms such as nucleosomal positioning, interaction 
with the nuclear matrix and DNA replication. Nucleosome positioning 
has been established as having a passive role in allowing trans-acting 
factors access to promoters that are otherwise compacted into 
chromatin. Conversely, formation of positioned nucleosomes over 
promoters appears to repress transcription in some cases by blocking 
critical sequences. The bending of DNA induced by nucleosomes may
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also facilitate the interaction and binding of trans-acting factors 
(Felsenfeld 1992; Wolffe 1994). The nuclear matrix is the scaffolding 
that organises DNA in the nucleus. A large body of indirect evidence 
suggests that interaction of the scaffold-associated regions (SAR) of 
DNA with the nuclear matrix can affect both transcription and 
replication (Gasser and Laemmli 1987; Getzenberg et al. 1991; Jack and 
Eggert 1992). DNA replication can activate transcription either by 
allowing trans-acting factors access to regulatory sequences which are 
otherwise obscured by the positioning of the nucleosomes (Wolffe 
1994) or by allowing the introduced DNA to shed its bacterial 
methylation pattern acquired during DNA preparation and to acquire a 
pattern of mammalian methylation which in some cases appears to be 
critical to gene regulation (Bird 1992; Hasse et al. 1992).
One disadvantage of stable transfection is that it takes three 
weeks or more to generate stably transfected cells for assay whereas 
transient expression can be assayed within 48 hours. Another 
disadvantage is that there is no control over the number of copies or 
site of integration into the host genome. The introduced DNA has been 
shown to integrate in a head to tail tandem configuration, and copy 
number and expression level are often uncorrelated (Jaiswal et al. 1987; 
Bishop and Smith 1989). Insertion can occur in any one of a number of 
locations and the influence of surrounding sequences may give rise to 
position effects in some cases (Wilson et al. 1990). Such effects can be 
minimised by using a polyclonal population of cells.
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4.1.5 Overview of this chapter
The aim of the work described in this chapter was to localise the 
promoter region and identify any cis-acting regulatory elements within 
the 5’-untranslated region of the mouse IL-5Ra gene that may be 
involved in cell type-specific regulation of the gene. For this purpose, 
the 5-untranslated region was fused to the luciferase reporter gene and 
subjected to progressive deletions from the 5'-end. A method for 
making internal deletions called 'scanning deletion mutagenesis' was 
developed during this study to map regulatory elements.
The versatility of electroporation made it the method of choice 
for the introduction of the constructs into cell lines for analysis. 
Transient transfection of a control vector, RSV-LUC (luciferase gene 
driven by the rous sarcoma virus promoter) into BCLi(5Bib) cells was 
initially utilised to optimise electroporation conditions. However, due 
to reasons outlined in Section 4.1.3, stable transfection was used to 
establish stable cell lines containing the mouse IL-5Ra promoter- 
luciferase constructs. The cell lines used in this study were BCLi(5Bib), 
CH27 and FDC-P1. The work described in Chapter 3 has shown that 
BCLi(5Bib) and CH27 cells constitutively express the mouse IL-5Ra 
gene, but FDC-P1 cells do not. The study of cell type-specific expression 
of the mouse IL-5Ra gene described in this chapter was based on the 
comparison of luciferase activities expressed by the promoter-luciferase 
constructs in these stable cell lines.
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4.2 Materials and Methods
4.2.1 Reagents and cell lines
Mouse BCLi(5Bib) and CH27 and FDC-P1 cells were maintained 
as described in Section 3.2.1. Restriction enzymes and DNA modifying 
enzymes were from Promega (Madison, WI) or New England Biolabs 
(Beverly, MA) unless otherwise stated. Plasmid pMClneoPolyA was 
from Stratagene (La Jolla, CA). Neomycin analog G418 was from 
Gibco/BRL (Grand Island, NY) and Calbiochem (La Jolla, CA).
Luciferase Assay System kit was from Promega. Coenzyme A 
(trilithium salt), luciferin (sodium salt) and ATP were from Sigma 
(St. Louis, MO). Bradford reagent for protein assay, Gene Pulser 
(electroporation instrument) and electroporation cuvettes with a 
0.4 cm electrode gap were from Bio-Rad (Hercules, CA).
4.2.2 DNA manipulations
Basic recombinant DNA methodologies including plasmid DNA 
preparations, restriction enzyme digestions, subcloning, and 
sequencing have been described in detail in Section 2.2.
4.2.3 Construction of the mouse IL-5Ra promoter-luciferase 
plasmids
The original translational start codon in exon 4 (+4742) was 
removed by digestion of pSNC5 with Ncol and subsequent treatment
with SI nuclease digestion and T4 DNA polymerase. This generateed 
an 8kb blunt-ended genomic fragment which was ligated into the 
blunt-ended Hmdffl site of pSKLUC, a modified pBluescript vector 
containing the promoterless ludferase reporter cassette (Figure 4.2.3.). 
This fusion results in the in-frame replacement of the ATG 
translational start codon of the mouse IL-5Ra gene in exon 4 with that 
of ludferase and this was confirmed by sequencing. This construct was 
designated pl4LUC. The polylinker 5' to the insert had earlier been 
modified to give Sail, Notl and Xhol sites (Figure 4.2.3.). The Notl and 
Xhol sites were needed for exonuclease HI digestion and the Sail site for 
scanning deletion mutagenesis (see below).
4.2.4 Nested deletion with exonuclease III
To map the minimal region and identify cis-acting regulatory 
sequences, the 8 kb 5'-untranslated region of the mouse IL-5Ra in 
pl4LUC was progressively deleted from the 5-end down to the 
transcriptional start site with exonudease IQ. The plasmid was digested 
with Notl, the ends filled-in with a-phosphorothioate dNTPs using 
Klenow fragment of DNA polymerase I and the plasmid digested with 
Xhol. Digestion with exonudease HI was carried out at 30°C and 
aliquots were removed at 30 second intervals. Single stranded tails 
were removed using SI nudease, the ends made flush with Klenow 
fragment of DNA polymerase I and the plasmid circularised with T4 
DNA ligase. This procedure has been described in greater detail in 
Section 2.2.22. The extent of deletions in individual mutants was 
determined by sequencing.
Transcription start
2 3 4
Ludferase
pSKLUC
0  SV40 small t intron 
0  & Poly A
5'-untranslated region 
was excised by digestion 
with Ncol and blunt- 
ended with SI nuclease.
Ligated into blunt-ended 
Hindin site of pSKLUC
Figure 4.2.3. Construction of the mouse IL-5Ra promoter-reporter plasmid. The ludferase 
vector (pSKLUC) was constructed by subcloning the ludferase expression 
cassette from pXPl(Nordeen 1988) into modified pBluescript SK(-).
Insertion of the 8 kb upstream region of the mouse IL-5Ra into pSKLUC 
resulted in a construct designated p!4LUC.
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4.2.5 Scanning deletion mutagenesis
For this procedure, another series of nested deletions from the 
3-end were prepared in order to progressively delete sequences from 
the transcriptional initiation site to the upstream region. This was 
carried out on plasmid pSNC5 which carries 11 kb of the 5'-upstream 
sequence of the mouse IL-5Ra gene. Like pl4LUC, this plasmid also has 
a Sail site 5' to a Notl site. The Notl site was similarly digested and 
filled-in with a-phosphorothioate dNTPs and the plasmid then 
digested with Clal and exonuclease IQ. This was followed by treatment 
with SI nuclease and Klenow fragment of DNA polymerase I and T4 
DNA ligase. The extent of deletion in individual deletion mutants was 
determined by sequencing.
The size and position of internal deletions were determined by 
the choice of 5' and 3' deletion mutants combined at the common Sail 
site, as outlined in Figure 4.3.2.
4.2.6 Optimising electroporation conditions
To optimise for current pulse duration, lx l 07 BCLi(5Bib) cells 
were electroporated with 20 pg of RSV-LUC (De Wet et al 1987) at 
0.3 kV and capacitance of 125, 250, 500 and 960 pF, in 500 pi of complete 
RPMI 1640 medium. Luciferase activity was assayed 18 hours after 
transfection.
The amount of plasmid transfected was also varied to 
establish the minimal amount required for the detection of luciferase
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activity above the background. Amounts of 10, 20, 30, 40, 50 and 60 pg of 
RSV-LUC were transfected into BCLi(5Bib) cells. Ludferase activity was 
again assayed 18 hours after transfection.
The rapid turnover of ludferase mRNA and protein (Maxwell 
and Maxwell 1988; Thompson et al. 1991) made it necessary to conduct 
a time course for the luciferase assay. Transient expression of ludferase 
by the control plasmid, RSV-LUC, was measured by harvesting 
transfected BCLi(5Bib) cells at 8,15,18, 21, 38 and 45 hours after 
transfection.
4.2.7 Stable transfection
The optimum electroporation parameters determined for 
BCLi(5Bib) cells were used for all three cell lines. The current pulse, at 
a voltage of 0.3 kV and capadtance of 250 pF, was delivered to lx l 07 
cells in 500 pi of complete culture medium containing 30 pg of DNA in 
a 0.4 cm cuvette.
In stable expression experiments, permanent cell lines were 
established by co-transfecting promoter constructs with the plasmid 
pMClneoPolyA which contains the neomycin phosphotransferase 
gene under the control of the strong constitutive thymidine kinase 
promoter. The integration of pMClneoPolyA into the host genome 
confers resistance to the neomycin analog G418. The co-transfection 
was carried out with 30 pg of Sail linearised promoter-luciferase 
constructs and 10 pg of Seal linearised pMCINeopolyA using the 
electroporation conditions listed above. Selection for G418 resistance
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was performed 48 hours after transfection by culturing cells in the 
presence of G418 at the final concentration of 500 |!g/ml. Cells were 
maintained in the presence of G418 for at least two weeks by which 
time any sensitive cells were killed. The polyclonality of the transfected 
cells were estimated by measuring the growth rate of the transfected 
cells while cultured in the presence of G418. The doubling time of each 
cell line enabled the original cell numbers on the day of electroporation 
to be calculated. The complexity of the polyclonal population of cells 
increases with increasing number of viable cells on the day of 
electroporation which continue to grow in G418 media. To assay for 
ludferase activity, lxlO6 cells were seeded into a 60 mm dish and 
harvested after 18 hours.
4.2.8 Ludferase assay
Initially, ludferase activity in transfected cells was measured 
using a commerdal kit, the Ludferase Assay System (Promega). Later, 
reagents for the assay was made up according to the manufacturer's 
recipe.
Transfected cells were recovered from a 60 mm dish and washed 
once with PBS and then lysed in 100 pi of lysis solution containing 
25 mM Tris-phosphate pH 8.7, 2 mM DTT, 1% Triton X-100, 2 mM 1,2- 
diaminocyclohexane-N,N,N',N'-tetraacetic acid and 10% glycerol. The 
lysate was then centrifuged at 12 OOOxg for 5 minutes at room 
temperature.
The supernatant was assayed for luciferase activity by adding 20 
pi of supernatnant to 100 pi of assay reagent containing 20 mM Tricine 
pH 8.7, 1.07 mM magnesium carbonate, 2.67 mM MgS0 4 , 0.1 mM 
EDTA, 33.3 mM DTT, 270 pM coenzyme A, 470 pM luciferin and 530 
pM ATP. Immediately after mixing the supernatant with the assay 
reagent, light emission was measured for 10 seconds in a luminometer, 
Lumat LB9501. Output was quantitated as relative light units (RLU). 
Protein concentration was determined by method of Bradford (1976) 
using commercial Bradford reagent (Bio-Rad). Luciferase activity in cell 
lysates was normalised according to protein content and expressed as 
relative light units (RLU) per 100 pg of protein.
4.3 Results
43.1 Construction of the mouse IL-5Rq promoter-luciferase 
plasmids for gene regulation studies
The IL-5RCC gene is unusual in that there are several short open 
reading frames begining with ATG codons proximal to the translation 
start site for the protein. The significance of the upstream open reading 
frames is not dear. The translation start site for the receptor protein 
was chosen as the fusion point with the luciferase reporter, in order 
not to disrupt any possible translational control mechanism proximal 
to this region.
A series of 5'-deletion mutants of the promoter region of the 
mouse IL-5Ra gene was prepared using exonuclease EH as described in 
the methods section. Several of these deletion clones were selected for
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gene expression studies: -2619LUC, -1970LUC, -1536LUC, -1290LUC, 
-930LUC, -826LUC, -637LUC, -432LUC and -92LUC. These clones 
covered an area between 2619 bp and 92 bp upstream of the 
transcription initiation site (Figure 4.3.1).
The method of scanning deletion mutagenesis (see below), was 
used to generate constructs carrying internal deletions. For example, 
-11064(A2705-91)LUC and -11064(A6213-91)LUC (see Figure 4.3.1.) were 
used to facilitate the characterisation of sequences up to 11064 
nucleotides upstream of the transcription initiation site.
4.3.2 Scanning deletion mutagenesis
Nested deletion with exonuclease III (Henikoff 1984) relies on 
digesting DNA with two restriction enzymes, one to generate a 
3'-overhang and the other to generate a 5-overhang or blunt end. 
Exonuclease IQ will not digest DNA from the 3'-overhang or an 
a-phosphorothioate nucleotide filled end, but digestion will proceed 
from the 5’-overhang or blunt end. If a unique restriction site were to 
be placed just upstream  from the 3'-overhang or a-phosphorothioate filled 
end, it would be protected from digestion. At the end of each 
exonuclease IQ procedure, recircularisation of the plasmid would result 
in the unique restriction site being placed at the endpoint of each 
deletion.
When two series of such deletions, one from the 5'-end and the 
other from the 3'-end of the DNA are carried out, the endpoints of all 
deletion mutants from both series will have the same unique
-11064 5'-end of 
IL-5Ra gene
-11064
-11064 -6214
-3281 LUC 
-2619 LUC 
-1970 LUC
-1536 LUC 
-1290 LUC
-930 LUC 
-826 LUC 
-637 LUC 
-432 LUC 
-92  LUC
-11064(A2705-91)LUC 
-11064(A6213-91) LUC
Figure 4.3.1. Digramatic representation of the mouse IL-5Ra promoter-ludferase
constructs used in stable transfection experiments. Empty boxes represent 
untranslated exons; filled box represents translated exon 4 which contains 
the translation start codon. The ludferase reporter gene (luc) was fused 
in-frame to exon 4 with the ludferase ATG codon replacing the 
endogenous ATG (+4742). Numbers denote the positions in the gene 
relative to the transcription start site (+1) and broken lines denote 
sequences that have been deleted.
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restriction site. This feature facilitates the combining of deletion 
mutants from each series to generate internal deletions of various sizes 
throughout the DNA fragment of interest (Figure 4.3.2). Since the 
deletion can be moved up or down the DNA fragment, this procedure 
has been labelled "scanning deletion mutagenesis".
4.3.3 Effect of varying capacitance on electroporation 
efficiency
Before the above constructs were tested, it was necessary to to 
establish the optimum conditions for electroporation and luciferase 
assay. The electroporation device used in this study was the Gene 
Pulser (BioRad), a capacitor discharge instrument that charges its 
internal capacitor to a certain voltage and then discharges an 
exponentially decaying current pulse through the DNA-cell 
suspension. The duration of the current pulse governs pore size 
formation and is a function of the initial voltage, capacitance setting 
and resistance of the circuit (including the sample). Changing the 
capacitor size allows more or less charge to be stored resulting in longer 
or shorter decay times and hence different effective pulse durations.
The aim was to find a pulse that kills 20-50% of the cells. This figure 
has been found to result in optimal transfection (Chu et al. 1987; Potter 
1988; Ausubel et al. 1994).
Using control plasmid, RSV-LUC, the effect of varying 
capacitance on the efficiency of electroporation of BCLi(5Bib) cells was 
examined. Capacitance was set at 125, 250, 500 and 960 |iF, and voltage at
Exom
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Exonuclease m  deletion 
from 5’ and 3'-end (filled 
box represents unique 
restriction enzyme site).
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3B
3C
1
] 5A 
] 5B 
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Series of 5' deletion 
mutants.
Series of 3' deletion 
mutants.
Combining 5' and 3' 
deletion mutants, eg. 5B 
and 3C, results in deletion 
of the region represented 
by broken lines.
Figure 4.3.2. Schematic representation of the scanning deletion mutagenesis 
procedure. Internal deletions of various sizes throughout a DNA 
fragment can be generated by combining 5' and 3'-end 
deletion mutants.
0.3 kV. Luciferase activity measured 18 hours after transfection was 
highest when 250 pF capacitance was used (Figure 4.3.3.).
4.3.4 Effect of DNA concentration on reporter gene activity
Using the optimum parameters for electroporation, the effect of 
the amount of plasmid DNA was determined. BCLi(5Bib) cells were 
transfected with 10, 20, 30, 40, 50 and 60 pg of RSV-LUC DNA at 0.3 kV 
and 250 pF, and luciferase activity measured 18 hours later. Activity of 
luciferase was found to increase with increasing DNA concentration up 
to 20 pg (Figure 4.3.4.). However, between 30 and 60 pg of DNA the 
activity stayed around the same level as that of 20 pg of DNA, probably 
reflecting saturation beyond this concentration. A DNA concentration 
of 30 pg was chosen for subsequent experiments because a slight excess 
of DNA would compensate for the different sizes of plasmid used and 
to provide sufficient plasmid necessary to generate reporter activity 
significantly above background (260 RLU in this experiment).
4.3.5 Time course of luciferase activity
Luciferase mRNA and protein have been reported to have a 
high rate of turnover (Maxwell and Maxwell 1988; Thompson et cd. 
1991). As such, it was necessary to determine the peak of activity in a 
transient assay. Luciferase activity in BCLi(5Bib) was measured 8,15,18, 
21, 38 and 45 hours after transfection, and was found to be at its highest 
level 15 hours after transfection (Figure 4.3.5.). Indeed, by 21 hour the 
activity had decreased to half that seen at 15 hour.
1200 -
RLU 900 -
6 0 0 -
Capadtance (uF)
Figure 4.3.3. Effect of varying capadtance on electroporation effidency.
RSV-LUC was transiently transfected into BCLi(5Bib) cells 
at a voltage of 0.3 kV but varying capadtance of 125, 250, 500 
and 960 pF. Ludferase activity was then assayed 18 hours post 
transfection. RLU: relative light units.
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Figure 4.3.4. Effect of DNA concentration on reporter gene activity.
10,20, 30, 40,50 and 60 pg of RSV-LUC DNA was transiently 
transfected into BCLi(5Bib) cells and luciferase activity 
measured 18 hours post transfection. RLU: relative light 
units.
1500 -
1000 -
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Time (hours)
Figure 4.3.5. Time course of transient expression of ludferase in
BCLi(5Bib) cells. RSV-LUC was transiently transfected into 
the cells and ludferase activity was then measured at 8,15, 
18, 21, 38 and 45 hour intervals post transfection.
RLU: relative light units.
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However, the time of harvest in stable transfection experiments 
was not crucial since in these studies the steady-state level of luciferase 
was measured.
4.3.6 Deletion analysis of the upstream regulatory region
In order to examine the activity of the upstream regulatory 
sequences in a normal chromosomal environment, reporter gene 
constructs were studied using stable transfection. A series of 5'-end 
deletions of the upstream regulatory region was generated by 
exonuclease III digestion of the plasmid p!4LUC. These deletion clones 
contain various lengths of the upstream  regulatory region, extending 
from -92 to -11064 (Figure 4.3.1.).
Deletion clones -1536LUC, -1290LUC, -930LUC, -432LUC and 
-92LUC, and promoterless control plasmid, SKLUC, were stably 
transfected into BCLi(5Bib) cells. Three separate transfections were 
carried out for each construct. All of the constructs expressed luciferase 
activity with exception of the control which showed only low  
background activity (Figure 4.3.6.1). The highest levels of activities 
were obtained with -930LUC and -432LUC which were approximately 
40 to 50 times the background (100 RLU). These constructs carry 930 and 
432 bp of upstream sequences respectively. -92LUC gave activity that 
was 14 times the background. This construct carries only 92 bp of 
upstream sequences. However transfection efficiency in BCL}(5Bib) 
cells appeared to be low. The number of individual clones after 
transfection was estimated from the growth rate (doubling time of 52 
hours) to vary from 50 to 300 colonies per transfection. This indicated a
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Figure 4.3.6.1. Luciferase activities of the mouse IL-5Ra promoter-luciferase 
constructs in BCLi(5Bib) cells established by stable 
transfection. Constructs indicated above were co-transfected 
with pMClneoPolyA into BCLi(5Bib) cells and stable cell lines 
were established by selection with G418. After that, lxlO6 cells 
were seeded into a 60 mm dish and luciferase activity was 
measured after 18 hours. Each bar represents the mean (± SD) 
of three separate transfections. SKLUC is the promoterless 
control vector and RLU denotes relative light units.
low level of polydonality in the transfected cell population and so 
promoter activity of the constructs might be affected by position effects. 
Therefore, the experiment was repeated with another cell line, CH27, 
which also expresses the mouse IL-5Ra gene (see below).
The deletion clones -2619LUC, -1536LUC, -1290LUC, -930LUC, 
-826LUC, -637LUC, -432LUC and -92LUC were transfected into FDC-P1, 
a cell line that does not express the mouse IL-5Roc gene. Three separate 
transfections were carried out for each construct and all the transfected 
cells showed stable expression of ludferase adtivities which ranged 
from 6 to 36 times above the background (1800 RLU) as seen in 
-2619LUC and -826LUC respectively (Figure 4.3.6.2). The very high level 
of reporter activity in -826LUC might be the result of a higher copy 
number of the construct integrating into the host cell genome. On the 
whole, the reporter activity in these stable cell lines was generally 
much higher than that of the BCLi(5Bib) stables, possibly due to the 
high transfection efficiency of these cells. This is reflected in the large 
number of individual colonies obtained after transfection which was 
approximately 10 000 to 18 000 colonies per transfection (calculated 
from the growth rate of a 21 hour doubling time). These results 
showed that the element(s) responsible for cell type-specific activity do 
not appear to be present in the 2619 bp of upstream sequences tested. 
The method of scanning deletion mutagenesis was used to construct 
-11064(A6213-91 )LUC and -11064(A2705-91)LUC for the characterisation 
of sequences upstream of -2619 in order to search for cell type-specific 
regulatory sequences. Interestingly, ludferase activity was suppressed 
in FDC-P1 cells transfected with these constructs (Figure 4.3.6.2). The 
-11064(A2705-91)LUC construct contained sequences of the core 
promoter and sequences between -11064 and -2706. However, in the
125000-,
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Figure 43.6.2. Luciferase activities of the mouse IL-5Ra promoter-ludferase 
constructs in FDC-P1 cells established by stable transfection. 
Constructs indicated above were co-transfected with 
pMCl neoPolyA into FDC-P1 cells and stable cell lines were 
established by selection with G418. After that, lxlO6 cells 
were seeded into a 60 mm dish and luciferase activity was 
measured after 18 hours. Each bar represents the mean (± SD) 
of three separate transfections. SKLUC is the promoterless 
control vector and RLU denotes relative light units.
109
11064(A6213-91)LUC construct, sequences between -6214 and -2706 were 
deleted (Figure 4.3.1) but suppression of luciferase activity was not 
relieved, suggesting a ds-acting negative regulatory element(s) between 
-11064 and -6214 that was able to confer cell type-specific activity.
This negative element should not have any effect in cells 
constitutively expressing IL-5Ra, such as BCLi(5Bib) and CH27. Owing 
to the low degree of polyclonality in the BCLi(5Bib) stables, the stable 
transfection experiment was repeated using CH27 cells. These cells 
have a doubling time of 25 hours. Stable transfectants on the day of 
electroporation were calculated from the growth rate to have approxim ated 
800 to 3 000 colonies per transfection. This is a significant improvement 
in complexity of the stable cell population. Three separate transfections 
were performed for each construct and, like the BCLi(5Bib) stables, all
constructs expressed reporter activities, including -11064(A6213-91)LUC 
and -11064(A2705-91)LUC whose activities were suppressed in FDC-P1 
stables (Figure 4.3.6.3). In fact -11064(A2705-91)LUC showed the highest 
level of luciferase activity in CH27 cells which was 20 times above the 
background (105 RLU). This implied that the suppression of luciferase 
activity in FDC-P1 cells was not artifactual, but actually due to a ds- 
acting negative element present in sequences between -11064 and -6214.
4.4 Discussion
The work described in this chapter was aimed at analysing 11064 
nucleotides of sequences upstream of the transcription initiation site of 
the mouse IL-5Ra gene for element(s) that might be involved in the 
regulation of this gene in a cell type-spedfic manner. The luciferase
Figure 4.3.6.3. Luciferase activities of the mouse IL-5Ra promoter-luciferase 
constructs in CH27 cells established by stable transfection. 
Constructs indicated above were co-transfected with 
pMClneoPolyA into CH27 cells and stable cell lines were 
established by selection with G418. After that, lxlO6 cells 
were seeded into a 60 mm dish and luciferase activity was 
measured after 18 hours. Each bar represents the mean (± SD) 
of three separate transfections. SKLUC is the promoterless 
control vector and RLU denotes relative light units.
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gene was used as the reporter gene and constructs fused to this reporter 
gene were introduced by electroporation into cells that express this 
gene and cells that do not. The study of transcriptional regulation of 
the mouse IL-5Ra gene was based on the comparison of reporter gene 
activities in the cell lines established by stable transfection.
In addition, a simple and efficient method for making internal 
deletions has been developed during the course of this study called 
"scanning deletion mutagenesis". This method uses exonuclease HI for 
creating unidirectional nested deletions from the 5'- and 3'-end of a 
DNA fragment. The deletion endpoints of the 5'- and 3'- mutants were 
designed to have the same unique restriction site. This feature allows 
the 5'-deletion mutants to be combined with the 3'-deletion mutants. 
The size and position of the internal deletion is dependent on the 
choice of 5' and 3' mutants that are put together (Figure 4.3.2.).
For the dissection of the 5’-upstream region of the mouse IL-5Ra 
gene, various lengths of the 5'-upstream region were generated by 
nested deletion and scanning deletion mutagenesis (Figure 4.3.1) and 
fused to the ludferase reporter gene. These constructs were transfected 
into BCLi(5Bib), a B-cell leukemia line; CH27, a B-cell line; and FDC-P1, 
an early myeloid line.
Since BCLi(5Bib) and CH27 cells express the mouse IL-5Ra gene 
constitutively, it was not surprising to find that all constructs expressed 
ludferase activity in these cells. The shortest construct, -92LUC, having 
only 92 bp of upstream sequences was active in both cell lines (Figure 
4.3.6.1 and 4.3.6.2). This region possibly contains the core promoter 
sequences and includes the putative TATA-like motif, TAATA (-57),
I l l
and an API (-85) consensus binding site. Deletion of other upstream 
consensus binding sites for SP1 (-189), NF-IL6 (-207), NF-KB (-291),
AP3 (-380), PU.l (-572) and GATA-1 (-702) suggested that they do not 
have a role in the cell type-specific regulation of the mouse IL-5Ra 
gene. The transcription factor PU.l is a member of ets superfamily of 
genes previously described as being exclusively expressed by B-cells and 
monocytes/macrophages (Klemsz et al. 1990). Deletion of PU.l 
consensus binding site at -572 did not affect promoter activity.
Various constructs were also stably transfected into FDC-P1 cells 
which do not express the mouse IL-5Ra gene. However constructs 
carrying sequences up to -2619 were also active in FDC-P1 cells (Figure 
4.3.6.2). On the other hand, -11064(A2705-91)LUC which has the core 
promoter region and sequences between -11064 and -2706, and 
-11064(A6213-91)LUC which also has the core promoter region and 
sequences between -11064 and -6214 (Figure 4.3.1) gave only background 
levels of luciferase activity comparable to that of the promoterless 
control plasmid SKLUC. All constructs were transfected in triplicate 
with the same results. This suggested the presence of a negative cis- 
acting regulatory element between -11064 and -6214. In contrast, the two 
constructs were active in CH27 cells (Figure 4.3.6.3). Since both CH27 
and BCLi(5Bib) express IL-5Ra constitutively, they serve as positive 
control cell lines for the transfection experiments. The above results 
suggest the presence of a negative element(s) between -11064 and -6214 
which may be involved in the cell type-specific expression of the 
mouse IL-5Ra gene.
While this work was in progress two other relevant studies were 
reported. The first involved a limited study on the mouse IL-5Ra
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promoter region (Imamura et al. 1994). In this study, the transcription 
initiation site was mapped to 14 bp upstream of the site determined 
here, and two constructs, covering -96 to +160 and -1371 to +160 
(similar to -92LUC and -1536LUC respectively) fused to the CAT 
reporter gene were transiently transfected into Y16 cells (an IL-5 
dependent early B-cell line), FDC-P1 (an early myeloid line) and 
NIH3T3 (a fibroblast line). While Y16 cells express the mouse IL-5Ra 
gene, FDC-P1 and NIH3T3 cells do not. Construct -96 to +160 was active 
in all three cell lines, in agreement with the results obtained here for 
-92LUC (Figures 4.3.6.1, 4.3.6.2 and 4.3.6.3). However, in marked 
contrast to the result obtained here for -1536LUC (Figure 4.3.6.2 and 
4.3.6.3), construct -1371 to +160 showed no activity in NIH3T3 and Y16 
cells. This finding is difficult to explain since Y16 cells constitutively 
express the mouse IL-5Ra gene and, consequently, any construct 
containing the IL-5Ra promoter should be active in this cell line. The 
reason for the differences with the present work is not clear although it 
should be noted that in the present study the translational start codon 
of the reporter gene replaced the endogenous translational start codon 
at position +4742 so as not to disrupt any translational control 
mechanism proximal to this site, whereas in the study by Imamura 
et al. (1994), the reporter gene was placed at +160. In addition, that study 
used transient expression assays in contrast to stable transfection in 
the present work. The stable transfection system used here, with 
integration of the transfected construct into the chromosomal DNA, 
is likely to be a closer approximation to the normal gene regulation.
The second study was on the promoter region of the human 
IL-5Ra gene (Sun et al. 1995). Analysis using transient transfection 
identified a 34 bp region between -432 and -398 in the human IL-5Ra
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promoter sequence as having tissue-specific enhancer activity. The 
corresponding region in the mouse is occupied by a 52 bp AC 
dinucleotide repeat. Comparison of the promoter regions of the mouse 
and human genes (described in Section 2.3.4) showed 68% identity at 
position -561 to-314 in the human sequences with position -392 to -147 
in the mouse. However, the deletion of this region did not affect 
promoter activity in this study. The lack of correlation between the 
promoter activities of the human and the mouse IL-5Ra gene may 
explain the differential regulation of the two promoters in eosinophils 
and B-cells in the two species. This is reflected in IL-5 being active on 
eosinophils but not on B-cells in humans, but active on both lineages 
in the mouse (Clutterbuck et al. 1987; Sanderson et al. 1988). Perhaps 
IL-5 has a broader biological role in the mouse and the IL-5Ra gene has 
somewhat different regulation.
In the present study, the finding of a negative regulatory region 
is the first evidence of a regulatory element(s) which could explain the 
cell type-specific expression of the mouse IL-5Ra gene. Suppression of 
gene expression was observed in a cell line (FDC-P1) that does not 
express the mouse IL-5Ra gene suggesting the possibility of a repressor 
protein binding to the negative regulatory region. Transcriptional 
repression may then form the basis cell type-specific expression of 
the mouse IL-5Ra gene. Before definite conclusions can be drawn, 
further investigations are required to confirm this preliminary finding. 
First of all the negative regulatory region should more specifically 
localised by further deletion analysis. Having narrowed down the 
negative regulatory region, the subsequent steps would be the 
detection, isolation and characterisation of the transcriptional repressor 
protein that binds to this region. The binding of the repressor protein
to the specific regulatory region may be detected by footprinting and 
electrophoretic mobility shift assays. A strategy for isolating the 
repressor protein may be devised based on its specific binding to 
the negative regulatory sequences which could be coupled to a 
chromatographic medium. Characterisation of the purified protein 
by N-terminal sequencing would then facilitate the design of 
oligonucleotides for the eventual cloning of its cDNA and genomic 
sequences.
On the other hand, the negative regulatory region is predicted to 
contain CpG islands (see Section 2.3.2). The methylation of these 
islands is known to cause transcriptional repression (Bird 1993; 
Brandeis et al. 1993). Regulation by methylation may be investigated by 
genomic sequencing of genomic DNA from IL-5Ra expressing cells, 
such as BCli(5Bib) and CH27, in comparison with nomexpressing cells 
like FDC-P1. In addition, the use of a methylation inhibitor, such as 
5-azacytidine, may aid in verifying the role of DNA methylation in the 
cell type-specific expression of the mouse IL-5Ra gene. Furthermore, 
this region has striking homology to the human and C. elegans 
fork head family of transcription factors (see also Section 2.3.5).
Whether this element is involved in the regulation of the mouse 
IL-5Ra gene awaits further investigation.
Studies of eukaryotic gene expression often focus on the 
mechanisms of transcriptional activation. However, transcriptional 
repression is also an important means of regulating many genes. 
Transcriptional repressors are known to interfere with various steps in 
transcriptional initiation (Jackson 1991; Herschbach and Johnson 1993; 
Cowell 1994).
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IL-5 is believed to be a late-acting factor in eosinophil 
development. Understanding the mechanisms of transcriptional 
repression of the IL-5Ra gene should add to the understanding of the 
processes involved in the commitment of multipotential myeloid 
progenitors to the eosinophil lineage and subsequent eosinophil 
development and maturation.
CHAPTER FIVE
TARGETING THE MOUSE IL-5Rcc GENE
5.1 Introduction
Although extremely valuable, in vitro systems using cell 
cultures provide only a limited insight into the function of genes and 
their encoded proteins in vivo. For this reason transgenic animals 
have gained wide popularity as experimental model systems providing 
a true in vivo environment for evaluating gene and protein function, 
and defining the spatial and temporal expression of genes in 
development. Transgenic animals are usually generated by direct 
microinjection of DNA fragments into the pronuclei of single-cell 
embryos. However, this procedure has several disadvantages. 
Integration of the foreign DNA has potentially deleterious effects on 
endogenous genomic sequences at the site of integration and there is a 
lack of control over the number of copies integrated. Moreover, the 
inserted gene is out of its normal chromosomal position and, hence, its 
regulation may be affected. In addition, it is not possible to inactivate
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specific genes by this method. These disadvantages are overcome using 
homologous recombination to make changes in specific genes at their 
normal chromosomal location. This relatively recent technique is 
commonly referred to as gene targeting.
5.1.1 The basis of gene targeting
Using gene targeting it is possible to precisely and permanently 
modify genetic information at a chosen locus and this technique allows 
the modification to be transmitted through the germline to future 
generations. Gene targeting involves making the chosen alteration on 
cloned genomic DNA and then introducing it into mouse embryonic 
stem (ES) cells by microinjection or electroporation. The introduced 
DNA is incorporated into the targeted genomic locus by a homologous 
recombination event. Once identified, ES cell clones containing the 
desired alteration are then microinjected into recipient blastocysts for 
return to pseudo-pregnant foster mothers where they can develop into 
chimeric pups. The breeding of germline chimeras yields heterozygous 
animals that can then be interbred to homozygosity for the chosen 
alteration (Capecchi 1989; Frohman and Martin 1989; Koller and 
Smithies 1992; Pascoe et al. 1992; Waldman 1992; Fassler et al 1995).
The gene targeting procedure is summarised in Figure 5.1.1.
5.1.2 Targeting vectors
The transfer of altered DNA into the genome of ES cells can 
occur in two general ways depending on the design of the targeting
neo HSV-tk
Establish ES 
line from ICM
Electroporation of 
targeting vector
Blastocyst injection 
and transfer to 
pregnant females
Expansion and analysis 
of ES cells to identify 
heterozygous lines
I Positive-negative
Selection
Figure 5.1.1. Summary of the steps undertaken to generate a targeted mouse 
by homologous recombination (Fassler et al. 1995).
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vectors: sequence insertion and sequence replacement. Both types of 
targeting vectors generally carry a selectable marker such as the 
neomycin phosphotransferase (neo) gene for detection of integration. 
The placement of the neo gene within coding sequences (exons) is 
designed to disrupt the function of that particular gene.
In sequence replacement, the vector is linearised outside the 
region of homology. Upon homologous pairing between the genomic 
sequence in the vector and the endogenous gene, a double cross-over 
recombination event replaces the endogenous sequence with 
homologous sequences in the vector (Figure 5.1.2).
In sequence insertion, the vector is linearised within the region 
of homology so that the ends of the linearised DNA lie adjacent to one 
another. Pairing of these DNA ends with their genomic homolog 
followed by recombination at the double strand break results in the 
entire vector being inserted into the endogenous gene producing a 
partial duplication of the gene (Figure 5.1.2).
While both insertion and replacement vectors have been used 
successfully to create targeted gene inactivation ('knockouts'), the 
replacement type has proven to be more popular as it does not result in 
the duplication of genomic sequences or the addition of extraneous 
vector sequences, and it allows the use of the positive-negative 
selection strategy (see below) for non-selectable genes. In addition, with 
insertion vectors, there is always the possibility of reversion to the 
wild-type through intrachromosomal crossover (Capecchi 1989).
/
neo
S «q u « n c*  Inser t ion  v e c to r
\
neo
Figure 5.1.2. Gene disruption by sequence replacement and sequence insertion vectors.
In sequence replacement vectors, homologous pairing between genomic 
sequences in the vector and the endogenous gene results in a recombination 
event which replaces the endogenous sequences with the vector sequences 
containing neo. With sequence insertion vectors, a double-strand break in 
the genomic sequence in the vector places the ends of the vector adjacent to 
one another on the genomic map. A recombination event at or near the 
double-strand break results in insertion of the entire vector into the 
endogenous gene and, hence, producing a duplication of a portion of the 
gene (Deng and Capecchi 1992).
5.13 Embryonic stem cells
The success of gene targeting is highly dependent on the 
maintenance of the pluripotency of the ES cells throughout the whole 
procedure of genetic manipulation. These cells are derived from the 
inner cell mass of the preimplantation embryo (the blastocyst) and are 
grown in vitro in the presence of primary embryonic fibroblasts, 
transformed embryonic fibroblast (STO) cells or leukemia inhibitory 
factor (LEF). If handled properly, the ES cells retain pluripotency and, 
when reintroduced into recipient blastocysts, are capable of 
contributing to all cell lineages including the germline of the resulting 
chimeric mice (Capecchi 1989; Pascoe ei ai. 1992).
5.1.4 Detecting homologous recombination
Random integration of introduced DNA into mammalian 
genomes generally occurs at a much higher frequency than 
homologous recombination. Hence, much effort has gone into 
devising suitable strategies for the isolation of cells in which the rare 
event of homologous recombination has occurred.
Some genes are directly selectable, like the hypoxanthine- 
guanosine phosphoribosyl transferase (Hprt) gene. When this gene is 
inactivated, cells become resistant to the base analogue 6-thioguanine 
but are unable to grow in hypoxanthine, aminopterin thymidine 
containing media (HAT). For genes that are expressed in ES cells, a 
promoterless selectable marker can be coupled to the promoter of the 
gene of interest to enable detection of expression after homologous
recombination. However, most genes are not expressed in ES cells and 
do not have a selectable phenotype when one or both copies are 
inactivated. Therefore, in these cases, detection of the rare ES cell 
clones which have undergone the desired homologous recombination 
event can only be achieved by using an enrichment (positive-negative 
selection) and/or screening (PCR/Southern analysis) procedure.
In the positive-negative selection strategy of enrichment, a 
replacement vector is used containing part of the gene to be targeted 
into which has been inserted the neo gene under the control of a strong 
constitutive promoter, like the yeast phosphoglycerate kinase (PGK) 
promoter. Also included is the herpes simplex thymidine kinase 
(HSV-TK) gene located outside the region of homology. In the event of 
homologous recombination, the HSV-TK gene will be lost and the ES 
cells are able grow in the presence of neomycin (G418) and gancyclovir. 
On the other hand, random integration will result in the entire vector 
integrating into the genome including the HSV-TK gene. These cells 
will be killed as a result of the production of toxic phosphorylated 
gancyclovir by HSV-TK (Mansour et al. 1988).
Following the positive-negative selection procedure, it is 
necessary to screen the G418 and gancyclovir resistant colonies to 
confirm that the homologous recombination event has indeed taken 
place. Using appropriate probes, this can be achieved by Southern 
analysis. However, this screening process is time consuming and 
cumbersome when the frequency of homologous recombination is low 
and in these circumstances PCR is commonly used. Primers for PCR 
are typically designed to amplify a fragment between the neo gene and 
a region of the targeted genome just outside the genomic region in the
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targeting vector. This design allows the detection of the homologous 
recombination event by generating a PCR product of a particular size. 
Conversely, if random integration has taken place, the two primers 
will not be juxtaposed, hence, no PCR product will result (Kim and 
Smithies 1988; Kim et al. 1991).
5.1.5 Generating the targeted mice
Having identified ES cell clones with the desired alteration at the 
chosen locus, these cells are then introduced into recipient blastocysts. 
Introduction of targeted ES cells into the blastocoel cavity is 
traditionally accomplished by microinjection. A more simple and less 
demanding method has recently been developed in which the targeted 
ES cells are simply co-cultured with morulae-stage embryos to promote 
aggregation and subsequent internalisation of the ES cells into the 
embryo which are then cultured to the blastocyst stage (Wood et al. 
1993). Like microinjected blastocysts, these blastocysts are implanted 
into pseudo-pregnant foster mothers for development into chimeric 
mice. Inter-breeding of heterozygous germline chimeras leads to the 
generation of mice homologous for the altered gene.
5.1.6 Types of alterations and their applications
Using the gene targeting methodology, three basic types of 
alterations can be made to a chromosomal sequence: restoration-of- 
function, loss-of-function and subtle alterations. Restoration-of-
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function by correcting genetic defects holds promise of an approach for 
effective human gene therapy (Shesely et al. 1991).
Loss-of-function alterations through disruption of coding 
sequences are commonly referred to as 'targeted gene knockouts'.
Where targeted gene inactivation is lethal, procedures have been 
developed to selectively inactivate the gene of interest in a particular 
tissue as exemplified by the inactivation of the DNA polymerase ß (an 
enzyme involved in the development of T and B cells) in lymphoid 
tissues (Gu et al. 1994) using the Cre and lox system (Fukushige and 
Saver 1992). By disabling a gene, it becomes feasible to learn about gene 
structure and function, and ultimately create animal models for genetic 
diseases.
Several techniques have now been developed to introduce subtle 
alterations to selected sequences on the genome (Hasty et al. 1991; 
Valancius and Smithies 1991; Askew et al. 1993; Detloff et al. 1994; Wu 
et al. 1994). Such alterations permit the in vivo studies of the function 
of mutant proteins. Also possible is the study of the different isoforms 
of a protein by altering the genome in such a manner that only a 
particular isoform is expressed.
5.1.7 Overview of this chapter
The isolation and characterisation of the mouse IL-5Ra gene 
presents a unique opportunity for further investigating its role in vivo 
by gene targeting. Because of the specialised nature of gene targeting 
this research was done in collaboration with Dr K. Matthaei, (Gene
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Targeting Facility, JCSMR). There were two aims of the present work. 
Firstly, to produce a mouse deficient in the IL-5Ra by insertional 
inactivation of the endogenous IL-5Ra gene, and secondly, to produce 
a mouse that could express the transmembrane form of this receptor 
but not the soluble form. While the first mouse was designed for 
investigation of the biological role of the IL-5Ra, the intention of 
producing the second mouse was to probe the role of the soluble form 
of this receptor about which little is known.
5.2 Experimental Design
The rationale for selecting a particular region for the making of 
the targeting constructs and the design of these constructs will be 
described in detail below.
5.2.1 The knockout targeting vector
When designing a knockout construct, serious consideration 
has to be given to the choice of site for insertional disruption. Ideally, 
a genomic region containing a functionally important element should 
be selected for disruption to guarantee complete inactivation of the 
gene. Of course, the inserted DNA may also cause a variety of other 
effects such as the termination of transcription or translation or the 
incorporation of new protein sequence resulting in disruption of 
protein structure. Since it is the extracellular domains of membrane 
bound receptors that engage their ligands, inactivation of the mouse 
IL-5Ra gene could involve the disruption of one of the exons encoding
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the extracellular domain. In the absence of crystallographic and 
functional data for critical sites in this region, the choice of target sites 
has to be guided by the location of conserved features and the 
availability of restriction sites.
As noted in Chapter 2, the region around exon 7 and 8 of the 
IL-5Ra is highly conserved between human and mouse with regard to 
size of exons and introns, and the exons share 71 % homology at the 
amino add sequence level. In addition, within exon 8, there are two of 
the four cysteine residues highly conserved between members of the 
cytokine receptor superfamily which are believed to form disulphide 
bridges. One of these cysteine residues, the fourth residue, lies within 
the recognition site of restriction enzyme Sphl. Hence, disruption of 
the extracellular exon 8 at the Sphl site with the neo gene should lead 
to the inactivation of the IL-5Ra gene.
5.2.2 The soluble form targeting vector
The soluble form of the IL-5Ra is generated by alternative 
splicing which removes the transmembrane exon (Takaki et al. 1990). 
Elimination of expression of the soluble form of the receptor requires 
the removal of introns flanking the exon encoding the transmembrane 
domain so that alternative splicing activities that normally generate 
the soluble form of the receptor do not occur. This was accomplished in 
the present work by replacing the genomic sequences at this particular 
region with the cDNA.
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In this case, the neo marker was positioned downstream of the 
polyadenylation signal sequence in the 3'-untranslated region to avoid 
disrupting the mouse IL-5Ra gene. Since there are no introns between 
the last exon (exon 13) and the 3'-untranslated region, after the 
insertion of the neo marker gene, the genomic fragment was used to 
replace cDNA sequences downstream of the unique BstBl site present 
in exon 13 and the cDNA. This modification added the 3'-untranslated 
region and the neo marker to the cDNA without altering any coding 
sequences.
There is an Eco81I site 782 bp downstream of the 5'-end of the 
cDNA and this site is situated in exon 7 in the gene. Replacement of 
genomic sequences downstream of this site with the modified cDNA 
was carried out to generate the soluble form targeting vector. 
Homologous recombination in the region around exon 7 and the 
3'-untranslated region downstream of neo marker should result in 
an allele that has all the intronic sequences between exon 7 and 13 
removed and replaced with the cDNA. Provided there are no 
cis-regulatory elements in those introns, expression of the altered 
gene would be expected to give rise only to the transmembrane form 
of the receptor.
5.3 Materials and Methods
5.3.1 Plasmids
Genomic IL-5Ra chain gene was cloned (refer to Chapter 2) from 
BALB/c leucocyte genomic library (Clontech; Palo Alto, CA) and later
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subcloned into pBluescript SK- (Stratagene; La Jolla, CA). Plasmid 
pl4410 carrying the HSV-TK gene was generously provided by 
Dr Manfred Kopf (Max Planck Institute for Immunobiologie; Freiburg, 
Germany). The PGK-Neo plasmid was constructed by Bruce Mann 
(Ludwig Institute, Melbourne) and later modified by Xiao-Wen Wang 
(Gene Targeting Group, JCSMR).
5.3.2 DNA manipulation
Basic DNA manipulations such as plasmid preparation, 
restriction enzyme digestion, ligation, transformation, screening for 
recombinations, PCR and sequencing have been described in detail in 
Section 2.2.
5.4 Results
5.4.1 Construction of the knockout targeting vector
A 3.5 kb genomic fragment carrying exons 7 and 8 was digested 
with Sphl and the 3'-protruding ends were made blunt ended with T4 
DNA polymerase. This removed two of the three bases coding for the 
cysteine residue and the gene was disrupted by inserting the neomycin 
phosphotransferase (neo) expression cassette. The neo gene was excised 
from its vector (PGK-Neo) by digestion with EcoRI and HindlU, made 
blunt ended with T4 DNA polymerase and ligated into the blunt ended 
Sphl site of the genomic fragment. The resulting recombinant 
molecule now has neo inserted into exon 8 (Figure 5.4.1.1).
E - ^ H  
-----1 NEO1------
EcoRI, Hindlll & 
blunt-ended
I
H
SphI & blunt-ended
NEO
H
POSITIVE 
CONTROL 
for PCR
BH
— | HSV-TK
BamHI, bliunt-ended & 
Hindlll
KpnI/XhoI 
ExoIII 
SI nuclease 
Hindi«
— [hsv-tkJ-
PCR primers
KNOCKOUT \ r . ~ , — L 
CONSTRUCT NEO
Insertion of the neo cassette 
into exon 8 of mouse IL-5Ra 
genomic fragment.
The resultant 
recombinant genomic 
fragment has neo 
disrupting exon 8 .
Ligation of Exolü/Sl 
nuclease treated genomic 
fragment into a vector 
contaning HSV-TK to 
generate the positive control 
vector for PCR and the 
knockout construct.
Figure 5.4.1.1. Construction of the mouse IL-5Ra knockout vector. Filled boxes
represent exons; thick horizontal lines represent intronic DNA; thin 
horizontal lines represent vector DNA; NEO: neomycin 
phosphotransferase cassette; HSV-TK: herpes simplex virus 
thymidine kinase cassette; S: Sphl; E: EcoRI; H: Hindlll; B: BamHI; 
K: Kpnl; and X: XhoL
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To take advantage of PCR as a screening procedure, it was 
necessary to truncate up to about 100 base pairs from the 5-end of the 
construct. Owing to the lack of suitable restriction sites in this region, 
the 5'-end was digested with exonuclease ID. For this procedure, the 
construct was digested with restriction enzymes Kpnl and Xhol which 
cleave their respective sites on the vector adjacent to the 5'-end of the 
recombinant genomic fragment. Kpnl generated 3'-overhang ends 
which were not a substrate of exonuclease HI and this procedure 
protected one end of the plasmid from digestion. Xhol generated 
5'-overhang ends that allowed the exonuclease III to digest into the 
5'-end of the genomic fragment. Following controlled treatment with 
exonuclease DI, the ends of the plasmid were blunt ended with SI 
nuclease and Klenow enzyme and then digested with HindUl. The 
recombinant genomic fragment was then ligated into a vector (pl4410) 
carrying the HSV-TK gene (the negative selection marker) that has 
been treated with BamHl, blunt ended with T4 DNA polymerase and 
then cleaved with Hin din to generate ends compatible with the 
genomic fragment (Figure 5.4.1.1).
As a result two very similar constructs were prepared which 
differed only at the 5'-end. The longer construct served as a positive 
control for optimising PCR conditions using primers which bound to 
the neo gene and the 5'-extreme of the genomic fragment. The latter 
region is absent from the shorter construct which is the knockout 
targeting vector for electroporation into ES cells. As a result of 
homologous recombination, the missing region of the 5'-end would 
be reconstituted (Figure 5.4.1.2). Performing PCR with primers designed 
for the positive control construct will generate a product that is 
identical in size to the positive control where homologous
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recombination has occurred. On the other hand, if random integration 
has taken place, then the 5-end would not have been reconstituted and 
no PCR product would be produced.
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5.4.2 Construction of the soluble form targeting vector
A unique EcoRI site was identified 723 bp downstream of the 
polyadenylation site in a genomic fragment carrying the last exon (exon 
13) and the 3'-untranslated region. The neo gene was introduced into 
the blunt ended EcoRI site. This strategy introduced a selectable marker 
without disrupting the gene (Figure 5.4.2.1).
The recombinant genomic fragment was used to replace cDNA 
sequences downstream of the corresponding BstBl site in the cDNA 
without creating any alteration to the cDNA. This was accomplished by 
treating the genomic DNA with Notl, followed by blunt ending with 
T4 DNA polymerase and cleavage with BstBl. The cDNA was treated 
with EcoRI, T4 DNA polymerase and BstBl, and then the genomic 
DNA fragment was ligated into the cDNA (Figure 5.4.2.1).
There is a unique Eco81I site 782 bp downstream of the 5'-end of 
the cDNA which maps to the corresponding site in exon 7. The 
modified cDNA derived above was then ligated into the vector 
carrying HSV-TK and the genomic fragment containing exons 7 and 8 
by treating the modified cDNA with Hin dm, T4 DNA polymerase and 
Eco81I, and the genomic vector with Smal and Eco81I. The resultant 
construct carries 645 bp of intronic sequences preceding exon 7 but no 
introns between exon 7 and exon 13 (Figure 5.4.2.1).
13
— | h s v -t k |-
^ h h
c  Sm Nr _V
Bs
EcoRI, Hindlll & 
blunt-ended
EcoRI & 
blunt-ended
Sm N
NEO
El Bs 
cDNA
Bs
EcoRI, blunt-ended & 
BstBI
Notl, blunt- 
ended & BstBI
NEO
7 8
Hindlll, blunt-ended & 
Eco81I
7-13
Smal
Eco81I
HSV-TK I — In e o I
Insertion of the neo cassette 
into the EcoRI site situated 
723 bp downstream of the 
polyadenylation site.
Reconstitution of the cDNA by 
adding to it the 3'-untranslated 
region containing the neo 
cassette.
Transfering the recombinant 
cDNA to the corresponding 
Eco81I site in exon 7 .
The resultant construct is now 
devoid of intronic sequences 
between exons 7 and 13.
Figure 5.4.2.1. Construction of the soluble form targeting vector. Filled boxes
represents exons or coding region of cDNA; empty box represents 
untranslated region; thick horizontal lines represent intronic DNA; 
thin horizontal lines represent vector DNA; NEO: neomycin 
phosphotransferase cassette; HSV-TK: herpes simplex virus 
thymidine kinase cassette; E: EcoRI; H: Hindlll; Bs: BstBI; Sm: 
Smal; N: Notl; El: Eco81I.
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Homologous recombination between this construct and its 
genomic locus should give rise to an altered IL-5Ra gene devoid of 
intronic sequences between exons 7 and 13 (Figure 5.4.2.2). This strategy 
effectively eliminates alternative splicing events which normally 
generate the soluble form of the receptor. The altered gene should 
therefore only be capable of expressing the transmembrane form of the 
receptor.
For PCR screening of ES cells electroporated with the soluble 
form targeting vector, the positive control vector used in the knockout 
work could also be used here for the same purpose. The same 5'-end 
primer can also be used but a new 3'-end primer designed to bind to 
exon 8 is required. Where homologous recombination has occurred the 
PCR products will be of the expected size, but in the wild-type, the PCR 
products will be 76 bp longer due to the presence of intron 7.
Both targeting constructs were prepared but unfortunately time 
did not permit the completion of this work and the experiments are 
continuing in the Gene Targeting Laboratory. ES cells have been 
electroporated and are being screened for homologous recombination 
events by PCR. Positive cells will be injected into blastocysts and the 
blastocysts transferred into pseudo-pregnant mothers to generate 
chimeric mice. The heterozyous chimeric mice will then be tested for 
incorporation of the modified allele into the germline and, if 
successful, will be subsequently interbred to generate mice homozygous 
for the desired modifications.
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5.5 Discussion
Gene targeting technology is a powerful technique for studying 
and defining the role of specific gene products in the context of a whole 
animal. The power of this approach lies in its ability to specifically alter 
genomic sequences within their chromatin and chromosomal 
environment and the possibility for the alteration to be transmitted 
through the germline.
Knockouts for genes such as the homeobox genes has helped to 
decipher the function of these genes in development (Chisaka and 
Capecchi 1991; Chisaka et al. 1992). Cytokine knockouts are also proving 
to be informative, providing a more realistic indication of their 
respective roles in vivo. Extrapolation from in vitro studies to the role 
of cytokines in vivo is complicated by the uncertainty of when the 
cytokines are expressed, what levels are expressed and the possibility of 
shared activities with other cytokines or modulation of activities by 
other cytokines.
Where receptors are shared by several other cytokines, the 
effects of inactivation of the shared receptor subunit appears to be 
severe. An example is the IL-2 receptor. IL-2 knockout mice did not 
show appreciable perturbation in thymocyte and peripheral T-cells 
populations (Schorle et al. 1991) possibly because of overlapping 
activities of other T-cell growth factors like IL-4, IL-7 and IL-15. 
However, in patients suffering from X-linked severe combined 
immunodeficiency (XSCID) a severe phenotype characterised by 
absence of T-cells is observed (Noguchi et al 1993b). This condition is 
due to mutations to the IL-2 receptor y-subunit which is shared by IL-2,
IL-4, IL-7 and IL-15 (Takeshita et al. 1992; Kondo et al. 1993; Noguchi et 
al. 1993a; Giri et al. 1994).
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A shared cytokine receptor that has been inactivated in mice is 
the common ß-subunit (AIC2B) of the IL-5, IL-3 and GM-CSF receptors. 
Unlike the inactivation of IL-2 receptor y-subunit, no severe pathology 
was observed in this case except for a minor lung lesion and rather 
subdued eosinophil response to parasite infections (Nishinakamura 
et al. 1995). This is possibly because of the redundancy in receptor 
subunit and cytokine action unique to this subfamily in the mouse. 
While IL-5 and GM-CSF function may be abolished, IL-3 could still 
transmit signals through its specific ß-subunit (AIC2A). The lung 
lesion is most likely due to the loss of GM-CSF activity as similar 
pathology was seen in GM-CSF knockout mice (Dranoff et al. 1994; 
Stanley et al. 1994). The effect on eosinophils may be due to the 
inactivation of the IL-5 response. In this case, the inactivation of shared 
receptors give an indication of the total role of the cytokines involved 
but without the inactivation of the cytokines themselves or their 
specific receptor a-chains. However, it is difficult to delineate the 
individual roles of cytokines through the inactivation of the shared 
receptor. Since the IL-5Ra is IL-5 specific, its inactivation would be 
expected to show the portion of the phenotype attributable to IL-5 in 
comparison with that of the ß-subunit knockout. The IL-5Ra knockout 
would also be useful for establishing receptor-deficient cell lines and to 
further study the role of IL-5 in vivo.
There are still a number of uncertainties about the role of IL-5 
in vivo which could be addressed effectively with such a model. These 
include the role of IL-5 in asthma, parasite infections and antibody
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production. Preliminary evidence from the study of Fasciola hepatica 
infections has suggested that this parasite may secrete an IL-5-like 
substance having similar properties to IL-5 (Milbourne and Howell 
1993). An IL-5Ra knockout mouse would enable the involvement of 
the IL-5 receptor in the regulation of the eosinophilia caused by this 
parasite to be tested. The possibility that eosinophils are in some way 
involved in the life cycle of this parasite rather than in host defence 
deserves further investigation.
The utility of targeted mice capable of expressing only the 
transmembrane form of IL-5Ra is in elucidating the function of the 
soluble form in vivo. As discussed earlier in section 1.6, although the 
physiological role of soluble receptors is not fully understood, three 
probable roles have been ascribed, ie., antagonist, agonist and carrier. 
Evidence to support all three functions has been presented but there 
is little convincing data available for the IL-5Ra soluble form. Soluble 
receptors need not necessarily have the same function. It is quite 
possible that the individual soluble receptors could have different 
functions depending on the system. In this respect, the targeted mouse 
that only expresses the transmembrane form of the IL-5Ra may prove 
to be critical in defining the function played by soluble receptor in vivo.
Although time did not permit the generation of the targeted 
IL-5Ra mice and their analysis, concrete steps have nevertheless been 
taken towards this goal by the successful construction of targeting 
vectors for inactivating the IL-5Ra gene and for directing the IL-5Ra 
gene in expressing only the transmembrane form of the receptor. 
Completion of this work will provide powerful animal models for 
addressing the biology of IL-5 and its receptor in vivo.
CHAPTER SIX
GENERAL DISCUSSION
6.1 An overview of this thesis
IL-5 is believed to be a late acting factor in eosinophil 
development and to play a central role in the selective elevation of 
eosinophil numbers in parasitic infections and allergies. Since receptor 
expression is pre-requisite to cytokine response, an understanding of 
the underlying mechanisms regulating the expression of the mouse 
IL-5Ra gene is highly relevant to the activities of IL-5 in promoting 
eosinophil development and, in mice, B-cell development and 
antibody production.
The work described in this thesis was aimed ultimately at 
gaining a better understanding of the mechanisms leading to the 
expression of the mouse IL-5Ra gene in a cell type-specific manner.
The first step towards this goal was the isolation of the full-length gene
from a genomic library and the determination of its nucleotide 
sequence, as described in Chapter 2. The determination of the complete 
sequence of the gene provides a solid basis for all future studies of this 
gene only some of which can be accomplished as part of the work 
described in this thesis. Characterisation of the gene involved 
determination of the transcriptional start site and polyadenylation site 
as described in Chapter 3 and the identification of tissue culture lines 
expressing the gene. These cell lines were important models for gene 
regulation studies (Chapter 4).
Chapter 4 describes the linking of the promoter region to the 
ludferase reporter gene and the analysis of expression of the reporter 
gene constructs following stable transfection into cell lines either 
expressing or not expressing the gene. This approach, in combination 
with deletion analysis, helped to identify regions upstream of the start 
of transcription carrying ds-acting regulatory elements involved in the 
cell type-specific expression of this gene.
In addition to the studies on gene regulation, the availability of 
the full-length mouse IL-5Ra gene and its nucleotide sequence 
provided the opportunity to begin a study of its role in vivo using gene 
targeting techniques. Chapter 5 describes the construction of gene 
targeting vectors designed to enable the generation of mice having 
their IL-5Ra gene functionally disrupted or modified so that only the 
transmembrane form of the receptor protein is expressed.
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6.2 Structure of the mouse IL-5Ra receptor gene
In the work described in Chapter 2, the mouse IL-5Ra gene was 
shown to span 38.6 kb from the transcription start site to the 
polyadenylation site and to be organised into 13 exons. The overall 
organisation of the gene is similar to that of other members of the 
hemopoietin or class I cytokine receptor superfamily. Members of this 
superfamily share four highly conserved cysteine residues and a 
WSXWS motif in the extracellular domain (Cosman et al. 1990; Sato 
and Miyajima 1994a).
Although the genes of members of this superfamily differ 
considerably in size, due mainly to the differing sizes of their introns, 
their genomic structure and gene products show striking similarities. 
This level of similarities is highly suggestive of the possibility that 
members of this superfamily may have evolved from a single ancestral 
gene. As such, gene structures of other members of this superfamily, 
when determined, are expected to conform to this basic pattern.
At approximately 6.5 kb upstream of exon 1, there is a 1.0 kb 
stretch of sequences that has a GC-content of 80%. This level of GC- 
content usually suggests the presence of CpG islands which may have 
implications for the regulation of the IL-5Ra gene. Alternatively, its 
function may relate to another gene immediately upstream (see below).
Sequence similarity comparison with sequences in the Genbank 
and EMBL databases, uncovered numerous repetitive elements 
dispersed throughout the mouse IL-5Ra gene. These elements should 
not be dismissed as "junk" DNA in light of accumulating evidence that
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they may have some functional significance (reviewed by Mattick 
1994). For example, the LINE element has been associated with 
transcriptional repression in the rat insulin 1 gene (Laimins et al. 1986) 
and the CA dinudeotide repeat instability has been associated with 
colorectal cancer (Thibodeau et al. 1993; Mironov et al 1994).
An interesting feature uncovered during sequence similarity 
searches is a 0.8 kb portion of the GC-rich region that has 84% 
homology with the human fork head domain (Galili et al. 1993) and 
67% homology to the C. elegans homolog (Kohara et al. 1994) at the 
amino acid sequence level. The fork head family is a diverse family of 
transcription factors involved in tissue-spedfic and developmental 
gene regulation. Members of this family share a highly conserved 
DNA-binding domain referred to as the fork head domain (Weigel 
and Jackie 1990). This level of homology suggests the possibility that a 
member of the fork head family of genes lies immediately upstream of 
the mouse IL-5Ra gene. Confirmation of this possibility will require 
the demonstration of a mRNA derived from this gene.
6.3 Transcriptional regulation of the mouse IL-5Rcc gene
The expression of the majority of eukaryotic tissue-specific genes 
has been found to be regulated at the level of transcription (reviewed 
by Maniatis et al. 1987; Herschbach and Johnson 1993)). To investigate 
whether the cell type-spedficity of the mouse IL-5Ra gene expression is 
similarly regulated, stable cell lines were generated by transfection of 
various mouse IL-5Ra promoter-reporter gene constructs into mouse 
cell lines that express the IL-5Ra gene [BCLi(5Bib) and CH27] and a cell
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line that does not express the IL-5Rcx gene (FDC-P1) and reporter gene 
activity has been evaluated. The results suggest that gene regulation does 
involve transcriptional mechanisms and have provided evidence that 
transcriptional repression may be involved.
A 4.8 kb region, which has a 1.0 kb stretch of GC-rich sequences, 
situated 6.5 kb upstream of the transcription start site has been 
identified to be responsible for mediating transcriptional repression.
This region is predicted to contain negative as-acting regulatory 
elements. Further deletion and site directed mutagenesis are necessary 
in order to define this element in detail.
Of interest is the finding that this 1.0 kb stretch of GC-rich 
sequences has a GC content of 80% which is indicative of the presence 
of CpG islands. CpG islands are short regions of the genome that are 
characterised by a high density of CpG dinucleotides which are 
generally unmethylated. The observation that several methylation 
sensitive rare cutter restriction enzyme sites are clustered around 
this region provides further support for the presence of these islands 
(Brandeis et al. 1993; Tate and Bird 1993). This region also has 
homology to the fork head family of genes but the characterisation of a 
functional fork head gene and its delineation from elements involved 
in the mouse IL-5Ra gene regulation awaits further work.
Although the exact mechanism of transcriptional repression of 
the mouse IL-5Ra gene is not certain at this stage, there are at least two 
possible mechanisms by which this repression may be mediated. They 
are the binding of a frans-acting repressor protein and DNA 
methylation.
Transcriptional repressor proteins generally inhibit transcription 
by blocking any step in the transcription initiation pathway. Some of 
the modes of action of these repressors have recently been defined and 
include: (i) competition - repressors may compete for DNA binding 
with either the transcription complex itself or with activators of 
transcription; (ii) masking - repressors may block activator function by 
directly contacting the adjacent DNA-bound activator and masking the 
domain responsible for transcriptional stimulation; and (iii) silencing - 
repressors may cause alterations in chromatin structure that results in 
especially compacted chromatin which obscures the DNA from the 
transcriptional machinery (Jackson 1991;Herschbach and Johnson 1993).
Like repressors, methylation of cytosine residues at CpG 
sites (CpG islands) also has a negative impact on transcription. 
Transcriptional repression mediated by methylation has been 
implicated in the regulation of tissue-specific and developmental 
genes, and the inactivation of X-chromosomes in female mammalian 
cells. Methylation has been postulated to inhibit gene expression by 
preventing the binding of transcription factors to regulatory sequences, 
by interfering with the function of active chromatin or by attracting 
specific proteins that repress transcription to the methylated DNA 
(reviewed by Bird 1993; Brandeis et al. 1993; Tate and Bird 1993).
6.4 Animal models for studying the biology of IL-5 and its 
receptor
The determination of the nucleotide sequence of a gene permits 
its comparison with other genes and its placement within gene
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families based on the degree of homology. From these comparisons, 
clues to the possible function of the gene product may be gained. 
Nevertheless, empirical determination of the function of the gene 
product remains one of the central challenges of biology. Numerous in 
vitro techniques are available to help analyse function and, frequently, 
are the only feasible means through which to make progress. However, 
the ultimate test of function can only be performed in vivo.
Transgenic mice have been a very popular in vivo model system 
for studying gene regulation, development, pathogenesis and the 
treatment of diseases (reviewed by Merlino 1991; Taverne 1993)). 
Recently, another technique where mice are genetically altered by 
targeted homologous recombination has become the technique of 
choice for the generation of animal models because of the precise 
control over the type of alteration, the site of integration and the gene 
copy number afforded by this technique. Therefore, gene targeting 
constructs were prepared to enable the generation of two mouse 
models for studying the biology of IL-5 and its receptor.
In the 'knockout' model, the IL-5Ra gene was to be inactivated 
by the disruption of an exon. In the absence of evidence for the 
existence of other IL-5 binding proteins, the inactivation of IL-5Ra is 
predicted to mimic the effect of the loss of IL-5 function due to the loss 
of signal transduction. This model could effectively address the in vivo 
role of IL-5 in asthma, parasite infection and antibody production. In 
addition, this model could be used, in parallel with normal mice, to 
evaluate the involvement of IL-5Ra with the IL-5-like substance 
secreted by Fasciola hepatica that has been demonstrated to mimic the 
action of IL-5 in a number of in vitro assays (Milbourne and Howell
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1993). The possibility of the recruitment of eosinophils by this parasite 
for its life cycle and not for host protection has important implications 
to the study of antiparasite immunity.
In the second model, a targeting construct was designed so that 
homologous recombination would result in the generation of mice 
capable only of expressing the transmembrane form of IL-5Ra protein. 
While in vitro studies have suggested an antagonistic role for the 
soluble form of IL-5Ra (Devos et al. 1993), its in vivo activities may 
well be different. The above model may prove to be critical in defining 
the role of the soluble IL-5Ra in vivo. However, time did not allow the 
completion of this section of work which is still in progress.
Overall, the studies described in this thesis have provided a 
complete characterisation of the primary structure of the mouse IL-5Ra 
gene and its transcripts and have made contributions to the 
understanding of its regulation. If the gene targeting work is successful 
it may lead to important advances in understanding the biology of IL-5 
and its receptor.
APPENDIX
NUCLEOTIDE SEQUENCE OF THE MOUSE INTERLEUKIN-5 
RECEPTOR a-CHAIN GENE AND FLANKING REGIONS
NB. Numbers preceded by '+' or denote numbering of nucleotides 
relative to the transcription initiation site, where '+' indicates downstream 
sequences and indicates upstream sequences. Numbers in brackets 
indicate numbering of nucleotides relative to the first nucleotide in the 
5'-end. Exons are underlined with dots.
CAGTGAGGGC TGAGTGAAAC 
GGATTCACTC TGGCATTGAT 
AGGTTCTTTG GGCCAGGTCC 
AGGAACCCTG TGCCCAGGGA 
CCATGCTACT GGGTCCCTTT 
CTGGGCCAGG CATGAGCCTA 
ACGCCTCCTT CCAACCTGGA 
ACATCACCCC TGTGCTATTC 
TCAGGAGGGT GGTTTCTTTC 
GGGGGGGGGT GTTCTCTTGA 
TAAAACCTAT TCGTCTTTAA 
AGATCAGGAT TCCCTGGCAG 
TGGGCTTTGA AAGAGGAGTC 
TGTCCTCACT TGCCCCTGAG 
TTGACAGCTC AGCAGCGGTG 
TTCTTGAGTC AGGATGGGGG 
GGGAACTACT GGGGAGGCTG
TGAGGGCACA AGAAGGCAGG 
TCTCTACCTC TGTTGATGGG 
TTGTGTTCTC GGGAACTCTC 
ATAGATTGTG GAAGCAATTG 
AGCCTTGCCT CTTCAGCTCA 
CCCTGGAGGT TCTCCCAGCT 
GGCCTACTCT GGACACCAGT 
TTTTCCCCCT GCCACTGGGG 
ATTTTATTTG TTTGTTTGTT 
GACTCCTAGG AGGGCCAGAT 
GCCCATAGTG GGGAGGTGGA 
GGTGGGTGCA GGTGACAGCA 
CTGGAGCACA GAGCCACTAC 
TGAGCCGGGG AAGCTGGCAC 
GCAGGGGCTA TTCTGAGAGC 
TGATCACTGA GGTGGCTGCA 
CTGGCACTGC TTGATGGTTA
ATGGAAAGGG ATCGCATGTT 
TGGACAGTTT TCTGGCCAAA 
CGTAGCTACT TGATCTGCTT 
AAGTGGCCTT AGATTTTCTA 
GCCCCACCCA CTTCCGGGCA 
GTCCTGATGT CCCCTCTGCC 
CCCTCCCCCT GCTTCCATAG 
CATCAAATGT CAAACAGGCT 
TTGTTTGATA ACTGTGGCTT 
GGGTTTTGCC ATGGTCTAGC 
CTCTCTGCTT TCACAGGGTG 
GCCAACCCCA AGTACTGACT 
ACACATCAGG ACTCAGAGAA 
CGAGCAGCGG GACACAAACT 
TGGGAGGGGC TGAGACAGGA 
TTGGGACACT GTGTGGGATA 
CAAGTGTTAA AGAGTTGTAT
CCGGTAAGAA -11014
(70 )
GGAGAACATC -1 0 9 4 4
(140)
TCCTGACACA -1 0 8 7 4
(210)
AAGGGGCCCT -1 0 8 0 4
(280)
CTGTCCCAGC -1 0 7 3 4
(3 5 0 )
TTCTATAGAC -1 0 6 6 4
(4 2 0 )
GTGTCCCCAG -1 0 5 9 4
(490)
CTGCTGGGCA -1 0 5 2 4
(560)
GCGGGGGGTG -1 0 4 5 4
(630)
TCTGTCCAAG -1 0 3 8 4
(7 0 0 )
AGAAAGATGA -1 0 3 1 4
(7 7 0 )
GCCTTCCGGG -1 0 2 4 4
(8 4 0 )
GCCACCCTCT -1 0 1 7 4
(910)
CTGGAGGGCC -1 0 1 0 4
(980)
GAGGAAGCAG -1 0 0 3 4
(1050)
TGCATGGTCT -9 9 6 4
(1120)
GGGCAAGCAC -9 8 9 4
(1190)
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A C G G T G C A A G T G A T C A A G T G T G T G T G C A T C A A A G T G C A C G T G T A C G T C C T T G C T G A A G A A G G T G T G A A A G -9 8 2 4
(1 2 6 0 )
C A A G C A T G C C TG TG T G G G G G A G G A G G A G A C A G A G G A A G G T A A G C A A A T A G G A G C T T G T T A G G G A G C TG A A -9 7 5 4
(1 3 3 0 )
T G G G T G TG G G A G T G G G T C N C A G T G A A A G G A C A C T G A G C T G G A G A G C T T G C ATG G G G G AG G G G AG G G AG G A -9 6 8 4
(1 4 0 0 )
G C C A A T G G T T A A G A A A A C C A G A G G A A G A T A A G G A T T A T G T A A C T A G A C T T T G A A T A T A G G G C A T T G G G T A -9 6 1 4
(1 4 7 0 )
A G C G A G C C A G T G A A T G T G A G T G G A G G T G T G T G C T C A T C A T A T G A G C C G T G G A G A C T A T G T G AG C C G G G G A -9 5 4 4
(1 5 4 0 )
A A A T A C A C A T G A G C A A C A A G A A T C G T T T C T G G A C T G A T T C T G A G C C T G G T A C T A T T G T T C A G A G T C T T A T -9 4 7 4
(1 6 1 0 )
T T C A T A C T T C A G T C G T C C T G G G A A G G C A G C A N C A T G G T G A T A C A T G A C G G C A G G G T A G A A A A C A G G G G C T -9 4 0 4
(1 6 8 0 )
C C G A G C A G C G A A A T G A C T T G C C A T A C T C C T T T G G A T C A C G G T C A G A T T G C C T C C T G A T G A G T G T G T G T A A -9 3 3 4
(1 7 5 0 )
G C A G G G A G T G A A C A A G C C T G T G A G T G A A C A A G A A A G T C A G T G T G C C C T A G T G A G T G T G T T A G G G A G C T G A -9 2 6 4
(1 8 2 0 )
C C G T G C C A G A C A T A G G C C C C A G A G G A C A G G A C A G A C A G C A G C T G T G G C C A C T A G G C A G G C A G G G G C AG AG -9 1 9 4
(1 8 9 0 )
C A G A T C C T G A G T C A G C C T C T G G G C A T T T C T G C C A A C C T G G C T T C C C A A C C C T G C A G T G A C A G C C T G T G C C -9 1 2 4
(1 9 6 0 )
A G A A C C C C C A G C T A A G T T T C A T C C A G C C A T G G T G T G G T C C C C A G C A A G C T C T C A T G T C A C A C T A A G A G C C -9 0 5 4
(2 0 3 0 )
A G G C C T G A T C T C A A G G A T G G C A A G A A G C T A G C C T C C A A G G A A C T C A A G A A G T A G A G C C A G T G T T G A C T C C -8 9 8 4
(2 1 0 0 )
C C A G G C A A G A A G G G C A T C T A T G A A C T G T G G G A A G G G G C C A G C A G T G A T T T C A G C C C T G G A T G G T T C T A A A -8 9 1 4
(2 1 7 0 )
C A G A A C C A C C T G G A G C A T G T G T A T A T G T A A G G G G G TA G C A C A T A G T T C C C A T A C C C A C C C C T G C C T T T G G -8 8 4 4
(2 2 4 0 )
G A C G T G A C T C A G G C T G A T G T T A A T C A T C T G C A A A A T G G G C T T G C T C C A T C C C C C A T C C C C TG G G A G A G C T -8 7 7 4
(2 3 1 0 )
C C A G C C T G T C A A T C A A A G C C C T A C C T G C T T T C A C T T A C T T C T A T C C T C T C C C T G G G C T T C A A T C T G A G G A -8 7 0 4
(2 3 8 0 )
A A G G A A G T T T T T A A A G A G G A G G C T G T T T C C C T T A G T G A G A A T A C A G C T C T T C T A C T G C C C A G A G A A C T C C -8 6 3 4
(2 4 5 0 )
A C C T C C C T A G T C C C T T T A G G A A G C A G G T A C T G G C C A G G A G G A G G T T A A G A C T T G G A A A C T C T A G T G T T G G -8 5 6 4
(2 5 2 0 )
A C A T G T T A A T T T T G G T A G G T T G C T T C C C C C A C T C T G G A C C T C A G T T T C C T G A T C A G C A A A A C A G G A G A C T -8 4 9 4
(2 5 9 0 )
G T G C C A A A G G G A C A T G A A G G T T T G C T G G C A G G G C A G C A A G C A T C T G G G C A A G C A G G G A A T A G T C A G G C A T -8 4 2 4
(2 6 6 0 )
G T G A G G G G G T T T G A G T T A G A A G A A G T G C C A G G G T T A G A C T G A T G T T T A A G C T G A G T T T T G G T G G A G G C C T -8 2 5 4
(2 7 3 0 )
C A C A G C T G G G A A T G T T T G T A G G C A T A C G G C A T A G C C T G A G C A T A G G C T G G C A G A T G G A G T G G T G A C T G G A -8 2 8 4
(2 8 0 0 )
G A C T T A G C C T C C C G G A C C C T T T G G G A T G A G G T A A T G G A C T G C A T A A C C T C T T A G G A G C T G C T C C C T T T G A -8 2 1 4
(2 8 7 0 )
G G T C A C G T G A C G A T G G G A T T A A C A T C T G A G T C C T C T A C T A G T C T A T A C A G T A G G G A C C T C A T T T G T C T C C -8 1 4 4
(2 9 4 0 )
A T T T G C T G C T C T T A C C A T A G A G C C C T G A A A G A A G A C A G G A A C A A T G A A A A T G T T C A A T A T A T A C C C A T T A -8 0 7 4
(3 0 1 0 )
A A C G A G T G A G T T C C T C C C C A A C C G T T C T T A A C T T T G G G G G T G A G C A C T T G T T T C A A C A G C C C C T T T G G G A -8 0 0 4
(3 0 8 0 )
A C C T T C C A C A G C C T G G A A G A C A G T G G T A C C T A A A G T G A G G T C C C T A G T G C C T G T C A G C T T G C T A G A A A T G -7 9 3 4
(3 1 5 0 )
T G A A G T C T C G G C C C C A G C A C A G A C C T G C C G C C A G A C A C T C G A C G G TC G G G G T T C A G G C A T C T G T T T T A A T -7 8 6 4
(3 2 2 0 )
C C T C T G T A G G A T A A A A C C T A C C A C A C A C T G A A C T T T G A G A A C C A A T G C T C T A A A A T T G T G C T T G C A A G C A -7 7 9 4
(3 2 9 0 )
C A G T A A A A G C C C A G G A A G C C C C A T T T G C A C A G A G A A C A G G T A G G G T T G T G G T A T A A C G C C T G G C C T A C A A -7 7 2 4
(3 3 6 0 )
T C C A G G A A T T A T C A A A C C A T T T C T T T T C C C T A G A C T G G T C C A T G G C A C A A A G A G A C G A G A G T T A G A T C A A -7 6 5 4
(3 4 3 0 )
C C C T T A G T C T G G C T G T T G G A A G G A A G A C T T G G A A A C G T C A A G G G T C C A G A A G A G G A G G G C G G G G C A T T T C -7 5 8 4
(3 5 0 0 )
T G G G G A T G G T A G A A G C G G G G A G G G A C C A G T G T T C C G A G C C C C G C C C C A T T T C T G T T G C C C C G G G A A A C C C -7 5 1 4
(3 5 7 0 )
143
CGGGTTGTAA CAATAACTGC TGACGCGCTC CTGGGAGGAA TCCTTTGAAG GTTGTGGGCG GGGCAGCCCC -7444
(3640)
GCTGTGCACC AATGGAAGCA CTCGGGATCC GCCCCTACGT TGCCCTCCCC GAGCCCGGCA GGGGGCGGGG -7374
(3710)
CCGCGCCAGA CGTTTCTCGC CTGCTCCCTA GGGGGCGCTG TGGCGTGCGG GGCTTCGGCG GGGTCGCCCT -7304
(3780)
TAGCGGGAGC TCCACGCCCC CCACAGTCAG CAGGCGGGGC ACCCAGTAAG CAAGGATTCC GCGGCCCTGG -7234
(3850)
CGAGCACGCC CCGCCTCCTT TTGCTCCGGG TCCGCCCCGT CCCCGTCCCC CGCCCATCCC GAGGTGCAGC -7164
(3920)
CGGCGCTGAG CGCGGCAGGC GCGGGACTGG CGCTGGAGCC GGAGCGGCGG CGGCATTCAC GGGGCGGCGG -7094
(3990)
CGGCGCGGGC TCTGGCACGG GCTCGGGCTC CGGCATGGTG CAAGCCAGCC TCGTCCCGGG AGAGCGGGGC -7024
56% homology to human fork head domain (4060)
CCGCGCGCGG GACCGGCGCC GCGGAGCGGC GGCAGCGGCG GTGGCGGTGG TGGCTGCGGG CACAGACAGG -6954
(4130)
CGGCAGGTGC TAGAAGCTGG GCTGGGCGAG GTGTGTGCCC GCTGGGCTCC CGGGCCGCCG CCCCCTCACT -6884
(4200)
GCCTGGGTCT TTGCCTCCCT CCGTGCTCGC CAGTTTGTCC AGCCTCCTGC CTCCGCTCCC CGGCCCATGG -6814
(4270)
CGCCCCGCGG TTGAGCCGGC GCCGCCAGGG ACCCCTCCCG CGGGCCTCCC CGGGGCGCGC AGATCCCAGA -6744
(4340)
GCCGCGCGCC CACCCTCCGC GGAGCCTCCC TCCCTGCCTC GCCCGAGCCG GGCGGGACCA TGGCTGCGAA -6674
82% homology to human fork head domain (4410)
GCTGCGAGCG CATCAGGTGG ACGTGGACCC GGACTTCGCG CCGCAGAGCC GGCCGCGCTC GTGTACCTGG -6604
(4480)
CCTCTGCCGC AGCCGGACTT GGCCGGCGAC GAGGACGGGG CGCTGGGTGC AGGAGTAGCC GAGGGTTCCG -6534
(4550)
AGGACTGCGG GCCGGAACGC AGGGCGACGG CCCCAGCGAT GGCCCCAGCG CCTCCGCTGG ACGCAGAGGT -6464
87* homology to human fork head domain (4620)
CGGACCCTTG CGGAAAGCGA AGAGCTCCCG ACGGAACGCG TGGGGGAACC TTTCCTACGC CGACCTCATC -6394
(4690)
ACCAAAGCCA TCGAGAGCGC CCCGGACAAG AGACTCACGC TCTCGCAGAT CTACGACTGG ATGGTCCGCT -6324
(4760)
ACGTGGCGTA CTTCAAGGAT AAAGGCGACA GCAACAGGTC GGCCGGCTGG AAGGTGGGGC ATCCGGGCTC -6254
(4830)
CGGGCAGGCT ACAGGGAGGG GGGCTCTGGA ACACCCCTAG GGGTCATGGA GTGCGCGCCC AGGGCGTGGG -6184
(4900)
GCAGGTCAGT TGACAGGCGG GGGCATGCTG GCAGCAGCTG TATTCATTCA TGTCCCCTAG GAAGGATGCG -6114
(4970)
CGGGATTGGA GGTCTGGTAG GGTGACAGGG GATACCTTTT TGAGGCATCC CAGAGGATTA TCCCTGGCCT -6044
(5040)
GTCATTGAGC GTATAATAGC ATAACTCATT TCCAGACCAC GGACAGTAGG GAGCCCCCTT TGTTTTGTGT -5974
(5110)
GACTTGTTTT ACCCTCTCCA CCAGGGTACT TGCTTTAAAG AGCTGGAGTC ATGACCCGGG GCTCCTGTCT -5904
(5180)
GCTTTCCCTC TCAAATCTTC CCTGGCCTTC CTGACACTGG CCCCATGGTG AAGAGTGCTA ACAGATCAAG -5834
(5250)
CCTCCCCCCC CCCCAACCCC ATGCAATTCT TTCTATAGTG TTGAGAGTTC ATCCTGGAGC CTAGTCGGGG -5764
(5320)
TGAAAAGCAT GGCAGACCAC CGGAGATGAG TTCTTCATGG GGCAGTTGTC AGCCCCTTCC CTGGTACAGC -5694
(5390)
ATGGGGTGGG GGAGGTGCTT TAGGCTCCCT GCTGGGACTT GTGGGAATGG TGTTGAGGTC TGGGGGGGGG -5624
(5460)
GTCTATTTCT ACCCACTCGG GCAACTTATC TCTCACTTCC CTGGCTTTCT GGGCTCAGAT GCACTTAAGG -5554
(5530)
AGTGGGGCAC CCCTAGAGAG ACCTCAGTGG CAGGCAGTGG AAAGGGGAGA GCCATCTTGG GAGAAGACTT -5484
(5600)
GGATGGGGGC TTTACTGGAT TGTAGCTTCT AGATCCAGCT CCTCCTCTGT CCATCTTGTT GGGAAATGGG -5414
(5670)
GCTAGCCTAT GCACTTGGGG GTGAAAAGGC ATGAGGGGAC CTCTTGTGGG AGAGGTAGTC ACTGTGAGGA -5344
(5740)
AGACATGTCT GTGACCAGAG ATGAGGCTGT TTGGGGTGTT GATTGGCAGC AAGATCTGAG GAGAGGGGCA -5274
(5810)
GCAGCCATGG CCAGATCTAG ATGCACTTGG GAGTCCTGAT CTGGGAGCCC CCGGCTCTTG GGATTCCTGT -5204
(5880)
ACACTGGCAT CTTCTTTGGC TCTCCTTGAC CATTATGGGG CAGGAACACA AGACACAGAA GTAGACCTGA -5134
(5950)
144
G TCTCATCCC C TC C A T TTT C CAGTCCCCTA C A TC TC A G TT CCCACCAGAA TA C A A C TTT C TC TC AAG TG T -5064
(6020 )
GCCCTGCTCT TGGGCTTGCT C TG C TTC TTG TCTG CTG TG T CCAC C TTC C T TC C A C TC C TT CCCAGAGATG -4994
(6090 )
TA G TC A C TC T CCTCAGGCAC AGGGTCCCAG TTCC TC C TC C AAGAAG CCTT CCC TAAC AC T TG TTAG CTAG -4924
(6160)
CTCAGGACTC CCACCTACCC A C C T T T T T T T TTCCTGGCCC TAAGGCATGC ATC ATG AG TC A A TC A TG TG T -4 85 4
(6230 )
G C C CTACC TT CCTGCTTCCC TTCC C TTC C C T T C C T T T A C T TTTGAACGAC GGTGTCAGTG TTAG G AC TC T -4 7 8 4
(6300)
TCTG TCCCCA TG G C ACC TTA CAGAGAGTCT GGCCCAAGAA GCCACCAGTG TATG C ATG C T GAGAGTAAAG -4 71 4
(6370 )
AGATGGGTAG ATG G TAAAAG AGACTGTGGA TTGGCGAAGA GTGCCAGGAC CTGAGCAGAT CAGGAGGGCT -4 64 4
(6440 )
TC C TG TAAG A GGCAGAGCTC CAGCAGGTTT GGATGGATGA AGGAGACTGG GGAAAGATAG GAAGCAGGGA -4574
(6510)
TT TG A A G C T A GAAGCCTGGA GGCAGCTGCA G TTCTGAG CA AGCATGTTGG GGCCGAGCTC TGTGCCAGAC -4504
(6580)
T C TT C C C A TA TC TT TA A A G C TC TC AG TAG T CCCTGAGCTG G G TTT TA C TA TA A C C A TTC A TAGGGGTGGT -4434
(6650)
CTCTGAGGCC CAGAGGACGA G A G TC A A TTA ACTGCCTAAG G TTC TA C TC C AACCAAG GTA TGTCACCCAC -4 36 4
(6720 )
CTCTCCCGGT CCCAGCAAGC CTCTG G AACA TGCCTGGCTA GCCCTGGCGA GAGGAAGCTG CTGCTGGTGT -4294
(6790 )
TGAACAGAGG CCG ACATAAA AC ATAG G ATA TGATGGCAGC GTGCTTAGAG ATAATTG AG C CCCATG AGTT -4224
(6860 )
C A TTT C T C A G ACTGTGAGAC TGAGGCCTGG GGAGGTAATA GGACTCTCCC CTGAGAGTGT CAGCAAGCAG -4154
(6930 )
TAAGCCCTGG ATAAGGACCC G A A T C T A TC T GCCCATTGAC TGCAGTTCCC ACCGCACCAT ACTGTTAGGG -4 08 4
(7000)
GCATGCTGGT C CTCC C TG TA C CTC ATTC C C AGTCCTGGAC TGGAGCACTG GGTGAGCAGC C CC AAG C TTT 
LINE1 repeat
-4 0 1 4
(7070 )
G C T T T T A C T T TTGGTCCTGG C AAG AAAC C A CCCAGACACT GGAGGGGATC g t t a a t c t g a T T C T G A T T T A -3944
(7140 )
A C TTT G A TA C C TG ATATG TG TC TAG G AAG T T ftT C C G T T T C ATCTAfSG TTT TC G AG TTTTG TTG A G TA TTG -3 87 4
TC T T T T G T A G TAG G ATC TG A TG A TG T TTT G G A TTTC C TC A G G ATC TG TTA TT A TG T C T C C T T T T T A A T T T
(7210 )
-3 80 4
C TC IATTTTG T TA A T TA G G A T ACTGTCCCTG TflC C C T C T A G TTACITCTAGC T A A ^O iflT T T A TC T A T C T T G T
(7280 )
-3 73 4
T G A T T T T C T C AAAGAACCAG C TC C TG G TTT A G T TG A T TC T T T G A A TA G TT C T T T T T G T T T C CAC TTG G TT
(7350 )
-3 66 4
G TTTTC AG C C G TA A G TTTG A T T A T T T T T C T n r T ^ T C T A n T C A TC TTG G A T r ;A A T T T flC T T (7C TTTC C TTT
(7420 )
-3 59 4
T A G A C T TTC T AGGTGTGCTG TCAGACAGGT AG TG TATG C T T T C T C T A G T T T C TT TTTG G A GAGACTCAGG
(7490 )
-3 52 4
H C T A TC A C T T TT C C TC TTA G n A C T flC T T T C ATTCST^TCCC a t a a c ;t t t g g C ITA T ^TT G TG flC T T C A T T T T
(7560 )
-3 4 5 4
C A TTA A A C TC T A A A A A G T T T T T A A T T T C T T T C T T T A T T T C TTC C TTG A C C A AG G TATC AT TGAGTAGAGT
(7630 )
-3 38 4
G TTG TTC C G T TTC C AC ATG A A TG TTG G G TT T C T A T T A T T T A TG G TG TTA T TG AAG ATTAG G CTTAGTCCA
(7700 )
-3 31 4
TG GTG ATCTG ATAGGATGCC TA G G A TA A T T T C A A TA C A TA ATC ATG CAC A TC A TA TG C A A A A A T A T T A A T
(7770 )
-3 24 4
TG A TC A TA TG TC TA A G A G TT TA C TT C T G A A C T G T TA G T TT T A T C T TTG TG A TC A G TA TG T T T T C A A T A A T
(7840 )
-3174
TT A A G TA G A T C A TTG TG T C T C T A A T A T T T T A A G T A A G TT T G T TC A TG T A T T T G T A T T A C A TG TA TT A G A T
(7910 )
-3104
G AG AAACACA TG A A TA A A G T A A A A G A A A TA TT A A T A T T G C TG TA TT A G A A G G A A TTA C TT CACTCCCGGT
(7980 )
-3034
TC TG CAC TG A TG TG TA C A TC C A T G C T T T T T TACCTTGGCC TTACAG G TG T GGCTGACAGA G T A T A C T T T A
(8050 )
-2 96 4
GGGATGCGGC T T T T A A T T C T G G TTT TC A TC C TG C TG TATG C TC TAAG C C T TAG AATTG AG C A G A TA A TC A
(8120)
-2 89 4
C C ATG AG C TT AAATGGGTGG T T T T G C C C T T AGGCCCTGCT G C TT TC A TTG TA A A A A C A A T ATGCCCTGGG
(8190)
-2 82 4
A A G T C C TA T T TACAACCG TC CTGCAGATGC C TG AAC C AAA CCTGAACCCA TT A TG T G A TC TAG AACC C AA
(8260)
-2 75 4
(8330 )
145
TGTAAAATAA ACCAGACTCC AGTGACAAAT CAGACATGCA GGTGAGAAGC AGATGCCTTT CAGTGATGAA -2684
(8400)
CATTGCTAAG CTCTCATGTC TGTTCTGTAT AAATAGCTAA GACACCTACA ATTTAGTTAT AACCTCCTAA -2614
(8470)
CTTAGACATA CATAACCTAC AACTTAGACA TAACCTCTCA TTCTTCATCT GACTAATTGA CATTTAAAAA -2544
(8540)
GTGTGTTTAT GTGTGTGTGT GTGTATTCAT TGTTTTTCCT ATAATAGCTA CTTATCAAAA GTCCTTGATA -2474
(8610)
ATAATGGAAA GAGTGGTACA TACTTGTAAT CCCAGCACAC AGAAGGAAGA GGCAAGAGAA TCACAAGTTC -2404
(8680)
AAGCCAATCC CTGGATACAC AGATAGTCTA AGGCCAGTCC AGGTTACATA AGACCCTGGT GGGGTGGGAG -2334
(8750)
GAACATAAAG ATGCTTACCA CAATCACAAT CACAATCAAT CACCCATTTT ATTGTCCACA TAGTCAATGT -2264
(8820)
TGAGAGGCTG TCTTTTACCC ATCCCTATAT TTTTTTTCCC ATTGCAGAGA AACCTGCAAT GAGTTTCAGT -2194
(8890)
CTCTTCCATA TAAACGTTGC TCTACAGATC ACACTTTAAT AAACTCATCT AGCCAGAGTT TAAGGAGAAT -2124
(8960)
CCAGTGAATT TTGCTTCCTA TGTAATTACA ATTCAGATTT CAACTACACC ATTTGGCTGG ATCCTCACTA -2054
(9030)
TTTTCTTTCT GAAGGAAAGA GGGAAATTTA AAAAACCAAA CCAAACCAAT TTTGTGAATT CTTTTTGAAT -1984
(9100)
GTTCCACTAT GTCTTTGAAC ACTTATATTT TATCTTAAAG AATGAAATAG ATGCCATAAA ATATAACCTA -1914
(9170)
TGTAAATTCC TGCCTTTGTT TATGTCCTTT GAGTTCACAG GAAAACATGG GAGAATGGGA AGCGTATTGT -1844
(9240)
TTATTTTTTA TTGGTAGAGT AAGTTAAAAT ATCAAACAGC ACACTTGGGG AACAACAGCA TTCAGAGACA -1774
(9310)
TAGCCGGAAT AATTTTCTGA AAATCTTCAG AGTGTCTGGC ATTGTGCATA TCTGAAATCT GTAAATACAT -1704
(9380
TTTGAATAAC CATGTGTAAG AAATACAACA AATGTTAAAA GTAGCCTTTC AGGACACAGC GTTCCGTGCT -1634
(9450)
TATGATGAGT AGTATTTTCA GTGTTCTTTA GTAATGCATC TAAACTAAGA CACACAGAGT AGGTAGGCCA -1564
(9520)
GATGGCTGAA ACTCTGTCTA ACCTTTCCTG GACAGCTCTC AGCAAAGAGC AGGAGTTTTT TCTGCTTCTT -1494
(9590)
GTTTCACTTC TTCTTTCCCC AAGGAAGATC ACATTGTTTG GGTCATCAAA CAACGATTGA TCTGGTTTCA -1424
(9660)
TTTTGGCTTC CCTTTCAAAC GGTTACCTTG GGAACCCCGG GCACAGACAC AGCACTGTAC TTACACCGTG -1354
(9730)
CGAGCGGACA CTGAGCCCCG CAGCAACTTT TTTCAGGGGA CTCATCATTT ATCATCTCAC AAACAGAAAC -1284
(9800)
ACGGATTTGG CCTCCACAAT GGCTTCTCTA TGTCTGCCCC CTCTTCTCTG AAAGACTTCT CTGCTGGCTT -1214
(9870)
CTCTGGGGAC TAGGAGTCCT GCACCAGGTC TTTGAGAGGC AGTTACTACT ATCTGGCTCA AATAAGAAAG -1144
(9940)
CACTGAACAC AGTTCTCATG TACTCTCACC CTAAGCCAGT GCTTTGTACA CCTGTGGGAC ATGACTCCCA -1074
(10010)
CAACAGGGGT CACATATCAG ATATCTTGCA TATCAGATAT CTGTATTATG ATTTGGAACA GTAGCAACAT -1004
(10080)
TACAATTATG AAGTAACAAG GGAATAATTT TATGGTTGGG GTTAGAACCA TTGCTCTAAG CCATAATTAA -934
(10150)
AGGGGGGGAA ATACCTGCTC TGCTAGTCAC TCAGCATGAA AATCCTCAGA CTAAAACACC CAGAGAAAAG -864
(10220)
CAAAGGGCAG GAGACTCCAA GAGCATCTGT ATCAACTGAA GAACAACAAT AAGGCCAGGT TGCCACACTG -794
(10290)
GGCACTGGAA GATGACTCGG GGGAAATATG TGGAGTGTGC CTTGGAGACT GTCACTGTCA GGGCTGATGA -724
GATA-1 (10360)
CGGATGAGCT GGGTCAGGCT AGATAGACCC TAGCAATTTA TTAGAGCCAG ACTCCTAGGC AATTCTCTCT -654
(10430)
CTACATGTTC ACTTAAGGGT TCAGAGCTTC ATAACAAAGC AGAAGTCAGG AGTCTCAGAA ATGCACTTCA -584
PU.l (10500)
AAATCAGGGT GGAGGAACCT GCCCATGTGT CAGGCCCTGT GACCTATCAA CTCACAAGCC TTCTGTTGGG -514
AC dinucleotide repeats (10570)
ATATTGACCA AACACAGTAT CTTTGCTTAT ATGCAAGCAC ACACTTGCGT GCAACACACA CACACACACA -444
AP3 (10640)
CACACACACA CACACACACA CACACACACA CACACCAGGC TAAAGCTCGC AGAGTTCTCA GATTGTGGTA -374
(10710)
146
XATGAAGGAG GCAAGCCTTT GTCAGTGAAC AGTATGATCA CTAAGACTCT AGTGTGGGCC CTCTCTAATG -304
NF-KB (10780)
GGTTGCTCTC TTGGGAATGT TCTTCCAAAG AGCAGTTGTG TGGTCTTTCC ATTGTAAGAG AAACTGCAGG -234
NF-IL6 SP1 (10850)
TGTCTTCTTA ACCATGACAG TTCTGATGAT GAAAGAGTAA AGAACCCGCC TTAAAGTCAA ACACCAGTGC -164
(10920)
ACCCAGAAAG TAGATGCACA GCTGCAGGCT CAGAGCTCGG CAGCCACTGT ACTTCTTAGT AACCAGGAAT -94
API TATA (10990)
CAAACGTTTG ACTCACTGTG GGGTTGGTAG GGCAGATAAA TACGTTTTTC TATGACTAGG CTGGAGACAC -24
I— transcription Initiation site Exon 1 (11060)
GCCCAGGACC CCCACCAAAA GGAGGGACAG GAAAAGAfiAA .ATA&T.TG5I&.AACACAQMA. AXGT.XXCMT +47
PU.l (11130)
AfiAAAAAAGA GGAAAC.AQAA. T.C.X&TAG.£C£.XfiT.XftTS.AQCAfiAgA&A..fiAQC.TAAg.QP.. .XfiSfiPAXftCS +in
(11200)
AAACJA.QAAG. AAGg.xcAQT5. GACA5.QX.C.QC. GG.TAXQCA?!..T.QJ’.AIT.T.TJ'.Q..XTGATGGC.XC. .TSTAJS.T A&C +187
(11270)
.QX?.'tT.?AT.TI..?.XAQ.QAA.QGT gagtcctgtt aaagtaatgt c t tgtgtttt gccaaaaccc c t ggaaatag +257
(11340)
AAGACATTTG TTTCCTCCTG CTGTTGACAG TTTATTAAAA GAAGTATATA TCTAATGACA AGACTTCTTA +327
(11410)
AAAAATATAC GAGTTTAGAA AATAGGCTAT AGATCTAGTT AGATATAGTC AGAATAAGTT TCAGAGTTAA +397
(11480)
TTTCAAGAGT TACAAATTTA GAGACAAACA ACAATAAGGT AGTGATGTCA TAAACTGAAG TTATTTTTTT +467
(11550)
CTGCTTTCTG CTGAAATATC TTTGGTATCT GTGATTTTTA TTTTATCTAA AATGTACAAA AAGCTTATGA +537
(11620)
GATGTCTCAC TTGGCTTTAT GGTCACTAGT TAGGTACCTA AAACCAGGAA GATATATATT CCAGATATAC +607
Repetitive element resembling human mlcrosatelllte UT7972 (11690)
AAAAAGCATG GATGGAAAGG AATCGAGAGA AAGAAGAAAG AGAGAGAGAG AGAGAGAGAG AGAGAGAGAA +677
(11760)
AGGAAAGAAG GAAGAAAGAA AGAGAGGAAG GCCAGAAAAA ACGATAATTC AGTGGATTAT AATTTTGAAC +747
(11830)
ACTTCATTAC CTATTATTTC TGTATGTTCA TATGGTCTCT TCAATAGTTG GCTGGTGATA AATATATGTA +817
(11900)
GTTGATTATT AAACATTTAT ATTTTGAAAT ATAATCAAGA TTTGGAAATC AAACTGTCTC ATTTGTTTAA +887
(11970)
CAGTACTTAA CATGCAATGT GGGGAAATTT TTAAGTAATG CATTCAAGAA GCCAGTCTTG CCAGGCATTG +957
(12040)
CCCACACAGC CTCACAGCTG ATCTAAGCCA TCCCTTGTTG ATGTTGAACA GACTTGCCTT GCCTCACAAG +1027
(12110)
GGCTGAGTAA TGACTTGTCC CTATTCTTCT CTGGACCAAT ACTGATAGGC ATGTGCCCTG GACCTGACAG +1097
(12180)
GGTGATACAT GCTGGGGCTA TGATGGAAAG CTAGATACAA CAGGCAGTGG TGGTTCTCGA CTTCTAACGT +1167
(12250)
TGAGAACCTG TGGAACTGAA GGGATCATCC ATAGTCAGGT ATGTCCACCA ACGAGGAAGC ATCTATGTGG +1237
(12320)
ATCTTAGTGC CAAATGGGAT TGGTGAGATG TAGTTAAATA TTGAGATACT TGTAGCAAAC ACTCTGTCTA +1307
(12390)
TGCAGAATAC TGAGGGTGGC AGCTATTCAG GTCTGGTTTT ACGGAGTTTT ATAGTTTTTT GTGTTTGTGG +1377
(12460)
CCACATCTTG AACATAGTGG TGGTATTTTA GAATATTTTA GAAAATCATT TGGAAGTCCA GTGGTGGGAA +1447
(12530)
AAATAAAGTG TTGTGAGGGT CATCCCATTG GTCATTTATA TTTTTGTGAG TATGTCCAGT TTTCACTGTG +1517
(12600)
GAGGTTACGT GGTGTATCTA GCTAAACACA TCCTGTGCTT AATGTCTCCA TCACCCTCAC TAAAAAATTG +1587
(12670)
TGTTTTATGG CTGACTACGC TGTACAGGGT TAAAACGGAG AAGCAAATTC TTTACTTGCA ACACTCTAAA +1657
(12740)
AGAGCATGGA TTCTCCTAGC GGCTTTTTAA TTTCTGCCAT TAAGGTTGTG CTTGGAATTA GATGTCACAA +1727
(12810)
CAAGGTCTCA AACAAAGTCT CTAAAAATGG GACTGTCAAT TTAATTTTGG TTGTAAAATG AATACTCCAG +1797
(12880)
GCCAAAAAAA ATGAATTTGG AAGGGAAAAT TATATTTCTG AACTTCGGCA GAATTTGACC AATTCTCAGG +1867
(12950)
AACACTGGGG AAGTCCATCA TTAATGGCCA GAGCCTGACT CAAGTTAATT TCTAGAAACA TCTGCCATGA +1937
(13020)
AAGAGCTCAC GCTCCTTTGC TCTTCTAAAT TTCAAGGAGG GCTCTCAAGA AATTTAAGAT CACTCACAGA +2007
(13090)
147
AATGTTACGT GAACAAGTTT CTTCTAATCA CCATCAAAGG TAGAGCATGT ATACCTGGCG GTAGGTAGGC +2077
(13160)
AATCTTTATT TACTATATTC TTCTTAATTT ACACCTCAGT TTAATAATGC AATGGGTTTG AATTTTATTT +2147
(13230)
TAATTGGTAG CCAAGAGAAA AGCGACTTAA TTATGTTGTC ATCTTGAGAT TGTACAAATA AATAAAGCTA +2217
(13300)
CTGGATTAAC TATATTTTAA TATGGTATCT TACAGTTTAT TTGATAGTAG TGGAAATTTT TGAATGTATG +2287
(13370)
AACCAAAAAG CTTGAATCTT TTTCCCCCTA ACTAAAGGTG ATGTCTCCTG CAAAAAGGTC ATGTGCTTTA +2357
(13440)
AGCAGCCACA AGGAGTATTT TGGGAAAACA GAGTCAGTTA ATCACAGGAA GCAAAGAGTC AGATACGGAA +2427
(13510)
GCTCCAATAA TATCCAGCCT TTGCTGAAAT TTATCTGTTC AGTTTTGAGA TATTTGTGGC CTATTTGAGC +2497
(13580)
ACCTTGCGCT GTCCAATATC TCAAAGGTAT TGCCTATGGC ATAAAAAAAT CAGGAGATAC GAAAAATCAT +2567
(13650)
GCTGCCATTA ATGGCCAAAA CTTCGTTTTA AAAAATGTTT GAGTGATCAA ACTTGAAAGA GAATTCTATT +2637
(13720)
TTCAGGCACT ATAAAATCAG AATACAAGGT AAATTCTAGG GGAGAGTGCT TACTAATATA AAATATCCAA +2707
(13790)
TTACCTCCCC ACTGAGATAT TCAGCAGAGT CATTATTTAC TTCAACAATT TAATTGCGAA GGATAAACAG +2777
(13860)
ATGTTTGTTA TTTTTACAAG CACTGTGTTA AGACACTTCC TGTTTTATCA GTCAGTAAAA GTCACTACAG +2847
(13930)
GGTATTAATT TGAGGGTTTT TTTTTTTTTT TTCCTGAACC AGAATTGTTA ATGAAAACCA CTAAGGTAGG +2917
(14000)
ACATATAGAA CATTGTGTCA GGAAATGCTG ACATCTAAAG ATGTAGCTTT CATAATTTGA AGCAGCAGTT +2987
(14070)
ATCTTTGTTG TTACTAAGGA TATGTTAGCT GAGCCTCTCA GGCTCATTGC GTTAGAAATG CTTCTTTAGC +3057
(14140)
AGGAAATGTC CGACTTGTCG AAAATTTAGA AAACGAATGC AGTGTCTGCT TTCATGGAAA CTGGCACAAG +3127
(14210)
TCTGGGAAGT AAGTTTATTT GAAAATAACA AAGGAAGAAG GAAGAGTCGA ATGCCTTCTA TATGCTGTCC +3197
(14280)
GTTTACAGCT GCTGTGTTAT TCCTCTAACT TGGGCAGCAT GTTAAGTAAG ACTTTGTAAG ATAAGACAAA +3267
(14350)
ATAATGAAGC AAGCGTATCT 
GTACTGGAGT AAGACTTTGA 
ATTAATTTAA AAAGTTATTT 
CXTCKSCAC. J.QA5.Q J.AQAT.
R Repetitive element 
TTAGATATAT TCTTTATATA
GGTATTAATT
AAATTCCTGG
ATTGTGGAAC
CACAQCC.gCG
CATTTGAAAT
TTGAAAAATT ATCCATTTAA TGAAGGTCTT TCCCTTGGCT
CCACTTAAGT AATTGTATAA AGAAAAGCTT CATCTTATTG 
Exon 2
TGTT AAG.Q AT.. C.TAAC.Q AG.GC.. .X C.T.IC.CACAQ. .T.Q T.GhGGhbG
TAAGTCATCT TTTTTAAAAA ATTGCTTATT ATTATTATTA 
TTAAAATGCT ATGCGGAAAG TTGCCTATAC CGTGGGCGGG
+3337
(14420)
+3407
(14490)
+3477
(14560)
+3547
(14630)
+3617
CCCTGCTCCC CTACCCACCC ACTCCCGCTT CTTGGCCCTG GCACACAAGA
Poly
TATAATGTTT
’ GT repeats 
TGTTTTGTTT
(14700)
+3687
TGTTTTGTTT TGTTTTGTTT TGTTTTGTTT TGTTTTGTTT TGTTTTGTTT TTAAACTGAG GAGACACACA
(14770)
+3757
GGTGGAAGCA ATACACACTG CTCTTCCTTA GTTAAGCTTG AGAAAGTTTG TGGGGGAAAC TCCAGGTCTC
(14840)
+3827
TGATCCGCAG GTCCCAACAG GAACTGTTAC GTGCCCCTGT TGGACTTCAG GGCTGAGACT GTTTGCTTTT
(14910)
+3897
TCTCATTCAC TGAATCTAAC AATCTATTTC CCTTTTGTTG GGTTGTCAAG
Exon 3 (14980)
+3967
T ACT TACACT. .T T TCCAQGTA TTTGGCTATG TTTCTTTGTC TTCTCCTGGC CTGTTCTCAT CTGGGTGCTT
(15050)
+4037
CAGACAGTAA ATCATGCTCT CCCAAACTCA AAGCACCACA AATTGATCCT GAAATTTTAA AGGCACTATA
(15120)
+4107
TGTTTCTCAC ATTATAAATT GTTATCAATG TAAGTTTCTT GTCACATTGA CTTTGGGAAG AAGAGTAGTG
(15190)
+4177
GAGATAGAAC CTAGGACTTC CTAGATAACA CTCTGTCACC AAGCCCCTAA TTGAAAAGCA CATGGATGTA
(15260)
+4247
AGTGGTAGGG TTTATGTTTG TTATTAATTG CTTAGAACTT TTCCCATCCC GAAGACTGCT CTAGTGTCCT
(15330)
+4317
GGATACTGAT CCCTTCTTCC TTTTCTTCTA GCTCTACATA TTTGCTCACT GGATTCTAGC AGGAAGATCC
(15400)
+4387
(15470)
148
A TC TC TCTTT GTGTATATTA TAAACTTTAG TTCATTCTTT GTGAGTCAAA TAAGAAGTCT GTTTGTACCT + 4457 
(15540)
GTTTCACCCC CAAGCACAAA CTGGGAGCAT GTTCTCAATT AATTATTAAT TTACATGTCA AATGTTCCCA + 4527 
(15610)
AAGACTATGA ATCTTCAGCC CAAGAGCAAA GTTCCATATG TTTGCGTTCC CAGCATGCAA GAGAGATGAC + 4597 
(15680)
AAGCTTTTGC CAAATGACCA ATGCTCTATT TTATGTTGGA AAGTAGCCGC CAGCCTTCCT TACAAATGAC +4667
(15750)
Exon 4
AATACAGTGA TTTGGATTTT TGTTTTCCAT GTTTCCAACA G ;tA T X £G .Q C X .A C £A T G £T G £.£X G X G JIA C X
M e tV a lP  r o V a l L e u L e
+4737
(15820)
A AT.XXTXC.T.Q. .QGhQQ I.T.IG.G..GAAGAGXGGA. A fiC IG Ä C I.TA ..«X A A X C A C Ä L.A öA A G IG T A A  GCATCTTCTA 
u I l e L e u V a l  G ly A l a L e u A  l a T h r L e u G l  n A l a A s p L e u  L e u A s n H i s L  y s L y s P
+4807
( 1 5 8 9 0 )
CTCAATAACG TTTG G TTTTG  TTAAAGTACA TTATAAAATA GGTAATAGGG TTTTCTCCTA  AATAAGCATT +4877
(15960)
CTACTGGGAA AGTTTGATAA TACAGTATAA ACTCTTGAGA TTTAAGAAGG CCATGTGGGC AAAAATGTAA +4947
(16030)
ATTCTATGCT TCAATGGGAA ATTCAATTCT AAGAGTACAA ACGGGCATCG TGGAAGAAAG CAGCCTCTGG +5017
(16100)
AGGCCACATT TAGGACTTGC AGCTCCCCTG GCAACTTTAC AAAAGGCTTC AAACGAAGTA AGAACAAGCT +5087
(16170)
CTA CCTTTTC TC T T T T C T C T  CCCTCCCCCC AAAACTTGTT GATCTAAGGG TTTAGTATGA TAACAGAGGT +5157
(16240)
TAATAGAGGA AACTTGTCTG ATGGCATCAG ACCAGCTCTG TCTAGAACTT TCTATTAAAA CCACATTTTC + 5227 
(16310)
ACCAAGCAGT TAAAATATAC ACAGTACATC CAGAGCAATG AACTGTGGGG TTTAGCTAGC TAATTTGGAT +5297
(16380)
GTGAGAAGCC ACAGTAGCCA GTGGCTGCTG GAATAAAGGT GAACTACATA GATANCCCTG GAANCCCTTG +5367
(16450)
CGTGTCAAAT GCAGATGCAG AGTCATGAAG GGCCTTTAAA GGTCAATGGA AAAGCACGGA CAATGTAGTT + 5437 
(16520)
AATGAATAAA TTAAAGACTG TAGTACGTGG ATCACAATGT ATGGTGTTAC CCTAATTTGG GTGAGAAATT + 5507 
(16590)
TTAAGAAGTT GTTTAATATG CCCAGAAAAA TATAACCAAG ATGAGATGTG TTCTGACCTT TTTA CTCTCT +5577
(16660)
CCTCTTTG CT CA TTA TG TTT TACTTCATCT CTACATTGAT GCTCTACAAT CAGTGGGTAC TGATTCTTTA + 5647 
(16730)
ATTAAGTGAA A TA TTTTA TT TTGAAAACAA A TCCTCTTTC CTACTCAAAT AGTTTTGACT ATGGCTCATA +5717
(16800)
ATGAAGAAAT ACATGCATTT TACATTGTGA ATTACTGATT CTTAAGTAGG TACTTTTATA CAATGGAAAC +5787
(16870)
CAGATGCCTA TGAGACAACT GTTGTCATGC TTGATATAAC CGCCATTCCT A G TGTTTTCT ACTTATCTTC + 5857 
(16940)
TATACTACTG TAAAGGCGGC GGGGGGCGGG GGGATTAGAA CTTCTGAAGT TATCAAAACC TTTTCAATGA + 5927 
(17010)
TG CTTA TTTT TAAACTACAG CTTCAATAAC AATGTAGTAG GCTATTCATA TTCAAGTAAA ACATGCGAAA + 5997 
(17080)
GTTACAAATA ACACCTGAAC AATGAACTAG CAATAATTTT AAAGAAACTT TGCCAAATTA TTTCGGAATT +6067
(17150)
ATATATTCTA ACAAACTACA ACAAACCAGT ATGTTATTTA ATAAAGTAAT TAAAATATAT TCAAGACCAG +6137
(17220)
GAATATTGCT CAGTGGTAAT CTACCTGAGT TTCATCCCCA GCATATAGTA CACACACACA AAAGTGCTCT + 6207 
(17290)
Exon 5
TTATGGACAA CTGTGCATTG TATCATTGGT T T TC TT TT TG  TTTTTAATCA A T A G ^X T^A C .. XT.GXA.QCAQC
h e L e u L  e u L e u P r o P r
+ 6277 
(17360)
XfiT.QAAXXTI. AQC A.XXM A5. . C S A G T S G m . A f i a X M & T X . .C.TXTX ACAC.T.. £?.Q  ACG CAA A . .XC.CXGA.QCAA
o V a l A s n P h e  T h r l l e L y s A  l a T h r G l y L e  u A l a G l n V a l  L e u L e u H i s T  r p A s p P r o A s  n P r o A s p G l n
+6347
(17430)
g a q c a a a g g c _ a i g .t x g a ^ c.T. a g a g x a t c a c  . g x q a a ^ x a a . a t g ? c c c a c a  . ASAASAGSAA g t a a g t g t c t  
G l u G l n A r g H  i s V a l A s p L e  u G l u T y r H i s  V a l L y s I l e A  s n A l a P r o G l  n G l u A s p G l u
+ 6417 
(17500)
GGTCTGATGA CAATCACTAC TGAGAGGGAA TATTCCCTTC TAAACTGCAG TTTTCCTCA T GAAGTGAAAG +6487
(17570)
TCTTGATAAA AAATAACCAA TTACTAAAGA CCATCTTGTT GTGTTAGCAG TAGGATCTAT AAAGTGAATT + 6557 
(17640)
AGACCAATGC TATTATTCAA GATGAAACAG TAGCATAGGT TTTATCTCAA GGAAAATTCT CTCCTTCAAG + 6627
(17710)
A A A G A A TA C T 
ACACCCCCCG
CCTTAC TG C C
TG TGTGTG TG
C C T C T C T TTC  TC C C TC C TC T TT TC A TC C C T 
AC dinucleotide repeats 
TG TGTGTG TG TG TGTGTG TG TGTGTGTGTG
TTTC C TC C C T
TGTGAGAGAG
C TC TC C C TC T
AGAGAGAGAG
+ 6697 
(17780) 
+ 6767
CT dlunucleotlde repeats 
AGAGAGAGAG AGAGAGAGAG AGAGAGAGCA TG TG T TTG TT C TG TA C TTG T TAGTGTGGGT TTG TG C AC AT
(17850) 
+ 6837
ATACAGG CCA GTGTGCATGC AGGTGTGTGA AGCCCACAGG T T G A C A C T TT C CTTAAC CAC TCTCCAAGAC
(17920) 
+ 6907
A T T T T A T T T T TTGAGAGAAG GCTCTCACTG AGTTGCTAGG TC C G TC A TTT TTG C TAG G TT GATGAGCCAA
(17990) 
+ 6977
TG ACATTTG G GGATCCACCT GTCTCTGCCT TA TC C TC A G T GCTGAGGTTA CAGGTGCATC CTGCCATACG
(18060) 
+ 7047
A C TA G A A TTC T A C A T T T A T T G T A A A A T T T A TTGACTGAGC CACCTCCACA G C TTG TTTA C C A A C T TTT G A
(18130) 
+ 7117
AG TG TA A TG T ATG TG A TA G T A C TG T TTA C A TA C C TC C A A A AC TG TCAATC AAACCAGAAG G AAATTG TG A
(18200)
+7187
GCAAAATG GT ACAAGCTCCG CAAAGCCAAG G TTAAG G TAA A G T TC A TG T A C TA TG TTA T G GG TC TTAAG T
(18270)
+7257
T G A C T T C T T A GAG TCTCTG A TTTA TG G TA G GG ATG TAG TA ACATGACTG C CACG TATTGC A TT T G T A G T A
(18340) 
+ 7327
AGGTGAAAGA AAGGGAGGTG C A A T T T G T A T T A A C C A T T T T G C AG TAAATA T G A A A T T T T A AA G G A TTTC A
(18410) 
+ 7397
TG TCAAGAAG TTGCTCCTGG AGAGGAGACT GGCATCAAAG A TG A G A A TA A
B1
A AG AC AAC TT
repeat
GGGAGGCAGA
(18480) 
+ 7467
GACAGGTGGG TG TG TG AG TT GAAAGGTAGG GGGAAGTAGA GAG TATG TTG AAGGAGAGCC AGGACTACCC
(18550) 
+ 7537
A G A A A A A A A A C TC TG TC TC A A A A A A A A A A A A A A A A A A A C A AG AAAA AG AA AGAAGAGGAA T A T A T T C A T G
(18620) 
+ 7607
TG TTAC TG AG A A A C TG T G TT A A T T T T A C A A T G A T T T T C T T A G A T T A T T T C A C T C C A T T T T A C TTA T G C A T
(18690) 
+ 7677
C A T T T T C A T C GTGGAGTCAA GG G C CTATTT G A T TA A TG TT G T T T T T C T C T TA C A TG TC A T GATTGGTGGG
(18760) 
+ 7747
T T T T A T T T T A
Exon 6
GXATGATAGC. AGAAAGACX6.AAAfi££AATG./T.G£GAClCGC&..£TXGACClAACi.G£TX£G£AG.Q
(18830) 
+ 7817
T y r A s p T h r A r g L y s T h r G lu S e r L y s C y s V a lT h r P r o L e u H is G lu G l y P h e A l a A l (18900)
X AC&&TG AGS. A Q fA T O X S A . AGAfi?Aft?£ A . XACMCXC.TG. .G£CAQCAQ£T..GGG£TX£TSC:. . :CG*AC.T£ AAA + 7887
a S e r V a lA r g T h r I l e L e u L y s S e r S e r H i s T h r T h r L e u A la S e r S e r T r p V a l S e r A l a G lu L e u L y s (18970)
.QCT.CCAqCAQ GTAAAGGACA TGGGGCATCT G A G TTT TTG T ATCTG ACACC C C TC A A A TC A GGAAAGAAAA + 7957
A la P r o P r o G
G C C ACC TTTC ATTAACC AG C GCTG TGCCTT G C AATAC C AT TC C A C A A C A T C C A C A TTC C A ACCATGCCTG
(19040) 
+ 8027
TTA G G C TTTC C TCTGCACAC TC C TG TA A G T CACC C CTAAA TT TA TA C TG G ACTCTAGTGG AAGCTGGGGC
(19110) 
+ 8097
T T C T T G T A A T TA TA A G C A G A G G TAGCTTTG A T C A A A C A TT TTA A C A C A G A C A A A TA C A A A CACAAG ATTG
(19180) 
+ 8167
G AAAAA AG AA ATAG GTAG NC TATCAG ACCC TAG G ATATG T C A T T T T T C T A A A T C A T A T A T G TCTTAG C C T
(19250) 
+ 8237
C A C A T T T A T T A C T G T T T T T C A A G T C T T T C T C C TA TC C A C T TCATCGGAGA AG AAG ATC AT G C C TA TA A T A
(19320) 
+ 8307
TTA G TC A G C T T T C T T T T G A C T A T A A C A A A T A TG TA A G A T A A TA C A C C C A T T T T G G T T T A T GG TTTCAG TG
(19390) 
+ 8377
GGGGTTTCCA CCCCTGACCT GGCAGCCCAT CATG TTTAG G CCATG TG G TA ACACAG TGCA TTA TG TC A G A
(19460) 
+ 8447
AGCAGGTGGT A G A TG TC TA A AGCCAGGAAG C AAACAG GAA GC AC AAAAAA GACAAGGGTC T A A T T A T C T T
(19530) 
+ 8517
TA A A G A TG T A TC C CC AAAC A CCTCCCAGAA G ACCCAATTC AGCAAGGGTT C TC C A C TT C T C AATAAC ACC
(19600) 
+ 8587
AAG AG CTACA GAACAAAG TC T T A A A A A A A A AAAAAAAAAA AAAAAAAAAA A A A A A A A A C A AACCCTGGGG
(19670) 
+ 8657
G C TC AC TTAG CCAAAACTG C TAG ACTG AG A C TG TG TTA G T GGCAACATAG ATG C TTG C A T T A A C T C A T A A
(19740) 
+ 8727
TT C T TC A A A G AG TTC CC AAC A G G C TTA A C T CTGAGTAAGG AGGGTGCTTC A A TG A A TA C A GAG G AATATA
(19810) 
+ 8797
(19880)
150
A A T A TG A G TA  A TTTTG TG C C  A T A T C T T A A A  G C C A TTA TTC  TA TC TC TC A G  G ACCAACTAA G A A C TTC A A T +8867
(19950 )
T A T A T G A T A T  T T C T T T C A G T  G TTA A G T TT C  T A T A G T T T T A  A T T A T T T C C T  GCATACCTCC A A C A C A TG TT + 8937
S i re p e a t
A A TA C C A A G T A T G T A T A A T T  TA T G C C A TTA  ACCAAGTG AA AAG TCAGCCA GGCGTGGTGG TG CAC AC CTT
(20020 ) 
+ 9007 
(20090)
TAATCCCAG C ACTCGGGAGG TAGAGGCAGG C G A ATTTC TG  AGTTCGAGGC CAGCCTGGTC TACAACGTGA + 9097 
(20160 )
GTTGGAGGAT AGGCAGGGCT ATACAG AGAA ACCCTGTCTG AACACCCCTC TTGCTCCCCC C A AA A AA A A C + 9147 
(20230)
C C AACCAAG T G AAAAGTCAC A C T G A A T A T T  CATGGCTTGG AAC C AG AAAA C TG C TTTG AC  A TG AC ATAG T + 9217 
(2 0300 )
C TG TG TG G AT G C TTA G TA TG  TAGACAGATG C A TA TA TG TG  TA C A T A C A T A  C ATG CACACA CAGGGGGAAG + 9287 
(20370 )
GGAGAAGGCT TG C A TTC A TG  G G C TCC ATAT TC A TG A A TTC  A A C A A TC A A A  A G C A T TC T A A  TAC AAAAG C A + 9357 
(20440 )
T T A A A G TA C A  TA C TG C TA G T G AACAG ATTC TT T T A T G C C A  C TA C C A TC TA  A A TA AC A G TC  T A A A C T A T T T + 9427 
(20510 )
C CAG AG TACT T A T G T T C A A T  A T T C T A A G T T  A TA TA G A AA G  T A T T T A T A T T  A G A C C A A ATA  C TG TA TA AG T + 9497 
(20580 )
TA TATG C AA G  A TG A C A TC A T ATTAG AG AC C  TG AG C A TC TT A A G TTT TT A G  CATGAGGAAA AG TTC TG G AA + 9567 
(20650 )
T C C A T A T T A T  AGATACAGAG G T A TG A TTG T A TA G A C A T A T  G T A T A T A T G T  C A T A T A T A A T  A TG C A TA TG T + 9637 
(20720 )
G TG TTA C A AG  GGAAACTAGC C A G TC A G TTT C TTG TC TC C A  A C T T C T A T A T  ATCAATG G G A G GATCTCTCC +9707
(20790 )
TC TTG C C TC C  T C T T T C C A T T  N A AA G A TA C T C TATG AC AG T G A TA A A A A A A  TC A A T C T A T A  A C T G T T T T A A + 9777 
(20860 )
G A A A A A A T A A  A A A C T C T T T C  C TC A C TTA A G  A T T T C C T C T T  TAGAGAGGTT C TC C C TA A C T G TAG TCCACA + 9847 
(20930 )
A A A T A T T T C T  T T T G A T T C T T  TA A G A A A C A A  GAACAAG TCT G TTTTG A C A G  AGTGCTCTGG G TATC A C A A A + 9917 
(21000 )
C A T A A T T T T G  GGAAATCTGG T A C A A A A A A A  A C A T TT G A A A  TCG CAG G TTT TAAG TCATG G  CATG TTAAG G + 9987 
(21070 )
G G A C TTTTG T AAG CTGTTGG AC AC TG AC TC  T A T A A T G T A A  GGATAAGATC TTG G G G TATT GCCAAAACGC +10057
(21140 )
ATCCCCTGAG TG G TA ATC C A  T G T A A T T C A T  GGGACATGGA TA T TA A G G A A  TG G C TC A TA T AACTG AG AAA +10127
(21210 )
GGAAAGAGAA TCAAGAGAGC T T C C T C A A T A  A A A C C TC TC A  TTTA C A G C C A  GAAAAACTGG A A T C C A T A C A +10197
(21280 )
TCATGTGGGG CAGTGCCTG A TA G TC TG G TA  TT G A T A A A T A  GAGCACAAGA A TG C TG AAG T TGCTGGACAC +10267
(21350 )
ATG AC ACTAG  A C T T G A A C T T  TC A A AC A TC C  ATC TC A C A G A  C A TA T A T C C A  T A T C T A C A T C  TAAAG TAG C T +10337
(21420)
CA G AA G G TTT TC A TG TC A AG  G C T T TA TA A C  TC C A G TTTC A  TT TC TTC A G G  A AA TTTG C C C  TTTG C A A A TG +10407
(21490 )
A G T T T C T A T A  AATG G A TG C T TG TG G TCAC T C A C A A TC A A T A G T A T T T C A A  GCAAAAGCAT A A A A TTC A G A +10477
(21560 )
Exon 7
AGGCATCAAG G C A A T G T T T T  G T C C T TT G TA  TT TA TG G TC C  CCTAGf i &T. QX. . . C. QGTI ÄCf i &A
l y S e r  P r o G ly T h r S  e r V a lT h r A s
+10547
(21630 )
n L e u T h r C y s  T h r T h r H i s T  h r V a lV a l S e  r S e r H i s T h r  H is L e u A r g P  r o T y r G ln V a  I S e r L e u A r g
+10617
(21700 )
TGCAC.g.TGQC. T.XGJTGQGAA G G ATQ CC?CT . GAQGAg.AC.AQ. A Q T  A T  T T.C C.T.. A T £ C  T AC AGG TC A G TG TC TA  
C y s T h r T r p L  e u V a lG ly L y  s A s p A la P r o  G lu A s p T h r G  I n T y r P h e L e  u T y r T y r A r
+10687
(21770 )
Exon 8
T T T T T A C T T A  T G C A A A T T A T  C T A T T T C C T C  TT C C C T T A T A  A A A A C T C A T A  G G T A T TT C A A  TTTAGGT.T.TG
g P h e G
+10757
(21840 )
f i l G m X G A ß .  .T f iA Ä A A Ä If iC . .C M C . A A X A G A . G C A G A G A X 5C . A C  T .G AA C A G A . h h X  AC.T S C AT.. CC.T.QGT.TI.C.C
l y V a l L e u T h  r G lu L y s C y s  G ln G lu T y r S  e r A r g A s p A l  a L e u A s n A r g  A s n T h r A la C  y s T r p P h e P r
+10827
(21910 )
C A G f iA C A m . A T C .A A C A C C A . A A f if iG C X T f iA . CCACC.T.IC.C.T. .G C &C AG AXXA.. A T S G G X G A A fi - C M .CC.C .TG CI 
o A r g T h r P h e  I l e A s n S e r L  y s G ly P h e G l  u G ln L e u A la  V a l H i s I l e A  s n G ly S e r S e  r L y s A r g A la
+10897
(21980 )
151
££AA3SAA<?£. .SC' C6T.TPAQT.  . cc:aQT.T.Q£CA..T.XSGTaagaa agacttatcc caag g t g g ga +i0967
AlalleLysP
ATAATGAAAT
roPheAspGl
AGCACAAACT
nLeuPheSer
TGGCACAGGA
ProLeuAlal
AAGGGTTTTG
. l e A
CTACCTTTCA AATGTTAAAC AGCCATCTAG
(22050)
+11037
CTAACATAGG AAAACTACTG AGGCAGAGTT CCCAACTTTA AGGCTACATA AATAATGTAG GAGACTGTCC
(22120)
+11107
TGCATATAGT AAGATGTTTA GAGACATTCT TGGCCCCTAT CTATCAGTCC AACTTGTATG TTCTACTGGT
(22190)
+11177
TCTGCTACCC TGAGTTGTGA CCAAATCCCA ACTCAAACAC ATCCCATTGA AGGTAGAGTT CTCCCTGGTA
(22260)
+11247
GAAAATGGCT GCTCTAGGAA AAGCAAACTC ACTCCCTAAG AGAAGTCATA GTAGTGCTCA TCTGTTCTGA
(22330)
+11317
CTGCTTTCAT GAAATATCTG TCCACGAATA TTGTAATAGC TTGTACCCAG AATTATTCTG AGCCTTTCCC
(22400)
+11387
CCACAGCATT GTCCCTCAGC ACTCCAAAGG TATCCAGGTT TTCCATCATC TAGCTCTTCT TTCAAAGCTA
(22470)
+11457
ACCCTCTCCG ATCATCACTG ATCCTTCACA GTGGTTTGGA CTTATCTCTA GACATTTAAA CAATATGTCC
(22540)
+11527
ACAGATCTCT CCCCTCCCCT CCCTACCCGT CCCCTCCTCT CCTCTATCTT CCTCTTTCCT TCCCCACCCT
(22610)
+11597
TTTCTTCCTT TCTCATACAT GTATATGTAA TGGATACTGG TACAGGTGTG CTTATCCATT TAGAAGCCTA
(22680)
+11667
TGAATAACAT CAAGATATCT TCTTAGATTG CTTTTCCACT TTATTTTGTG GGGAGAAGGA ATTTTCAATG
(22750)
+11737
GATCTGGAAC TTGTCATTTT GGCTAGACTG GTTTGCTAAG GTAGCAAGGT CCTAGGATCC ACCTATCCAT
(22820)
+11807
Rep e t e t l v e
ATTACCCTAC
e lement r e s e m b l i n g  rat S A 2 C A  m l c r o s a t e l l l t e  
TGT.TAAAGTA ACTTTTATTC TGCTAAAGTA ATCATTGTAT CTGAGGTTTA CTGCTTCAGT
(22890)
+11877
(22960)
GTAGTAAGGT AGTGCTAGTC GTAGAAACTT GTATCCTCTG CACAACCTAA TCTAGGCCTA GACTATTTTC +11947
(23030)
GCCCTCTGAG ACTTACTACT GAATAAGCTC ACGCTTCCAC CTGTGAGTTT TTTTCTGAGC TGGCTGGCCA +12017
(23100)
GTTCAGCTGT TTTGGCCCAA ACTCCTTTCT ATAACTTCAA TCTGGCTTCA TTTTTTAGCC TCTCCTGAAC +12087
(23170)
TTCTCTGCTT TGCCTCAAAC TAACTCTAGC TAAGAATTCA TTCTTATTTT CTGGCTCCTC CTCATTCTCT +12157
(23240)
GGCACATTCT GTCATCACCC GTGTGTAGCT TGTTCTCTGT CTACAGCCTA TCTCTGTACA ACTTTCCCAG +12227
(23310)
TAAAGCCGCC TCTCCTGCTC TCCCCCCTCT CTCTGCACTG CTCTCTTAAG GCACTCCCCT TTCCTCTCTC +12297
(23380)
CTCTTGTGAG AGCCCGGCAC GGCATATGTT ATTCTGTAAC ATCTTTCTCT GATTTGTCAG TTAGGCACCA +12367
(23450)
CTTTTAAACA TGGGTTCTTC CTTCTACAAA TTAACTTTAC CATTATTGTT TGGAATTAAA GATGTGTACT +12437
(23520)
AAAGACATGT CTGTATTCCA GCCAGAGGGA TTAAAGGTAT GTGCTAAGGA CTGACTCATG CCACAACTAG +12507
(23590)
AAACAGTTTT GTTTTGTTTT CAGTAAATAA CACAGTCTTG AGGTTCACAG AGTTCACAAT CAAATATCCT +12577
(23660)
GAAATACCCA ACTACCACCA CCGCCACCAG CTCTGGGGTT ACAGCTCTTT TCACCTGGGT GCTGGGAAGC +12647
(23730)
TAAACTCAGG TCCTGGTGCT AGTGTGGAAG TGCTTCACTC CTGTACAGAC ATAATTAGCT CAATGTTCTT +12717
(23800)
TTAACTCAGA AGCTTCTTGT TCTATCTGAC CAAACAATCC AAAGAAAACA ATCTACCAAT AACAAAAAAT +12787
(23870)
AAACACTAAA GCCAGAAAGG AGAAGTGATT TACTCAGAGT TGTCCCCCTG CTGGGAAATG GCGGTGGGAC +12857
(23940)
ACATTGTCTA CGGTCTCTCC ATCAGCATAG TCTATCTTGG AAAGCTTAAG AGATGCTGAG TGCACAATAC +12927
(24010)
AGTGAGTGAG CTGAGAGGGA AAAAGAATCA ATCAATCACT TTCATTGTAG TGATTTCTGT TCTCTATATG +12997
(24080)
TGTAAGTCTA TTTGGTACAG CCAAACCAAG AACCTCATAT GAAGCTACTT GCTTCCTGTG GCTTTGACAC +13067
(24150)
TGGTTGATTT AGACCTGATG GTAAACCTTG AGAAGAACAT ATCTTAGGAA GGGTGGGTTG GAGCTAGCAG +13137
(24220)
Exon 9
CCCTGATCAC TGATTGTACA GACCTGCCAC TGACCTCTCT CCGTCTTACC TAGßf.CM?!..5MTGG.T.QCÄ +13207
spGlnVa lAsnProPro (24290)
152
AGSAAT.QXCA. .CASTGPAAAT. .XGAM.QCAAX. .XC.T.QXC.XATA. .TACA.QXGGGA. .GÄAACS ACXX. XXT.QXC.XXT.Q +13277
A rg A s n V a lT  h r V a l G l u I l  e G lu S e r A s n  S e r L e u T y r I  l e G l n T r p G l  u L y s P r o L e u  S e r A la P h e P  (24360)
.QA5AXCAXT.Q..aX T A A C X A T ..5AQXT.QMAA. IX T A X M C A Q . AAAAAAT.QP.T..fAQATXfAQG t a a t t c t t c a  +13347
r o A s p H is C y  s P h e A s n T y r  G lu L e u L y s I  l e T y r A s n T h  r L y s A s n G ly  H i s I l e G l n  (24430)
TATGGTTCCA GTATTCCATG ATAGGCATTC AGTATTTGTG AAACATTTAA ACGGTGGTTC TCAACCTTCC +13417
(24500)
TAATGCTGTG ATCTTTAGTA TAGTTCTTCG TGTTGTGGTA TTTTTGCTGT TATTTCCATA ACTGTAGTAT +13487
(24570)
TGCTACTGTT ATGAACTGTA ATGTAAATAT TTTTGAGCAT AGAGGTTTGC CAAAGGGATC ACAACTCACA +13557
(24640)
GGTTGGGAAA CTGTTGATTT AAAAGTTTCA GTATTGACTG CCCTGGGTGT TTTTACGTAC TAGGAAAGTC +13627
(24710)
AATGATAACT TACATCTGCC CGAGGTATTA CAGAAATAAA TCAAATCTTA CAGGACTTTT ATATTGAAAG +13697
(24780)
AACATACTTT GGGTTCAAAA ATAATACAAA AAATAAAATG AAACTCATTT GTAAGAGCTT TGCAAAAATA +13767
(24850)
CAAATGATAC AACTATTGGG CAATGTAGGA AAGCAAGTTT TCCAAAGGTT ACAAATACCC TAGGAGCCTG +13837
(24920)
TAATTCTACT TCTAGGTATA CATACAAAAT ACTTAGAAAC AGGGTCTCAA AAGGGTACTT GGAACCCCAT +13907
(24990)
GATTACAACA GCATTACCCA CTATAGCCAA GAGCTAAAGC AGCCCTGATA TCCACTAACA GATGAATAGA +13977
(25060)
GTCAGGCTTG GTGGCACACA CCTATGATTC CAGCACCCAA GACAAAGGCT GAGATAGGAG AAATGTTATA +14047
(25130)
AATTTGAGGC TAGTCTAGAC TGAATAGCAA GATTCTTACA TGAAAACAAA CAATCTGAAC CCCCAAACCA +14117
AC d l n u c l e o t l d e  r e p e a t s  (25200)
GGGAATAGGA ATACAAAGAC AAAATGGCAC AC.AC.ACAC.AC ACAC.AC.AC.AC ACACACACAC ACACACACGC +14187
(25270)
ATGCATGAAC AAAGAGACAT TATTCAGTCT TTGAAAGGAA ATTCTGATAC ATGTTATGAA TAAACCTAAG +14257
(25340)
GACAGCAAGC AAGGTGAAAT AAACACATGA CAATGGACAA ATAGTATACG ACTAGGATAT GATTCTGCCT +14327
(25410)
TTAGTGAGAT GCCAAGGGTA GTAAAAACAC ATATAAACAG AACGTAGTAT CATGGCTGCC AGGAAGTGGG +14397
(25480)
GAATGGAAAA TGAGGGACCA ATGTGAGGCT TTCATCACTG GGTGAAGTGA ACTGAACAGA GGGTCTCGTG +14467
(25550)
CATGCAGAGT ATGACACATA CCCCCAGCCA GGAAGCTCTC AGTCATGCAA GAAGAAAAGC ATGTTGTAGT +14537
(25620)
CGCTTGCACA GCAGCATGGC TCTTTACCAT TTCTGCCCAC TTGAAAGCAG TCACAAATCT GAGAAGTCAG +14607
(25690)
GATTTCACCT CATGCCTTAC AAAATAGAAG AAATTAAGAG CCTGTGAGAT GGCTCAGCAG ATAAAGGCAC +14677
(25760)
TCGCTGTTCA
TCAAGTTATC
AATGATTAAA
GAATGCTTCC
CTCTCACCTC
AGAGACAAAC
AGGAGTTCGG
CACACGTGTG 
LINE1 r e p e a t  
TAATATCCAA
TTCCTGGAGC
CTGTGGCATA
TATATACAAA
CTCCAAGGTG
CATGCACACA
GAGCTCAAGA
GAAGGAGAGA
CATAAATAGA
AGCTGGATTC
ATAGACTGTC
TGCATCTAAA
CAGAAATTCA
+14747
(25830)
+14817
(25900)
+14887
AATAACCCCA TTAAAAATGG GGTACAGAGC TAAATAAAGA ATTCTCAACT GAGGAATACC AAATGGCTGA
(25970)
+14957
GAAGCACCTG AAAAAATGTC CAACATCCTT AATCATCAGG GAAATGCCAT CAAAACAATC TTGAGATTCC
(26040)
+15027
ACCTCACACC AGTCAGAATG GCTAAGATCA AAAATTCAGG TGACAGCAGA TGGTGGCAAG AAGGTGGAGA
(26110)
+15097
AAGAGGAACA CTCCTCGATT GTTGGTGGGA TTGCAAGCTT GTACAACCAC TGTGGAAGTC AGTCTGGAGG
(26180)
+15167
TTCCTCAGAA AATTGGACAT AATAGTACTG GAAGATGCAG CAATACCTCT CCTGGGCATA TAACTAGAAG
(26250)
+15237
TTCCAACTGG TAATAAGAAC ACATGCTCCA CTATGTTCAT AGCAGCCTTA TTTATAATAG CCAGAGCTGG
(26320)
+15307
AAAGAAGCCA GATGTCCCTG AAGAGAGGAA TGGATACAGA AAATGTGGTA TATTTACACA ATGGAGTACT
(26390)
+15377
ACACAGCTAT TAAAAACAAT GGATTTATGA GATTCTTGGA CAAATGGATG TATCTGGAGG ATATCATCCT
(26460)
+15447
(26530)
153
GTGTGAGGTA ACCCAATCAC AAAAGAAGTC ATTAGATATG GAGTCACTGA TAAGTGGAAA TTAGCCCAGA +15517
AACATAGAAC ACCCAAGAAA AGACAAACTA AACACAGTTA AACCAATATC TACAAATTGA CTTCTAGGGG
Poly GT repeats
TTAGCACATA AAGAGAGATA AGGCCTTGTT TTTGTTTTTG TTTGTTTGTT TGTTTGTTTT GTTTTGTAGT
CTGGAATAAG CCAAATCCTA TGCCCTATTA ATTTTAAATT ATGTGCCAAA TCATGGGACA TATTACTGTC
CTGTGTCCTG CCAGGCTGGT GGTTCACATA AAAGTAAATC AATATATAAG ATAAGTCCTA CTCTGGCAAG
TAAGGTCAGG GCCTCCCTGT CATAGGAAAG ATCAACAAAA TGCAGAGGAG AGAGGAGACA AAGCAACCTT
GTAGTCTAGA GCTGAATGCA ACCTGGGGGA GATCAGAAAT AGTCTTTGTG AAGGACTGGC TTTCTTTTGT
AAACTTCTAA TCTACCATAG GTTAGCACTT TCATAAAATA AGTTAAAAAG GATCAACTAA AATATATTAT
D3nds3 mlcrosatelllte
ATATATATGT ATTTCAACTA TATATTAAAT GTTATACACA TAAATATTAT ATATATATAT ACACACATAC 
ATATGCACAC ACACACACAG TCAAAGATAG GAATGTACAA ACCAATATGT GTGCAAGCAC AATTCACGCG
CTTGGATGTC ACAGCAATGT CCAATGGCTC CCCCAGTTTC TAAACTGTGC TCTCACTCTC AGCATTGATC
TTATCAGAGA CCGGTAATCA GCACTTCCTG ACATGTAGCA CAACCACACT GTGCTTGGTA GGGGTGTGAG
GAGAGGAATA ACCCCGAGGT GTGCCAGGGA GGCATGTTTC CTTTAGCCAA GTGGGAGTGA CTGAGCGGGC
CTGAACACCA GGTGAACACT AGACATGTAA CCCTGAACCT TACATAGGGA CTTCAGAGTG GCTCTGTGAA
CTNNTTATTA AAAGCCAAAC AGNATCTATA GTAACACCCC AGTCATGGGC AATGAGCAGC ACCCATGGAT
TTTTCCTGAT AGAGAAGTGT AGCGTTTGCA GGATAGAAGG GTAATTTTGG CAGCAGTGTG CAAGTTGGAT
GTGTGGGGGT GGGGCTGGGT GTGGGGGTGG GACCATGCAT ACGAAGGGTT TTGAGCTAGT AGGACAATCC
AAGCAATAGA CCAGGAAAGC CCATGCAGGC TGTGGCCATT GGGTAAGGCT AGATAGATAC AAACTATGTG
CTTTTTAGAA CTGTGACATT ACCAATGTGG AAGGGCAAAG TAACAGAGAT TATGTGTGCT GTTGGAACTG
ACTCCAACTT TTCCACTTGA AACATTAATT TGTCCACACA GCATCACCTA GCCCTTCAAC TGACCATTTT
ATTTATTTCA GTTACAAGAT CACTTTTTCC CTCGGGGTAA CTGCCAAGAA ATCACACTGG AACTCTGTAG
AATAAACTCA TAACTATGCT CTATTGATTT TAGATTACTT GTTAAATAAT GAGCCACATT ACCCACATTT
GACCTCTCAA GCTGGTATTT TACATAAATT ACATGTCTAG GCATTATTAT AATGTTATTT TTTCCCATTT
Exon 10
(26600)
+15587
(26670)
+15657
(26740)
+15727
(26810)
+15797
(26880)
+15867
(26950)
+15937
(27020)
+16007
(27090)
+16077
(27160)
+16147
(27230)
+16217
(27300)
+16287
(27370)
+16357
(27440)
+16427
(27510)
+16497
(27580)
+16567
(27650)
+16637
(27720)
+16707
(27790)
+16777
(27860)
+16847
(2 7930)
+16917
(2 8000)
+16987
(28070)
+17057
(28140)
AGAAC.Q AAAA. AC.T.QAT.Q6C.Q. AATAAGTIC.A .XCXCAAAAAX. .TGAXGAXGTX-XQTA.C ATAXT. .C.CAXT.Q AAQX +17127
L y s G l u L y s L e u I l e A l a A s n L y s P h e l l e S e r L y s I l e A s p A s p V a l S e r T h r T y r S e r l l e G l n V a (28210)
SA G A fiC A fiC X . S IP A G C .T S A C . .G m C A & A A X . & S A G G A A G S . .T fi& G K S A S T . .& 6 A f iT £ & & £ . i m m G T f i +17197
l A r g A l a A l a V a l S e r S e r P r o C y s A r g M e t P r o G l y A r g T r p G l y G l u T r p S e r G l n P r o I l e T y r V a l (28280)
.QGTGAGTCCC TGTTGTGTAT TTAAAAGCAG TGGCAGTGTA AAATCCCGGA AAGTGTACAT GTTCACTCAG +17267
G
GTCTTGAAGT GGTCTCATCT TGACTGACTG TCTAATCTTC CAACCATCTA CTGTGTCTGC AACTAGACAT
(28350)
+17337
GGATGTCCTA GAAACCTAGT TGTCCTGCTT TCTCCCTAGC ACTTGCCAGG C TT ATTTTAT TTTGTCCAAT
(28420)
+17407
T C T T G T T T T T ATTTAGATTT TTCTGGTTGT GCTCCCAACC ACATTGTGTG TCTCTAAGTG CATGCATGAG
(28490)
+17477
TGAAGTTTGT ACGTTTGTAC AGGCATGAGT ACTCTGTGCT CACAGAGGCC AAAGACAGTG TATTCTGTTC
(28560)
+17547
TATCATTCTC TG CTTTGTTC CCTTGGAAAC ATGGTCTCTT GTTGAACCTT GAGCTAGGCT GGTATCTAGT
(28630)
+17617
AAACCCCAGA AGTCCTCCAG CCTCTGCCCA CAACAGCGTT GTGTTTAGAG GTCCTCAGGC AGCGACACCC
(28700)
+17687
(28770)
154
AGGTTTTCCC ATGGGTGTGA 
GTATCTTCCC AAACTCTATT 
GTTAAGAAAT GGACATCCGG 
GCATAGTTTT AAAACTACAA 
TGTCGTTATT TCTGTTTCTT 
GNAGTCCATC ACACAATTCT 
GCCCTTGGGA AGAACTACTC 
TGTTTCCCTT TTAAAGGNTT 
CTTTAGCCTA ACAGATAGTA 
CCTACTGTTA TTTATGATCA 
TGGATGAAGG GGTGCATTTC 
TAGATGATTT TTCATGTATT 
AAGCATAGGT CATTTGCTTA 
ACCCAGTCTC TTAGCACTCT 
TTGGCATAGA GGATTTTGTG 
TTGACAGCAT ACTTAAGGAG 
TTACTTGGGC TACAGGGTGT 
TCACAGCTGA TGTTTACCAA 
AGAGCTAGGT CTGGTCGTGC 
ACCCAACCCA AACAGCCTTG 
GCAGCACCAT GCGTTTCCTG 
ACCTACTTCA TAATTTTGCT 
AATGAACCTG ACCCGATACA 
CATGCTGCAA GATTGTGACA 
GGTGTGCCGT GAGCTTTGTT 
GCACACAAAC CTGAAACTAC 
AATATTAATA CAGACCAAAA 
TAATGGTGCT TTTTGAGTGC 
GGAAGCAGCA GTAGACAAAA 
CCAAGTTAGA AAACACAGTA 
TAGTCTTTGC CACATGTCTG 
GACCTAACAG CTAACCTTTC 
ATGACTGCCA CTCCCCAACA 
TCATACACTT TCCACTCTCC
GGAATTTGAA CTCCGTCCCC 
TATTTAGAGT AGGTATTTTA 
TCCTCTTTTA ACCTAGTGTC 
AATTGGCACT GATCACTCCT 
GGGTTTTATG CATGCTTAAC 
TCCTTTTGGC CTTTTAAAAC 
TAGTCCCCAT CATTGTAATT 
TTAAAATTGA ATAATATTAG 
TATAGGTCTA CTAATTTAGG 
AATTAACTGC GTGCCATTCA 
TTGGATAAAG AAAGTTACTG 
CCCTTAGCTA AGTTTATCAA 
CATCTGCAAG CATCAGGGAT 
GCCATGGTGC GGTAAGACCC 
GTTAAGGCTG GTTACATCTC 
AAATTTCTTT CAGGCACATG 
GAGTCCATGG GAAATTCTTG 
GTATATTGAC AAGGAGACAA 
TGCCCTGACC TCTACAGGAG 
TGCTGTGCCA CAGCCATGAC 
GGGAGAGGAA CTGAAAGGAA 
GAGGTGAGTC TTCCTCTCCC 
GATAGGAACT CTCTTAAAAA 
AGACTCATCA GTCTCAGGAA 
TATTTGTAGC CCGTGGATTC 
TGATGTTTAT CGTTGTTGTC 
GACTTCAGAT AAATATGGTA 
TTGAGTTTTG AAGTtCTTAG 
TCAGGAGGTC TGGATTTTAG 
TAATTTGGAG AAGAATTCTG 
AGACTAAGTG AAGTACCATG 
TGGGCATCAG TTTCCTTATC 
TTCACCACCA AAGGATTGTG 
TGCTCTCTTA CCATTTCCTA
TATGCTTATA CAGCACTCTT 
TTTTCAGAGA ATTGCAGATT 
TCCCAATGGC AACATCTTGC 
TCATACTTCT TGGAGCATAC 
ACTTATGTCA CAGCTCAGTC 
ACACCCATCC TCTTTTGCTC 
TTGCCATACT CGGGTGTGAA 
GGTTCATGAA ACTTGGATCT 
CATCTCTTGG ACATCTGTGT 
TGACAAATAA CAGGGAATGG 
GTACAAGTAG ACATTTTCAG 
GAAACTCATT CTTATCTGGA 
GGGTTGAACC CTAGATTAAC 
TACATGTTGA AAAGTACTTA 
TGAAAACCTA TGGGATATTC 
CTAAAATTAT CTACTAAAGT 
GGCACTGACC TGTGCCCTGT 
GAGTAGTGGA AGGATQAAGA 
AACGTTGTCC CAGTTGAACA 
AACATCTGGG GATGGGCACT 
GATGAAGGGA ACTGAAATTT 
TCCCTTTTCC CCCAGGTTGA 
ATGCTTCATT TGCACAAGTA 
TTTTTAACCA GATAATTACT 
CATTTACAAA ATGGTTTATG 
CCAACTTTGC CACATAAACA 
GAGATCAAGA TCAGGGTCAT 
ACAGTGTTGA CTATTGAAAC 
CCATGACTCT GCTGATTGTG 
AGAATAAACT CAGGTTTTAA 
CCAGTCTGGG TTCTACTACT 
TGTAAAGGTG ACTGTTCCCT 
GGTAAGACTG TGAACCCTAT 
AATAACAGCT TCCTGGCTTG
ACCTGCTGAG +17757
(28840)
CATAAGCTGT +17827
(28910)
AAAATCTTCA +17897
(28980)
GGATTTAATG +17967
(29050)
AAGATGCCAA +18037
(29120)
CTCATCTGAA +18167
(29190)
CTTATATATT +18177
(29260)
ATCCCTGAAC +18247
(29330)
TGGTTTTACA +18317
(29400)
GTAGCAACTA +18387
(29470)
AACAGCATCC +18457
(29540)
TGGATTTGGA +18527
(29610)
TTATAATAGG +18597
(29680)
GCAAATTAGA +18667
(29750)
CAGGGCAATT +18737
(29820)
AGTAATTCAT +18807
(29890)
GTGGTCTGAG +18877
(29960)
GGTGGAGCAC +18947
(30030)
GTTGTTCAAT +19017
(30100)
TGGGCTCAGA +19087
(30170)
GAATGGACTC +19157
(30240)
CACCCAACTA +19227
(30310)
ATACTCACTC +19297
(30380)
GTTGTTCTGA +19367
(30450)
CTTTTATCAA +19437
(30520)
AATTTAGACA +19507
(30590)
GGCTAAGAGT +19577
(30660)
TTTGGGATGA +19647 
(30730)
GTTCAATAAA +19717
(30800)
GAGGGGATGA +19787
(30870)
CTGATTCTAG +19857
(30940)
AATTGCTTCT +19927
(31010)
CGAGAGTCTA +19997
(31080)
GATCTGGCTG +20067
(31150)
155
CTTCCATCTG CTCCCGTCCT AGGTGTGCCT CACTGGTATT TACTACTGCA AATTCTATTT CATTCATTGC +20137
(31220)
CACCCAGTTC ATGCAGATGA TCTGATTAAT ATTAGTGCTT ACCTTATAAA TCCATCCTTT TTGGAATTTA +20207
(31290)
CTCCCCTGCT CAGTTTGGGA TCATTAGTGA ATTTAATCAA TGCAGACTCT CCATTTTCAT CAAGATGATT +20277
(31360)
AATAAACATA ATAGGAAGTC CAAGCCCCTC AGGGATATTT CACATGGCTC TTCCTTACCC CTGAAGAATA +20347
(31430)
CCATAATAAT TGTGCTCAGC TTGCAGTCTA TCCCGCAATT TTGCTGCTAA GTTCATTTCC TTCAGACTCC +20417
(31500)
CTTCTCTCCT ACATTGCCTT ACAAGTGGCC CCTGGGAGCC CTCCTGGATT TTCACTATTG GCCTCAACTG +20487
(31570)
AAATATCACC CATGCCTTTG ATATAAAATT CACCCCTATT ATTTTA A TTA  AGATAGGGAA ATAGAAGCCT +20557
(31640)
GGCAGTATTA AATGACTTAG TCATTGTCAA ATAGCCAAGA AGTAGCTATT AATGTGTCAT TTCCCCAAAT +20627
(31710)
ATGTGACATA TGAACCAATT AGCAAATTAG AATAGTTTAA ATTAGCTAAT TAACCCATTA TAACCCGAGG +20697
(31780)
TTGTTTCATA AAGAATGAGA CACAGAGGAA GTTGGATTGA TGGTGTAGGG GATTGGGGTA GGCAGGTGGC +20767
(31850)
TTCTGCTCTA GTTGGTAAGG TCAGTCCAAT AGGCACCGGG AGTGTAGATG GAAGTGAACA GTACAGCCAG +20837
(31920)
CAAAGAAGCT TGCTCTATCT GCTAGAGATT TTCCTTGAAT CTACTATCTT GCTCTGAGAT TTTCAGAGCA +20907
CTT t r in u c le o t id e  re p e a ts  (31990)
TGGACCTTCT TTCTTCTTCT TC TTCTTCTT CTTCTTCTTC TTCTTCTTCT TCTTCTTCTT CTTCTTCTTC +20977
TTCTTCTTCT TCTTCTTCTT CCTCTTCTTC TTCTATAGTG GCAGTTTTGT TTTATCAGTA CTCGTTATCA
(32060)
+21047
ACTGCCCTCC ATCAGCTAGC TTCTCCTTTA AGAGCTGAAC TTCCCAATTT CAAAAGTCTC TCTCCTCAGT
(32130)
+21117
CTTGAAGGTC CAGCTTCTGT TCTGTTGTTA TCTCTGCCAT CTCCTGTTTC CTGATCTGGG CCCTGGCACT
(32200)
+21187
GAAACTATTT TCTTTTTCAT GCTTTCTTTT CTCCTCTATT CTTTGACACT ATTCAGGTAC TAAGCATAAA
(32270)
+21257
ATAATTTTAG AAATAAATGT TCCTAGCATG CATCCTGACC CCTGGAAATG AGAATGTTGG CTGCATTTAT
(32340)
+21327
TTGTAGCTTT GACCCTGGCT AGGATCGGAC CTGTTTTTTG GTAAGAGATT AGACTGAAAA TCACTGGACT
(32410)
+21397
CAACAGTGGT TCTTAACCTG TGGGCCATGA CTCCCTCCCA GGTCACAAAT CAGCTATTTT GCATATCAGA
(32480)
+21467
TACTTACATT ACAATTCATA GCAGTAGTAA AACTACAGTT ATGAGATGCA GTGAAAAGAT TTTATGGTTG
(32550)
+21537
AAGGTTACCC ACAATATGAA GAACTGTATT AAAGTGTCAT AGCATTATAA AGGTGGAGAA CCATTGCTTC
(32620)
+21607
ATGTGAACAA CGAGCTTTCT CCACTCTCAG TGAAGGCTGT ATCTGCCACT CAGGACCTGG TATTATTAGA
(32690)
+21677
AGTGAGTGAA AATGTGTTCT TCTAAAAGGC TTTGTTTAGG CTTAAGATGA GTGGCACTTA ACCTGGGAGC
(32760)
+21747
AGGACAAGAC TCAGTCACCC CAGTTTTCAC ATGGCTCAGT CAGCAGTGTG GACACCATTT TCAGGGTGAC
(32830)
+21817
TGCTGCTATC TACTGGAACA AATCCTTCAG CAACAAAGAC ATGCTGCTCA TAGCCTTCAC TTGATTCTGG
(32900)
+21887
CCTTCACTTT CCTGCTATGG TGTGAGCCAG GGTGTGTATG
AC
TACATATGTG
d in u c le o t id e
TGTGTGTGTG
r e p e a ts
TGTGTGTGTG
(32970)
+21957
TGTGTGTGTG TGTGTGTGTG TGTGAGTGAG TGTGCAGGGT AATATGTGTC CTGGGGTGGG TATCAGAGCT
(33040)
+22027
AAGCAAAAAC CAATGTGGCA TGTTTAGTTG TGATCTGTTG ATATGCATTG TAATGCTAAA ATAGCTAAAT
(33110)
+22097
ACTGTACCTG AAGCTCTGTG CTATGAGTGA AATCTCATGT TTACCAGCTT TTGTTGTGCA AACATTGTTT
(33180)
+22167
CTNAATTTAA AACTATNNGT TAAATAAAAA TGGCTANAGC CAAATACTGG AGAGATTAGA AATAGGCAAG
(33250)
+22237
TTTTTTAG AT ATATGGTTAC AGAGAACCTG AAATGGTAGA GAGGAGGGCA GAACAAGGGA AAGATGAGAA
(33320)
+22307
GATGCCATGG GCTAAGGGAT TCTGAAAGCT CACCATGAGG GCTGGCCAGT CGGAATAAAA GCAGCCAAGC
(33390)
+22377
AAAAACATAG CAAGTCTTAT CATGGAGTTA TTGATTGGGG AGTAGATACT AATAGCTTCG AGGGTAGATA
(33460)
+22447
(33530)
156
TCTGCCCAGC TC TA G TG C TA TTTA A A G G A T T A T T A T A A A T A TA A A A G T T T TG C A T C T T T T ATCTGGGAAC +22517
(33600)
T G A A TG A T C A AAGGCAGGGT AG A A A TA TC C C AACTGAGAT T A A A T A A T T A CTACAACAGC TGCGGCACAC +22587
(33670)
AGGCATGCGT GCAGGATGGA AGGAGGACTT T T A T T C T T T G A C TTG G TG TT C ATGACAGAA GTGCAAAGCA +22657
(33740)
A T T T C C C T C T CCCTGAAGCT TATA G A C TC A AGGGCGGGGA GGAGATGGTG TT A T C T T G A A G ATCACTG AA +22727
(33810)
TG T A C T T C C T TCATG GTCCA C A G TC TA TC A AAG G AACTCA AGCTCCAGCT GTGGCCCCTT C TTTC C TC TG +22797
(33880)
TG CC TG TAG A TTTCCAG CAG C TC C C TTC A T CGTCTG TCTG TTTG C C C TTC T C TG TC TTTC TCG TCTG TTC +22867
(33950)
T C A T C C T T T C T T C T T A A A T T TC C AAAC TG T TGTGAGACAA GATACAAAGC AGAATAGGGA AGAAGAAAGG +22937
(34020)
G AAAC AG G TA CGAGGAAAGG G TC A G TTTC A C TTTC TC TG C G C TTTC A A A A G A A TTC TG TC C C TTTAG AG T +23007
(34090)
TT TA C A A G G T AAGAGAAGGG AAGCTCCGGG TCAAGACAGA GGGGAAATGC TTG G AAAG AA AAATAG GTG A +23077
(34160)
GCCATCAGCA GCAAGGGAAA CCCCGCTTCG TC TA C TG TC A CAGCTGCCAC TT T G G A A T T T TC TTTA C A A G +23147
(34230)
TG GGG GATTT CAGCTGGGCA GACATAGCAG TTG A G TC A A A C TG C TT C T TT GACTCAGGCT TC TG TG G TTT +23217
(34300)
CAAGGTTGGC TG GATCTTGC CTGATAAGCC TCAGGCCAGA CCACCTTGGC TCTGTGGGAC TG GTCTACCA +23287
(34370)
TC TTG A A G G T AAG G TTG CAT T A A G C T T T T A GG CTCTGTTC C A TA C TA C C A A G G A TTT TTA T T T T A T T T C A +23357
(34440)
T T T T T A A A T T TCAGG TATAG C T A C TTC TC T TGGTGGCCAT A T C A A T C A A T C TTC C ATG C T T A A T A N T TA G +23427
(34510)
GCCAAGGAAG G AC TC TATCC CTGG CTCTGT GCAAGATAAG T T T A T T C A C A  
B2 re p e a t
G T A TTTA G G A TA TC TC C C C A +23497
(34580)
A A T A T C A T T T G T TA A TA G A A AGATAGGAAG AGAGAGAGGG ATAAAG AGAG AGGGAGAGGG ATAAAG AGAG +23567
(34650)
AGGGAGAGGG ATAAAG AGAG AGGGAGAGGG AGAGGGAGAG GGAGCAGAGG GAGAGGGAGG AGAGGGAGAG +23637
GGAGAAGGAG AGGGAGAAGG AGAGAGAGGG AGCAGAGGGA GAGGAAGGGA GGAGGGAGAG GGGGAGAGGG 
A G G G G G A G G G  G G G AG G G AG A G G G A A G A G A G  G G A G A G G GAG ATGCTCAAAC CTGGTAATGG CCTAGGATTC 
AGCAGCAAGA CTACCTTTAT ACCTGTGAAT GCTGACTGAT GTTCTCATCC CAATTATTGT GCTCCAGTCA 
GAGAAACTGA GACAAGAGGG CAGACCTTGC TTGTGCTGTA GACTGCTGCA GAGAGGTTTC ATTTTACTAG 
TTCTTGGCCT GCTCAGGCTC CATGTAGGCC AAGCACTGGA GATGTTTACA TTGACCTCTG CAGGCAGTTT 
TTGTCTAAAT GTTTCATGCT GTGCATGACA CTCATTTTGT GTCTCTCCGT GTGTGATACG CCAGTGCATG 
TGTGTGTGCG CCTTTTCATC AATATTTTTT TTTTCTGCTG TCGAAACAAG CCAATTCAAG CTTAATTGAG 
AATATGGAGG CAGGTTTATT GGAGGCAGAT CTGGGAAGGA AGATTCACTT AGCTCACAGG AGGAGCCTAG 
GGAAATGGAG ATGCAGACAG GGAGACAGGG GAGTTAAGTA GAGAAAGAGA GAGCACATGC ATGCAGAGAG 
AAAGAAATGC AGAGACAGGG AGAAAGAGGG AGAGAGAAGG GAGTTGTAAC ATGTCTGGAT TATATAGAGA 
AGAGCCTCTG GGGGCGGGGA AGCCCAGTCC ATAGGTGGAA AGTTCACAAT AGAGGGTGGT GTGTGCCAGT 
CATACCTTGT AACTAGTGTG GACTGAGAAC CTGGAGATCA ATTTCGCTTG ATATGTAGAA TAGGCACCTC 
AGCCATCTGT CCAGGGTTTG AAACCCATGA TTCATAAGTG TATGGCTGTG GACGTGCATG TGCCTCAGTC 
CACTGTGGAA GTCACAGGAC AGTCCTCGGA TCTTGGTTCT CCTACTTGTC TTTGTGCAGT TGTACAAATC 
AGGCTAGCTC ACCCTCAGAC TTCTACAGAT TCTCCTATCT CATCTGCCCA TATTCCTGCA GGATTTTGCT 
AGGATTAAAA ATGCCTGCAC GTCTGCACCA GACCTTTATG TGGGCTCTGA ACTCAGGTTT TCAGACTTGT 
AGGAGTAAGC CATCTTGACA TCCCAATGCA ATATTTATCT CAACTCATAT TATTGAGGTA CGAGATTAAC
(34720)
+23707
(34790)
+23777
(34860)
+23847
(34930)
+23917
(35000)
+23987
(35070)
+24057
(35140)
+24127
(35210)
+24197
(35280)
+24267
(35350)
+24337
(35420)
+24407
(35490)
+24477
(35560)
+24547
(35630)
+24617
(35700)
+24687
(35770)
+24757
(35840)
+24827
(35910)
157
TGACTTCTGA CCCCCTTCTC CCTTTATACC CAGAATATCT GGAATTTATG TCTCCTAACC TTAAGTATTC
AGGCAGCACT ACAACTGTGG TTTTTCCCTT GAGGATCTGG GGAAATTAAC TGGATGCCTT TGCTCTGACA
CAATGTATTC ATCTCCATCA TAATTACCAC GAACATGGAC TGATTGGCTT CTGTGGACTT GCACAGATGC
TAAGCACTTT GTCTTAACAC ATTCACTCCT ACCCCAGCTT CAAAGCAATA CACAAAATGA AACAAATACA
CTGCTCAAGG AAGGCCACCT CAGCACCAAG AGACAGAACT AGGCTTAAAC CTCTCCCTTC TGTGTCTACT
GGATACCAGT AGCCAGCAGT ACAACCTGCC AGCCTGTAGT TATTTCCGCA GGTCCACAGA AAAATGGCTC
CACAGTGGCT CACAGAGAAG GATTCTGGGT TTGCAGGAGC TCTGAAAGGC ACTGGTTCTT TCTGAGAAGT
CTGCAGAGGA GATGAAAACT GTACTTTCCT TATTCTGATC TATCCAGTCT GAGCCTGATG GGGGTTATGA
AAACCACCAG CATCCACTCA GTCCAGAGAT TGCCAAGCCA TTCATGTACA TAGAGCAGTC TCCAAGGCTT
TGCCACACTG TCCTTCACCG GAGCCCAATT TCACCAGGAT ACCACAGCTT TGTGCATTTT TCAGTGGGTT
GTGGATTTTA TGCCTTTACC TTTTGCTCTC TGCCCCCATC CTTTGCCTTC TTAAACCTGG AGATCTCTCA
GAGTCCACCT AAAAGCTGCC ACAGAAAGCT CAATCCCAGA AGGTGACTTT TGACTTTTGC TTAAATTGGG
AACCTTTTGT GTGTGACACC ACAGCTTCAC CCTCCGACCA ATGGAAAGCC ATAGGAAGCT AGTTAAACCC
TGTATTGATA CCATCTTAAT TACTCAGCCC CGTTGATGCC ACTTAAACTT CTTCCATCAC CTGCTGGTTT
AAAAACACAG CAGGGCTGCT TTATTTGAGG GGCTCCATCA ATTTGCTAAT TGGTCCTTTT GCTTGAAACC
TATTGTTGAA TTGGAGTCAG ATTCAAAATC AATACTGAAG CAGTGAAAGT ACAAACTTGC ATGGATTAGG
GCTACTTTGG CCTCCGAATC AAATCCACCT CCTTAGATCT GTCATTCCCA ACTAATAGAT GGCAGGATTC
TAGAGCCAGA GAGACTTCAA TACCAAAGTA TGAGTCATTT GATGGAGCTT CAGGGCAGGC AAAGGCAGCC
AGAGCAATGC TAGCGTATCA TCACCTAGAG ATTTCCTGAC CTCTGTTGTC ACCATCACGC CCCATCCCGT
GCACACTTCC CACAGAATTT CCATGATGTT CTT TG TT TTA  CGGTTAACTA GCTGAGATGT CAGAAATGGA
AACCAAAGTC TACAGAACCA TATGACTGAG GCCTCTGAAT ACACTGAGTT AGTAAGGTCT GCAGAACACC
CAGAAATGAA GTGGAGGAGC TGAGGGCTTT TCCATAGGTA GACTATGACA CTTCCCCTCT CAAAAACTCA
TCTGTATCAT CAACTGAGAG TACCCAACCA TTTTGTAAGA AACATCTGTG GCTTCCTGAT TAATAGTATG
TAAGAAAAAA TATATGCCCT TTAAAACAAA TGATTCCAGT TACCTAGAAT TTTTCCTTTT TTTCTTTCTT
CTTTCTATTC CTACATCCCA ACTCCAGCCT CAGGATTGAA CTTAGAGCTT TGCCCAGGAG ATTAGAGAGG
AAATCTCTGA GTTCATGCAT CCCAGCTCAG AGGAGGTCAT GTGTCCTAGG ACGTCTGAAA ACATTGCTCA
CT dinucleotide repeats
ACTTTTAGCG TACTGAAACG CTTAATAATT TTGCTAGGTG TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC 
TCTCTCTCTC TCTCTCTCTC TCCCTCCCCA TTCATAAAAG AACTAGTGAG ATAGCTTGGC AGGTAAATGT 
TCTCGCTGCC TAGCATGATC ATGATCATCT CATTCAATCT CTGAGACCCA CATGGCGAAA GGAGAGAATC 
CAATCTGACA TGTTGTCCCT TGATGTGCAC ACGTGTACCT TGTGTTGTCC CTTGATGCGC ACACATGTAC 
CGTGTACTGT CTTTTGATCT ACATACATGT ACCTTGATGC CTACAATCTT CTATCATAAA AGAAATAAAT 
GTTGAAAAAA AGGTAGAGAT AAAATTTTAA TAACTGAACC GATAAAAATT TACAAGTCAT TTTTAGTCGA 
CAGTATGTGA ATGTGATTTC TCGCACTGAA TTTTTGCCTG TCAATGTATA TTTCCTTTGA GGCGAGGCTC 
ACAATGCTTA TGTTCTTGAG CACGAGTTCT GCTCTTCCTG TGGTCATATG GGAGGGGAGC CTGGAGAGGC
+24897
( 3 5 9 8 0 )
+24967
( 3 6 0 5 0 )
+25037
( 3 6 1 2 0 )
+25107
( 3 6 1 9 0 )
+25177
( 3 6 2 6 0 )
+25247
( 3 6 3 3 0 )
+25317
( 3 6 4 0 0 )
+25387
( 3 6 4 7 0 )
+25457
( 3 6 5 4 0 )
+25527
( 3 6 6 1 0 )
+25597
( 3 6 6 8 0 )
+25667
( 3 6 7 5 0 )
+25737
( 3 6 8 2 0 )
+25807
( 3 6 8 9 0 )
+25877
( 3 6 9 6 0 )
+25947
( 3 7 0 3 0 )
+26017
( 3 7 1 0 0 )
+26087
( 3 7 1 7 0 )
+26157
( 3 7 3 4 0 )
+26227
( 3 7 3 1 0 )
+26297
( 3 7 3 8 0 )
+26367
( 3 7 4 5 0 )
+26437
( 3 7 5 2 0 )
+26507
( 3 7 5 9 0 )
+26577
( 3 7 6 6 0 )
+26647
( 3 7 7 3 0 )
+26717
( 3 7 8 0 0 )
+26787
( 3 7 8 7 0 )
+26857
( 3 7 9 4 0 )
+26927
( 3 8 0 1 0 )
+26997
( 3 8 0 8 0 )
+27067
( 3 8 1 5 0 )
+27137
( 3 8 2 2 0 )
+27207
( 3 8 2 9 0 )
158
TGGCTAACTC CTTCCTAACG ATTGCCTTAA ATACACTTCT GATGCAGTAA TTTCCACATC ATGAGGAGTT +27277
(38360)
TATTAGTTGG AGGACATATA ATCAGTTGCC TTGCCCTCCA TGATATTTGC TTCTTTACTG AGAATCTTCA +27347
(38430)
CTTATCTACA TAAGAGGTAA GGTGGCTAAG CCAGTTGAAA AGATTTTTTG TAATCATGGT CCGAGGATAA +27417
(38500)
CGATACTGTT ATCAGGACTT GGCATATCAG GCTAGTGGAT ATTGTACAAT TTGAGCCACA AATGACTGTG +27487
(38570)
TGTGACCATG ATAATAGTTA CACCACTTTT TGTTCTTCTC ACAGGACTCA AAGTTTTGCT GTGTGTCTTT +27557
(38640)
GTAAAAGAGT TCTGAACAAA TAGATGACAT GGTTAATGCT TTTCAATGCC TTTTTTTAGG AGAAGAAAAC +27627
(38710)
AACAACAACA ATAAATAATA ATAATATACT ATGCAGTCCT GACTAGCATG TAACTTGCTA TGTTGATCAG +27697
(38780)
TCTGGTCTCT GACTTGCTTT TATCCTCCTG TCTCTGTCTC TCAAAAGTTG GGGTGATAGG CACATCTCAC +27767
(38850)
TATTCCAGTG TGTGCAAATT CCTGCTTATA ACACACATAA AATTTTTTAA AAGATTTTTT TCTAAGTATG +27837
(38920)
TGGGTGTGTC TGAGTGTGTG TTTGTGTTCA TGCGTGTGAT GCCTTCAGAG GCCAGATGGC TCAGACTGCT +27907
(38990)
TGAAGTCAGG GCCTTAAGAT GATTCTATGC CATCTCAAAT GGGTGCTGGG AAACAAACTC CAGACCTCTG +27977
(39060)
CTAGAACAAT ATAAGCATTT AATTGCTGAA CAATCTCTCT AGCTCTAGCT CAGGATTTTA CCAAAGTGTC +28047
(39130)
TCAGTGCCAC CTATAGCTTG AGAATGTCAA GGACACTGGA CATTTGTAGA GCAGCCAACC TCACATAGTC +28117
Poly GT repeats (39200)
ATGGCCAGTG TTTGGAAGGA GTATTTTGTT TTTGTTTTTG TTTGTTTGTT TTTTGTTTTT TGTTTTGAGT +28187
(39270)
GGCCAGATAC AGCGTACACC TTTAATTACT TCCAGAGCCT AGCCTCTCCA GGCTCCTTCC CCATATGACC +28257
(39340)
ACGTGAAGAG AAGAACTTAT GCTCAAGAAC ACAAGCGTTG TGAGCTTCAC CTCAGAGAAA ACATAACTTG +28357
(39410)
TCAGGTAAAT TCAACGCAAG AAATCACGTT CAAATACTGT TGAGTAAAGA GGAGGCTTCA GAAACACACA +28397
(39480)
TCTGACACAA AGCAAGCTTT CCCCACAGTA AAAGTAGACC CAGCCGCAAA GGTGATGATG CTCAGGGCGT +28467
(39550)
GGTTCTTGAT AACAAAGCAA CACCTAGAGT ACGCTAAATA ATTAAACACG TAGAATAGGA TGAGTGAAGA +28537
(39620)
ACGCCTGAAC TCCATAAAGA AATGGCAGCA TATACGAAGC CAGCACACGC AGCACACCCT CAGTGTTACG +28607
(39690)
GAGGGAGAGG AATAGGCTGG GAACCCTGCC TTAGATTGAG GGAGGCAATC ATTAGCTTTG TTTCTTGTTG +28677
(39760)
TCCTGAATGA CAGTTGTGTG TCCTCAGTGG ATTTCACTCC CTTTCTCTGT TTTAGTTTTT CTATATCTGC +28747
(39830)
ACAGGGAGCC CTGGGAGTAA ATTAACGGTG TACACTGTGT CTGGCCACTC AAAAATGTAC ATATAAAAAT +28817
(39900)
GTGTGCAGAG AAGAAGTTTT CAGTTAATCC TTGAGAGTTA TGACTTTTAT ATTTTTGTAC TGTATAACTT +28887
(39970)
CCAAACTACT ACAGGTGAAA ATATACCGCT TTTGTAAAAT TAGTCTTGTG TAAAGTGTGT GTACAGAAGT +28957
(40040)
GGTGGTGGCC TGGATAGAAT AAATATTACC AGAAAAAAAA AAAAAGAATC AGGAGTGTGG TGGATTTGCA +29027
(40110)
GGCTCTGGTG TTATAACTTG GTGTGAGGTG AGGTGACCAA AATGTCCAAC TTCACTGTGC AGGGTCTGGA +29097
(40180)
ACCGAGGTCT CTAGGCTAAG CAAGGACAGA TGCAGGCGTC AGAAGCATAA AGCCTTACAT TTATGACTGT +29167
(40250)
GCATAGGAAT CAGGTATGCT GAGGGTGTGA GGAAGGAACA GGAGCTATAA AATATCTATG GAAATATCTA +29237
(40320)
TGTGTCTCCA AGGATTCTGT TTGGGTATTG AAAAGACAGA GAGTGAAATG AAGAAGCTGG TGAAAGAAGT +29307
(40390)
AATTACTGAC TGTTTTCGTT TCTTTTGTTG TTTTGAGACA GCCTCTCCCT TGTTATAGCC CTGGGGAAGG +29377
(40460)
GGCATCTCTA ACTCACCCTC CTTCTACCTT GGCTATTCAG ATTCTGAGAT TACAGCTGTG CAGCCTCATG +29447
(40530)
CCTGGGTAAC AGTGGGTTTG ATGAAACGTA GAACACAAAT TTGTTTGTGT TTTCTCAGGT TGGCAAAATA +29517
(40600)
CACAAGTGAG TGTGGGCTTT GGGGATTTTA TAGTCTAAAC CTAGAGCTAC ATGTCAGGGC AGTGTCAGGA +29587
(40670)
159
AAAGGAAAGA CTTTGGGATT TCATGGAATG AAAAATCTGT ATGTCTAAAA ACAAACTTGT CAATGCTCAA +29657
(40740)
AGAACAGACT
AAGTGCCATT
TGAATTCAAA
AGTCCTGTGA
ATGAGTACAT
GTGATAAGAA
GAAGAATGGG
ATAGAGAAGG
TTTTTTGAGT
TGTGAGTGTG
ATGGCCAAAG
ATCCCTTCAG
CAATGATATG
AATTAACATA
TTGAGAGAGA
AATGCACTGA
CAAAGAGCCA
ATAGGAGTAT
TACTAATAAC
CCAAAAGAGG
AAGGGAACCT
TGGCTTCCCT
ATTATATACA
B 1
ATTTTTGAAG
ACAGGAGATG
GCTGGAATTT
GAACTCAGCT
TATATGAAGA 
re p e a  t
GATTCATTTA
GGATTAGAGA
TAAAAGAGGG
GTGGACAGTT
TGTCATAATG
TTGTATTTAT
TGGTTGTGAG
+29727
(40810)
+29797
(40880)
+29867
(40950)
+29937
(41020)
+30007
CCACCATGTG TTGCTGGGAA TTGAACTCAA GATCTCTGGA AGAGCAGTCA GTGCTCTTAA CCACTGAGCC
(41090)
+30077
AACTCTCCAG CCCCAACTAA TAACATTTTA AAAAAGATAG GCTGGAGAGG TGGCTCATTT GGTGGAATGC
(41160)
+30147
TTGTTTAGGA TACACAAAGC AACGGATTTA ATCTCCAGAA GTACATAAAG GAGATGCAGT AGGACACTTA
(41230)
+30217
GGAAGTAGAG GCAGGAAGAT CAAAAACTCA AGTTCATCCT CCATAACATG CTGAGTTTGA GGCCAGTCTA
(41300)
+30287
GGAGTACATG AGACCTTGCC TCAAAACTTA CATTAAAAGA AAAGAAGAAA TTTAGGGGAG AGAACAGAAG
(41370)
+30357
ACAAAGTTAG GACAGAAATT AGGGATTTTT TGGGTTTTTT TAAAGAAAGA CATTTCCAGT GACTATAAAA
(41440)
+30427
GGAGTTCCTG AGGTATGAAA ATACAGAAGT CTGAATCATT TTTTCCATGA TTTATTAATT CTTTTTATAT
(41510)
+30497
CCTGATTGCT GCCCCTCACA TAATGCCCCT GTTCCCCATT TTCCTTCTCC TCTGAGAGGG TGGGGGCTCC
(41580)
+30567
CCTGGCTATC CCCCCACCAT GGCACATCAA GTCTCTGCAG GGTTAGGTGG ATCCTCTTCC ACTGCAGCCA
(41650)
+30637
GACAAGGCAG CCCAGTTTGG GGACACAGAA GCCTGAATCT TTATTCAAGA ATACAGTCTG GGCAGTGAGA
(41720)
+30707
GAAGACAGTA TTTGATGATA GCTAGGGAAG ATGGTAGAAC AGGTAAAACT ACTTCCACTA GCTTAGTCAA
(41790)
+30777
GATAAAGGAT T.CTATGAATA TTTGAAGGCA GAAATGAGGA GATTAAGGAG GAGATTAAAG CTTTGGGAAA
(41860)
+30847
GTGGAGAAGA AACCTGACCA AGGACAGGGA AGAGATGAGG AGAGGCATGA ACTGCCAGCA TTAAATCCAG
(41930)
+30917
ATATTTCTCT CCTGTGATAA TTGGACAGTT TGTAGGGCTT TGAATGACTT GAAGGGTTTT TTTTTTTTTA
(42000)
+30987
AAGCACTAGG ATATTCAGAA ATGCTCAAAA ATCCCCATTT ACATGCATTT CTTGTTGTAC AGAAGAAATC
(42070)
+31057
ATAGCAAACT TAAGGTTTGT TTTTTTTTCT TGCTTTTTAT CCTGGAGAAA CATGGTTTGA ACCTTGCCAC
(42140)
+31127
AGTGCTTTCT TAGTACAACT ATCCTCAAAT CATGGCCTGA GTCATTATTT GCTTTCTGCA GATCTCCTCT
(42210)
+31197
GATGGACTTC AAGCTGAAGG ATTGGAGGTG TCAAATGCAT TCTCTTAGTC ACTGAGTCAC TGTAACTTGT
(42280)
+31267
GTACCTGACA AGAGTCTAAG AGATACTTAC TAAATGGACA GATGGGTAGA TGGATGGGTG GGCAGATGGA
(42350)
+31337
AAAATGGATG GATGGATGAA TGAATGCATG AATCAGCTCT CTCCCTGGGA AAGAGAACTA ACTGTAACTC
(42420)
+31407
AGGATTTGCT TTTGATCTCT GAAAGTGAGT CCAGCAGATA ACACAAAAGA AAACTACTTC CACTAGCGCC
(42490)
+31477
ATTTAATCAG AAACCTTTGA TTTTTCGGGT CTGCGTTCCT GAAATTAAAT AGACTAACAA GTACCTCCCT
(42560)
+31547
TACCCTCCCA CCCTACCTTG CTTTTCACAG TCTGATGTAG TCTTTAAAGG TCATAGAAGT GTCTCCAATA
(42630)
+31617
TAGAGAATAG GATCCCATTA GAGAATAGGA TGGTATGCAA AACACTTCCT GTGCTGACCA ATGACAGTTT
(42700)
+31687
TTTACTTCCT GTTCTATGAA ATGGGAAATG AGGGGAATAG GGGCTTTGAG GATAATTACA GCCATACAGT
(42770)
+31757
GTGTACTGTA GATTCTAATA CTTGCACCAC TATGAATATT TTCACATACT TCCTAAGTTT CATTTCCAAG
(42840)
+31827
TAGGTAGATG CCACTATGGA AATAGATTTC ATTCTACTCT AATAAGGTTT CTGAATTGTC TTGTGCTTTT
(42910)
+31897
GTAGCTTTTC CACCTAACAC CCTACTAGGC ATCTGAAGCT CTAAGCACCA GCACCCAGGG GGCATGGGGT
(42980)
+31967
(43050)
160
ACGGGTGGGC TCCAAAACAC TGGCTGATTG ACTGAATTAA TCAGGCTTAA ATTAGTAATA ATTGAAAAGC +32037
(43120)
CCTTAGTGTC CTTTCCCCTA GAACAATATT GTGAGATGGG TGTTAGCTCC TTTGGCAGAG GAGATGTCTG +32107
(43190)
AGGCTCCGTT CTCTACTAGC TGCTCACCCT TGACCAGCAT CACCCAGCAC CTTCAATTCA AACCCAAGCC +32177
(43260)
CTCTGAAGCC CCA TTCTTCT A A TTTTA TTT ATCCTCCCTG ACTTTGACTT TG CTTTCTCT TTCCTCACCT +32247
(43330)
Exon 11
TTGAACCAQfi.ÄAAGßAÄAfi5L.AÄßXCÄXTfifi.^A5AATfiG,CÄ..TfiIffAITfiXG..5;TßC,CAACAfi.fiX«;c;TfiCTI
1 y L y s G l u A r g  L y s S e r L e u V  a l G l u T r p H i  s L e u I l e V a l  L e u P r o T h r A  l a A l a C y s P h
+32317
(43400)
GGT.QXTGXTA.AXCTXXT.Q AC. .XCAXCX6CAG. A 6T G T a g g t a  t t a t t c c c a t  t c c a g g g c t g  c a t t t c c t t c  
e V a l L e u L e u  I l e P h e S e r L  e u l l e C y s A r  g V a
+32387
(43470)
CTGTGTAAGG CTCCTGGTTA TCAGGTGAGA TTAACATCAT GGTGTTTTAG GATGCCTTTA CTGGCAAGGA +32457
(43540)
AGAGAGGAGC CAAAAATAAA ACATGACACA CAGCAGCTAC ACAAGACACA GCACAGTCCC CAGCCACCTC +32527
(43610)
ACACTCCTCA AATCTGCTAT TTAAATTTCT ATAGAGGTTT TGGCCACTGT G TTCTTTTCC TTCATGGCTC +32597
(43680)
CCCTTTCCA C A CTTCTTTG T GTTTTGACAT CTCCTATAAA AAGGCAGCAG TTAAACCAAG TTTTCAATCA +32667
(43750)
CTACACTGCC TTCCCATATG GGCCTCTGTG GTCAGAGGCT GACCTCTGCC TTGGCTTTCA AGTTCCCGGT +32737
(43820)
CCAGTGAGGT GACTATCCTT AGGTCAAATG CAAATTCTCC AAAGGCTTCA TAGATCTCAC ATCTTATCTT +32807
(43890)
ACAGCCTGCA AATGGCTACA TCTGATCTCC CCCACATCCA CCCCTCCCTT TCCATCTATC ACTAAGGCAA +32877
(43960)
A GTTCTGCTT TATCCTAAGA ACTTAGGCTG TAACTGCCAT AGTAAATGGC ATTACCCCTT ACCAAGTTAT +32947
(44030)
TCTTAGATGC TGAGTGTGGG TGACAGGCAG CAGTTCAAAG GAAAGGGAAA GAAAAGAGGG AACGGTGAAA +33017
(44100)
TCATCACAAC TAAAGGAGAA AAACTAGACT GAGCAGTGAC TGAGTAGCCA AGAGAAAGAT GCTGCTGACC +33087
(44170)
AGCTTTACAC GTCAGGTTTG CCAATGCGTG CCAACGTGAA TTGGTTCTGC CTTCCTCTTC CTTGGAGATC +33157
(44240)
TCAGAAGCCA CATCCCAGCC TGGCTGCAAC CCAAGGTCTT CAATGGTGAA GATGTTTAGA AATCTTAGCC +33227
(44310)
AATGGACAAT CTAAATTTAT AACACAGCTA TACATGAAAC TAATTTACTC AATGTTTGAG TAGAAATTTG +33297
(44380)
Exon 12
GGCAAGTGGA TTGTTTATAC TCATCCAGTT CCTTCCCTAT TGTCAGCJXCX..CAXTXAT.Q£A .C.CAGCXXC.XX
I C y s  H i s L e u T r p T  h r A r g L e u P h
+33367
(44450)
.TC.CAC.C.QGT.T. .C.CGC.CC.C.CAA .A C A 6TA A CA X . .CAAA6AXGT.C - .C.CXCXSCXTA. GT.QAAX A TG A . .QGT AAT ACT A 
e P r o P r o V a l  P r o A l a P r o L  y s S e r A s n l l  e L y s A s p L e u  P r o V a l V a l T  h r G l u T y r G l  u
+33437
(44520)
AAAAATACAA AGAGGTGACA TCCTAAGTAC CCAGGGATGA GTATCAGGTT ATCAAGATTC CTCTGTATGT +33507
(44590)
CTATGTATAC ATGTGCCAGT TAATACCTGT ATGTATGTAT GTATGTGTAT TTGTATGTAT G TCTCTGTTT +33577
(44660)
CACATGCATG TGTATGTGCA TGTGCATATG TGTACATGTG TGTATGTATA CTTGTGTGCA AAATTAGCTA +33647
(44730)
TAGATATTTT GTCTCTACAT CTACATTTTG GGAAAGTATT ATTCAATAAT AATGGCTCTT GCCATTTAAA +33717
(44800)
CCTGAATTTC CATTTCATAT ACACCATCTT TTAAATGATC TCTGTTAATT ACTCTAAGAA CAGGAATTTT +33787
(44870)
TC C TG TTC CT TTTCTGTACA TAAGAGGCAC AGATGAGAAC CTGACGAAAC AATGTTGTCA GGATTATTGT +33857
(44940)
AGCTTTGTAA AATTGACATT ATGTAGGCAG AGGTCTAAAA GTGATCCTCC CTAAGACATT TTCGTTAAAT +33927
(45010)
CTTTTG A A TT a t t a t a c a t t  t t a g a g c c t a  c c t a t c a g t t  t t c t a g a a g g  c a g a a a a g a g  t g g t g a g a g g +339977
(45080)
GAAAGGGAAG AATATAGGCA GCAGGATTTT T T T T T C T T T T  AAGAGAAGAT ATCACTATGT AGCTCTGACC +34067
(45150)
CTTCTAGGAC TTGCTATGAA GACCAAACTG ACCTTAAACT GGCAGATCCA CTTGACTGCC TCTTGAATTC +34137
(45220)
TGGGTTTAAA GGCAGGGCAC TGGAAATCTC TGGTAAATCT GAACTTTTGT GGTTAATTGG GGTGGAGGGA +34207
(45290)
161
GCAACATTCT AATCCTATTG 
CAAGCTTTTC TGTGTATTTC 
CGAAGACAGC AACCTCTTCA 
GGCAAATGTA CTAATGAATA 
ATTGGGCTTC ATTTACTAAC 
CCATTGTGGA TGAAGAATCT 
GGTTACTTTC AGCAAATCTC 
AGTAGGTTAC TAAGCTACTG 
ACTCTTCACT GAGGGAACAG 
GTAGATCTAC CTTTGTTCAT 
GAGTCAAAGT GACACTTCCA 
CCCTATAAAG CCTAGAAAGG 
TTCTGGGCTT CTGGATTGTT 
GTTGGTTTCA GTATATGCAT 
CCCATTGCAG AATTTTATAT 
AGGGACTGAA AAAAAAGTGT 
GAGCTGACCA TAGCTGGATT 
CCATTGCATT CCATTCCTGG 
CACTGGGAAG TACCTCACTA 
TAAGAATGTA GTTCAAAACT 
GCCGCCAGCA TTTGCTTAGA 
AAGCCCAATG CAAAATGCTG 
TGTCTGAAGC CAAAGATGCA 
GAACGCTCAA AAATCACAGA 
TTTTCAGACT CCAGCACAGA 
TCTGAATTTT TAGATTTCTT 
TCCCCCACAT TATTCCCACT 
GATTATTTCC AATATTTTCC 
GAGTACATGA TGATATAAAG 
AGAAGACCCT CAACAACAAT 
AATTGTAAAA GAAAGCTTTA 
TTTATAGCTA CAGTTTCTTC 
TTACTTCAAA CCAACTGTGA
AAAAGAAATC AAAGATGAAA
CCAGCATGCT CATATATTGA 
TGTTATATTG CACTCTGTTG 
GATAAAGACA TAAACATTTA 
AACATGGCTG TGTTATAAAA 
TTCTGATTTA GATCCAGGAA 
CATGGCTAGT TATAGAGGAA 
AAGGATTCTT TAGAGTCCTT 
AAGTAAGGAA TTGATGCTGG 
ACCACCCACA CTGGCTCACA 
TTAAGTGTGA CTGTTTCTTT 
CCATTTGTCC TGTTCTCTTA 
TTAGGTTAAT ATGCTGCAAC 
GATAATTAAA ATCAAGTCGT 
AGGATTAATA TCAACATTGC 
GAAAGATTGT AGCAAAGGGA 
TACCAGTATT ATGTCTAAAA 
ACATGCAGCC ATGTTGTGTT 
GAACTCTGAT CCAAGAAAAG 
GTGGAAAATG AAGCTCTCCA 
GCTTGCAGAT ATCAAAGGCT 
ATCTACACAA TCCACCCCAC 
CGGGGGTGGC TATTACACTG 
AAGCAGTGGG TTTAGGGGCT 
TCACAGAAGG CAATGGCAAT 
AATTATTTTA CAATAGTCAA 
AGAGATGAGT TTCTAGTTGA 
ATATAATATA AAGTATATGT 
AATTATTCCC TTTTTTTTGG 
AAAAAAATCT ACATACCTAT 
AATAATACAG TTTATAAAAA 
TGCTTCAAGA AAGGCTGAGA 
TTCCCACTTG ACTTTTCCTA 
AAAAAACAAA AGAAAAAAAA
TGTTCCCTAA AAGACCTGTA
GGTCTTCTGT AGTTCCTGTC 
ACCTTATCTT TCAGTAGATT 
AAGTAGAATT GTTTGTTATA 
CTTTATTCAC AAAATAAGAT 
CTTTCCTAAT AGACTTAGAT 
TACAGAAGTT GATGAAAAAG 
GGTAATTTCA ATTTGGAATA 
CTGTCATGGT GCCCTGTGTT 
TATGGTTCTT TGGAAAGGAA 
CTCTTTGTTG TGCCAGAGGA 
ATGGGACATT TGAAGGCTGA 
TGGTGAAGGA AACTGGTTTA 
GTGTTTAGCA TAATGACGTG 
CTGGCTTCTC AGGGTAACTT 
GAGGCAAGTG GGAAATATGA 
TTTCAACCTA AGATAGAGTG 
CCAGCCTCTC CACTCAAAGG 
AAGGTCCATT CCTGCCATTG 
TTTTGAGAGC TGATCCTTAT 
GTGACACTCA AATTCCTGAT 
ACTGTAAATC CTCTTAAAAT 
CCTAGTCTGA GGAATAATAA 
TACTGAAACT TACACCTCCA 
GCTGGAGCTG TTGCTAAGCA 
TAGAAAGTTA CCATTTTTTT 
CTTTTTGCAA TGGTAACCAG 
GATTCAGAAC TATTTATGCT 
ATTGGAATGG GTGTTGAAAA 
GCAAGGGCTA GGGCAATATA 
TAAATCTGTG TGTCCCTGTT 
AAATGGAATA GGGTATATTT 
GTTTCTAAAC AGACTACTGT 
AAGAAGAAAA AAGAAAAGAA
AGAAGTTGCT TTGTTTTGCA
A G C A A C A TTT +34277
GGCTACTGAT
(45360)
+34347
GTGTG TC TAT
(45430)
+34417
AACAAGCCAG
(35500)
+34487
G T T G C T T C A A
(45570)
+34557
T C A C CA A A A T
(45640)
+34627
AC T T A T A G A C
(45710)
+34697
TG ATCCTGGT
(45780)
+34767
CAAGCCATGT
(45850)
+34837
AAGCAGACTG
(45920)
+34907
T A C C T C A T T T
(45990)
+34977
A GAG CTTACT
(46060)
+35047
GAGTAGACTA
(46130)
+35117
A C TC TGT GAA
(46200)
+35187
A C A G A T T A T T
(46270)
+35257
A A C A A G T A A A
(46340)
+35327
TAACAGCCAT
(46410)
+35397
GCACCATGAC
(46480)
+35467
TTGATGAGGG
(46550)
+35537
A TA A A A T G G T
(46620)
+35607
T A C T T C A A A T
(46690)
+35677
CAAGAACACT
(46760)
+35747
TACTTGGTAG
(46830)
+35817
A G G T T T T G T T
(46900)
+35887
AA G A T C T T A C
(46970)
+35957
A G A G A T T T C T
(47040)
+36027
G G G T T T T T C A
(47110)
+36097
TGTGCTGGAT
(47180)
+36167
TCTCAATGGC
(47250)
+36237
AC T T C A T C A C
(47320)
+36307
AGGAGATAAG
(47390)
+36377
T C T T T A A A A G
(47460)
+36447
AAGAAA GAAA
(47530)
+36517
Exon 13
gaääggkgg
(47600)
+36587
L y s P r o S e r (47670)
162
A A JQhhhQQh.A A m G & A 6 T . .X G C A C A X .T f iX . QJ.Q5hh.QhQQ. . T m i l l C A  . hQXQMQQQh. hhWQ.QhQ.QX
AsnGluThrL ysIleGluVa IValHisCys ValGluGluV alGlyPheGl uValMetGly AsnSerThrP
IXT.QftTGGCA TTTTGCCATT CTGAAATGAA CTCATACAGG ACTCCGTGAT AAGAGCAAGG ACTGCTATTT 
he***
B1 repeat
CTTGGCAAGG AGGTATTTCA AATGAACACT CAGAGCCAGG CGGTGGTAGA GCTCGCCTTT AATACCAGCA
+36657
(47740)
+36727
(47810)
+36797
CCTGGGATGC ACAGACGGGA GGATTTCTGA GTTCGAGGCC AGCTTGGTCT ATAAAGTGAG TTCCAGGACA
(47880)
+36867
GCCAGAGCTA CACAGAGAAA CCCTGTCTCG AAAAAACAAA CAAACAAACA AACAAACAAA AATGAACACT
(47950)
+36937
CAATTTGAAT GCAAGTCACC AACCCATCCA GACATGAGTC ACCAATGTCC CATTTCATAA AGTGTGCATG
(48020)
+37007
CCTCACTCAA ACCTCCTTGC TCACAGCATA GCACCAGACT CACCCAGAGC ATGGGCCTTT GGTTTCCTAC
(48090)
+37077
CCAGAGTACC ATGTTATACC AGTGTGTCTT TGAAAGTTGC TTGACTTACC TTGAACTTTT TGCACAGGAG
(48160)
+37147
ACAGTTTTTT TAAGCTAATG TCACACATGT TTACTTTGGG TTAAGTTGCC AGTGGTAGCA CTCAGCTACA
(48230)
+37217
GTGACAGGAG GAAAGGATAG AACTCATTGA GAGTGAACCC AAATTCAAGA CTGTCTTTCC TGACGCAAGT
(48300)
+37287
GGGAGACACA ATTTCATGGT GCTTTTCCCC TTTGAGTTCT AGAATAGTTT TCTTTCTAGA ACTGTGCCTG
(48370)
+37357
TGTCTTAAAG CATAAGGTAA CATTGAGGCA AAAACAAAGA CTATGTCCCA CATGTCCCTG TGTTCCATAG
(48440)
+37427
GCCTGTTCAA GGAAATGTCT AAGCCAAAGT AAGTTTAAGT CACCGTGCCT GGGGTGAAAA AGATGGTTCA
(48510)
+37497
GATGACGAAG AAGCATGAGG GCCTGAGATT GATCAACCAG CATCAAGAAA CAACAACAAC AACAGCAGCA
(48580)
+37567
GCAACAACAA AACAGTGCAA GAAGCACATT CCTATAACCC CAGAGTTGGG AGATAAAGAC AAGAGGATCC
(48650)
+37637
ATGGGAATTG TAGTTCAACC AGTTTAGCCA ATTATGTTAT CTCTAGGTTC ACTGAGAGAA ATGGTCTTAA
(48720)
+37707
AAATTTAAGG TGGAGAGTGA CTAGGCAGAT CCTCTGATAC TGACTTCTGC CCTAAATATG CATACACATG
(48790)
+37777
TACACACACA ACACAAAGAC ACCATTCCCT ATTGAGAGAG AAGACAGAAG CTTGTTCAAG GATTAAATTC
(48860)
+37847
TTCAAGGCTT CTAGGTACTC TGGAAATGAC CTGAGAAAGA CATTGAAAAT AATTCTGCTT TGGAGGTGAT
(48930)
+37917
TGCTGGATCT AGAATGTACT TCCCAAAGAG ATGTTGATGA AAGAGCCTTC ATGGCAACCT GTTGGTCAAC
(49000)
+37987
TCATGCTTAG TCAATTCTAA TCTCTTAAAT TAGGGTTTCC TATACATATT ACAATTGTAT AAAAATGTAT
(49070)
+38057
TCTCTAAATA TCTTCATTAA TGAAGCTGTA TCTATAGGTC TTTTTGATGG GCTGAACATA GAAGCAAACA
(49140)
+38127
CACTTATGTG TTGGGAAGAG GAATAAGTAG TGATAGAGGG ACCTAGTGGT AGTTATTTTA CATAGTCCTG
(49210)
+38197
AAGAGCTAAA GACAATGAAA GAAGAAATGG TACTCACAASL
Llml2 repeat
AGAGAGAGCT ATGTCGGGGT CCTGTCAGCC
(49280)
+38267
AAATCTTGCT AGTATATGCA ATAGTGTCTG GGTTTGGTGG TTGTATATTG GATGGTTCCC TGGGTGGGGC
(49350)
+38337
AGTCTGTGGA TGGTCTTTCC TTGCATCACA GCTGTGAAAT TTGTCTCTGT AACTCCTTCC ATGAGTATTT
(49420)
+38407
TGTTCCCCAT TGTAAGAAGG AGTGAAGTAT CCACACTTTG GTCTTCCTTC TTCTTGAGTT TCATGTGTTT
(49490)
+38477
TGCAAATTGT GTGCCTGGCA ATACAGAAGC
R repetitive element 
AGATGGTCAC AGTCATCTAT TGGATGAAAC ACAGGGCCCC
(49560)
+38547
TAATGAAGGA GCCAGAGAAA GTACCCAAGG AGCTAAAAGG GTCTGCAACC CTATAGCAGG AACAACAATA
(49630)
+38617
TGAACTACCC AGCAACCCTC AGAAATGTAA ATGAAGAAAA
Poly A 
TATCTAATAA _&AAATGCCTT AAAAAAAAGA
(49700)
+38687
AAAGGTACTC AAAATCCACA ACATAACTTA CTTTTTATGT ACTTTATAGA GATGGTTTAG TCAGGTTTCA
(49770)
+38757
TAATCTGGGT GAAGTGCACA TGGAGTACAA AACATCCCTT GTCATGGCTC TTATGCATTA ACATAGAACC
(49840)
+38827
ATCCACCATT CTGTGCTCAG AATGAAAGGT ACAGCAGTCA TGGACAACTG CTAATATTAG ATCTTTTCTA
(49910)
+38897
(49980)
163
AAGGGTCAGA TCACCATACC AGATTCTCTG TACTGTCTCT CTGCTCTTTA CAAGTCTGTA CTGTGTCACT +38967
(50050)
GGCATACACA TTACTGCCTA CCCCCATTAA TGATACAGTA AATGTGGAAA AGAAAGGTCA ATTGCTAGGA +39037
(50120)
AAGGGTACAG TAATAAGACT CAGAGGAGCT CAGTAACACA GAGGAGATTA TCACATGAAA GTTGAAGTTG +39107
(50190)
ACTTTAGGGG TCAGTCCAGG AAGTTGAGGC TCATGGAAGT GTGGCTATAA GAGGCAAAGA GTTTATTTGA +39177
(50260)
TCAACTAACT TACCAAGAAT CTATCAAAAT GGTACTAAAG ACTCTTTATA ATGGACACTG GTCTGATTGA +39247
(50330)
GCAGGTCTCG GGTGGAGTCA AGAATTTTCA AGATCAGCAA TTTGAAAGTA AGGCTGTGGG TCTGTATACC +39317
(50400)
ACACTTTGAT AAATTATTAG GAACATCACA ACTTGAAAGC TGACTAATAA AAGACAGAAA TGACCAACCC +39387
(50470)
CAAGAATTCT CTGTCTCTTG TCTTGCAAAG AAAGCATAGA AACACCATTT TGGAAACCTA CCTCTACTTT +39457
(50540)
GGACTTGGAG GCTGGATTAG AAGCAGAAGC AGGGAAGCTG CCCTCATACA AGGCCAGTTG TTAGTTTTAT +39527
(50610)
GTGTATAGGT CTCTCTTGAG AGATGCCTCC CTAGACCTAG AAGCAGGCAT TCCTCTAGAT GTCACAGACC +39597
(50680)
TCCTGACCAC ATCCCTGGCT GGTGCTATTA TCTAATCAAG GTACATGTAT AAAAAGCAAT ACAAATAGTT +39667
(50750)
CCTGTGGCCA TGTCAACATG TGGACTTATT CTTCCTGATT CTTGGGTTAG GACAATCATT CTTTGGGAAT +39737
(50820)
CCATATCCAA CATTATCTCT TCTATGAAGA TTTCAAAATG TACCCAACAG TTTATTTGCT TCTCTGCTTG +39807
(50890)
ACAATATGCC CTAGGAACAC TAGCATTATG CATATGAAAT GTATCTTTTT
B1 re p e a t
ATTTGCAGGG TCTAGAACAG +39877
(50960)
TACATAACCT TTAAGAATTA CATATGGTTA TAGGACCQGA GAGATGATCC AGAGGCTAAG AGCACTGATT +39947
(51030)
GTTATTCTAG AGGATATGGG CTTGATTTCT AGCCACTTGG ATGGTAGCTC ACAACCATCT ATAACTCAGG +40017
(51100)
TCCCAGGGGA TCTGATGCAC TATTATTTAG CTGGCATTTG CTACATTGTG GGTTCTTCTT TTTTTTACCC +40087
(51170)
TTCTCCATCC CCTTTCTTCT ACCTGTTCAA TCCTCTAACA CTAGATAAAA GGAAGAAAGG ATAGAAAGGA +40157
(51240)
AAGAAAACAG ATCCCTTAGT AAAATCAGGG GTAAAAAGGG GGGCAATGTT ATCCTTAGAC TACTTCCTGC +40227
(51310)
TGAGTAGGGT CACTGAGTTC CATGATGCAA GTTTGATCCT CATTACTTCT TGTTGGTGTT TCTTCTTTGT +40297
(51380)
GCATGACTAC TTAACAAACT GTGACCAACA GCCCACTACC ACCACCAATA ATAATCATAA CCACCACCAC +40367
(51450)
CACCCACCCA CCCACCCTCA AGGCCCTAGC ATTTATATAC CCCCAAGTCC TCAAAATTCC AAATGTCATA +40437
(51520)
CAATTGCAGA AACTGTCTGC AGTTGGCAAA TCCTGTTTCC TCCCCCGATC CCCAACCTCC AACTAGAGAG +40507
(51590)
CAAGGCAAAT CATAGTCATC TGCTGAAGTC CCATGTACCC CACACCTGGG ATTAAAAAAA A A A A A A A A A A +40577
(51660)
AAAACCTTAT ATTTGTGTGT ATGTTTAGGA AATCAAAAAT CCAAATTTTT GGGACAGTAT CTCTCACTGA +40647
(51730)
ACCTACACTC TTATGGCTTT GGTGGGCTCT AGCATGGAAG TGGCACACAG GCATTCATTG CAAAACACTC +40717
(51800)
ATACACATAA CATTTAAAAA TTATATATGG TGAGTGAACC AGCTAAAGTT CTCTTAGCCC AGGCATATCA +40787
(51870)
CTTTGCAAAT AGTTAAAATT CAACTGTATT CAGCAGGGAT TATCAAGGCA ATGGCACAGG AAGAAAGACA +40857
(51940)
GTGTCTAATA GGAATGTAAT TGAAAGTACC TGGGAGACAC CTTGTGGGTG ATAGAAGCGA GGTCACAGTA +40927
(52010)
CTGATTCTCA CTGGAATAGG ACAGGGACCC ACCTTCCTCC TAGAGCCTTC ACAGTCATAG CATGTGGACA +40997
(52080)
AACAGAGGTT CTTTAAGATA TTCTTTACAA GAAGAGTTTA TTCCAACCCC TTTCCTTGGT ACTTGGCATT +41067
(52150)
GATATAAAGG GAGTTTGAGG AGACTGGCAG ACGGAGGGGA TGAAGCTTAT GTCTGCAACA GCCAAAACAC +41137
(52220)
CTGAGCTTCA TTGAAATACC TCAGGCCTAG AGCTATTTAT GCTGGCTGAG GAAGAAGCCA CTTGGGCAAA +41207
(52290)
GAACATCCTG ATTAAAAATC CAAACGTTTT GGAGGTGAGA CTTGTATGTG TCAGGGCCAT CTGTTGGCAA +41277
(52360)
164
A G T T C A T A A A C T G T A A G T G C T A A T C T G T T A A A G A T G C A G T A G A C T G C T G G T G A G A A C T G A G A A C T G T A A A + 4 1 3 4 7
( 5 2 4 3 0 )
C A A C T T T T G A T G G C T G G G G A A A G G T G A T G A G C C T G G T T G G A A C A G G A C C G A G T G T C A T C C T C A G G A T T C G + 4 1 4 1 7
( 5 2 5 0 0 )
G G T G G C A A A A G C T A C G G A G C T G C T C C T G C T T T C A A G T C C C A C A C A T C G A G T T C C A G G A T A C A A A C T T T T C + 4 1 4 8 7
( 5 2 5 7 0 )
T C A A G G C T T T C T T T T A G A A T T T G T A T T G A G T T A A A T G A C A A T T T C T A C T T T C T T C A G C A T C T T G A G G G A G + 4 1 5 5 7
( 5 2 6 4 0 )
T A G A T G T G A A T G T A A A T G T G G T T C A A G A T G G A A A C C T T T T A A C A T A A A G G A T T T A T C T A A G T C T T C C T A G + 4 1 6 2 7
( 5 2 7 1 0 )
T C A A G A G A G G A A A A G T T C T G A T T T T C C C A A G T A G A C A T T C C C T C T T C T G T C T T A A T C A T C C C A C G T T G A G + 4 1 6 9 7
( 5 2 7 8 0 )
C A T T G G T A A G A G C C T C T G A A C T A A A T T T C T A A C C T C C A G G A T T T T C T C T A T C T T A A A G G T G T A T T T T C T G + 4 1 7 6 7
( 5 2 8 5 0 )
T A T T C T G T C C A A A A C C C T A A A A G A G C A C T T C C C T A A A T C A A A G C T C A T C G G A T C A A G A A G T C C A T T G T T A + 4 1 8 3 7
( 5 2 9 2 0 )
T C T A G T T T C T C T G T A G T G C T C C A G C A A A A C T G C A C A A A A T C C A A C C T C T A T T C T T C T T C T T T C C C T A T G A + 4 1 9 0 7
( 5 2 9 9 0 )
C T G C T T A A C A T T T T C T C C A A T G A A A A A G C C T T C T G A T T A T T T T T A C A A T C C T G T T C T C C C C A C A T C T T C T + 4 1 9 7 7
( 5 3 0 6 0 )
A A G A T T T A G C T C T C A A C A C A T C T A A G T C T C C C T T C A A T T T C C C A T T T G A T G G A T G T G C C C C T G T A T G T T T + 4 2 0 4 7
( 5 3 1 3 0 )
G T C A G A T G C C T T C T G C G T A A T G C T T C A C C A A C C A A C T A T T T G T T T C T T A T T T A C T T T G T A A G T A C T C T G A + 4 2 1 1 7
( 5 3 2 0 0 )
G G T C A A G A A A G G T T C C T G A T G T G C C T T T A T T T A C A T A G G C C C T T A G T A G G A A C T G A G T G C T G G C T G A G C T + 4 2 1 8 7
( 5 3 2 7 0 )
G A G C A A G A T A G A A G A A A T G G A A G C A T C C A A C A G A T A T T T A G A A C T C T A A T C C A G A A T C A C A T A T T A A A A G + 4 2 2 5 7
( 5 3 3 4 0 )
C T G T G T G A T T A T A C C A G A A A T G A A A G A A C C A T C A A A T A G T G T A A T A A G A A T T C T C A G T T G A A A T C A C T C A + 4 2 3 2 7
( 5 3 4 1 0 )
T T T G A T C T G T A G A C A G C C A G C T G C T A G C A C C A C T C C A C A T G C A T A T G T A T G C A G A A T A C C C A C A C T G T A G + 4 2 3 9 7
( 5 3 4 8 0 )
C A C T C A G A G A A G T G T C T G T G C A C T G A G C A C T T C C C C C A G C T T T G C G A G C C  A T T T G A T A A T  
M T  repetitive element
T T A T A T A T A T + 4 2 4 6 7
( 5 3 5 5 0 )
A T A T A A A A T C A G G A A C A C A A A G T A G C T G T A g c t g t a g c t g T A C T G G C T G A T T T T G T G T G T C A A C T T G A C A + 4 2 5 3 7
( 5 3 6 2 0 )
g a a g g t g g a g T T A T C A C A G A G A A A G G A G C T T C A T G A G G A A A G G C T C C A T G A G A T T C A G C T G T A A G G T T A T + 4 2 6 0 7
TTTCTCAATT AGTGATCAAG GTGGGAGGGC CCATTGTGGG TGGTGCCATC CCTGGGCTGG TAGCCTTGGA
(53690)
+42677
TTCTACAAGA GAGCAAGGGA GGGGAATTAA GGAAGAGGGG TGGATGGCCT GTGGATGAGC TGTTGGTTGG
(53760)
+42747
TGACCTGCTT AGTTCCAGCC CTGACTTCCT TTGGTGATGA ACAGCAACAT GGAAGTGTAA GCTGAATAAA
(53830)
+42817
CCCTTTCCTC CCCAACTTGG TTGTTGGTCA TGATGTTTTA TACAGGAATA GAAACCCTGA CCAAGACAGT
(53900)
+42887
AGCCCAGGTG TGTTAAGTTG AAAATTTAAT GTGCTTTTAT TTTTCACCAG AAAGTGTGTT ATTAATTTCA
(53970)
+42957
TTTCTTTTAT TCAAATTGAA AGCAAAGATT GGTCCCTAGC AGATGATAAA AATGCAACAA TACATAAACC
(54040)
+43027
AGGGAGAAGG AGGAAGAAGA GGACGAGATG GAGGAGGGAG GAAACAATAA TGTAGTGGTA CAGTTTAAAG
(54110)
+43097
GCAGTTGACT TGTAAATGTT CCTATTGAGG ACTCTATAGT CTGTGTTGCA GCTTCGTGTC TCTGACATAA
(54180)
+43167
CAGGAAGTCC ACGTAGGAGT GGCTGTGACC TCATATTTAC TTACAGAGAG TGGGCCAACA GCCTAGCTTT
(54250)
+43237
CACAGGTGGC TCAATAGTTT ACTTGTACGG AACTTAATAC CCCAAATATG TTACTTAATA CCCCAAATAT
(54320)
+43307
GTTACTTGAA GGGTCGTGTT CCTTTCCAGT TATTTGGAAA AAAAAACAAT TTGAGTAAAT GTTTAATCCA
(54390)
+43377
ATAAAAACAT TTTCTTTTGA GCTGTGTTGG TGAGAAACAT GATTACTCCA CTGAACTTAA CCTTGTTACT
(54460)
+43447
AATTGGTTTT GCATGAAAAC ACAGGTGTGG GACTTTTGTT CCTATTTTTA GTCTGTCCAC ATTTTAATGC
(54530)
+43517
CATATTTCAA ATACATGCAT GTTTTGGTCT TCTCCAATAA ATTATAAGGA GAAATGTCTC AGTCCTTTTA
(54600)
+43587
TCTCCATTTC CTCAGCACAA CACCCAGCTT TTACCTATTG ATCACTCAAT AATAAAATAT AACCAATAAA
(54670)
+43657
(54740)
165
ACTG ATAGTC A TTTGTTG TC AGATACTTTG TCCTAAAGAT TAATAAATCT T T T T T T T T C T A ACTTGTTG T + 43 7 2 7
(5 4 8 1 0 )
ATG G C TTC CA TTCTTGGTAA GAAGATCATT TTA TATA A CT CTTTAA A G TA TTTCTGGAAT TTTTC TC CA C + 43797
(5 4 8 8 0 )
T T C C T T G T T A TTGCCTTGCC A CTTA A CTTT TGCTTTGGAA A TA TC C TTTT A TTTTAA TA T TTTTTCAGGG + 43867
(5 4 9 5 0 )
G CAACTGTAA GAGAAACCTT ATTATCCACC AACTCTGGCT CTCATGATGC AGGGCACTCA CATGCATGCA +43937
(5 5 0 2 0 )
TGCATGCAAA CAAGCAATCA TGTACCACCT AATAAAAAGA GATATTAGCC AATGAAACAG TG TTCCAATT +44007
(5 5 0 9 0 )
AGCAAACCTC ATGCTTCTGG CCCAGAGCCA TC AATTTTAG ACATTGACAA GCCCCTGGAA GTTTGAACTC +44077
(5 5 1 6 0 )
A A A A TTAA TG ACTTCATGGA AGCCATTGCA TTTC TTTC C C TGCANGATTT GTCACATACA GAGAAGGATC + 44147
(5 5 2 3 0 )
A A TC A A A TTT A TATTTC A AA CCAATATTG C ATGTAGCATA CTTATG CTTA AAAAGAAAAT ACTCACTTG T + 44217
(5 5 3 0 0 )
TTTC TCC A AG A TCCAAG TTT GACCTGGCCT C TTG TA TTTT ACCTAGTACC CTGAACTGGC CATACTGCTA + 44287
(5 5 3 7 0 )
T TA TA G C TT A AGGGGGGAAG GGCTTTTGAT TCAAATGCAA GTGAAAAACC ATTTGCAG TA CAAGAAAGAG + 44357
(5 5 4 4 0 )
AAG CTG CCCT GTTAGACCTC TCTGGAGTAA GGAAAGCACT AGAGGAAACC ATGGGGTCTC TCTGCAGGAA + 44 4 2 7
(5 5 5 1 0 )
TTG TA TTTG G GAGCTCATCA CAGCCCTGGT CAATTTCAAC ACTAACACAA AACACCTTGA AGGCCCACTA + 4 4 4 9 7
(5 5 5 8 0 )
TTTG C C AC C T TAAATTACTG G TG CTG TTTA GACACTTTAT GTATGTATGT A TGTATGTAT GTATCAT + 44564
(5 5 6 4 7 )
REFERENCES
Abdul-Meguid, S.S., H.S. Shieh, W.W. Swith, H.E. Dayringer, B.N. Violand and L.A. 
Bentle (1987). Three dimensional structure of a genetically engineered variant of 
porcine growth hormone. Proc Natl Acad Sei USA 84: 6434-7.
Aharoni, A., N. Baran and H. Manor (1993). Characterisation of a multisubunit human 
protein which selectively binds single stranded d(GA) and d(GT) sequence repeats in 
DNA. Nucleic Acids Res 21: 5221-8.
Alam, J. and J.L. Cook (1990). Reporter genes: application to the study of mammalian 
gene transcription. Anal Biochem 188: 245-54.
Altschul, S.F., W. Gish, W. Miller, E.W. Myers and D.J. Lipman (1990). Basic local 
alignment search tool. J Mol Biol 215: 403-10.
Alwine, J. (1985). Transient gene expression control: effects of transfected DNA stability 
and trans-activation by viral proteins. Mol Cell Biol 5: 1034-42.
Alwine, J.C., D.J. Kemp and G.R. Stark (1977). Method for detection of specific RNAs in 
agarose gels by transfer to diazobenzyloxymethyl-paper and hybridisation with DNA 
probes. Proc Natl Acad Sei USA 74: 5350-4.
Anderson, S. (1981). Shotgun sequencing strategy using cloned DNase I generated 
fragments. Nucleic Acids Res 9: 3015-27.
Arai, K., F. Lee, A. Miyajima, S. Miyatake, N. Arai and T. Yokota (1990). Cytokines: 
coordinators of immune and inflammatory responses. Ann Rev Biochem 783-836.
Askew, G.R., T. Doetschman and J.B. Lingrel (1993). Site directed point mutations in 
embryonic stem cells : a gene targeting tag-and-exchange strategy. Mol Cell Biol 13: 
4115-24.
Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. 
Struhl (1994). Current Protocols in Molecular Biology. New York, John Wiley & Sons.
Azuma, C , T. Tanabe, M. Konishi, T. Kinashi, T. Noma, F. Matsuda, Y. Yaoita, K. 
Takatsu, L. Hammarstrom, C.E. Smith, E. Severinson and T. Honjo (1986). Cloning of 
cDNA for human T-cell replacing factor (interleukin-5) and comparison with the 
murine homologue. Nucleic Acids Res 14: 9149-58.
Bankier, A.T., K.M. Weston and B.G. Barrell (1987). Random cloning and sequencing by 
the M13/dideoxynucleotide chain termination method. Methods Enzymol 155: 52-93.
Basten, A. and P.B. Beeson (1970). Mechanism of eosinophilia II. Role of lymphocyte.
J Exp Med 131:1288-305.
Bazan, J.F. (1990). Structural design and molecular evolution of a cytokine receptor 
superfamily. Proc Natl Acad Sei USA 87: 6934-8.
Bazan, J.F. and D.B. MacKay (1992). Unraveling the structure of IL-2. Science 257: 
410-3.
Belyavsky, A., T. Vinogradova and K. Rajewsky (1989). PCR-based cDNA library 
construction: general cDNA libraries at the level of a few cells. Nucleic Acids Res 17: 
2919-32.
167
Benton, W.D. and R.W. Davis (1977). Screening of Xgt recombinant clones by 
hybridisation to single plaques. Science 196: 180-2.
Berchtold, M.W. (1989). A simple method for direct cloning and sequencing cDNA by 
the use of a single specific oligonucleotide and oligo(dT) in a polymerase chain reaction 
(PCR). Nucleic Acids Res 17: 453.
Berk, A.J. and P.A. Sharp (1977). Sizing and mapping of early adenovirus mRNAs by 
gel electrophoresis of SI nuclease-digested hybrids. Cell 12: 721-32.
Bertolini, J.N., C.J. Sanderson and E.M. Benson (1993). Human interleukin-5 induces 
staphylococcal A Cowan 1 strain-activated human B cells to secrete IgM. Eur J Immunol 
23: 398-402.
Bickmore, W.A. and A.P. Bird (1992). Use of restriction endonucleases to detect and 
isolate genes from mammalian cells. Methods Enzymol 210: 224-44.
Bird, A. (1992). The essentials of DNA methylation. Cell 70: 5-8.
Bird, A.P. (1987). CpG islands as gene markers in the vertebrate nucleus. Trends Genet 
3: 342-6.
Bird, A.P. (1993). Functions of DNA methylation in vertebrates. Cold Spring Harbor 
Sym Quant Biol 58: 281-5.
Bimboim, H.C. and J. Doly (1979). A rapid alkaline extraction procedure for screening 
recombinant plasmid DNA. Nucleic Acids Res 7: 1513-23.
Bischoff, S.C., T. Brunner, W.A. De and C.A. Dahinden (1990). Interleukin 5 modifies 
histamine release and leukotriene generation by human basophils in response to diverse 
agonists. J Exp Med 172: 1577-82.
Bischoff, S.C., W.A. de and C.A. Dahinden (1992). Peptide analogues of consensus 
receptor sequence inhibit the action of cytokines on human basophils. Lymphokine 
Cytokine Res 11: 33-7.
Bishop, J.O. and P. Smith (1989). Mechanism of chromosomal integration of 
microinjected DNA. Mol Biol Med 6: 283-98.
Bloem, L.J. and L. Yu (1990). A time-saving method for screening cDNA or genomic 
libraries. Nucleic Acids Res 18: 2830.
Bradding, P., J.A. Roberts, K.M. Britten, S. Montefort, R. Djukanovic, R. Meuller, C.H. 
Heusser, P.H. Howarth and S.T. Holgate (1994). Interleukin-4, -5, -6 and tumor necrosis 
factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a 
source of these cytokines. Am J Respir Cell Mol Biol 10: 471-480.
Bradding, P., I.H. Feather, S. Wilson, P.G. Bardin, C.H. Heusser, S.T. Holgate and 
P.H. Howarth (1993). Immunolocalization of cytokines in the nasal mucosa of normal 
and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human 
allergic mucosal inflammation. J Immunol 151: 3853-65.
Brandeis, M., M. Ariel and H. Cedar (1993). Dynamics of DNA methylation during 
development. Bioessays 15: 709-13.
Breathnach, R. and P. Chambon (1981). Organisation and expression of eukaryotic split 
genes for proteins. Annu Rev Biochem 50: 349-83.
168
Brinster, R.L., J.M. Allen, R.R. Behringer, R.E. Gelinas and R.D. Palmiter (1988).
Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sei USA 
85: 836-40.
Broide, D.H., M.M. Paine and G.S. Firestein (1992). Eosinophils express interleukin 5 
and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic 
inflammation in asthmatics. J Clin Invest 90: 1414-24.
Bronstein, I., J. Fortin, P.E. Stanley, G.S.A.B. Stewart and L. Kricka (1994). 
Chemiluminescent and bioluminescent reporter gene assays. Anal Biochem 219:169-81.
Brusselle, G.G., J.C. Kips, J.H. Tavernier, J.G. Van der Heyden, C.A. Cuvelier, R.A. 
Pauwels and H. Bluethmann (1993). Attenuation of allergic airways inflammation in 
IL-4 deficient mice. Clin Exp Allergy 24: 73-80.
Butterworth, A.E. (1984). Cell mediated damage to helminths. Adv Parasitol 23: 
144-235.
Campbell, H.D., C.J. Sanderson, Y. Wang, Y. Hort, M.E. Martinson, W.Q. Tucker, A. 
Stellwagen, M. Strath and I.G. Young (1988). Isolation, structure and expression of 
cDNA and genomic clones for murine eosinophil differentiation factor. Comparison 
with other eosinophilopoietic lymphokines and identity with interleukin-5. Eur J 
Biochem 174: 345-52.
Campbell, H.D., W.Q.J. Tucker, Y. Hort, M.E. Martinson, G. Mayo, E.J. Clutterbuck, C.J. 
Sanderson and I.G. Young (1987). Molecular cloning, nucleotide sequence, and expression 
of the gene encoding human eosinophil differentiation factor (interleukin-53.
Proc Natl Acad Sei USA  84 : 6629-33 .
Capecchi, M.R. (1989). Altering the genome by homologous recombination. Science 244: 
1288-92.
Cardell, S., B. Sander and G. Möller (1991). Helper interleukins are produced by both 
CD4 and CD8 spleenic T cells after mitogen stimulation. Eur J Immunol 21: 2495-500.
Chang, M.-S., G. Engel, C. Benedict, R. Basu and J. McNich (1994). Isolation and 
characterisation of the human interleukin-9 receptor gene. Blood 83: 3199-205.
Chen, C. and H. Okayama (1987). High efficiency transformation of mammalian cells 
by plasmid DNA. Mol Cell Biol 7: 2745-52.
Chihara, J., J. Plumas, V. Gruart, J. Tavernier, L. Prin, A. Capron and M. Capron (1990). 
Characterization of a receptor for interleukin 5 on human eosinophils: variable 
expression and induction by granulocyte/macrophage colony-stimulating factor. J Exp 
Med 172:1347-51.
Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald and R.W. Rutters (1979). Isolation of 
biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 
18: 5294-9.
Chisaka, O. and M.R. Capecchi (1991). Regionally restricted developmental defects 
resulting from targeted disruption of the mouse homeobox gene Hox 1.5. Nature 350: 
473-9.
Chisaka, O., T.S. Musci and M.R. Capecchi (1992). Developmental defects of the ear, 
cranial nerves, and hindbrain resulting from targeted disruption of the mouse homeobox 
gene Hox 1.6. Nature 355: 516-20.
169
Chomczynski, P. and N. Sacchi (1987). Single step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-9.
Chu, G., H. Hayakawa and P. Berg (1987). Electroporation for the efficient transfection 
of mammalian cells with DNA. Nucleic Acids Res 15: 1311-26.
Clutterbuck, E., J.G. Shields, J. Gordon, S.H. Smith, A. Boyd, R.E. Callard, H.D. 
Campbell, I.G. Young and C.J. Sanderson (1987). Recombinant human interleukin 5 is an 
eosinophil differentiation factor but has no activity in standard human B cell growth 
factor assays. Eur J Immunol 17:1743-50.
Coffman, R.L., B.W. Seymour, S. Hudak, J. Jackson and D. Rennick (1989a). Antibody to 
interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 245: 308-10.
Coffman, R.L., D.A. Lebman and B. Shrader (1989b). Transforming growth factor ß 
specifically enhances IgA production by lipopolysaccharide-stimulated murine B 
lymphocytes. J Exp Med 170:1039-44.
Comelis, S., I. Fache, J. Van der Heyden, J. Tavernier, R. Devos, W. Fiers and G. 
Plaetinck (1995). Characterisation of critical residues in the cytoplasmic domain of the 
human interleukin-5 receptor alpha chain required for growth signal transduction. Eur J 
Immunol 25:1857-64.
Cosman, D., S.D. Lyman, R.L. Idzerda, M.P. Beckman, L.S. Park, R.G. Goodwin and C.J. 
March (1990). A new cytokine receptor superfamily. Trends Biochem Sei 17: 265-70.
Cowell, I.G. (1994). Repression versus activation in the control of gene transcription. 
Trends Biochem Sei 19: 38-42.
De Vos, A.M., M. Ultsch and A.A. Kossiakoff (1992). Human growth hormone and 
extracellular domain of its receptor, crystal structure of the complex. Science 255:
306-12.
De Wet, J.R., K.V. Wood, M. DeLuca, D.R. Helsinki and S. Subramani (1987). Firefly 
luciferase gene: Structure and expression in mammalian cells. Mol Cell Biol 7: 725-37.
De Wet, J.R., K.V. Wood, D.R. Helsinki and M. DeLuca (1985). Cloning of firefly 
luciferase cDNA and the expression of active luciferase in Escherichia coli. Proc Natl 
Acad Sei USA 82: 7870-3.
Deininger, P. (1983). Random subcloning of sonicated DNA: application to shotgun 
sequencing analysis. Anal Biochem 129: 216-223.
Denburg, J.A., J.E. Silver and J.S. Abrams (1991). Interleukin-5 is a human 
basophilopoietin: induction of histamine content and basophilic differentiation of 
HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood 77: 1462-8.
Dent, L.A., M. Strath, A.L. Mellor and C.J. Sanderson (1990). Eosinophilia in transgenic 
mice expressing interleukin 5. J Exp Med 172:1425-31.
Desreumaux, P., A. Janin, J.F. Colombel, L. Prin, J. Plumas, D. Emilie, G. Torpier, A. 
Capron and M. Capron (1992). Interleukin 5 messenger RNA expression by eosinophils in 
the intestinal mucosa of patients with coeliac disease. J Exp Med 175: 293-6.
Detloff, P.J., J. Lewis, S.W.M. John, W.R. Shehee, R. Lagenbach, N. Maeda and O. 
Smithies (1994). Deletion and replacement of the mouse adult beta-globin genes by a 
'plug and socket' repeated gene targeting. Mol Cell Biol 14: 6936-43.
170
Devereux, J., P. Haeberli and O. Smithies (1984). A comprehensive sequence analysis 
programs for VAX. Nucleic Acids Res 12: 387-95.
Devos, R., Y. Guisez, S. Comelis, A. Verhee, d.H.J. Van, M. Manneberg, H.W. Lahm, W. 
Fiers, J. Tavernier and G. Plaetinck (1993). Recombinant soluble human interleukin-5 
(hIL-5) receptor molecules. Cross-linking and stoichiometry of binding to IL-5. J Biol 
Chem 268: 6581-7.
Devos, R., G. Plaetinck, d.H.J. Van, S. Comelis, J. Vandekerckhove, W. Fiers and J. 
Tavernier (1991). Molecular basis of a high affinity murine interleukin-5 receptor. 
EMBOJ 10:2133-7.
Diederiechs, K., T. Boone and P.A. Karplus (1991). Novel fold and putative binding site 
of granulocyte-macrophage colony stimulating factor. Science 254: 410-3.
Disteche, C.M., C.I. Brannan, A. Larsan, D.F. Schorderet, D. Gearing, N.G. Copeland, 
N.A. Jenkins and L.S. Park (1992). The human pseudoautosomal GM-CSF receptor a  
subunit gene is autosomal in mice. Nature Genet 1: 333-6.
Dranoff, G., A.D. Crawford, M. Sadelain, B. Ream, A. Rashid, R.T. Bronson, G.R. 
Dickersin, C.J. Bachurski, E.L. Mark, J.A. Whitsett and R.C. Mulligan (1994). 
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary 
homeostasis. Science 264: 713-6.
Dubucquoi, S., P. Desreumaux, A. Janin, O. Klein, M. Goldman, J. Tavernier, A. Capron 
and M. Capron (1994). Interleukin 5 synthesis by eosinophils: association with granules 
and immunoglobulin-dependent secretion. J Exp Med 179: 703-8.
Fand, W.J., D.E. Johnson and L.T. Williams (1993). Signalling by receptor tyrosine 
kinases. Annu Rev Biochem 62: 453-81.
Fassler, R., K. Martin, E. Forsberg, T. Litzenburger and A. Iglesias (1995). Knockout 
mice: how to make them and why. The immunological approach. Int Arch Allergy 
Immunol 106: 323-34.
Fattah, D., D.J. Quint, A. Proudfoot, R. O'Malley, E.D. Zanders and B.R. Champion 
(1990). In vitro and in vivo studies with purified recombinant human interleukin 5. 
Cytokine 2: 112-21.
Feig, L. (1993). The many roads that lead to Ras. Science 260: 767-8.
Feinberg, A.P. and B. Vogelstein (1983). A technique for radiolabelling DNA restriction 
endonuclease fragments to high specific activity. Anal Biochem 132: 6-13.
Feigner, P.L., T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, 
G.M. Ringold and M. Danielsem (1987). Lipofection: a highly efficient, lipid mediated 
DNA-transfection procedure. Proc Natl Acad Sei USA 84: 7413-7.
Feigner, P.L. and G.M. Ringold (1989). Cationic liposome-mediated transfection.
Nature 337: 387-8.
Felsenfeld, G. (1992). Chromatin as an essential part of the transcriptional mechanism. 
Nature 355: 219-24.
Femandez-Botran, R. (1991a). Soluble cytokine receptors : their role in 
immunoregulation. FASEB J 5: 2567-74.
171
Fickett, J.W. (1982). Recognition of protein coding regions in DNA sequences. Nucleic 
Acids Res 10: 5303-18.
Fregien, N. and N. Davidson (1986). Activating elements in the promoter region of the 
chicken beta-actin gene. Gene 48: 1-11.
Frohman, M.A. and G.R. Martin (1989). Cut, paste, and save: new approaches to 
altering specific genes in mice. Cell 56: 145-8.
Frohman, M.A., M.K. Dush and G.R. Martin (1988). Rapid production of full-length 
cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide 
primer. Proc Natl Acad Sei USA 85: 8998-9002.
Frolova, E.I., G.M. Dolganov, I.A. Mazo, B.V. Smirnov, P. Copeland, L. Steward, S.J. 
O'Brien and M. Dean (1991). iLinkage mapping of the human CSF-2 and IL-3 genes. Proc 
Natl Acad Sei USA 88: 4821-4.
Fukunaga, R., E. Ishizaka-Ikeda, C.X. Pan, Y. Seto and S. Nagata (1991). Functional 
domains of the granulocyte colony stimulating factor receptor. EMBO J 10: 2855-65.
Fukushige, S. and B. Saver (1992). Genomic targeting with a positive-selection lox 
integration vector allows highly reproducible gene expression in mammalian cells. Proc 
Natl Acad Sei USA 89: 7905-9.
Galili, N., J.R. Davis, W.J. Fredericks, S. Mukhopadhyay, F.J. Rauscher III, B.S. 
Emanvel, G. Rovera and F.G. Barr (1993). Fusion of fork head domain gene to PAX3 in 
solid tumour alveolar rhabdomyosarcoma. Nature Genet 5: 230-5.
Garber, A.T. (1993). Simplified purification of single-stranded DNA for 
dideoxynudeotide chain terminating DNA sequencing. BioTechnicjues 14: 542-4.
Gasser, S.M. and U.K. Laemmli (1987). A glimpse at chromosomal order. Trends Genet 
3: 16-22.
Gearing, D.P., J.A. King, N.M. Gough and N.A. Nicola (1989). Expression doning of a 
receptor for human granulocyte-macrophage colony stimulating factor. EMBO J 8: 
3667-76.
Getzenberg, R.H., K.J. Pienta, W.S. Ward and Coffey (1991). Nudear structure and 
three-dimensional organisation of DNA. J Cell Biochem 47: 289-99.
Giri, J.G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, 
L.S. Pack, D. Cosman and D. Anderson (1994). Utilisation of the ß and a  chains of the 
IL-2 receptor by the novel cytokine IL-5. EMBO J 13: 2822-30.
Glisin, V., R. Crkvenjakov and C. Byus (1973). Ribonudeic acid isolated by cesium 
chloride centrifugation. Biochemistry 13: 2633.
Godowski, P.J., D.W. Leung, L.R. Meacham, J.P. Galgani, R. Hellmiss, R. Köret, P.S. 
Rotwein, J.S. Parks, Z. Laron and W.I. Wood (1989). Characterisation of the growth 
hormone receptor gene and demonstration of a partial gene deletion in two patients 
with Laron-type dwarfism. Proc Natl Acad Sei USA 86: 8083-7.
Goodall, G.J., C.J. Bagley, M.A. Vadas and A.F. Lopez (1993). A model for the 
interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. Growth Factors 
8: 87-97.
172
Goodwin, E.B., P.G. Okkema, T.C. Evans and J. Kimble (1993). Translational regulation 
of tra-2 by its 3' untranslated region controls sexual identity in C.elegans. Cell 75: 
329-339.
Gorman, D.M., N. Itoh, N.A. Jenkins, D.J. Gilbert, N.G. Copeland and A. Miyajima 
(1992). Chromosomal localization and organization of the murine genes encoding the 
beta subunits (AIC2A and AIC2B) of the interleukin 3, granulocyte/macrophage 
colony-stimulating factor, and interleukin 5 receptors. J Biol Chem 267: 15842-8.
Gough, N.M., D.P. Gearing, N.A. Nicola, E. Baker, M. Pritchard, D.F. Callen and G.R. 
Sutherland (1990). Localisation of the human GM-CSF receptor gene to the X-7 
pseudoautosomal region. Nature 345: 734-6.
Gough, N.M. and S. Raker (1992). Localization of the IL-5 receptor gene to the distal 
half of murine chromosome 6 using recombinant inbred strains of mice. Genomics 12: 
855-6.
Gould, S.J. and S. Subramani (1988). Firefly luciferase as a tool in molecular and cell 
biology. Anal Biochem 175: 5-13.
Graham, F.L. and A.J. Van der Eb (1973). Transformation of rat cells by DNA of human 
adenovirus 5. Virology 52: 456-67.
Gu, H., J.D. Marth, P.C. Orban, H. Mossmann and K. Rajewsky (1994). Deletion of a 
DNA polymerase beta gene segment in T cells using a cell type-specific gene targeting. 
Science 265: 103-6.
Hanahan, D. (1985). Techniques for transformation of E.coli. In DNA cloning volume 1: 
practical approach. Glover, D.M. (ed). Oxford, IRL Press. pl09-35.
Handy, D.E. and H. Gavras (1992). Promoter region of the human o2A adrenergic 
receptor promoter. J Biol Chem 267: 24017-22.
Hara, T. and A. Miyajima (1992). Two distinct functional high affinity receptors for 
mouse interleukin-3 (IL-3). EMBO J 11:1875-84.
Harada, N., Y. Kikuchi, A. Tominaga, S. Takaki and K. Takatsu (1985). BCGFII 
activity on activated B cells of a purified murine T cell-replacing factor (TRF) from a T 
cell hybridoma (B151K12). J Immunol 134: 3944-51.
Hasse, A., W.A. Schulz and H. Sies (1992). De novo methylation of transfected CAT 
gene plasmid construct in F9 mouse embryo carcinoma cells. Biochem Biophy Acta 1131: 
16-22.
Hasty, P., R. Ramirez-Solis, R. Krumlauf and A. Bradley (1991). Introduction of a 
subtle mutation into the Hox 2-6 locus in embryonic stem cells. Nature 350: 243-6.
Hayashida, K., T. Kitamura, D.M. Gorman, K. Arai, J. Yokota and A. Miyajima (1990). 
Molecular cloning of a second subunit of the human GM-CSF receptor: reconstitution of a 
high affinity GM-CSF receptor. Proc Natl Acad Sei USA 87: 9655-9.
Heaney, M.L. and D.W. Golde (1993). Soluble hormone receptors. Blood 82:1945-8.
Heldin, C.-H. (1995). Dimerization of cell surface receptors in signal transduction. Cell 
80: 213-23.
Henikoff, S. (1984). Unidirectional digestion with exonuclease III creates targeted 
breakpoints for DNA sequencing. Gene 28: 351-9.
173
Herndon, F.J. and S.G. Kayes (1992). Depletion of eosinophils by anti-IL-5 monoclonal 
antibody treatment of mice infected with Trichinella spiralis does not alter parasite 
burden or immunologic resistance to reinfection. J Immunol 149:3642-7.
Herschbach, B.M. and A.D. Johnson (1993). Transcriptional repression in eukaryotes. 
Ann Rev Cell Biol 9: 479-509.
Hershey, A.D., P.E. Dykema and J.E. Krause (1991). Organisation, structure, and 
expression of the gene encoding the rat substance P receptor. /  Biol Chem 266: 4336-74.
Hirai, K., M. Yamaguchi, Y. Misaki, T. Takaishi, K. Ohta, Y. Morita, K. Ito and T. 
Miyamoto (1990). Enhancement of human basophil histamine release by interleukin 5.
J Exp Med 172: 1525-8.
Hitoshi, Y., N. Yamaguchi, S. Mita, E. Sonoda, S. Takaki, A. Tominaga and K. Takatsu 
(1990). Distribution of IL-5 receptor-positive B cells. Expression of IL-5 receptor on 
Ly-1(CD5)+ B cells. J Immunol 144: 4218-25.
Hsieh, C., S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O'Garra and K.M. Murphy (1993). 
Development of Thl CD4+ T cells through IL-2 produced by Listeria-induced 
macrophages. Science 260: s v i-q .
Ihle, J.N. and I.M. Kerr (1995). Jaks and Stats in signalling by the cytokine receptor 
superfamily. Trends Genet 11: 69-74.
Ihle, J.N., B.A. Wilthuhu, F.W. Quelle, K. Yamamoto, W.E. Thierfelder, B. Kreider 
and O. Silvennoinen (1994). Signalling by the cytokine receptor superfamily : JAKs and 
STATs. Trends Biochem Sei 19: 222-7.
Imamura, F., S. Takaki, K. Akagi, M. Ando, K. Yamamura, K. Takatsu and A. 
Tominaga (1994). The murine interleukin-5 receptor alpha-subunit gene: 
characterization of the gene structure and chromosome mapping. DNA Cell Biol 13: 
283-92.
Ingley, E., R.L. Cutler, M.C. Fung, C.J. Sanderson and I.G. Young (1991a). Production and 
purification of recombinant human interleukin-5 from yeast and baculovirus expression 
systems. EurJ Biochem 196: 623-9.
Ingley, E. and I.G. Young (1991b). Characterization of a receptor for interleukin-5 on 
human eosinophils and the myeloid leukemia line HL-60. Blood 78: 339-44.
Inoue, C., A. Ichikawa, T. Hotta and H. Saito (1990). Constitutive gene expression of 
interleukin-5 in Kimura's disease. Br J Haematol 76: 554-5.
Isobe, M., Y. Kumura, Y. Murata, S. Takaki, A. Tominaga, K. Takatsu and Z. Ogita 
(1992). Localization of the gene encoding the a  subunit of human interleukin-5 receptor 
(IL5RA) to chromosome region 3p24-3p26. Genomics 14: 755-8.
Jack, R.S. and H. Eggert (1992). The elusive nuclear matrix. Eur J Biochem 209: 503-9.
Jackson, M.E. (1991). Negative regulation of eukaryotic transcription. J Cell Sei 100: 
1-7.
Jaiswal, A.K., L.A. Neuhold and D.W. Nebert (1987). Human p450IAl upstream 
regulatory sequences expressing chloramphenicol acetyltransferase. Biochem Biophy 
Res Commun 148: 857-63.
174
Kanakura, Y., B. Drucker, S.A. Cannistra, Y. Furukawa, Y. Torimoto and J.D. Griffin 
(1990). Signal transduction of the human granulocyte- macrophage colony-stimulating 
factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of 
cytoplasmic proteins. Blood 76: 706-15.
Karasuyama, H. and F. Melchers (1988). Establishment of mouse cell lines which 
constitutively secrete large quantities of interleukin 2, 3,4 and 5 using modified cDNA 
expression vectors. EurJ Immunol 18:97-104.
Kim, H.S., B.W. Popovich, W.R. Shehee, E.G. Shesely and O. Smithies (1991). 
Problems encountered in detecting targeted gene by the polymerase chain reaction. Gene 
103: 227-33.
Kim, H.S. and O. Smithies (1988). Recombinant fragment assay for gene targeting based 
on polymerase chain reaction. Nucleic Acids Res 16: 8887-8903.
Kinashi, T., N. Harada, E. Severinson, T. Tanabe, P. Sideras, M. Konishi, C. Azuma, A. 
Tominaga, L.S. Bergstedt, M. Takahashi, F. Matsuda, Y. Yaoita, K. Takatsu and T. 
Honjo (1986). Cloning of complementary DNA encoding T-cell replacing factor and 
identity with B-cell growth factor II. Nature 324: 70-3.
Kishimoto, T., T. Taga and S. Akira (1994). Cytokine signal transduction. Cell 76: 253- 
62.
Kitamura, T. and A. Miyajima (1992). Functional reconstitution of human interleukin-3 
receptor. Blood 80: 84-90.
Klemsz, M.J., S.R. McKercher, A. Celala, C.V. Beveren and R.A. Maki (1990). The 
macrophage and B-cell-specific transcription factor PU.l related to the ets oncogene. 
Cell 61: 113-24.
Kodama, S., N. Tsuruoka and M. Tsujimoto (1991). Role of the C-terminus in the 
biological activity of human interleukin 5. Biochem Biophys Res Commun 178: 514-9.
Kohara, Y., H. Mitsuki, A. Nishigaki, T. Motohashi, A. Sugimoto and H. Tabara 
(1994). Unpublished C.elegans cDNA sequence. Genbank accesion no.:D36336
Koike, M. and K. Takatsu (1994). IL-5 and its receptor: which role do they play in the 
immune response? Int Arch Allergy Immunol 104: 1-9.
Koller, B.H. and O. Smithies (1992). Altering genes in animals by gene targeting. Ann 
Rev Immunol 10: 705-30.
Kondo, M., T. Takeshita, N. Ishii, M. Nakamura, S. Watanabe, K. Arai and K. 
Sugamura (1993). Sharing of the interleukin-2 (IL-2) receptor y chain between receptors 
for IL-2 and IL-4. Science 262:1874-7.
Koop, B.F. and L. Hood (1994). Striking sequence similarity over almost 100 kb of 
human and mouse T-cell receptor DNA. Nature Genet 7: 48-53.
Kremer, E., E. Baker, R.J. D'Andrea, R. Slim, H. Phillips, P.A.B. Moretti, A.F. Lopez,
C. Petit, M.A. Vadas, G.R. Sutherland and G.J. Goodall (1993). A cytokine receptor gene 
cluster in the X-Y pseudoautosomal region ? Blood 82: 22-8.
Kunimoto, D.Y., K.C. Allison, C. Watson, T. Fuerst, G.D. Armstrong, W. Paul and W. 
Strober (1991). High-level production of murine interleukin-5 (IL-5) utilizing 
recombinant baculovirus expression. Purification of the rIL-5 and its use in assessing the 
biologic role of IL-5 glycosylation. Cytokine 3: 224-30.
175
Laimins, L., M. Holmgren-Koenig and G. Khoury (1986). Transcriptional "silencer" 
element in rat repetitive sequences associated with rat insulin 1 gene locus. Proc Natl 
Acad Sei USA 83: 3151-5.
Lamer, A.C., M. David, G.M. Feldman, K. Igarashi, R.H. Hacket, D.S.A. Webb, M. 
Sweitzers, E.F. Petricoin III and D.S. Finbloom (1993). Tyrosine phosphorylation of 
DNA binding proteins by multiple cytokines. Science 261: 1730-3.
Lee, C.C., X. Wu, R.G. Gibbs, D.M. Cook and C.T. Caskey (1988). Generation of cDNA 
probes directed by amino add sequence: cloning of urate oxidase. Science 239:1288-91.
Lee, J.S., H.D. Campbell, C.A. Kozak and I.G. Young (1989). The IL-4 and IL-5 genes are 
closely linked and are part of a cytokine gene cluster on mouse chromosome 11. Somat 
Cell Mol Genet 15: 143-52.
Lehrach, H., D. Diamond, J.M. Wozney and H. Boedtker (1977). RNA molecular weight 
determinations by gel electrophoresis under denaturing conditions: a critical 
reexamination. Biochemistry 16: 4743-51.
Lewin, B. (1990). Commitment and activation at PolII promoters: a tail of protein- 
protein interactions. Cell 61: 1161-4.
Limaye, A.P., J.S. Abrams, J.E. Silver, E.A. Ottesen and T.B. Nutman (1990). Regulation 
of parasite-induced eosinophilia: selectively increased interleukin 5 production in 
helminth-infected patients. J Exp Med 172: 399-402.
Lin, J.J., M. Smith, J. Jessee and F. Bloom (1992). DH11S: an Escherichia coli strain for 
preparation of single-stranded DNA from phagemid vectors. BioTechniques 12: 718-21.
Linnekin, D. and W.L. Farrar (1990). Signal transduction of human interleukin-3 and 
granulocyte-macrophage colony-stimulating factor through serine and tyrosine 
phosphorylation. Biochem J 271: 317-24.
Loh, E.Y., J.F. Elliot, S. Cwirla, L.L. Lanier and M.M. Davis (1989). Polymerase chain 
reaction with single sided specificity: analysis of T cell receptor delta chain. Science 
243: 217-20.
Lopata, M.A., D.W. Cleveland and B. Sollner-Webb (1984). High level of a 
chloramphenicol acetytransferase gene by DEAE-dextran-mediated DNA transfection 
coupled with a dimethylsulfoxide or glycerol shock. Nucleic Acids Res 12: 5707.
Lopez, A.F., M.F. Shannon, S. Barry, J.A. Philips, B. Cambareri, M. Dottore, P. 
Simmons and M.A. Vadas (1992). A human interleukin 3 analog with increased 
biological and binding activities. Proc Natl Acad Sei USA 89: 11842-6.
Lopez, A.F., M.A. Vadas, J.M. Woodcock, S.E. Milton, A. Lewis, M.J. Elliott, D. Gillis, 
R. Ireland, E. Olwell and L.S. Park (1991). Interleukin-5, interleukin-3, and 
granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell 
surface receptors on human eosinophils. J Biol Chem 266: 24741-7.
Lopez, A.F., C.J. Sanderson, J.R. Gamble, H.D. Campbell, I.G. Young and M.A. Vadas 
(1988). Recombinant human interleukin 5 is a selective activator of human eosinophil 
function. J Exp Med 167: 219-24.
Lu, L., Z.H. Lin, R.N. Shen, D.J. Warren, T. Leemhuis and H.E. Broxmeyer (1990). 
Influence of interleukins 3,5, and 6 on the growth of eosinophil progenitors in highly 
enriched human bone marrow in the absence of serum. Exp Hematol 18:1180-6.
176
Luthman, H. and Magnusson (1983). High efficiency polyoma DNA transfection of 
chloroquine treated cells. Nucleic Acids Res 11: 1295-707.
Maizeis, R.M., D.A.P. Bundy, M.E. Selkirk, D.F. Smith and R.M. Anderson (1993). 
Immunological modulation and evasion by helminth parasites in human population. 
Nature 365: 797-805.
Mandler, R., C.C. Chu, W.E. Paul, E.E. Max and C.M. Snapper (1993). Interleukin 5 
induces S mu-S gamma 1 DNA rearrangement in B cells activated with dextran-anti- 
IgD antibodies and interleukin 4: a three component model for Ig class switching. / Exp 
Med 178:1577-86.
Maniatis, T., E.F. Fritsch and J. Sambrook (1982). Molecular cloning: a laboratory 
manual. New York, Cold Spring Harbor Laboratory. p370.
Maniatis, T., S. Goodboum and J.A. Fischer (1987). Regulation of inducible and tissue- 
specific gene expression. Science 236:1237-45.
Mansour, S.L., K. Thomas and M.R. Capecchi (1988). Disruption of the proto-oncogene 
int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to 
non-selectable genes. Nature 336: 348-52.
Mantegna, R.N., S.V. Buldyrev, A.L. Goldberger, S. Havlin, C.K. Peng, M. Simons and 
H.E. Stanley (1994). Linguistic features of noncoding DNA sequences. Phy Rev Lett 73: 
3169-72.
Marrack, P. and J. Kappler (1994). Subversion of the immune system by pathogens. Cell 
76: 323-332.
Matsumoto, R., M. Matsumoto, S. Mita, Y. Hitoshi, M. Ando, S. Araki, N. Yamaguchi,
A. Tominaga and K. Takatsu (1989). Interleukin-5 induces maturation but not class 
switching of surface IgA-positive B cells into IgA-secreting cells. Immunol 66: 32-8.
Mattick, J.S. (1994). Introns: evolution and function. Curr Opin Genet Dev 4: 823-31.
Maxwell, I.H. and F. Maxwell (1988). Electroporation of mammalian cells with a 
firefly ludferase expression plasmid: kinetics of transient expression differ markedly 
among cells. DNA 7: 557-62.
McClanahan, T., S. Dalrymple, M. Barkett and F. Lee (1993). Hematopoietic growth 
factor receptor genes as markers of lineage commitment during in vitro development of 
hematopoietic cells. Blood 81: 2903-15.
McCutchan, J.H. and J.S. Pagano (1968). Enhancement of the infectivity of simian virus 
40 deoxyribonucleic acid with diethylaminoethyl-dextran. J Natl Cancer Inst 41: 351- 
7.
McHeyzer, W.M. (1989). Combinations of interleukins 2, 4 and 5 regulate the secretion 
of murine immunoglobulin isotypes. Eur J Immunol 19:2025-30.
McKenzie, A.N.J., X. Li, D.A. Largaespada, A. Sato, A. Kaneda, S.M. Zurawski, E.L. 
Doyle, A. Milatovich, U. Francke, N.G. Copeland, N.A. Jenkins and G. Zurawski 
(1993). Structural comparison and chromosomal localisation of the human and mouse 
IL-13 genes. J Immunol 150: 5436-44.
McKenzie, A.N., B. Ely and C.J. Sanderson (1991a). Mutated interleukin-5 monomers are 
biologically inactive. Mol Immunol 28: 155-8.
177
McKenzie, A.N., S.C. Barry, M. Strath and C.J. Sanderson (1991b). Structure-function 
analysis of interleukin-5 utilizing mouse/human chimeric molecules. EMBO J 10: 
1193-9.
Melton, D.A., P.A. Krieg, M.R. Rebagliati, T. Maniatis, K. Zinn and M.R. Green (1984). 
Efficient in vitro synthesis of biologically active RNA and RNA hybridisation probes 
from plasmids containing a bacteriophage Sp6 promoter. Nucleic Acids Res 12: 7035-56.
Merlino, G.T. (1991). Transgenic animals in biomedical research. FASEB J 5: 2996-3001.
Metcalf, D., J.W. Parker, H.M. Chester and P.W. Kincade (1974). Formation of 
eosinophilic-like granulocytic colonies by mouse bone marrow cells in vitro. J Cell 
Physiol 84: 275-90.
Migita, M., N. Yamaguchi, S. Mita, S. Higuchi, Y. Hitoshi, Y. Yoshida, M. Tomonaga, 
I. Matsuda, A. Tominaga and K. Takatsu (1991). Characterization of the human IL-5 
receptors on eosinophils. Cell Immunol 133: 484-97.
Miki, T., T. Matsui, M.A. Heidaran and S.A. Aaronson (1989). An efficient directional 
system to construct cDNA libraries containing full length inserts at high frequency. 
Gene 83: 137-46.
Mikol, D,DV P, Rongnoparut, B.A. Allwardt, L.S. Marion and K. Stefansson (1993). The 
oligodendrocyte-myelin glycoprotein of mouse: primary structure and gene stucture. 
Genomics 17: 604-610.
Milboume, E.A. and M.J. Howell (1993). Eosinophil differentiation in response to 
Fasciola hepatica and its excretory/secretory antigens. Int J Parasitol 23: 1005-9.
Milbum, M.V., A.M. Hassell, M.H. Lambert, S.R. Jordan, A.E.I. Proudfoot, P. Gräber 
and T.N.C. Wells (1993). A novel dimer configuration revealed by the crystal structure 
at 2.4 Ä resolution of human interleukin-5. Nature 363: 172-6.
Mironov, N.M., A.-M. Aguelon, G.I. Potapova, Y. Omori, O. Gorbunov, A. Klimenkov 
and H. Yamasaki (1994). Alterations of (CA)n DNA repeats and tumour suppressor 
genes in human gastric cancer. Cancer Res 54: 41-4.
Mita, S., A. Tominaga, Y. Hitoshi, K. Sakamoto, T. Honjo, M. Akagi, Y. Kikuchi, N. 
Yamaguchi and K. Takatsu (1989). Characterization of high-affinity receptors for 
interleukin 5 on interleukin 5-dependent cell lines. Proc Natl Acad Sei USA 86: 2311-5.
Mita, S., N. Harada, S. Naomi, Y. Hitoshi, K. Sakamoto, M. Akagi, A. Tominaga and 
K. Takatsu (1988). Receptors for T cell-replacing factor/interleukin 5. Specificity, 
quantitation, and its implication. J Exp Med 168: 863-78.
Miyajima, A., A.L. Mui, T. Ogorochi and K. Sakamaki (1993). Receptors for 
granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. 
Blood 82: 1960-74.
Miyajima, I., L. Levitt, T. Hara, M.A. Bedell, N.G. Copeland, N.A. Jenkins and A. 
Miyajima (1995). The murine interleukin-3 receptor a  subunit gene: chromosomal 
localization, genomic structure and promoter function. Blood 85:1246-53.
Miyazaki, T., M. Maruyama, G. Yamada, M. Hatakeyama and T. Taniguchi (1991). 
The integrity of the conserved 'WS motif' common to IL-2 and other cytokine receptors 
is essential for ligand binding and signal transduction. EMBO J 10: 3191-7.
178
Moser, R., P. Groscurth, J.M. Carballido, P.L.B. Bruijnzeel, K. Blaser, C.H. Heusser and 
J. Fehr (1993). Interleukin-4 induced tissue eosinophilia in mice : correlation with its in 
vitro capacity to stimulate the endothelial cell-dependent selective transmigration of 
human eosinophils. J Allergy Clin Immunol 92: 312-24.
Mosmann, T.R., J.H. Schumacher, N.F. Street, R. Budd, A. O'Garra, T.A.T. Fong, M.W. 
Bond, K.W.M. Moore, A. Sher and D.F. Fiorentino (1991). Diversity of cytokine
synthesis and function of murine CD4+ T cells. Immunol Rev 123: 209-29.
Mosmann, T.R. and R.L. Coffman (1989). Thl and Th2 cells : different pattern of 
lymphokine secretion lead to different functional properties. Ann Rev Immunol 7:145- 
73.
Mui, A.L.-F., H. Wakao, A.-M. O'Farrell, N. Harada and A. Miyajima (1995). 
Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 
transduce signal through two STAT5 homologs. EMBO J 14:1166-75.
Mui, A.L.-F. and A. Miyajima (1994). Cytokine receptors and signal transduction. Prog 
Growth Factor Res 5: 15-35.
Murakami, M., M. Narazaki, M. Hibi, H. Yawata, K. Yasukawa, M. Hamaguchi, T. 
Taga and T. Kishimoto (1991). Critical cytoplasmic region of the interleukin-6 signal 
transducer gpl30 is conserved in the cytokine receptor family. Proc Natl Acad Sei USA 
88: 11949-53.
Murata, Y., S. Takaki, M. Migita, Y. Kikuchi, A. Tominaga and K. Takatsu (1992). 
Molecular cloning and expression of the human interleukin 5 receptor. J Exp Med 175: 
341-51.
Murata, Y., N. Yamaguchi, Y. Hitoshi, A. Tominaga and K. Takatsu (1990). Interleukin 
5 and interleukin 3 induce serine and tyrosine phosphorylations of several cellular 
proteins in an interleukin 5-dependent cell line. Biochem Biophys Res Commun 173: 
1102- 8 .
Murray, N.E., W.S. Brammar and K. Murray (1977). Lambdoid phages that simplify 
the recovery of in vitro recombinants. Mol Gen Genet 150: 53-61.
Nishinakamura, R., N. Nakayama, Y. Hirabayashi, T. Inoue, D. And, T. McNeil, S. 
Azuma, S. Yoshida, Y. Toyoda, K. Arai, A. Miyajima and R. Murray (1995). Mice 
deficient for the IL3/GM-CSF/IL-5 ßc receptor exhibit lung pathology and impaired 
immune response while ßiL3 receptor deficient mice are normal. Immunity 2:211-22.
Noguchi, M., Y. Nakamura, S.M. Russell, S.F. Ziegler, M. Tsang, X. Cao and W.J. 
Leonard (1993a). The interleukin-2 receptor alpha chain is a functional component of 
interleukin-7 receptor. Science 262: 1877-80.
Noguchi, H., H. Yi, A.M. Rosenblatt, A.H. Filiporich, S. Adelstein, W.S. Modi, O.W. 
McBride and W.J. Leonard (1993b). Interleukin-2 receptor alpha chain mutations results 
in X-linked severe combined immunodeficiency in humans. Cell 73:147-57.
Nordeen, S.K. (1988). Luciferase reporter gene vectors for analysis of promoters and 
enhancers. BioT echniques 6: 454-7.
Noma, T., H. Nakakubo, M. Sugita, S. Kumagi, M. Maeda, A. Shimizu and T. Honjo 
(1989). Expressions of different combinations of interleukins by T cell leukemia cell lines 
that are clonally related. J Exp Med 169: 1853-8.
Nowak, R. (1994). Mining treasures from 'junk' DNA. Nature 263: 608-10.
179
Nussinov, R. (1990). Sequence signals in eukaryotic upstream regions. Crit Rev Biochem 
Mol Biol 25: 185-224.
O'Neal, K.D. and L.Y. Yu-Lee (1993). The protein rich motif (PRM): A novel feature of 
the cytokine/hemopoietin receptor superfamily. Lymphokine Cytokine Res 12: 309-12.
Pandit, J., A. Bohm, K. Jancarik, R. Halenbeck, K. Koths and S.H. Kim (1992). Three 
dimensional structure of dimeric human recombinant macrophage colony stimulating 
factor. Science 258: 1358-62.
Park, L.S., U. Martin, R. Sorensen, S. Luhr, P.J. Morrissey, O. Cosman and A. Larsen 
(1992). Cloning of low affinity murine granulocyte-macrophage colony-stimulating 
factor receptor and reconstitution of a high affinity receptor complex. Proc Natl Acad 
Sei USA 87: 4295-99.
Pascoe, W.S., R. Kemler and S.A. Wood (1992). Genes and functions: trapping and 
targeting in embryonic stem cells. Biochim Biophy Acta 1114: 209-21.
Patthy, L. (1990). Homology of a domain of the growth hormone receptor/prolactin 
receptor family with type III modules of fibronectin. Cell 61:13-14.
Paul, C.C., J.R. Keller, J.M. Armpriester and M.A. Baumann (1990). Epstein-Barr virus 
transformed B lymphocyte produce interleukin-5. Blood 75: 1400-3.
Paul, W.F. and R.A. Seder (1994). Lymphocyte responses and cytokines. Cell 76: 241-51.
Pestridge, D.S. (1991). SIGNAL SCAN: a computer program that scans DNA sequences 
for eukaryotic transcriptional elements. Comput Appl Biosci 7: 203-6.
Plaetinck, G., d.H.J. Van, J. Tavernier, I. Fache, T. Tuypens, S. Fischkoff, W. Fiers and 
R. Devos (1990). Characterization of interleukin 5 receptors on eosinophilic sublines 
from human promyelocytic leukemia (HL-60) cells. J Exp Med 172: 683-91.
Plaut, M., J.H. Pierce, C.J. Watson, J. Hanley-hyde, R.P. Norda and W.E. Paul (1989). 
Mast cell lines produce lymphokines in response to cross-linkage of FceRI or calcium 
ionophore. Nature 339: 64-7.
Pleiman, C.M., S.D. Gimpel, L.S. Park, H. Harada, T. Taniguchi and S.F. Ziegler 
(1991). Organisation of the murine and human interleukin-7 receptor genes: two mRNAs 
generated by differential splicing and presence of a type I-interferon-inducible 
promoter. Mol Cell Biol 11: 3052-9.
Potter, H. (1988). Electroporation in biology: methods, applications, and 
instrumentation. Anal Biochem 174: 361-73.
Proudfoot, A.E., D. Fattah, E.H. Kawashima, A. Bernard and P.T. Wingfield (1990). 
Preparation and characterization of human interleukin-5 expressed in recombinant 
Escherichia coli. Biochem J 270: 357-61.
Punnonen, J., G. Aversa, B.G. Cocke, A.N.J. McKenzie, S. Menon, G. Zurawski, R. de 
Waal Malefyt and J.E. de Vries (1993). Interleukin 13 induces interleukin-4 independent 
IgG4 and IgE synthesis and CD23 expression in human B cells. Proc Natl Acad Sei USA 
90: 3730-4.
Purkerson, J.M. and P.C. Isakson (1992a). Interleukin 5 (IL-5) provides a signal that is 
required in addition to IL-4 for isotype switching to immunoglobulin (lg) G1 and IgE. J 
Exp Med 175: 973-82.
180
Pusteil, J. and F.C. Kafatos (1982). A high speed, high capacity homology matrix: 
zooming through SV40 and polyoma. Nucleic Acids Res 10: 4765-82.
Reed, K.C. and D.A. Mann (1985). Rapid transfer of DNA from agarose gels to nylon 
membranes. Nucleic Acids Res 13: 7207-21.
Reeves, R., C.M. Gorman and B. Howard (1985). Minichromosome assembly of non- 
integrated plasmid DNA transfected into mammalian cells. Nucleic Acids Res 13: 
3599-615.
Rennick, D.M., S.L. Thompson, R.L. Coffman, B.W. Seymour, J.D. Jackson and S. Hudak 
(1990). In vivo administration of antibody to interleukin-5 inhibits increased 
generation of eosinophils and their progenitors in bone marrow of parasitized mice. 
Blood 76: 312-6.
Rich, A., A. Nordheim and A.H.-J. Wang (1984). The chemistry and biology of left- 
handed Z-DNA. Ann Rev Biochem 53: 791-846.
Robinson, D.S., Q. Hamid, S. Ying, A. Tsicopoulos, J. Barkans, A.M. Bentley, C.J. 
Corrigan, S.R. Durham and A.B. Kay (1992). Evidence of for a predominant Th2-type' 
bronchoalveolar lavage T-lymphocyte population in atopic asthma. Blood 79: 3101-9.
Rolink, A.G., P. Thalmann, Y. Kikuchi and A. Erdei (1990). Characterization of the 
interleukin 5-reactive spleenic B cell population. Eur ] Immunol 20:1949-56.
Rolink, A.G., F. Melchers and R. Palacios (1989). Monoclonal antibodies reactive with 
the mouse interleukin 5 receptor. J Exp Med 169:1693-701.
Rose-John, S. and P.C. Heinrich (1994). Soluble receptors for cytokines and growth 
factors : generation and biological function. Biochem J 300: 281-90.
Saiki, R.K., D.H. Gelfand, S. Stoffel, S.J. Scharf, R. Higuchi, G.T. Horn, K.B. Mullis 
and H.A. Erlich (1988). Primer-directed enzymatic amplification of DNA with a 
thermostable DNA polymerase. Science 239: 487-91.
Sakamaki, K., I. Miyajima, T. Kitamura and A. Miyajima (1992). Critical cytoplasmic 
domains of the common ß subunit of the human GM-CSF, IL-3 and IL-5 receptors for 
growth signal transduction and tyrosine phosphorylation. EMBO J 11: 3541-9.
Sambrook, J., E.F. Fritsch and T. Maniatis (1989). Molecular cloning: a laboratory 
manual (2nd ed). New York, Cold Spring Harbour.
Samoszuk, M. and L. Nansen (1990). Detection of interleukin-5 messenger RNA in Reed- 
Stemberg cells of Hodgkin's disease with eosinophilia. Blood 75:13-6.
Sanderson, C.J. (1992). Interleukin-5, eosinophils, and disease. Blood 79: 3101-9.
Sanderson, C.J. (1991). Control of eosinophilia. Int Arch Allergy Appl Immunol 94: 122-
6 .
Sanderson, C.J., H.D. Campbell and I.G. Young (1988). Molecular and cellular biology of 
eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B 
cells. Immunol Rev 102: 29-50.
Sanderson, C.J., A. C^Garra, D.J. Warren and G.G.B. Klaus (1986). Eosinophil 
differentiation factor also has B cell growth activity. Propose name Interleukin-4. Proc 
Natl Acad Sei USA 83: 437-40.
181
Sanderson, C.J., D.J. Warren and M. Strath (1985). Identification of a lymphokine that 
stimulates eosinophil differentiation in vitro . Its relationship to IL-3 and functional 
properties of eosinophil produced in cultures. J Exp Med 162: 60-74.
Sanger, F., S. Nicklen and A.R. Coulson (1977). DNA sequencing with chain­
terminating inhibitors. Proc Natl Acad Sei USA 74: 5463-7.
Sato, N. and A. Miyajima (1994a). Multimeric cytokine receptors : common versus 
specific functions. Curr Opin Cell Biol 6: 174-9.
Sato, S., T. Katagiri, S. Takaki, Y. Kikuchi, Y. Hitoshi, S. Yonehara, S. Tsukada, D. 
Kitamura, T. Watanabe, O. Wille and K. Takatsu (1994b). IL-5 receptor-mediated 
tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's 
tyrosine and Janus 2 kinases. J Exp Med 180: 2101-11.
Sato, N., K. Sakamaki, N. Terada, K. Arai and A. Miyajima (1993). Signal 
transduction by the high affinity GM-CSF receptor : two distinct cytoplasmic regions of 
the common ß subunit responsible for the different signalling. EMBO J 12:4181-9.
Satoh, T., Y. Uehara and Y. Kaziro (1992a). Inhibition of interleukin-3 and 
granulocyte-macrophage colony-stimulating factor stimulated increase of active ras- 
GTP by herbimicyin A , a specific inhibitor of tyrosine kinase. J Biol Chem 267: 2537-41.
Satoh, T., M. Nakafuku and Y. Kaziro (1992b). Function of Ras as a molecular switch in 
signal transduction. J Biol Chem 267: 24149-52.
Schenbom, E.T. and R.C. Mierendorf (1985). A novel transcription property of Sp6 and 
T7 RNA polymerases: dependence on template structure. Nucleic Acids Res 13: 6223.
Schimpl, A. and E. Wecker (1972). Replacement of T cell function by a T cell product. 
Nature (New Biol) 15-7:
Schorle, H., T. Holtschke, T. Hunig, A. Schimpl and I. Horak (1991). Development and 
function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 
352: 621-4.
Seminario, M.-C. and G.J. Gleich (1994). The role of eosinophils in the pathogenesis of 
asthma. Curr Opin Immunol 6: 860-4.
Shanafelt, A.B., A. Miyajima, T. Kitamura and R.A. Kastelein (1991). The amino- 
terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors. 
EMBOJ 10:4105-12.
Shen, Y., E. Baker, D.F. Callen, G.R. Sutherland, T.A. Willson, S. Rakar and N.M. 
Gough (1992). Localisation of the human GM-CSF receptor beta chain gene (CSF 2RB) to 
chromosome 22q 12.2 -> ql3.1. Cytogenet Cell Genet 61:175-.
Sher, A., R.L. Coffman, S. Hieny and A.W. Cheever (1990). Ablation of eosinophil and 
IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against 
Schistosoma mansoni in the mouse. J Immunol 145:3911-6.
Shesely, E.G., H.S. Kim, W.R. Shehee, T. Papayannopoulou, O. Smithies and B.W. 
Popovich (1991). Correction of a human ßs-globin gene by gene targeting. Proc Natl Acad 
Sei USA 88: 4294-8.
Shibuya, H., M. Yoneyama, Y. Nakamura, H. Harada, M. Hatakeyama, S. Minamoto, 
T. Kono, T. Doi, R. White and T. Taniguchi (1990). The human interleukin-2 receptor ß-
182
chain gene: genomic organisation, promoter analysis and chromosomal assignment. 
Nucleic Acids Res 18: 3697-703.
Shuai, K. (1994). Interferon-activated signal transduction to the nucleus. Cun Opin 
Cell Biol 6: 253-9.
Skorstengaard, K., M.S. Jensen, P. Sdahl, T.E. Petersen and S. Magnusson (1986). 
Complete primary structure of bovine plasma fibronectin. Eur J Biochem 161: 441-53.
Smith, L., J. Sanders, R. Kaiser, P. Hughes, C. Dodd, C. Heiner, S. Kent and L. Hood 
(1986). Huorescence detection in automated DNA sequence analysis. Nature 321: 674-9.
Smith, L.J., C. Redfield, J. Boyd, G.M.P. Lawrence, R.G. Edwards, R.A.G. Smith and 
G.M. Dobson (1992). Human interleukin 4. The solution structure of a four helix bundle 
protein. J Mol Biol 224: 899-904.
Sonoda, E., Y. Hitoshi, N. Yamaguchi, T. Ishii, A. Tominaga, S. Araki and K. Takatsu 
(1992). Differential regulation of IgA production by TGF ß and IL-5: TGF ß induces 
surface IgA-positive cells bearing IL-5 receptor, whereas IL-5 promotes their survival 
and maturation into IgA-secreting cells. Cell Immunol 140: 158-72.
Southern, E.M. (1975). Detection of specific sequences among DNA fragments separated 
by gel electrophoresis. / Mol Biol 98: 503-17.
Spriggs, M.K. (1994). Cytokine and cytokine receptor 'captured' by viruses. Cun Opin 
Immunol 6: 526-9.
Staden, R. (1987). Computer handling of DNA sequencing projects. In Nucleic acid and 
protein sequence analysis: a practical approach. Bishop, M.J. and C.J. Rawlings (eds). 
Oxford, IRL Press, p i73-217.
Staden, R. (1982). Automation of the computer handling of gel reading data produced by 
the shot-gun method of DNA sequencing. Nucleic Acids Res 10: 4731-51.
Stahl, N. and G.D. Yancopoulos (1993). The alphas, betas, and kinases of cytokine 
receptor complexes. Cell 74: 587-90.
Stanley, E., G.J. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J.A.M. Gall, D.W. Maher,
J. Cebon, V. Sinickas and A.R. Dunn (1994). Granulocyte/macrophage colony- 
stimulating factor-deficient mice show no major perturbation of hematopoiesis but 
develop a characteristic pulmonary pathology. Proc Natl Acad Sei USA 91: 5592-6.
Strauss, E., J. Kobori, G. Siu and L. Hood (1986). Specific-primer directed DNA 
sequencing. Anal Biochem 154: 353-60.
Studier, F.W. (1991). Use of bacteriophage T7 lysozyme to improve an inducible T7 
expression system. J Mol Biol 219: 37-44.
Sulston, J., Z. Du, K. Thomas, R. Wilson, L. Hillier, R. Staden, P. Green, J. Thierry- 
Mieg, L. Qiu, S. Dear, A. Coulson, M. Craxton, R. Durbin, M. Berks, M. Metzstein, T. 
Hawkins, R. Ainscough and R. Waterson (1992). The C. elegans genome sequencing 
projecta beginning Nature 356: 37-41.
Sun, Z., D.A. Yergeau, T. Tuypens, J. Tavernier, C.C. Paul, M.A. Baumann, D.G. Tenen 
and S.J. Ackerman (1995). Identification and characterisation of a functional promoter 
region in the human eosinophil IL-5 receptor alpha subunit gene. J Biol Chem 270:1462- 
71.
183
Swain, S. and R.W. Dutton (1982). Production of a B cell growth promoting activity, 
DL(BCGF), from cloned T cell line and its assay on the BCL1, B cell tumour. J Exp Med 
156: 1821-34.
Swain, S.L., L.M. Bradley, M. Croft, S. Tonkonogy, G. Atkins, A.D. Weinberg, D.D.
Duncan, S.M. Hedrick, R.W. Dutton and G. Huston (1991). Helper T-cell subsets:
Phenotype, function and the role of lymphokines in regulating their development.
Immunol Rev 123: 115-144.
Taguchi, T., W.K. Aicher, K. Fujihashi, M. Yamamoto, J.R. McGhee, J.A. Bluestone and 
H. Kiyono (1991). Novel function for intestinal intraepithelial lymphocytes. Murine 
CD3+, y8 TCR+ T cells produce IFN-gamma and IL-5. J Immunol 147: 3736-44.
Takahashi, T., N. Yamaguchi, S. Mita, Y. Yamaguchi, T. Suda, A. Tominaga, Y.
Kikuchi, Y. Miura and K. Takatsu (1990). Structural comparison of murine T-cell 
(B151K12)-derived T-cell-replacing factor (IL-5) with rIL-5: dimer formation is 
essential for the expression of biological activity. Mol Immunol 27: 911-20.
Takaki, S., H. Kanazawa, M. Shiba and K. Takatsu (1994). A critical cytoplasmic 
domain of the interleukin-5 (IL-5) receptor a  chain and its function inIL-5 mediated growth 
signal transduction. Mol Cell Biol 14: 7404-13.
Takaki, S., Y. Murata, T. Kitamura, A. Miyajima, A. Tominaga and K. Takatsu (1993). 
Reconstitution of the functional receptors for murine and human interleukin 5. /  Exp Med 
177: 1523-9.
Takaki, S., A. Tominaga, Y. Hitoshi, S. Mita, E. Sonoda, N. Yamaguchi and K. Takatsu 
(1990). Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 9: 
4367-74.
Takatsu, K., A. Tominaga and T. Hamaoka (1980). Antigen induced T cell replacing 
factor (TRF). Functional characterisationof a TRF producing helper T cell subset and 
genetic studies of TRF production. J Immunol 124: 2414-22.
Takeshita, T., H. Asao, K. Ohtani, N. Ishii, S. Kumaki, N. Tanaka, H. Munakata, M. 
Nakamura and K. Sugamura (1992). Cloning of the y chain of the human IL-2 receptor. 
Science 257: 379-82.
Tanabe, T., M. Konishi, T. Mizuta, T. Noma and T. Honjo (1987). Molecular cloning and 
structure of the human interleukin-5 gene. J Biol Chem 262:16580-4.
Taniguchi, T. (1995). Cytokine signalling through nonreceptor protein tyrosine kinases. 
Science 268: 251-5.
Tartof, K. and C.A. Hobbs (1987). Improved media for growing plasmid and cosmid 
clones. Focus 9:12.
Tate, P.H. and A. Bird (1993). Effects of DNA methylation on DNA-binding proteins 
and gene expression. Curr Opin Genet Dev Biol 3: 226.
Taveme, J. (1993). Transgenic mice in the study of cytokine function. Int J Exp Path 74: 
525-46.
Tavernier, J., T. Tuypens, A. Verhee, G. Plaetinck, R. Devos, J. Van der Heyden, Y.
Guisez and C. Oefner (1995). Identification of receptor-binding domains on human 
interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad 
Sei USA 92: 5194-8.
184
Tavernier, J., T. Tuypens, G. Plaetinck, A. Verhee, W. Fiers and R. Devos (1992). 
Molecular basis of the membrane-anchored and two soluble isoforms of the human 
interleukin 5 receptor a subunit. Proc Natl Acad Sei USA 89: 7041-5.
Tavernier, J., R. Devos, S. Comelis, T. Tuypens, d.H.J. Van, W. Fiers and G. Plaetinck 
(1991). A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5- 
spedfic a  chain and a ß chain shared with the receptor for GM-CSF. Cell 66: 1175-84.
Thibodeau, S.N., G. Breu and D. Schaid (1993). Microsatellite instability in cancer. 
Science 260: 816-9.
Thompson, J.F., L.S. Hayes and D.B. Lloyd (1991). Modulation of firefly luciferase 
stability and impact on studies of gene regulation. Gene 103:171-7.
Tominaga, A., T. Takahashi, Y. Kikuchi, S. Mita, S. Naomi, N. Harada, N.
Yamaguchi and K. Takatsu (1990a). Role of carbohydrate moiety of IL-5. Effect of 
tunicamycin on the glycosylation of IL-5 and the biologic activity of deglycosylated 
IL-5. } Immunol 144: 1345-52.
Tominaga, A., S. Takaki, N. Koyama, S. Katoh, R. Matsumoto, M. Migita, Y. Hitoshi,
Y. Hosoya, S. Yamaguchi, Y. Kanai, J.-I. Miyazaki, G. Usuku, K.-I. Yamamura and K. 
Takatsu (1990b). Transgenic mice expressing a B cell growth factor and differentiation 
gene (interkeukin-5) develop eosinophilia and autoantibody production. / Exp Med 173: 
429-437.
Troutt, A.B., M.G. Mcheyzer-Williams, B. Pulendran and G.J.V. Nossal (1992). Ligation 
anchored PCR: a simple amplification technique with single-sided specificity. Proc 
Natl Acad Sei USA 89: 9823-5.
Tsuruoka, N., K. Funakoshi, S. Kodama and M. Tsujimoto (1990). Interaction of 
interleukin-5 with its receptors on murine leukemic BCL1 cells and its implication in 
biological activity. Cell Immunol 125: 354-62.
Tuypens, T., G. Plaetinck, E. Baker, G. Sutherland, G. Brusselle, W. Fiers, R. Devos and 
J. Tavernier (1992). Organisation and chromosonal localisation of the human 
interleukin-5 receptor a chain gene. Eur Cytokine Netw 3: 451-9.
Ullrich, A. and J. Schlessinger (1990). Signal transduction by receptors with tyrosine 
kinase activity. Cell 61: 203-12.
Valancius, V. and O. Smithies (1991). Testing an 'in-out7 targeting procedure for making 
subtle genomic modifications in mouse embryonic stem cells. Mol Cell Biol 11:1402-8.
Van der Brüggen, T., E. Caldenhoven, D. Kanters, P. Coffer, J.A.M. Raaijmakers, J.-M.J. 
Lammers and L. Koenderman (1995). Interleukin-5 signalling in human eosinophils 
involves JAK2 tyrosine kinase and Statla. Blood 85: 1442-8.
Van Leeuwen, B.H., M.E. Martinson, G.C. Webb and I.G. Young (1989). Molecular 
organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5 and 
GM-CSF genes, on human chromosome 5. Blood 73:1142-8.
Van Oosterhout, A.J.M., A.R.C. Ladenius, H.F.J. Savelkoul, I. Van Ark, K.C. Delsman 
and F.P. Nijkamp (1993). Effect of anti-IL-5 and IL-5 on airway hyperreactivity and 
eosinophils in guinea pigs. Am Rev Respir Dis 147: 548-552.
Vaux, D.L., P.A. Lalor, S. Cory and G.R. Johnson (1990). In vivo expression of interleukin 
5 induces an eosinophilia and expanded Ly-IB lineage populations. Int Immunol 2: 965- 
71.
185
Waldman, A.S. (1992). Targeted recombinations in mammalian cells. Crit Rev 
Oncol/Hematol 12: 49-64.
/
Walsh, G.M., A.J. Wardlaw, A. Hartnell, C.J. Sanderson and A.B. Kay (1991). 
Interleukin-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, 
in a leucocyte integrin (CDll/18)-dependent manner. Int Arch Allergy Appl Immunol 
94: 174-8.
Walter, M.R., W.J. Cook, B.G. Zhao, R.P.J.J. Cameron, S.E. Ealick, R.L.J. Walter, P. 
Reichert, T.L. Nagabhusham, P.P. Trolta and C.E. Bugga (1992). Crystal structure of 
recombinant human interleukin-4. J Biol Chem 267: 20371-6.
Wang, J.M., A. Rambaldi, A. Biondi, Z.G. Chen, C.J. Sanderson and A. Mantovani 
(1989). Recombinant human interleukin 5 is a selective eosinophil chemoattractant.
EurJ Immunol 19:701-5.
Warren, D.J. and M.A. Moore (1988). Synergism among interleukin 1, interleukin 3, and 
interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells.
/  Immunol 140: 94-9.
Warren, D.J. and C.J. Sanderson (1985). Production of a T cell hybrid producing a 
lymphokine stimulating eosinophil differentiation. Immunology 54: 615-23.
Webb, C.F., C. Das, S. Eaton, K. Calame and P.W. Tucker (1991). Novel protein-DNA 
interactions associated with increased immunoglobulin transcription in response to 
antigen plus interleukin-5. Mol Cell Biol 11: 5197-205.
Weichenhan, D. (1991). Fast recovery of DNA from agarose gels by centrifugation 
through blotting paper. Trends Genet 7: 109.
Weigel, D. and H. Jackie (1990). The fork head domain: a novel DNA binding motif of 
transcription factors? Cell 63: 455-6.
Wightman, B., I. Ha and G. Ruvkun (1993). Posttranscriptional regulation of the 
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C.elegans. 
Cell 75: 855-62.
Wilks, A.F. and A.G. Harpur (1994). Cytokine signal transduction and the JAK family 
of protein tyrosine kinases. Bioessays 16: 313-20.
Williams, T.M., J.E. Burlein, S. Ogden, L.J. Kricka and J.A. Kant (1989). Advantages of 
firefly luciferase as a reporter gene: applications to interleukin-2 gene promoter. Anal 
Biochem 176: 28-32.
Wilson, C , H.J. Bellen and W.J. Gerhing (1990). Position effects on eukaryotic gene 
expression. Ann Rev Cell Biol 6: 679-714.
Winkelman, J.C., L.A. Penney, L.L. Deaven, B.G. Forget and R.B. Jenkins (1990). The 
gene for the human erythropoietin receptor: analysis of the coding sequence and 
assignment on chromosome 19p. Blood 76: 24-30.
Wolffe, A.P. (1994). Nucleosome positioning and modification: chromatin structure that 
potentiate transcription. Trends Biochem Sei 19: 240-4.
Wong, T.K. and E. Neuman (1982). Electric field mediated gene transfer. Biochem 
Bicrphy Res Commun 107: 584-7.
186
Wood, S.A., W.S. Pascoe, C. Schmidt, R. Kemler, M J. Evans and N.D. Allen (1993). 
Simple and efficient production of embryonic stem cell-embryo chimeras by co-culture. 
Proc Natl Acad Sei USA 90: 4582-5.
Wood, K.V. (1991). The origin of beetle luciferase. In Bioluminescence and 
Chemiluminescence: current status. Stanley, P.E. and L.J. Kricka, (eds). Chichester, 
Wiley, p ll-4 .
Wrighton, N., L.A. Campbell, N. Harada, A. Miyajima and F. Lee (1992). The murine 
interleukin-4 receptor gene: genomic structure, expression and potential for alternative 
splicing. Growth Factors 6: 103-18.
Wu, H., X. Liu and R. Jaenisch (1994). Double replacement: strategy for efficient 
introduction of subtle mutations into murine Colla-1 gene by homologous recombination 
in embryonic stem cells. Proc Natl Acad Sei USA 91: 2819-23.
Yamaguchi, Y., Y. Hayashi, Y. Sugama, Y. Miura, T. Kasahara, S. Kitamura, M. 
Torisu, S. Mita, A. Tominaga, K. Takatsu and T. Suda (1988b). Highly purified murine 
interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 
as an eosinophil chemotactic factor. J Exp Med 167: 1737-42.
Yamaguchi, Y., T. Suda, J. Suda, M. Eguchi, Y. Miura, N. Harada, A. Tominaga and K. 
Takatsu (1988a). Purified interleukin 5 supports the terminal differentiation and 
proliferation of murine eosinophilic precursors. J Exp Med 167: 43-56.
Yawata, H., K. Yasukawa, S. Natsuka, M. Murakami, K. Yamasaki, M. Hibi, T. Taga 
and T. Kishimoto (1993). Structure-function analysis of human IL-6 receptor: 
dissociation of amino and residues required for IL-6 binding and for IL-6 signal 
transduction through gpl30. EMBO J 12:1705-12.
Yokota, T., R.L. Coffman, H. Hagiwara, D.M. Rennick, Y. Takebe, K. Yokota, L. 
Gemmell, B. Shrader, G. Yang, P. Meyerson, J. Luh, P. Hoy, J. Pene, F. Biere, H. Spits, J. 
Banchereau, J. De Vries, F.D. Lee, N. Arai and K. Arai (1987). Isolation and 
characterization of lymphokine cDNA clones encoding mouse and human IgA- 
enhancing factor and eosinophil colony-stimulating factor activities: relationship to 
interleukin 5. Proc Natl Acad Sei USA 84: 7388-92.
Yousouffian, H., L. Zon, S. Orkin, A. D'Adrea and H.F. Lodish (1990). Structure and 
transcription of the mouse erythropoietin receptor gene. Mol Cell Biol 10: 3675-82.
Yuan, D., T. Dang and C. Sanderson (1990). Regulation of IgH chain gene transcription 
by IL-5. J Immunol 145: 3491-6.
Zinn, K., D. DiMaio and T. Maniatis (1983). Identification of two distinct regions 
adjacent to the human beta-interferon gene. Cell 34: 865-79.
